Ekso
Bionics Holdings, Inc.
Prospectus
67,134,768 Shares
Common Stock
This prospectus relates to the sale of
up to 67,134,768 shares of our common stock, par value $0.001 per share, by the selling stockholders of Ekso Bionics Holdings,
Inc., a Nevada corporation, listed in this prospectus. Of the shares being offered, 31,079,768 are presently issued
and outstanding, and 36,055,000 are issuable upon exercise of common stock purchase warrants. The shares offered by this prospectus
may be sold by the selling stockholders from time to time in the open market, through privately negotiated transactions or a combination
of these methods, at market prices prevailing at the time of sale or at negotiated prices.
The distribution of the shares by the
selling stockholders is not subject to any underwriting agreement. We will not receive any proceeds from the sale of
the shares by the selling stockholders. We will bear all expenses of registration incurred in connection with this
offering, but all selling and other expenses incurred by the selling stockholders will be borne by them.
Our common stock is traded on OTC Markets
under the symbol “EKSO.” On June 5, 2014, the last reported sale price for our common stock was $2.90 per share.
Our business and an investment in our
securities involve a high degree of risk. Before making any investment in our securities, you should read and carefully
consider risks described in the “Risk Factors” section beginning on page 8 of this prospectus.
You should rely only on the information
contained in this prospectus or any prospectus supplement or amendment thereto. We have not authorized anyone to provide you with
different information. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus
is only accurate on the date of this prospectus, regardless of the time of any sale of securities.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
This prospectus is dated June
20,
2014.
You should rely only on the information
contained in this prospectus. We have not authorized any other person to provide you with information that is different from that
contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We
take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give
you. The selling stockholders are offering to sell and seeking offers to buy these securities only in jurisdictions where offers
and sales are permitted. You should assume that the information contained in this prospectus is accurate only as of the date of
this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial
condition, results of operations and prospects may have changed since that date.
We are not making an offer of any securities
in any jurisdiction where the offer is not permitted.
TABLE OF CONTENTS
PROSPECTUS SUMMARY
The following summary highlights information
contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information that
should be considered before investing in our common stock. Potential investors should read the entire prospectus carefully,
including the more detailed information regarding our business provided below in the “Description of Business” section,
the risks of purchasing our common stock discussed under the “Risk Factors” section, and our consolidated financial
statements and the accompanying notes to the consolidated financial statements.
Unless the context indicates otherwise,
all references in this registration statement to “Ekso Bionics Holdings,” the “Company,” “we,”
“us” and “our” refer to Ekso Bionics Holdings, Inc., and its wholly-owned consolidated subsidiaries, Ekso
Bionics, Inc., and Ekso Bionics Limited; and references to “Ekso Bionics” refer to Ekso Bionics, Inc., and its subsidiary.
Overview
We are designing, developing and commercializing
wearable robots, or “human exoskeletons,” that have a variety of potential applications in the medical, military,
industrial, and consumer markets. Our exoskeletons are ready-to-wear, battery-powered devices that are strapped over the user’s
clothing, enabling individuals with neurological conditions affecting gait (e.g., spinal cord injury or stroke) to walk again;
permitting soldiers to carry heavy loads for long distances while mitigating lower back, knee, and ankle injuries; and allowing
industrial workers to perform heavy duty work for extended periods.
We are currently focusing primarily on
medical applications for people with lower extremity weakness or paralysis. Our products have been listed with the U.S. Food and
Drug Administration (“FDA”) and have received a CE Mark (indicating compliance with European Union legislation). We
have sold over 40
devices to rehabilitation centers and individual users for rehabilitation since February 2012.
We also have a collaborative partnership with Lockheed Martin Corporation (“Lockheed”) to develop products for able-bodied
exoskeleton applications.
We are at a key point in the growth of
its business. We intend to further penetrate the medical market and to begin to penetrate the military and industrial markets
over the next several years.
Based on technology initially developed
by an engineering team from the University of California, Berkeley, our devices employ a number of proprietary, advanced robotics
technologies.
Organizational History
We were incorporated in Nevada as PN Med
Group Inc. on January 30, 2012. Our original business was to distribute medical supplies and equipment to municipalities, hospitals,
pharmacies, care centers, and clinics throughout the country of Chile. Prior to the Merger (as defined below), our Board determined
to discontinue operations in this area and to seek a new business opportunity. As a result of the Merger, we have acquired the
business of Ekso Bionics and its subsidiary.
Our authorized capital stock currently
consists of 500,000,000 shares of common stock, par value $0.001, and 10,000,000 shares of “blank check” preferred
stock, par value $0.001. Our common stock is quoted on the OTC Markets (OTCQB) under the symbol “EKSO.”
Ekso Bionics
TM
was incorporated
on January 19, 2005, under the laws of the State of Delaware, to design, develop, and commercialize exoskeletons to augment human
strength, endurance and mobility. Since its inception, Ekso Bionics has achieved several significant milestones:
|
·
|
In 2006, Ekso Bionics designed and sold the first practical human exoskeleton.
|
|
·
|
In 2009, Ekso Bionics signed its first agreement with Lockheed establishing the companies’
collaborative partnership to ruggedize and commercialize an exoskeleton for military and other able-bodied applications.
|
|
·
|
In February 2012, we sold our first exoskeleton suit for medical applications, called Ekso™,
for use by complete spinal cord injured (“SCI”) patients at rehabilitation centers.
|
|
·
|
In July 2013, Ekso Bionics delivered a key technology upgrade for Ekso called Variable Assist,
expanding the potential user population by adding utility for incomplete SCI patients, stroke patients and patients with related
neurological disorders who can benefit from gait rehabilitation.
|
|
·
|
In December 2013, we delivered our first Ekso GT, a new generation Ekso with added hardware
and software functionality, including Variable Assist.
|
On December 16, 2013, we completed a 3.462-for-1
forward split of our common stock in the form of a dividend, with the result that the 6,350,000 shares of common stock outstanding
immediately prior to the stock split became 21,983,700 shares of common stock outstanding immediately thereafter. All share and
per share numbers in this prospectus relating to our common stock have been adjusted to give effect to this stock split, unless
otherwise stated.
On December 18, 2013, (i) we changed our
name from PN Med Group Inc. to Ekso Bionics Holdings, Inc., and (ii) we increased our authorized capital stock from 75,000,000
shares of common stock, par value $0.001, to 500,000,000 shares of common stock, par value $0.001 (the “common stock”),
and 10,000,000 shares of “blank check” preferred stock, par value $0.001.
On January 15, 2014, our wholly owned
subsidiary, Ekso Acquisition Corp., a corporation formed in the State of Delaware on January 3, 2014 (“Acquisition Sub”)
merged (the “Merger”) with and into Ekso Bionics. Ekso Bionics was the surviving corporation in the Merger and became
our wholly owned subsidiary. All of the outstanding Ekso Bionics stock was converted into shares of our common stock, as described
in more detail below.
In connection with the Merger and pursuant
to a split-off agreement, we transferred our pre-Merger business to our pre-Merger majority stockholder, in exchange for the surrender
by her and cancellation of 17,483,100 shares of our common stock.
As a result of the Merger and Split-Off,
we discontinued our pre-Merger business and acquired the business of Ekso Bionics, and will continue the business operations of
Ekso Bionics as a publicly-traded company under the name Ekso Bionics Holdings, Inc.
Also on January 15, 2014, we closed a
private placement offering (the “PPO”) of 20,580,000 Units of our securities, at a purchase price of $1.00 per Unit,
each Unit consisting of one share of the our Common Stock and a warrant to purchase one share of Common Stock at an exercise price
of $2.00 per share and with a term of five years (the “PPO Warrants”). Between January 29, 2014 and February 6, 2014,
we issued an additional 9,720,000 Units in subsequent closings of the PPO. Additional information concerning the PPO and PPO Warrants
is presented below under “Certain Relationships and Related Party Transactions—The Private Placement Offering.”
In addition, in connection with the Merger,
we changed our fiscal year from a fiscal year ending on March 31 of each year to one ending on December 31 of each year.
The Merger is being accounted for as a
“reverse merger,” and Ekso Bionics is deemed to be the acquirer in the reverse merger. Consequently, the assets and
liabilities and the historical operations that will be reflected in the financial statements prior to the Merger will be those
of Ekso Bionics and will be recorded at the historical cost basis of Ekso Bionics, and the consolidated financial statements after
completion of the Merger will include the assets and liabilities of Ekso Bionics, historical operations of Ekso Bionics and operations
of the Company and its subsidiaries from the closing date of the Merger. As a result of the issuance of the shares of our Common
Stock pursuant to the Merger, a change in control of the Company occurred as of the date of consummation of the Merger.
We continue to be a “smaller reporting
company,” as defined under the Exchange Act, following the Merger. We believe that as a result of the Merger, we have ceased
to be a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act).
See “Certain Relationships and Related
Party Transactions” below for more information about the Merger and related transactions.
Capital Needs
With the capital raised to date as described
above, we believe the Company has funding to implement our business plan, support operations and meet current obligations through
the middle of 2015. The Company will determine when and if to proceed with any additional financing in the future, and there can
be no assurance financing will be available to us when required on acceptable terms or at all.
About This Offering
This prospectus relates to the public
offering, which is not being underwritten, by the selling stockholders listed in this prospectus, of up to 67,134,768 shares of
our common stock. Of the shares being offered, 31,079,768 are presently issued and outstanding, and 36,055,000 are
issuable upon exercise of common stock purchase warrants. The shares offered by this prospectus may be sold by the
selling stockholders from time to time in the open market, through negotiated transactions or otherwise at market prices prevailing
at the time of sale or at negotiated prices. We will receive none of the proceeds from the sale of the shares by the
selling stockholders. We will bear all expenses of registration incurred in connection with this offering, but all
selling and other expenses incurred by the selling stockholders will be borne by them.
Selected Risks Associated With an Investment in Shares of
Our Common Stock
An investment in shares of our common
stock is highly speculative and is subject to numerous risks described in the section entitled “Risk Factors” and
elsewhere in this prospectus. You should carefully consider these risks before making an investment. Some of these risks include:
|
·
|
We
have a limited operating history upon which investors can evaluate our future prospects.
|
|
·
|
Our
products may not be accepted in the market.
|
|
·
|
We
are subject to extensive governmental regulations relating to the manufacturing, labeling
and marketing of our products.
|
|
·
|
The
technology of load carriage exoskeletons (such as our HULC® human exoskeleton) is
at a very early stage of development, and the technology may not be broadly adopted in
military or other markets.
|
|
·
|
We
may be unable to manage our growth and entry into new business areas.
|
|
·
|
We
have a history of losses and we may not achieve or sustain profitability in the future.
|
|
·
|
If
we are unable to obtain additional financing on acceptable terms, we may have to curtail
our growth or cease our development plans and operations.
|
|
·
|
You
could lose all of your investment.
|
|
·
|
You
may experience dilution of your ownership interests because of the future issuance of
additional shares of our common or preferred stock or other securities that are convertible
into or exercisable for our common or preferred stock.
|
|
·
|
There
currently is a very limited market for our Common Stock and there can be no assurance
that a consistent trading market will ever develop. Failure to develop or maintain a
trading market could negatively affect the value of our Common Stock and make it difficult
or impossible for you to sell your shares.
|
Corporate Information
Our principal executive offices are located
at 11414 Harbour Way South, Suite 1201, Richmond, California 94804. Our telephone number is 1-510-984-1761. Our website address
is
www.eksobionics.com
. The information on, or that can be accessed through, our website is not part of this prospectus.
THE OFFERING
Common stock currently outstanding
|
|
78,497,558 shares (1)
|
|
|
|
Preferred stock currently outstanding
|
|
None
|
|
|
|
Common stock offered by the Company
|
|
None
|
|
|
|
Common stock offered by the selling stockholders
|
|
67,134,768 shares (2)
|
|
|
|
Use of proceeds
|
|
We will not receive any of the proceeds from the sales of our common stock by the selling
stockholders.
|
|
|
|
OTC Markets symbol
|
|
EKSO
|
|
|
|
Risk Factors
|
|
You should carefully consider the information set forth in this prospectus and, in particular,
the specific factors set forth in the “Risk Factors” section beginning on page 8 of this prospectus before deciding
whether or not to invest in shares of our common stock.
|
|
(1)
|
As of June 20, 2014.
|
|
(2)
|
Consists of 31,079,768 outstanding shares of common stock and 36,055,000 shares of common
stock issuable upon exercise of common stock purchase warrants.
|
NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus contains forward-looking
statements, including, without limitation, in the sections captioned “Description of Business,” “Risk Factors,”
and “Management’s Discussion and Analysis of Financial Condition and Plan of Operations,” and elsewhere. Any
and all statements contained in this prospectus that are not statements of historical fact may be deemed forward-looking statements.
Terms such as “may,” “might,” “would,” “should,” “could,” “project,”
“estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,”
“attempt,” “develop,” “plan,” “help,” “believe,” “continue,”
“intend,” “expect,” “future,” and terms of similar import (including the negative of any of
the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain
one or more of these identifying terms. Forward-looking statements in this prospectus may include, without limitation, statements
regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development
of commercially viable pharmaceuticals, (ii) a projection of income (including income/loss), earnings (including earnings/loss)
per share, capital expenditures, dividends, capital structure or other financial items, (iii) our future financial performance,
including any such statement contained in a discussion and analysis of financial condition by management or in the results of
operations included pursuant to the rules and regulations of the SEC, and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above.
The forward-looking statements are not
meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based
upon our current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which we have no control over. Actual results and the timing of certain
events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks
and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may include, without limitation, our inability to obtain adequate
financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity,
our inability to expand our business, significant government regulation of pharmaceuticals and the healthcare industry, lack of
product diversification, volatility in the price of our raw materials, existing or increased competition, results of arbitration
and litigation, stock volatility and illiquidity, and our failure to implement our business plans or strategies. A description
of some of the risks and uncertainties that could cause our actual results to differ materially from those described by the forward-looking
statements in this prospectus appears in the section captioned “Risk Factors” and elsewhere in this prospectus.
Readers are cautioned not to place undue
reliance on forward-looking statements because of the risks and uncertainties related to them and to the risk factors. We disclaim
any obligation to update the forward-looking statements contained in this prospectus to reflect any new information or future
events or circumstances or otherwise.
RISK FACTORS
An investment in shares of our common
stock is highly speculative and involves a high degree of risk. We face a variety of risks that may affect our operations
or financial results and many of those risks are driven by factors that we cannot control or predict. Before investing
in our common stock you should carefully consider the following risks, together with the financial and other information contained
in this prospectus. If any of the following risks actually occurs, our business, prospects, financial condition and
results of operations could be materially adversely affected. In that case, the trading price of our common stock would
likely decline and you may lose all or a part of your investment. Only those investors who can bear the risk of loss
of their entire investment should invest in our common stock.
Risks Related to our Business and the Industry in Which
We Operate
We have a limited operating history
upon which investors can evaluate our future prospects.
Although Ekso Bionics was incorporated
in 2005, it did not sell its first Ekso medical device until 2012. Therefore, we have limited operating history upon which an
evaluation of our business plan or performance and prospects can be made. The business and prospects of the Company must be considered
in the light of the potential problems, delays, uncertainties and complications encountered in connection with a newly established
business and creating a new industry. The risks include, but are not limited to, the possibility that we will not be able to develop
functional and scalable products and services, or that although functional and scalable, our products and services will not be
economical to market; that our competitors hold proprietary rights that preclude us from marketing such products; that our competitors
market a superior or equivalent product; that we are not able to upgrade and enhance our technologies and products to accommodate
new features and expanded service offerings; or the failure to receive necessary regulatory clearances for our products. To successfully
introduce and market our products at a profit, we must establish brand name recognition and competitive advantages for our products.
There are no assurances that the Company can successfully address these challenges. If it is unsuccessful, the Company and its
business, financial condition and operating results could be materially and adversely affected.
Given the limited operating history, management
has little basis on which to forecast future demand for our products from our existing customer base, much less new customers.
The current and future expense levels of the Company are based largely on estimates of planned operations and future revenues
rather than experience. It is difficult to accurately forecast future revenues because the business of the Company is new and
its market has not been developed. If the forecasts for the Company prove incorrect, the business, operating results and financial
condition of the Company will be materially and adversely affected. Moreover, the Company may be unable to adjust its spending
in a timely manner to compensate for any unanticipated reduction in revenue. As a result, any significant reduction in revenues
would immediately and adversely affect the business, financial condition and operating results of the Company.
The industries in which the
Company operates are highly competitive and subject to rapid technological change. If our competitors are better able to
develop and market products that are safer, more effective, less costly, easier to use, or are otherwise more attractive, we may
be unable to
compete effectively with other companies.
The medical technology, industrial robotics
and military equipment industries are characterized by intense competition and rapid technological change, and we will face competition
on the basis of product features, clinical outcomes, price, services and other factors. Competitors may include large medical
device and other companies, some of which have significantly greater financial and marketing resources than we do, and firms that
are more specialized than we are with respect to particular markets. Our competition may respond more quickly to new or emerging
technologies, undertake more extensive marketing campaigns, have greater financial, marketing and other resources than we do or
may be more successful in attracting potential customers, employees and strategic partners.
Our competitive position will depend on
multiple, complex factors, including our ability to achieve market acceptance for our products, develop new products, implement
production and marketing plans, secure regulatory approvals for products under development and protect our intellectual property.
In some instances, competitors may also offer, or may attempt to develop, alternative therapies for disease states that may be
delivered without a medical device. The development of new or improved products, processes or technologies by other companies
may render our products or proposed products obsolete or less competitive. The entry into the market of manufacturers located
in low-cost manufacturing locations may also create pricing pressure, particularly in developing markets. Our future success depends,
among other things, upon our ability to compete effectively against current technology, as well as to respond effectively to technological
advances, and upon our ability to successfully implement our marketing strategies and execute our research and development plan.
Our products may not be accepted
in the market.
We cannot be certain that our current
products or any other products we may develop or market will achieve or maintain market acceptance. Market acceptance of
our products depends on many factors, including the Company’s ability to convince key opinion leaders to provide recommendations
regarding our products, convince distributors and customers that our technology is an attractive alternative to other technologies,
demonstrate that our products are reliable and supported by us in the field, supply and service sufficient quantities of products
directly or through marketing alliances, and price products competitively in light of the current macroeconomic environment, which,
particularly in the case of the medical device industry, are becoming increasingly price sensitive.
Dependence on patent and other proprietary
rights and failing to protect such rights or to be successful in litigation related to such rights may result in our payment of
significant monetary damages or impact offerings in our product portfolios.
Our long-term success largely depends
on our ability to market technologically competitive products. If we fail to obtain or maintain adequate intellectual property
protection, we may not be able to prevent third parties from using our proprietary technologies or may lose access to technologies
critical to our products. Also, our currently pending or future patent applications may not result in issued patents, and issued
patents are subject to claims concerning priority, scope and other issues.
Furthermore, we have not filed applications
for all of our patents internationally and may not be able to prevent third parties from using our proprietary technologies or
may lose access to technologies critical to our products in other countries. These include, in some cases, countries in which
we are currently selling products and countries in which we intend to sell products in the future.
Intellectual property litigation and infringement claims
could cause us to incur significant expenses or prevent us from selling certain of our products.
The industries in which we operate, including,
in particular, the medical device industry, are characterized by extensive intellectual property litigation and, from time to
time, we might be the subject of claims by third parties of potential infringement or misappropriation. Regardless of outcome,
such claims are expensive to defend and divert the time and effort of our management and operating personnel from other business
issues. A successful claim or claims of patent or other intellectual property infringement against us could result in our payment
of significant monetary damages and/or royalty payments or negatively impact our ability to sell current or future products in
the affected category and could have a material adverse effect on our business, cash flows, financial condition or results of
operations.
Some of the patents in the intellectual
property portfolio are not within our complete control, which could reduce the value of such patents.
Some of our U.S. patent applications (which
have associated international applications) are co-owned by the Regents of the University of California Berkeley. The Regents
of the University of California Berkeley has licensed its rights under many of these patent applications to us, but we do not
have a license to their rights under three of these patent applications. With respect to two of these co-owned patent applications,
the Regents of the University of California Berkeley has licensed their rights in the U.S. to an unrelated third party. The third
patent application will need to be fully prosecuted before it can be determined which claims are exclusive to us (through a previous
license) and which claims the Regents of the University of California Berkeley may license to other entities. We do not have complete
control over the prosecution of these patent applications. In addition, the license of patent rights under these patents to third
parties could reduce the value of the Company’s patent portfolio and limit any income or license fees that we might receive
if we were to attempt to transfer or license our rights under any of our co-owned patents.
Enforcing intellectual property
rights in foreign nations for military technology may be more problematic than enforcement in other industries.
In many countries, governments reserve
the right to allow local manufacturers to infringe patents in cases where it is beneficial to their national security to do so.
This could result in additional competition for us or our licensees from local manufacturers in foreign countries even though
those manufacturers are infringing patents we hold in those countries, which could adversely affect our ability to sell our products
in those countries for military use.
We are
subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of our products.
Our medical technology
products and operations are subject to regulation by the FDA, the European Union and other governmental authorities both inside
and outside of the United States. These agencies enforce laws and regulations that govern the development, testing, manufacturing,
labeling, advertising, marketing and distribution, and market surveillance of our medical products.
Under the Federal
Food, Drug, and Cosmetic Act, medical devices are classified into one of three classes — Class I, Class II or Class III
— depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety
and effectiveness. We believe our current products are Class I medical devices. Class I devices are those for which safety and
effectiveness can be assured by adherence to a set of guidelines, which include compliance with the applicable portions of the
FDA's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate,
truthful and non-misleading labeling, advertising, and promotional materials.
Following the introduction of a product,
these agencies will also periodically review our manufacturing processes and product performance. The process of complying with
the applicable good manufacturing practices, adverse event reporting, clinical trial and other requirements can be costly and
time consuming, and could delay or prevent the production, manufacturing or sale of our products. In addition, if we fail to comply
with applicable regulatory requirements, it could result in fines, delays or suspensions of regulatory clearances, closure of
manufacturing sites, seizures or recalls of products and damage to our reputation. Recent changes in enforcement practice by the
FDA, European Union and other agencies have resulted in increased enforcement activity, which increases the compliance risk for
the Company and other companies in our industry. In addition, governmental agencies may impose new requirements regarding registration,
labeling or prohibited materials that may require us to modify or re-register products already on the market or otherwise impact
our ability to market our products in those countries. Once clearance or approval has been obtained for a product, there is an
obligation to ensure that all applicable FDA and other regulatory requirements continue to be met.
We may
be subject to penalties and may be precluded from marketing
our products if we fail to comply with extensive governmental
regulations.
We believe that our Ekso, Ekso 1.1, and
Ekso GT products are FDA Class I medical devices when used in clinical settings. However, the FDA has not made any determination
about whether our medical products are Class I medical devices. Such a determination is not necessary in order for us to list
a Class I device with the FDA and bring that device to the U.S. market. However, from time to time, the FDA may disagree with
the classification of a new Class I medical device and require the manufacturer of that device to apply for approval as a Class
II or Class III medical device. In the event that the FDA determines that our medical products should be reclassified as Class
II or Class III medical devices, we could be precluded from marketing the devices for clinical use within the United States for
months, years or longer, depending on the specific change the classification. Reclassification of our products as Class II or
Class III medical devices could significantly increase our regulatory costs, including the timing and expense associated with
required clinical trials and other costs.
The FDA and non-U.S.
regulatory authorities require that our products be manufactured according to rigorous standards. These regulatory requirements
may significantly increase our production costs and may even prevent us from making our products in amounts sufficient to meet
market demand. If we change our approved manufacturing process, the FDA may need to review the process before it may be
used. Failure to comply with applicable regulatory requirements discussed could subject us to enforcement actions, including
warning letters, fines, injunctions and civil penalties against us, recall or seizure of our products, operating restrictions,
partial suspension or total shutdown of our production, and criminal prosecution.
Federal, state
and non-U.S. regulations regarding the manufacture and sale of medical devices are subject to future changes. The complexity,
timeframes and costs associated with obtaining marketing clearances are unknown. Although we cannot predict the impact,
if any, these changes might have on our business, the impact could be material.
Certain of our
competitors have reported injuries caused by the malfunction of human exoskeleton devices (in at least one case to the FDA). Injuries
caused by the malfunction or misuse of human exoskeleton devices, even where such malfunction or misuse occurs with respect to
one of our competitor’s products, could cause regulatory agencies to implement more conservative regulations on the medical
human exoskeleton industry, which could significantly increase our operating costs.
Product
defects could adversely affect the results of our operations.
The design, manufacture
and marketing of our products involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products,
or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events. These events
could lead to recalls or safety alerts relating to our products (either voluntary or required by the FDA or similar governmental
authorities in other countries), and could result, in certain cases, in the removal of a product from the market. A recall could
result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products.
Personal injuries relating to the use of our products could also result in product liability claims being brought against us.
In some circumstances, such adverse events could also cause delays in new product approvals.
When a medical
human exoskeleton is used by a paralyzed individual to walk, the individual relies completely on the exoskeleton to hold them
upright. There are many exoskeleton components that, if they were to fail catastrophically, could cause a fall resulting in severe
injury or death of the patient. Such occurrences could bring about costly litigation and could also bring about regulatory activity
on the part of the FDA or its foreign counterparts which could interfere with our ability to market our products.
When an industrial
or military exoskeleton is used by a healthy individual—for example to carry a heavy load—malfunction of the device
at an inopportune moment (such as when descending a stairway or navigating a precarious trail) could cause a fall resulting in
severe injury or death of the person using the device. Such occurrences could bring about costly litigation and could also bring
about regulatory activity on the part of the Occupational Safety and Health Administration or its foreign counterparts which could
interfere with our ability to market our products.
We could
be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs and adequate levels or otherwise
protect ourselves against potential product liability claims.
The testing,
manufacture, marketing and sale of medical devices entail the inherent risk of liability claims or product recalls. Product liability
insurance is expensive and may not be available on acceptable terms, if at all. A successful product liability claim or product
recall could inhibit or prevent the successful commercialization of our products, cause a significant financial burden on the
Company, or both, which in either case could have a material adverse effect on our business and financial condition.
If we are
not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse
effect on our business.
Healthcare providers
and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies
worldwide, private insurance companies, and managed care organizations. The manner and level of reimbursement in any given case
may depend on the site of care, the procedure(s) performed, the final patient diagnosis, the device(s) utilized, available budget,
or a combination of these factors, and coverage and payment levels are determined at each payer’s discretion. The coverage
policies and reimbursement levels of these third-party payers may impact the decisions of healthcare providers and facilities
regarding which medical products they purchase and the prices they are willing to pay for those products. Thus, changes in reimbursement
levels or methods may either positively or negatively impact sales of our products.
The Company has
no direct control over payer decision-making with respect to coverage and payment levels for our medical device products. Additionally,
we expect many payers to continue to explore cost-containment strategies (e.g., comparative and cost-effectiveness analyses, so-called
“pay-for-performance” programs implemented by various public and private payers, and expansion of payment bundling
schemes such as Accountable Care Organizations, and other such methods that shift medical cost risk to providers) that may potentially
impact coverage and/or payment levels for our current products or products we develop.
As our product
offerings are diverse across healthcare settings, they are affected to varying degrees by the many payment systems. Therefore,
individual countries, product lines or product classes may be impacted by changes to these systems.
Changes
in reimbursement practices of third-party payers could affect the demand for our products and the prices at which they are sold.
The sales of
our products could depend, in part, on the extent to which healthcare providers and facilities or individual users are reimbursed
by government authorities, private insurers and other third-party payers for the costs of our products or the services performed
with our products. The coverage policies and reimbursement levels of third-party payers, which can vary among public and private
sources and by country, may affect which products customers purchase and the prices they are willing to pay for those products
in a particular jurisdiction. Reimbursement rates can also affect the acceptance rate of new technologies. Legislative or administrative
reforms to reimbursement systems in the United States or abroad, or changes in reimbursement rates by private payers, could significantly
reduce reimbursement for procedures using the Company’s products or result in denial of reimbursement for those products,
which would adversely affect customer demand or the price customers may be willing to pay for such products.
Clinical
outcome studies regarding our products may not provide sufficient data to either cause third-party payers to approve reimbursement
or to make human exoskeletons a standard of care.
Our business
plan relies on broad adoption of human exoskeletons to provide neuro-rehabilitation in the form of gait training to individuals
who have suffered a neurological injury or disorder. Although use of human exoskeletons in neuro-rehabilitation is new, use of
robotic devices to provide gait training has been going on for over a decade and the clinical studies relating to such devices
have had both positive and negative outcomes. Much of the rehabilitation community has rejected the use of such devices based
on the data from some of these studies. Although we believe that human exoskeletons will outperform such robotic equipment, this
has not been proven. Furthermore, it may prove impossible to prove an advantage in a timely manner, or at all, which could prevent
broad adoption of our products.
Part of our business
plan relies on broad adoption of the Ekso device to provide “early mobilization” of individuals who have been immobilized
by an injury, disease, or other condition. Although the health benefits of other methods of “early mobilization” have
been demonstrated in clinical studies in fields such as stroke, those studies did not test early mobilization with human exoskeletons
directly. It may be necessary to provide outcome studies on early mobilization with exoskeletons directly in order to convince
the medical community of their effectiveness. Such studies have not been designed at this time, and may be too large and too costly
for us and our partners to conduct.
The technology
of load carriage exoskeletons (such as the HULC human exoskeleton) is at a very early stage of development, and the technology
may not be broadly adopted in military or other markets.
The most recent testing of our HULC technology
showed that the metabolic cost of load carriage while wearing the device varied greatly from subject to subject. This implied
that the device helped some subjects and hindered others. The source of this phenomenon and whether it will go away with training
of the subjects using the device remains unknown and requires further research and development. This phenomenon and others like
it could limit the adoption of such devices by militaries or other customers to a certain portion of their personnel or in the
worst case could make it impractical to deploy at all. If Lockheed is unable to market the HULC exoskeleton, it would negatively
affect our results of operations.
We may be unable to attract and
retain key employees.
The success of the Company depends on
our ability to identify, hire, train and retain highly qualified managerial, technical and sales and marketing personnel. In July
2013, thirty Ekso employees were furloughed in order to significantly reduce our cash expenses pending the completion of a financing.
Some of these employees have since accepted employment with other firms, and, therefore, will need to be replaced by new hires.
In addition, as the Company introduces new products or services, it will need to hire additional personnel. Currently, competition
for personnel with the required knowledge, skill and experiences is intense, and the Company may not be able to attract, assimilate
or retain such personnel. The inability to attract and retain the necessary managerial, technical and sales and marketing personnel
could have a material adverse effect on the business, results of operations and financial condition of the Company.
We will experience long and variable
sales cycles, which could have a negative impact on our results of operations for any given quarter and may result in volatility
in our stock price.
The Ekso device has a lengthy sales and
purchase order cycle because it is a major capital item and generally requires the approval of senior management at purchasing
institutions, which may contribute to substantial fluctuations in our quarterly operating results. Other factors that may cause
our operating results to fluctuate include:
|
·
|
general
economic uncertainties and political concerns;
|
|
·
|
the
introduction of new products or product lines;
|
|
·
|
the
level of market acceptance of new products;
|
|
·
|
the
timing of R&D and other expenditures;
|
|
·
|
timing
of the receipt of orders from, and product shipments to, distributors and customers;
|
|
·
|
changes
in the distribution arrangements for our products;
|
|
·
|
manufacturing
or supply delays;
|
|
·
|
the
time needed to educate and train additional sales and manufacturing personnel; and
|
|
·
|
costs
associated with defending our intellectual property.
|
In addition to these factors, expenditures
are based, in part, on expected future sales. If sales levels in a particular quarter do not meet expectations, we may be
unable to adjust operating expenses quickly enough to compensate for the shortfall of sales, and our results of operations may
be adversely affected.
International sales of our products
account for a portion of our revenues, which will expose the Company to certain operating risks. If we are unable to successfully
manage our international activities, our net sales, results of operations and financial condition could be adversely impacted.
Our business currently depends in part
on our activities in Europe and other foreign markets, making it subject to a number of challenges that specifically relate to
international business activities. These include:
|
·
|
failure
of local laws to provide the same degree of protection against infringement of our intellectual
property rights;
|
|
·
|
protectionist
laws and business practices that favor local competitors, which could slow our growth
in international markets;
|
|
·
|
the
expense of establishing facilities and operations in new foreign markets;
|
|
·
|
building
an organization capable of supporting geographically dispersed operations;
|
|
·
|
challenges
caused by distance, language and cultural differences;
|
|
·
|
challenges
caused by differences in legal regulations, markets, and customer preferences, which
may limit our ability to adapt our products or succeed in other regions;
|
|
·
|
multiple,
conflicting, and changing laws and regulations, including complications due to unexpected
changes in regulatory requirements, foreign laws, tax schemes, international import and
export legislation, trading and investment policies, exchange controls and tariff and
other trade barriers;
|
|
·
|
foreign
tax consequences;
|
|
·
|
fluctuations
in currency exchange rates and foreign currency translation adjustments;
|
|
·
|
foreign
exchange controls that might prevent us from repatriating income earned outside the United
States;
|
|
·
|
imposition
of public sector controls;
|
|
·
|
political,
economic and social instability; and
|
|
·
|
restrictions
on the export or import of technology.
|
If we are unable to meet and overcome
these challenges, then our international operations may not be successful, which could adversely affect our net sales, results
of operations and financial condition and limit our growth.
We may be unable to manage our growth
and entry into new business areas.
If the initial response to our exoskeleton
products exceeds the Company’s capacity to provide services timely and efficiently, then the Company may need to expand
our operations accordingly and swiftly. Management of the Company believes that establishing industry leadership will require
the Company to:
|
·
|
test,
introduce and develop new products and services including enhancements to our Ekso device;
|
|
·
|
develop
and expand the breadth of products and services offered;
|
|
·
|
develop
and expand our market presence through relationships with third parties; and
|
|
·
|
generate
satisfactory revenues from such expanded products or services to fund the foregoing requirements
while obtaining and maintaining satisfactory profit margins.
|
To be able to expand our operations in
a cost-effective or timely manner and increase the overall market acceptance of our products and services in this manner, we will
need additional capital and technical and managerial human resources. These additional resources may not be available to the Company.
Failure of the Company to timely and efficiently expand our operations and successfully achieve the four requirements listed above
could have a material adverse effect on the business, results of operations and financial condition of the Company.
The disruption or loss of relationships
with vendors and suppliers for the components of our products could materially adversely affect our business.
Our ability to manufacture and market
our products successfully is dependent on relationships with both third party vendors and suppliers. Although most of the raw
materials that the Company uses to manufacture our products are readily available from a number of suppliers, we generally procure
raw materials and components through purchase orders, with no guaranteed supply arrangements. Our inability to obtain sufficient
quantities of various components, if and as required in the future, may subject us to:
|
·
|
delays
in delivery or shortages in components that could interrupt and delay manufacturing and
result in cancellations of orders for our products;
|
|
·
|
increased
component prices and supply delays as we establish alternative suppliers;
|
|
·
|
inability
to develop alternative sources for product components;
|
|
·
|
required
modifications of our products, which may cause delays in product shipments, increased
manufacturing costs, and increased product prices; and
|
|
·
|
increased
inventory costs as we hold more inventory than we otherwise might in order to avoid problems
from shortages or discontinuance, which may result in write-offs if we are unable to
use all such products in the future.
|
In addition, failure of any one supplier’s
components could result in a product recall, which could materially adversely affect our business, operations and cash flows.
New product introductions may adversely
impact our financial results.
We may introduce new products with enhanced
features and extended capabilities from time to time. The products will be subject to various regulatory processes, and we will
need to obtain and maintain regulatory approvals in order to sell our new products. If a potential purchaser believes that we
plan to introduce a new product in the near future or if a potential purchaser is located in a country where a new product that
we have introduced has not yet received regulatory approval, planned purchases may be deferred or delayed. As a result, new product
introductions may adversely impact our financial results.
The acquisition of other companies,
businesses, or technologies could result in operating difficulties, dilution, and other harmful consequences.
We may selectively pursue strategic acquisitions,
any of which could be material to our business, operating results, and financial condition. Future acquisitions could divert management’s
time and focus from operating our business. In addition, integrating an acquired company, business or technology is risky and
may result in unforeseen operating difficulties and expenditures associated with integrating employees from the acquired company
into our organization and integrating each company’s accounting, management information, human resources and other administrative
systems to permit effective management. The anticipated benefits of future acquisitions may not materialize. Future acquisitions
or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities
or amortization expenses, or write-offs of goodwill, any of which could harm our financial condition. Future acquisitions may
also require us to obtain additional financing, which may not be available on favorable terms or at all.
The impact of United States healthcare
reform legislation remains uncertain.
In 2010, the Patient Protection and Affordable
Care Act (“PPACA”) was enacted into law. The legislation seeks to reform the United States healthcare system. It is
far-reaching and is intended to expand access to health insurance coverage, improve quality and reduce costs over time. We expect
the new law will have a significant impact upon various aspects of our business operations. The PPACA reduces Medicare and Medicaid
payments to hospitals, clinical laboratories and pharmaceutical companies, and could otherwise reduce the volume of medical procedures.
These factors, in turn, could result in reduced demand for our products and increased downward pricing pressure. It is also possible
that the PPACA will result in lower reimbursements. While the PPACA is intended to expand health insurance coverage to uninsured
persons in the United States, the impact of any overall increase in access to healthcare on sales of our products remains uncertain.
In addition, the new law imposes a 2.3 percent excise tax on medical devices that will apply to United States sales of our medical
device product. Many of the details of the new law will be included in new and revised regulations, which have not yet been promulgated,
and require additional guidance and specificity to be provided by the Department of Health and Human Services, Department of Labor
and Department of the Treasury. Accordingly, while it is too early to understand and predict the ultimate impact of the new law
on our business, the legislation and resulting regulations could have a material adverse effect on our business, cash flows, financial
condition and results of operations.
Healthcare changes in the United
States and other countries resulting in pricing pressures
could have a negative impact on our future operating results.
In addition to the PPACA, initiatives
sponsored by government agencies, legislative bodies and the private sector to limit the growth of healthcare costs, including
price regulation and competitive pricing, are ongoing in markets where we will do business. Pricing pressure has also increased
in these markets due to continued consolidation among health care providers, trends toward managed care, the shift towards governments
becoming the primary payers of health care expenses and laws and regulations relating to reimbursement and pricing generally.
Reductions in reimbursement levels or coverage or other cost-containment measures could unfavorably affect our future operating
results.
Continuing worldwide macroeconomic
instability, such as recent recessions in Europe and the debt crisis in certain countries in the European Union, could negatively
affect our ability to conduct business in those geographies.
Since 2008, the global economy has been
impacted by the sequential effects of an ongoing global financial crisis which has caused extreme disruption in the financial
markets, including severely diminished liquidity and credit availability. There can be no assurance that further deterioration
will not occur. Our customers and suppliers may experience financial difficulties or be unable to borrow money to fund their
operations which may adversely impact their ability to purchase our products or to pay for them on a timely basis, if at all.
Further, the continuing debt crisis in certain European countries could cause the value of the euro to deteriorate, reducing
the purchasing power of our European customers. Failure to receive payment of all or a significant portion of our receivables
could adversely affect our results of operations. In addition, financial difficulties experienced by our suppliers could
result in product delays and inventory issues.
Natural or other disasters could
disrupt our business and result in loss of revenue or in higher expenses.
Natural disasters, terrorist activities,
military conflict and other business disruptions could seriously harm our revenue and financial condition and increase our costs
and expenses. Our corporate headquarters are located in California, a seismically active region. A natural disaster in any of
our major markets in North America or Europe could have a material adverse impact on our operations, operating results and financial
condition. Further, any unanticipated business disruption caused by Internet security threats, damage to global communication
networks or otherwise could have a material adverse impact on our operating results.
Risks Related to our Financial Condition
We have a history of losses and
we may not achieve or sustain profitability in the future.
Ekso Bionics has incurred losses in each
fiscal year since its incorporation in 2005. We anticipate that our operating expenses will increase in the foreseeable future
as we continue to invest to grow our business, acquire customers and develop our platform and new functionality. These efforts
may prove more expensive than we currently anticipate, and we may not succeed in increasing our revenues sufficiently to offset
these higher expenses.
We may not be able to reduce the
cost to manufacture our products as planned.
Our business plan assumes that exoskeletons
can be manufactured more inexpensively than they are currently being manufactured. However, we have not yet found a way to significantly
reduce the manufacturing cost of our products and doing so may prove more difficult than expected or even impossible. For example,
if expectations for greater functionality of the products drive costs up as other factors drive costs down, the result may be
that the overall cost of manufacturing the product stays the same or even increases.
Our operating losses and lack of
revenues raise substantial doubt about our ability to continue as a going concern. If we do not continue as a going concern, investors
could lose their entire investment.
Our historical operating losses and lack
of revenues to support our cost structure raise substantial doubt about our ability to continue as a going concern. If we do not
generate revenues, do not achieve profitability and do not have other sources of financing for our business, we may have to curtail
or cease our development plans and operations, which could cause investors to lose the entire amount of their investment.
If we are unable to obtain additional
financing on acceptable terms, we may have to curtail our growth or cease our development plans and operations.
The operation of our business and our
growth efforts will require significant cash outlays and advance capital equipment expenditures and commitments. We will be largely
dependent on capital raised through the PPO to implement our business plan and support our operations. We believe that the net
proceeds of the PPO will be sufficient to fund us for approximately 18 months. Other than the PPO, at the present time, we have
not made any arrangements to raise additional cash. We anticipate for the foreseeable future that cash on hand, cash generated
from operations, and the amounts available under lines of credit will not be sufficient to meet our cash requirements, and that
we will need to raise additional capital through investments to fund our operations and growth. To date Ekso has been able to
raise needed capital for its business through equity and debt investment. We cannot assure you that we will be able to raise additional
working capital as needed on terms acceptable to us, if at all. If we are unable to raise capital as needed, we may be required
to reduce the scope of our business development activities, which could harm our business plans, financial condition and operating
results, or cease our operations entirely, in which case, you may lose all your investment. Financings, if obtained, may be on
terms that are dilutive to our stockholders, and the prices at which new investors would be willing to purchase our securities
may be lower than the price at which you purchase your shares.
Potential investors should be aware that
the value of an investment in the Company may go down as well as up. In addition, there can be no certainty that the market value
of an investment in the Company will fully reflect its underlying value.
Our reported financial results may
be adversely affected by changes in accounting principles generally accepted in the United States.
Generally accepted accounting principles
in the United States are subject to interpretation by the Financial Accounting Standards Board, the American Institute of Certified
Public Accountants, the Securities and Exchange Commission (“SEC”) and various bodies formed to promulgate and interpret
appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported
financial results, and could affect the reporting of transactions completed before the announcement of a change.
Changes in tax laws or exposure
to additional income tax liabilities could have a material adverse impact on our financial condition and results of operations.
We are subject to income taxes as well
as non-income based taxes, in both the U.S. and various jurisdictions outside the U.S. We are subject to ongoing tax audits
in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes
and penalties. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision.
However, there can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes
of these audits could have a material impact on our consolidated earnings and financial condition. Additionally, changes
in tax laws or tax rulings could materially impact our effective tax rate. Proposals for fundamental U.S. corporate tax
reform, if enacted, could have a material adverse impact on our future results of operations.
Investment Risks
You could lose all of your investment.
An investment in our securities is speculative
and involves a high degree of risk. Potential investors should be aware that the value of an investment in the Company may go
down as well as up. In addition, there can be no certainty that the market value of an investment in the Company will fully reflect
its underlying value. You could lose your entire investment.
You may experience dilution of your
ownership interests because of the future issuance of additional shares of our common or preferred stock or other securities that
are convertible into or exercisable for our common or preferred stock.
In the future, we may issue our authorized
but previously unissued equity securities, resulting in the dilution of the ownership interests of our present stockholders and
the purchasers of our Units offered hereby. The Company will be authorized to issue an aggregate of 500,000,000 shares of
Common Stock and 10,000,000 shares of “blank check” preferred stock. We may issue additional shares of our Common
Stock or other securities that are convertible into or exercisable for our Common Stock in connection with hiring or retaining
employees, future acquisitions, future sales of our securities for capital raising purposes, or for other business purposes. The
future issuance of any such additional shares of our Common Stock may create downward pressure on the trading price of the Common
Stock. We will need to raise additional capital in the near future to meet our working capital needs, and there can
be no assurance that we will not be required to issue additional shares, warrants or other convertible securities in the future
in conjunction with these capital raising efforts, including at a price (or exercise prices) below the price you paid for your
stock.
The ability of our Board of Directors
to issue additional stock may prevent or make more difficult certain transactions, including a sale or merger of the Company.
Our Board of Directors will be authorized
to issue up to 10,000,000 shares of preferred stock with powers, rights and preferences designated by it. See “Preferred
Stock” in the section of this prospectus titled “Description of Securities.” Shares of voting or convertible
preferred stock could be issued, or rights to purchase such shares could be issued, to create voting impediments or to frustrate
persons seeking to effect a takeover or otherwise gain control of the Company. The ability of the Board to issue such additional
shares of preferred stock, with rights and preferences it deems advisable, could discourage an attempt by a party to acquire control
of the Company by tender offer or other means. Such issuances could therefore deprive stockholders of benefits that could
result from such an attempt, such as the realization of a premium over the market price for their shares in a tender offer or
the temporary increase in market price that such an attempt could cause. Moreover, the issuance of such additional shares
of preferred stock to persons friendly to the Board of Directors could make it more difficult to remove incumbent managers and
directors from office even if such change were to be favorable to stockholders generally.
There currently is a very limited
market for our Common Stock and there can be no assurance that a consistent trading market will ever develop. Failure to develop
or maintain a trading market could negatively affect the value of our Common Stock and make it difficult or impossible for you
to sell your shares.
Our Common Stock is quoted on the OTC
Markets. The OTC Markets is a thinly traded market and lacks the liquidity of certain other public markets with which some investors
may have more experience. We may not ever be able to satisfy the listing requirements for our Common Stock to be listed on a national
securities exchange, which is often a more widely-traded and liquid market. Some, but not all, of the factors which may delay
or prevent the listing of our Common Stock on a more widely-traded and liquid market include the following: our stockholders’
equity may be insufficient; the market value of our outstanding securities may be too low; our net income from operations may
be too low; our Common Stock may not be sufficiently widely held; we may not be able to secure market makers for our Common Stock;
and we may fail to meet the rules and requirements mandated by the several exchanges and markets to have our Common Stock listed.
Should we fail to satisfy the initial listing standards of the national exchanges, or our Common Stock is otherwise rejected for
listing, and remains listed on the OTC Markets or is suspended from the OTC Markets, the trading price of our Common Stock could
suffer and the trading market for our Common Stock may be less liquid and our Common Stock price may be subject to increased volatility.
Our Common Stock is subject to the
“penny stock” rules of the SEC and the trading market in the securities is limited, which makes transactions in the
stock cumbersome and may reduce the value of an investment in the stock.
Rule 15g-9 under the Exchange Act establishes
the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price
of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For
any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person’s
account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction,
setting forth the identity and quantity of the penny stock to be purchased.
In order to approve a person’s account
for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives
of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the
person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny
stocks.
The broker or dealer must also deliver,
prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which,
in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms
that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers
may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make
it more difficult for investors to dispose of our Common Stock and cause a decline in the market value of our Common Stock.
Disclosure also has to be made about the
risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both
the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available
to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent
price information for the penny stock held in the account and information on the limited market in penny stocks.
Our stock
may be traded infrequently and in low volumes, so you may be unable to sell your shares at or near the quoted bid prices if you
need to sell your shares.
Until our Common Stock is listed on a
national securities exchange such as the New York Stock Exchange or the Nasdaq Stock Market, we expect our Common Stock to remain
eligible for quotation on the OTC Markets, or on another over-the-counter quotation system, or in the “pink sheets.”
In those venues, however, the shares of our Common Stock may trade infrequently and in low volumes, meaning that the number of
persons interested in purchasing our common shares at or near bid prices at any given time may be relatively small or non-existent.
An investor may find it difficult to obtain accurate quotations as to the market value of our Common Stock or to sell his or her
shares at or near bid prices or at all. In addition, if we fail to meet the criteria set forth in SEC regulations, various requirements
would be imposed by law on broker-dealers who sell our securities to persons other than established customers and accredited investors.
Consequently, such regulations may deter broker-dealers from recommending or selling our Common Stock, which may further affect
the liquidity of our Common Stock. This would also make it more difficult for us to raise capital.
An increase in the number of registered
shares of our Common Stock will increase our public float and may cause our stock price to decline.
With this registration statement, we are
registering an additional 67,134,768 shares of Common Stock, consisting of 31,079,768 outstanding shares of the Common Stock and
36,055,000 shares of Common Stock issuable upon exercise of outstanding warrants.
The registration
of the additional shares of our Common Stock will have the immediate effect of increasing the public float of our Common Stock
and any such increase may cause the market price of our Common Stock to decline or fluctuate significantly.
We do not anticipate paying dividends on our Common Stock,
and investors may lose the entire amount of their investment.
Cash dividends have never been declared
or paid on our Common Stock, and we do not anticipate such a declaration or payment for the foreseeable future. We expect to use
future earnings, if any, to fund business growth. Therefore, stockholders will not receive any funds absent a sale of their shares
of Common Stock. If we do not pay dividends, our Common Stock may be less valuable because a return on your investment will only
occur if our stock price appreciates. We cannot assure stockholders of a positive return on their investment when they sell their
shares, nor can we assure that stockholders will not lose the entire amount of their investment.
Being a public company is expensive
and administratively burdensome.
As a public reporting company, we are
subject to the information and reporting requirements of the Securities Act, the Exchange Act and other federal securities laws,
rules and regulations related thereto, including compliance with the Sarbanes-Oxley Act. Complying with these laws and regulations
requires the time and attention of our Board of Directors and management, and increases our expenses. Among other things, we are
required to:
|
·
|
maintain
and evaluate a system of internal controls over financial reporting in compliance with
the requirements of Section 404 of the Sarbanes-Oxley Act and the related rules
and regulations of the SEC and the Public Company Accounting Oversight Board;
|
|
·
|
maintain
policies relating to disclosure controls and procedures;
|
|
·
|
prepare
and distribute periodic reports in compliance with our obligations under federal securities
laws;
|
|
·
|
institute
a more comprehensive compliance function, including with respect to corporate governance;
and
|
|
·
|
involve,
to a greater degree, our outside legal counsel and accountants in the above activities.
|
The costs of preparing and filing annual
and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders is expensive
and much greater than that of a privately-held company, and compliance with these rules and regulations may require us to hire
additional financial reporting, internal controls and other finance personnel, and will involve a material increase in regulatory,
legal and accounting expenses and the attention of management. There can be no assurance that we will be able to comply with the
applicable regulations in a timely manner, if at all. In addition, being a public company makes it more expensive for us to obtain
director and officer liability insurance. In the future, we may be required to accept reduced coverage or incur substantially
higher costs to obtain this coverage. These factors could also make it more difficult for us to attract and retain qualified executives
and members of our Board of Directors, particularly directors willing to serve on an audit committee which we expect to establish.
Any failure to maintain effective internal control over
our financial reporting could materially adversely affect us.
Section 404 of the Sarbanes-Oxley Act
of 2002 requires us to include in our annual reports on Form 10-K an assessment by management of the effectiveness of our internal
control over financial reporting. In addition, at such time, if any, as we are no longer a “smaller reporting company,”
our independent registered public accounting firm will have to attest to and report on management’s assessment of the effectiveness
of such internal control over financial reporting. Based upon the last evaluation conducted as of December 31, 2013, our management
at the time concluded that our disclosure controls and procedures were not effective as of such date to ensure that information
required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and
reported within the time periods specified in SEC rules and forms. Specifically, our then-management determined that there were
control deficiencies that constituted material weaknesses, including our lack of an independent audit committee, including a financial
expert member and lack of appropriate cash controls and information technology controls. While our new management as a result
of the Merger believes that our control environment is substantially improved, our independent public accountants, in conducting
an audit of Ekso Bionics’ financial statements as of December 31, 2013, identified several control deficiencies that they
believed constituted a material weakness, in the aggregate. Our new management has not yet conducted a new formal evaluation of
our internal control over financial reporting and has not been able to make its own assessment on whether the internal controls
as of 2012 or 2013 were effective.
While we intend to diligently and thoroughly
document, review, test and improve our internal control over financial reporting in order to ensure compliance with Section 404,
management may not be able to conclude that our internal control over financial reporting is effective. Furthermore, even if management
were to reach such a conclusion, if our independent registered public accounting firm is not satisfied with the adequacy of our
internal control over financial reporting, or if the independent auditors interpret the requirements, rules or regulations differently
than we do, then they may decline to attest to management’s assessment or may issue a report that is qualified. Any of these
events could result in a loss of investor confidence in the reliability of our financial statements, which in turn could negatively
affect the price of our Common Stock.
In particular, we must perform system
and process evaluation and testing of our internal control over financial reporting to allow management and (if required in future)
our independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting,
as required by Section 404. Our compliance with Section 404 may require that we incur substantial accounting expense and expend
significant management efforts. We currently do not have an internal audit group, and we will need to retain the services of additional
accounting and financial staff or consultants with appropriate public company experience and technical accounting knowledge to
satisfy the ongoing requirements of Section 404. We intend to review the effectiveness of our internal controls and procedures
and make any changes management determines appropriate, including to achieve compliance with Section 404 by the date on which
we are required to so comply.
***
The risks above do not necessarily
comprise all of those associated with an investment in the Company. This prospectus contains forward looking statements that involve
unknown risks, uncertainties and other factors that may cause the actual results, financial condition, performance or achievements
of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward
looking statements. Factors that might cause such a difference include, but are not limited to, those set out above.
SELLING STOCKHOLDERS
This prospectus covers the resale from
time to time by the selling stockholders identified in the table below of (a) up to 30,300,000 outstanding shares of common stock
sold to investors in our 2014 private placement offering of common stock (the “2014 Offering”), (b) up to 779,768
outstanding shares of common stock held by certain other stockholders, (c) up to 35,830,000 shares of common stock issuable upon
exercise of common stock purchase warrants issued to investors and to the placement agent in our 2014 Offering, and (d) up to
225,000 shares of common stock issuable upon exercise of common stock purchase warrants issued to a former lender.
The selling stockholders identified in
the table below may from time to time offer and sell under this prospectus any or all of the shares of common stock described
under the columns “Shares of common stock owned prior to this Offering and Registered hereby” and “Shares Issuable
Upon Exercise of Warrants owned Prior to this Offering and Registered hereby” in the table below.
Certain selling stockholders may be deemed
to be “underwriters” as defined in the Securities Act. Any profits realized by such selling stockholder may be deemed
to be underwriting commissions.
The table below has been prepared based
upon the information furnished to us by the selling stockholders as of the date of this prospectus. The selling stockholders
identified below may have sold, transferred or otherwise disposed of some or all of their shares since the date on which the information
in the following table is presented in transactions exempt from or not subject to the registration requirements of the Securities
Act. Information concerning the selling stockholders may change from time to time and, if necessary, we will amend
or supplement this prospectus accordingly. We cannot give an estimate as to the number of shares of common stock that
will actually be held by the selling stockholders upon termination of this offering because the selling stockholders may offer
some or all of their common stock under the offering contemplated by this prospectus or acquire additional shares of common stock. The
total number of shares that may be sold hereunder will not exceed the number of shares offered hereby. Please read
the section entitled “Plan of Distribution” in this prospectus.
The following table sets forth the
name of each selling stockholder, the number of shares of our common stock beneficially owned by such stockholder before this
offering, the number of shares to be offered for such stockholder’s account and the number and (if one percent or
more) the percentage of the class to be beneficially owned by such stockholder after completion of the offering. The number
of shares owned are those beneficially owned, as determined under the rules of the SEC, and such information is not
necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any
shares of our common stock as to which a person has sole or shared voting power or investment power and any shares of common
stock which the person has the right to acquire within 60 days after June 20, 2014 (the “Determination
Date”), through the exercise of any option, warrant or right, through conversion of any security or pursuant to the
automatic termination of a power of attorney or revocation of a trust, discretionary account or similar arrangement, and such
shares are deemed to be beneficially owned and outstanding for computing the share ownership and percentage of the person
holding such options, warrants or other rights, but are not deemed outstanding for computing the percentage of any other
person.
Unless otherwise set forth below, based
upon the information furnished to us, (a) the persons and entities named in the table have sole voting and sole investment power
with respect to the shares set forth opposite the selling stockholder’s name, subject to community property laws, where
applicable, (b) no selling stockholder had any position, office or other material relationship within the past three years, with
us or with any of our predecessors or affiliates, and (c) no selling stockholder is a broker-dealer or an affiliate of a broker-dealer.
Selling stockholders who are broker-dealers or affiliates of broker-dealers are indicated by footnote. We have been advised that
these broker-dealers and affiliates of broker-dealers purchased our common stock in the ordinary course of business, not for resale,
and at the time of purchase, did not have any agreements or understandings, directly or indirectly, with any person to distribute
such common stock. The number of shares of common stock shown as beneficially owned before the offering is based on information
furnished to us or otherwise based on information available to us at the timing of the filing of the registration statement of
which this prospectus forms a part.
Selling Stockholder
|
|
Shares of
common stock
Beneficially
owned Prior to
the Offering
|
|
|
Shares of
common
stock owned
Prior to this
Offering and
Registered
hereby
|
|
|
Shares
Issuable Upon
Exercise of
Warrants
owned Prior to
this Offering
and Registered
hereby
1
|
|
|
Shares of
common
stock
Beneficially
Owned Upon
Completion
of the
Offering
2
|
|
|
Percentage of
Common
Stock
Beneficially
Owned Upon
Completion
of the
Offering
3
|
|
Aleksander Ablovatskiy
4
|
|
|
20,000
|
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
0
|
|
|
|
0
|
|
George Abraham
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Deepak H.Aggarwal
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Allan Lipkowitz Revocable Living Trust
UAD 8/26/2005
5
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Allen Chase Foundation
6
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Animeros Enterprises Limited
7
|
|
|
300,000
|
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
0
|
|
|
|
0
|
|
Renald & Catherine Anelle
|
|
|
80,000
|
|
|
|
40,000
|
|
|
|
40,000
|
|
|
|
0
|
|
|
|
0
|
|
Aaron Appel
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Barclay Armitage
|
|
|
28,000
|
|
|
|
14,000
|
|
|
|
14,000
|
|
|
|
0
|
|
|
|
0
|
|
B & H Electronics (H.K.) Limited
8
|
|
|
1,000,000
|
|
|
|
500,000
|
|
|
|
500,000
|
|
|
|
0
|
|
|
|
0
|
|
Michael & Julie Barber
9
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Kari D. Battles
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Bell Family Trust dated 2/2/1995 as Amended,
Hester L. Bell Trustee
10
|
|
|
400,000
|
|
|
|
200,000
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0
|
|
Bell Family Trust dated 2/2/1995 as Amended,
Lon E. Bell Trustee
11
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
David W. & Clelia D. Bernhardt
12
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Bialla & Associates Inc. Pension and
Profit Sharing Plan
13
|
|
|
149,262
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
49,262
|
|
|
|
*
|
|
Alan Bilzi
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Bionic Partners, LLC
14
|
|
|
6,771,737
|
|
|
|
2,445,000
|
|
|
|
2,445,000
|
|
|
|
1,881,737
|
|
|
|
2.4
|
%
|
Jonathan & Gina Blatt
15
|
|
|
169,810
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
69,810
|
|
|
|
*
|
|
David Blau
|
|
|
1,250,000
|
|
|
|
500,000
|
|
|
|
750,000
|
|
|
|
0
|
|
|
|
0
|
|
Christopher J. and Denise M. Blum
16
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Gregory J. & Heidi H. Borca
17
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
David Daniel Boren
18
|
|
|
84,445
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
44,445
|
|
|
|
*
|
|
Kenneth W. Borgnino
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
Andrew S. Brenner
|
|
|
450,000
|
|
|
|
200,000
|
|
|
|
250,000
|
|
|
|
0
|
|
|
|
0
|
|
Brian J. Brille
|
|
|
500,000
|
|
|
|
250,000
|
|
|
|
250,000
|
|
|
|
0
|
|
|
|
0
|
|
Brio Capital Master Fund Ltd.
19
|
|
|
800,000
|
|
|
|
400,000
|
|
|
|
400,000
|
|
|
|
0
|
|
|
|
0
|
|
Sergey Brudanin
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Robert Burkhardt
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
John Busby
|
|
|
500,000
|
|
|
|
200,000
|
|
|
|
300,000
|
|
|
|
0
|
|
|
|
0
|
|
Capital Ventures International
20
|
|
|
300,000
|
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
0
|
|
|
|
0
|
|
Scott Cardone
21
|
|
|
16,006
|
|
|
|
0
|
|
|
|
16,006
|
|
|
|
0
|
|
|
|
0
|
|
Gregg E. Chaplin
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
O. Stuart Chase
22
|
|
|
150,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Daniel B. Chestler
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Choi Family Trust dated March 15, 2001
23
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Joon Nak Choi
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Claude M. Penchina Revocable Family Trust
24
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Selling Stockholder
|
|
Shares of
common stock
Beneficially
owned Prior to
the Offering
|
|
|
Shares of
common
stock owned
Prior to this
Offering and
Registered
hereby
|
|
|
Shares
Issuable Upon
Exercise of
Warrants
owned Prior to
this Offering
and Registered
hereby
1
|
|
|
Shares of
common
stock
Beneficially
Owned Upon
Completion
of the
Offering
2
|
|
|
Percentage of
Common
Stock
Beneficially
Owned Upon
Completion
of the
Offering
3
|
|
Clem, LLC
25
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Joseph Codi
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Richard D.Cohen
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Marc Cohn & Sally Rogoff Cohn
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
Lee Harrison Corbin
|
|
|
225,000
|
|
|
|
100,000
|
|
|
|
125,000
|
|
|
|
0
|
|
|
|
0
|
|
Howard Cowan
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Chris Cozzolino
26
|
|
|
16,698
|
|
|
|
0
|
|
|
|
16,698
|
|
|
|
0
|
|
|
|
0
|
|
D. Jonathan Merriman Trust
27
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
David S. Uri Revocable Trust dated 12/7/2001
28
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Mark D’Azeveo
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Dafna Lifescience LP
29
|
|
|
346,400
|
|
|
|
173,200
|
|
|
|
173,200
|
|
|
|
0
|
|
|
|
0
|
|
Dafna Lifescience Market Neutral LP
30
|
|
|
74,400
|
|
|
|
37,200
|
|
|
|
37,200
|
|
|
|
0
|
|
|
|
0
|
|
Dafna Lifescience Select LP
31
|
|
|
579,200
|
|
|
|
289,600
|
|
|
|
289,600
|
|
|
|
0
|
|
|
|
0
|
|
David M. Rickey Trust dated May 8, 2002
32
|
|
|
75,000
|
|
|
|
30,000
|
|
|
|
45,000
|
|
|
|
0
|
|
|
|
0
|
|
Dave Rickey & Daughters Foundation
Charitable Trust
33
|
|
|
50,000
|
|
|
|
20,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Robert Dayton II
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Paul DeFeo
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Michael R. Diaz
|
|
|
75,000
|
|
|
|
37,500
|
|
|
|
37,500
|
|
|
|
0
|
|
|
|
0
|
|
Alfred J. DiFiore, Jr.
|
|
|
20,000
|
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
0
|
|
|
|
0
|
|
Robert W. Dilfer
34
|
|
|
103,625
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
53,625
|
|
|
|
*
|
|
Theodore G. Dimitry
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Barrett S. DiPaolo
35
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Carl J. Domino
|
|
|
250,000
|
|
|
|
100,000
|
|
|
|
150,000
|
|
|
|
0
|
|
|
|
0
|
|
Due Mondi Investments, Ltd.
36
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Stephen Dusterdick
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Jonas A. Edstrom
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
EFD Capital Inc.
37
|
|
|
137,158
|
|
|
|
0
|
|
|
|
137,158
|
|
|
|
0
|
|
|
|
0
|
|
Thomas Eisenberg
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
EMAC SRL
38
|
|
|
700,000
|
|
|
|
350,000
|
|
|
|
350,000
|
|
|
|
0
|
|
|
|
0
|
|
Suzanne B. Engel
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
F&M Star Alliance
39
|
|
|
500,000
|
|
|
|
250,000
|
|
|
|
250,000
|
|
|
|
0
|
|
|
|
0
|
|
Four JR Investments Ltd.
40
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Irwin James and Karen Kay Frankel
41
|
|
|
1,000,000
|
|
|
|
500,000
|
|
|
|
500,000
|
|
|
|
0
|
|
|
|
0
|
|
Robert David Frankel
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Charles Freeland
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Leon Frenkel
42
|
|
|
200,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
David Frydrych
|
|
|
220,000
|
|
|
|
110,000
|
|
|
|
110,000
|
|
|
|
0
|
|
|
|
0
|
|
John D. Gibbs
|
|
|
800,000
|
|
|
|
400,000
|
|
|
|
400,000
|
|
|
|
0
|
|
|
|
0
|
|
Gibralt Capital Corporation
43
|
|
|
1,125,000
|
|
|
|
500,000
|
|
|
|
625,000
|
|
|
|
0
|
|
|
|
0
|
|
Gottbetter Capital Markets, LLC
44
|
|
|
620,912
|
|
|
|
0
|
|
|
|
620,912
|
|
|
|
0
|
|
|
|
0
|
|
Selling Stockholder
|
|
Shares of
common stock
Beneficially
owned Prior to
the Offering
|
|
|
Shares of
common
stock owned
Prior to this
Offering and
Registered
hereby
|
|
|
Shares
Issuable Upon
Exercise of
Warrants
owned Prior to
this Offering
and Registered
hereby
1
|
|
|
Shares of
common
stock
Beneficially
Owned Upon
Completion
of the
Offering
2
|
|
|
Percentage of
Common
Stock
Beneficially
Owned Upon
Completion
of the
Offering
3
|
|
Gottbetter Capital Group, Inc.
45
|
|
|
650,060
|
|
|
|
25,000
|
|
|
|
50,000
|
|
|
|
575,060
|
|
|
|
*
|
|
Peter C. Gould
|
|
|
62,500
|
|
|
|
25,000
|
|
|
|
37,500
|
|
|
|
0
|
|
|
|
0
|
|
Jonathan P. & Laura Greene
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Murray W. Grigg
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Irwin Gruverman
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Gubbay Investments, LLC
46
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
H Investment Company LLC
47
|
|
|
500,000
|
|
|
|
200,000
|
|
|
|
300,000
|
|
|
|
0
|
|
|
|
0
|
|
Jay Haft
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Larry Haimovitch
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Marilyn Hamilton
48
|
|
|
492,063
|
|
|
|
200,000
|
|
|
|
200,000
|
|
|
|
92,063
|
|
|
|
*
|
|
Kimberly Hanley
49
|
|
|
2,197
|
|
|
|
0
|
|
|
|
2,197
|
|
|
|
0
|
|
|
|
0
|
|
Hannah Rose Holdings, LLC
50
|
|
|
50,000
|
|
|
|
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
|
|
Brad Harkavy
|
|
|
20,000
|
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
0
|
|
|
|
0
|
|
Robert W. Harrigan
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Todd Harrigan
51
|
|
|
68,400
|
|
|
|
0
|
|
|
|
68,400
|
|
|
|
0
|
|
|
|
0
|
|
Jeffrey W. & Tamara L. Hayzlett
52
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Hedge Capital Partners LLC
53
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Helmsbridge Holdings Limited
54
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Tim Hermann
55
|
|
|
43,698
|
|
|
|
0
|
|
|
|
43,698
|
|
|
|
0
|
|
|
|
0
|
|
Thomas A. Hillman
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Byron C. Hughey
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Daniel W. and Allaire Hummel
|
|
|
90,000
|
|
|
|
45,000
|
|
|
|
45,000
|
|
|
|
0
|
|
|
|
0
|
|
Alan and Patricia Hunstock
56
|
|
|
247,790
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
147,790
|
|
|
|
*
|
|
Andre Iseli
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Alec Jaret
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
John P. Funkey Revocable Trust dtd 2/26/96
57
|
|
|
32,000
|
|
|
|
16,000
|
|
|
|
16,000
|
|
|
|
0
|
|
|
|
0
|
|
Jonathan & Gina Blatt Children's Trust
58
|
|
|
58,608
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
18,608
|
|
|
|
*
|
|
Jong T. Choi, Roth IRA
59
|
|
|
400,000
|
|
|
|
200,000
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0
|
|
Howard A. & Susan Kalka
60
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Peter Scott Kastner
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Richard T. Kingston Jr.
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Mackie Klingbeil
|
|
|
225,000
|
|
|
|
100,000
|
|
|
|
125,000
|
|
|
|
0
|
|
|
|
0
|
|
Timothy M. Klohck
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Peter M. Knapp, Jr.
|
|
|
70,000
|
|
|
|
35,000
|
|
|
|
35,000
|
|
|
|
0
|
|
|
|
0
|
|
Ryan Konik
61
|
|
|
17,940
|
|
|
|
0
|
|
|
|
17,940
|
|
|
|
0
|
|
|
|
0
|
|
Stuart Krieger
|
|
|
300,000
|
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
0
|
|
|
|
0
|
|
John C. Kroening
|
|
|
70,000
|
|
|
|
35,000
|
|
|
|
35,000
|
|
|
|
0
|
|
|
|
0
|
|
Elizabeth Kweon
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Bill G. Lance
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
David Landskowsky
62
|
|
|
101,080
|
|
|
|
0
|
|
|
|
101,080
|
|
|
|
0
|
|
|
|
0
|
|
William S. Lapp
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Selling Stockholder
|
|
Shares of
common stock
Beneficially
owned Prior to
the Offering
|
|
|
Shares of
common
stock owned
Prior to this
Offering and
Registered
hereby
|
|
|
Shares
Issuable Upon
Exercise of
Warrants
owned Prior to
this Offering
and Registered
hereby
1
|
|
|
Shares of
common
stock
Beneficially
Owned Upon
Completion
of the
Offering
2
|
|
|
Percentage of
Common
Stock
Beneficially
Owned Upon
Completion
of the
Offering
3
|
|
Angela Layton
63
|
|
|
179,623
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
139,623
|
|
|
|
*
|
|
Lee J. Seidler Revocable Trust dtd April
12, 1990
64
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Craig L. Leipold
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Jonathan Kyle Leipold
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Mark Leopold
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
David Eliot Levin and Julie Scarpelli
65
|
|
|
74,629
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
24,629
|
|
|
|
*
|
|
Michael Levine
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Roman Livson
66
|
|
|
32,700
|
|
|
|
0
|
|
|
|
32,700
|
|
|
|
0
|
|
|
|
0
|
|
Eliezer Lubitch
|
|
|
400,000
|
|
|
|
200,000
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0
|
|
Lauren Lung
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Rod Manning
67
|
|
|
149,262
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
49,262
|
|
|
|
*
|
|
Joseph O. Manzi
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Mark Pacchini Rev. Living Trust dtd 8/21/92
68
|
|
|
150,000
|
|
|
|
75,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Martillo Finance Ltd.
69
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Mat 9 LLC
70
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Edward T. Maurer
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
Lindsey McGrandy
71
|
|
|
1,884
|
|
|
|
0
|
|
|
|
1,884
|
|
|
|
0
|
|
|
|
0
|
|
Charles & Diane Medici
72
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Merker Family LP
73
|
|
|
20,000
|
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
0
|
|
|
|
0
|
|
Meryle Evans Family Trust
74
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Oliver Mitchell
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Andrea I. Nathanson
75
|
|
|
5,000
|
|
|
|
2,500
|
|
|
|
2,500
|
|
|
|
0
|
|
|
|
0
|
|
Nervi Immobiliare SRL
76
|
|
|
500,000
|
|
|
|
250,000
|
|
|
|
250,000
|
|
|
|
0
|
|
|
|
0
|
|
Nexus Direct IRA, LLC FBO John Cotter IRA
#09-111251
77
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Northlea Partners, LLLP
78
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
Gilbert S. Omenn
|
|
|
140,000
|
|
|
|
70,000
|
|
|
|
70,000
|
|
|
|
0
|
|
|
|
0
|
|
Opaleye L.P.
79
|
|
|
17,000,000
|
|
|
|
8,500,000
|
|
|
|
8,500,000
|
|
|
|
0
|
|
|
|
0
|
|
OpusPoint Healthcare Innovations Fund L.P.
80
|
|
|
800,000
|
|
|
|
400,000
|
|
|
|
400,000
|
|
|
|
0
|
|
|
|
0
|
|
Lukas and Joanna Partridge
81
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Pauline M. Howard Trust, Candy D'Azevedo
TTEE
82
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Malcolm Plett
83
|
|
|
16,000
|
|
|
|
0
|
|
|
|
16,000
|
|
|
|
0
|
|
|
|
0
|
|
Karl and Kelly Post
84
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Itai Preis
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
Martin Prinz
85
|
|
|
48,408
|
|
|
|
0
|
|
|
|
36,408
|
|
|
|
12,000
|
|
|
|
*
|
|
William C. Purdon
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Stan Rabinovich
86
|
|
|
330,000
|
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
0
|
|
|
|
0
|
|
Scott Rapfogel
87
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Sofin Raskin
|
|
|
400,000
|
|
|
|
200,000
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0
|
|
Selling Stockholder
|
|
Shares of
common stock
Beneficially
owned Prior to
the Offering
|
|
|
Shares of
common
stock owned
Prior to this
Offering and
Registered
hereby
|
|
|
Shares
Issuable Upon
Exercise of
Warrants
owned Prior to
this Offering
and Registered
hereby
1
|
|
|
Shares of
common
stock
Beneficially
Owned Upon
Completion
of the
Offering
2
|
|
|
Percentage of
Common
Stock
Beneficially
Owned Upon
Completion
of the
Offering
3
|
|
Stan Rabinovich, C/F Benjamin
Rabinovich UTMA
88
|
|
|
20,000
|
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
0
|
|
|
|
0
|
|
Stan Rabinovich, C/F Jordan Rabinovich
UTMA
89
|
|
|
20,000
|
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
0
|
|
|
|
0
|
|
Stan Rabinovich, C/F Mia Rabinovich UTMA
90
|
|
|
20,000
|
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
0
|
|
|
|
0
|
|
Ramat Family Trust
91
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
William and Susan Reinhart
92
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Stephen A. Renaud
93
|
|
|
850,202
|
|
|
|
0
|
|
|
|
850,202
|
|
|
|
0
|
|
|
|
0
|
|
Haig Rickerby
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
RMR Wealth Management, LLC
94
|
|
|
67,725
|
|
|
|
0
|
|
|
|
67,725
|
|
|
|
0
|
|
|
|
0
|
|
Kevin Roe
95
|
|
|
99,262
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
49,262
|
|
|
|
*
|
|
Steve Roe
96
|
|
|
99,262
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
49,262
|
|
|
|
*
|
|
Roland F. Hartman - Revocable Trust Agreement
between Roland F. Hartman and Roland T. Hartman Trust Dtd. 6/5/1998
97
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Frank Ronchetti
|
|
|
10,000
|
|
|
|
5,000
|
|
|
|
5,000
|
|
|
|
0
|
|
|
|
0
|
|
Sheldon Rose
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
Edward Rosenthal
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Lindsay A. Rosenwald
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Stanton J. Rowe
|
|
|
160,000
|
|
|
|
80,000
|
|
|
|
80,000
|
|
|
|
0
|
|
|
|
0
|
|
RS & VS Ltd.
98
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Eric Rubenstein
99
|
|
|
121,209
|
|
|
|
0
|
|
|
|
121,209
|
|
|
|
0
|
|
|
|
0
|
|
Jonathan Rubinstein & Amy Stevenson
100
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Sack Family Investment Fund
101
|
|
|
250,000
|
|
|
|
100,000
|
|
|
|
150,000
|
|
|
|
0
|
|
|
|
0
|
|
Charles A. Saenger
102
|
|
|
142,952
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
92,952
|
|
|
|
*
|
|
Leo C. Saenger, Jr.
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Leo C. Saenger, III
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Daniel Salvas
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Kally and Nick Savvas
103
|
|
|
10,000
|
|
|
|
5,000
|
|
|
|
5,000
|
|
|
|
0
|
|
|
|
0
|
|
Robert Schoenbacher
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Benjamin D. Schulman
|
|
|
62,500
|
|
|
|
25,000
|
|
|
|
37,500
|
|
|
|
0
|
|
|
|
0
|
|
Dean and Elisabeth Sebby
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Aaron Segal
104
|
|
|
29,580
|
|
|
|
0
|
|
|
|
29,580
|
|
|
|
0
|
|
|
|
0
|
|
Donald P. Sesterhenn
|
|
|
60,000
|
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0
|
|
Boris Shames
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Kevin L. Shearan
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Barry Shemaria
|
|
|
92,500
|
|
|
|
40,000
|
|
|
|
52,500
|
|
|
|
0
|
|
|
|
0
|
|
Samuel Sherman
105
|
|
|
750,000
|
|
|
|
300,000
|
|
|
|
450,000
|
|
|
|
0
|
|
|
|
0
|
|
Steven Sherman
106
|
|
|
2,500,000
|
|
|
|
1,000,000
|
|
|
|
1,500,000
|
|
|
|
0
|
|
|
|
0
|
|
Michael Silverman
107
|
|
|
867,703
|
|
|
|
0
|
|
|
|
850,203
|
|
|
|
17,500
|
|
|
|
*
|
|
Steven J. Silverman
|
|
|
900,000
|
|
|
|
450,000
|
|
|
|
450,000
|
|
|
|
0
|
|
|
|
0
|
|
Selling Stockholder
|
|
Shares of
common stock
Beneficially
owned Prior to
the Offering
|
|
|
Shares of
common
stock owned
Prior to this
Offering and
Registered
hereby
|
|
|
Shares
Issuable Upon
Exercise of
Warrants
owned Prior to
this Offering
and Registered
hereby
1
|
|
|
Shares of
common
stock
Beneficially
Owned Upon
Completion
of the
Offering
2
|
|
|
Percentage of
Common
Stock
Beneficially
Owned Upon
Completion
of the
Offering
3
|
|
Silverman Insurance Partnership
108
|
|
|
2,000,000
|
|
|
|
1,000,000
|
|
|
|
1,000,000
|
|
|
|
0
|
|
|
|
0
|
|
Terry J. Siman
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Simpson Family Trust
109
|
|
|
149,262
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
49,262
|
|
|
|
*
|
|
Casimir S. Skrzypczak
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
John D. Smith
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Richard E. Stites
|
|
|
125,000
|
|
|
|
50,000
|
|
|
|
75,000
|
|
|
|
0
|
|
|
|
0
|
|
David & Susan Stollwerk
110
|
|
|
62,500
|
|
|
|
25,000
|
|
|
|
37,500
|
|
|
|
0
|
|
|
|
0
|
|
William N. Strawbridge
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Clayton A. Struve
|
|
|
350,000
|
|
|
|
150,000
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0
|
|
Scott Summit
|
|
|
40,000
|
|
|
|
20,000
|
|
|
|
20,000
|
|
|
|
0
|
|
|
|
0
|
|
Brian and Karen Sundheim
111
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Swiftwater FOF, LLC
112
|
|
|
1,000,000
|
|
|
|
500,000
|
|
|
|
500,000
|
|
|
|
0
|
|
|
|
0
|
|
The Jonathan S. Bean Family Trust
113
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
The Wiesenberg Family Revocable Trust
114
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Mark Tompkins
115
|
|
|
5,072,348
|
|
|
|
1,779,768
|
|
|
|
1,500,000
|
|
|
|
1,792,580
|
|
|
|
2.3
|
%
|
Triage Capital Management L.P.
116
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Garretson B. Trudeau
|
|
|
350,000
|
|
|
|
150,000
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0
|
|
Venture Lending & Leasing VI, LLC
117
|
|
|
1,371,328
|
|
|
|
0
|
|
|
|
225,000
|
|
|
|
1,146,328
|
|
|
|
1.5
|
%
|
Andreas Von Buchwaldt
|
|
|
250,000
|
|
|
|
125,000
|
|
|
|
125,000
|
|
|
|
0
|
|
|
|
0
|
|
Linda K. Wadensten
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
John V. Wagner, Jr.
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Christopher Washburn
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
James L. & Carolyn J. Welch
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Lance A. White
118
|
|
|
97,842
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
47,842
|
|
|
|
*
|
|
Craig Whited
|
|
|
550,000
|
|
|
|
250,000
|
|
|
|
300,000
|
|
|
|
0
|
|
|
|
0
|
|
Michael L. & Solange Whitehead
119
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Jason M. Willis & Amanda K. Willis
120
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Michael L. & Sharon D. Willis
121
|
|
|
300,000
|
|
|
|
150,000
|
|
|
|
150,000
|
|
|
|
0
|
|
|
|
0
|
|
Jackson L. Wilson, Jr.
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Ariel & Ella Yarnitsky
|
|
|
200,000
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0
|
|
Thomas Zahavi
|
|
|
100,000
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
0
|
|
|
|
0
|
|
Dov Zakheim
|
|
|
50,000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
|
0
|
|
|
|
0
|
|
Stefan Ziegler
|
|
|
400,000
|
|
|
|
200,000
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0
|
|
Michael Zimmerman
|
|
|
30,000
|
|
|
|
15,000
|
|
|
|
15,000
|
|
|
|
0
|
|
|
|
0
|
|
Total
|
|
|
|
|
|
|
31,079,768
|
|
|
|
36,055,000
|
|
|
|
|
|
|
|
|
|
*Less than 1%
|
1
|
An aggregate of 36,055,000
of the shares of common stock being offered by the selling security holders are issuable
upon exercise of common stock purchase warrants.
|
|
2
|
Assumes
all of the shares of common stock to be registered on the registration statement of which
this prospectus is a part, including all shares of common stock underlying common stock
purchase warrants held by the selling stockholders, are sold in the offering and that
shares of common stock beneficially owned by such selling stockholder but not being registered
by this prospectus (if any) are not sold.
|
|
3
|
Percentages are based
on the 78,497,558 shares of common stock issued and outstanding as of the Determination
Date. Beneficial ownership is determined in accordance with the rules of the SEC and
generally includes voting or investment power with respect to securities. Shares of common
stock underlying shares of preferred stock, options or warrants currently exercisable
or convertible, or exercisable or convertible within 60 days after the Determination
Date are deemed outstanding for computing the percentage of the person holding such shares
of preferred stock, options or warrants but are not deemed outstanding for computing
the percentage of any other person.
|
|
4
|
Aleksander
Ablovatskiy is a former employee of Gottbetter & Partners, LLP, which serves as legal
counsel to the Company and is an affiliate of Gottbetter Capital Markets, LLC, a registered
broker-dealer.
|
|
5
|
Allan Lipkowitz is
the trustee of Allan Lipkowitz Revocable Living Trust UAD 8/26/2005 and has sole voting
and investment power over the shares owned thereby.
|
|
6
|
O.
Stuart Chase is the Headmaster Emeritus of Allen Chase Foundation and has sole voting
and investment power over the shares owned thereby.
|
|
7
|
Vadim
Pushkarev has Power of Attorney of Animeros Enterprises Limited and has sole voting and
investment power over the shares owned thereby.
|
|
8
|
Horst
J. Pudwill is the director of B&H Electronics (H K) Limited and has sole voting and
investment power over the shares owned thereby.
|
|
9
|
Michael
K. Barber and Julie K. Barber are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
|
10
|
Hester
L. Bell is the trustee of Bell Family Trust dated 2/2/1995 as Amended, Hester Bell Trustee
and has sole voting and investment power over the shares owned thereby.
|
|
11
|
Lon
E. Bell is the trustee of Bell Family Trust dated 2/2/1995 as Amended, Lon E. Bell Trustee
and has sole voting and investment power over the shares owned thereby.
|
|
12
|
David
W. Bernhardt and Clelia Bernhardt are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
|
13
|
Vito
Bialla is the Chief Executive Officer and trustee of Bialla & Associates, Inc. Pension
and Profit Sharing Plan and has sole voting and investment power over the shares owned
thereby. Shares beneficially owned includes shares which do not relate to shares purchased
in the 2014 Offering as well as warrants to purchase 2,270 shares of common stock.
|
|
14
|
Hugh
Regan is the Manager of Bionic Partners, LLC and has sole voting and investment power
over the shares owned thereby. Shares beneficially owned includes shares which do not
relate to shares purchased in the 2014 Offering.
|
|
15
|
Shares beneficially
owned includes shares held by Jonathan & Gina Blatt which do not relate to shares
purchased in the 2014 Offering.
|
|
16
|
Christopher
J. Blum and Denise M. Blum are joint tenants with right of survivorship and have equal
voting and investment power over the shares owned thereby.
|
|
17
|
Gregory
J. Borca and Heidi H. Borca are joint tenants and have equal voting and investment power
over the shares owned thereby.
|
|
18
|
David
Daniel Boren is a member of the Board of Directors of the Company. Shares beneficially
owned includes options to purchase 44,445 of Common Stock currently exercisable or exercisable
within 60 days of the Determination Date, warrants to purchase 20,000 shares of Common
Stock currently exercisable and 20,000 shares of common stock.
|
|
19
|
Shaye
Hirsch is the director of Brio Capital Master Fund Ltd. and has sole voting and investment
power over the shares owned thereby.
|
|
20
|
Martin
Kobinger is the investment manager of Heights Capital Management, Inc., the authorized
agent of Capital Ventures International, and has sole voting and investment power over
the shares owned thereby.
|
|
21
|
Scott
Cardone is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Cardone received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
22
|
Shares beneficially
owned includes shares and warrants of Allen Chase Foundation for which O. Stuart Chase
has sole voting and investment power over the shares owned thereby.
|
|
23
|
Jong
Tae Choi is the custodian of Choi Family Trust dated March 15, 2001 and has sole voting
and investment power over the shares owned thereby.
|
|
24
|
Claude
M. Penchina is the trustee of Claude M. Penchina Revocable Trust and has sole voting
and investment power over the shares held thereby.
|
|
25
|
Carl
Bildner is the Member of Clem LLC and has sole voting and investment power over the shares
owned thereby.
|
|
26
|
Christopher
Cozzolino is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Cozzolino received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
27
|
David
Jonathan Merriman is the trustee of D. Jonathan Merriman Trust and has sole voting and
investment power over the shares owned thereby.
|
|
28
|
David
S. Uri is the trustee of David S. Uri Revocable Trust dated 12/7/2001 and has sole voting
and investment power over the shares owned thereby.
|
|
29
|
Nathan
Fischel is the Chief Executive Officer and Fariba Ghodsian is the Chief Investment Officer
of Dafna Lifescience Ltd. and they have joint voting and investment power over the shares
owned thereby.
|
|
30
|
Nathan
Fischel is the Chief Executive Officer and Fariba Ghodsian is the Chief Investment Officer
of Dafna Lifescience Market Neutral Ltd. and they have joint voting and investment power
over the shares owned thereby.
|
|
31
|
Nathan
Fischel is the Chief Executive Officer and Fariba Ghodsian is the Chief Investment Officer
of Dafna Lifescience Select Ltd. and they have joint voting and investment power over
the shares owned thereby.
|
|
32
|
David
Martin Rickey is the trustee of David M. Rickey Trust dated May 8, 2002 and has sole
voting and investment power over the shares owned thereby.
|
|
33
|
David
Martin Rickey is the trustee of Dave Rickey & Daughters Foundation Charitable Trust
and has sole voting and investment power over the shares owned thereby.
|
|
34
|
Robert
Dilfer is a financial consultant for the Company. Shares beneficially owned includes
shares which do not relate to shares purchased in the 2014 Offering as well as warrants
to purchase 1,359 shares of common stock.
|
|
35
|
Barrett
S. DiPaolo is an employee of Gottbetter & Partners, LLP, which serves as legal counsel
to the Company and is an affiliate of Gottbetter Capital Markets, LLC, a registered broker-dealer.
|
|
36
|
Robert
S. Beadle is the President of Due Mondi Investments, Ltd. and has sole voting and investment
power over the shares owned thereby.
|
|
37
|
Barbara
J. Glenns is the President of EFD Capital Inc. Ms. Glenns is an affiliate of a broker-dealer
which acted as placement agent in the 2014 Offering. Ms. Glenns received the warrants
in the ordinary course of business for her own account and, at the time of receipt, had
no agreements or understandings with any person, directly or indirectly, to further distribute
the securities.
|
|
38
|
Mario
Camia is the Chief Executive Officer of EMAC SRL and has sole voting and investment power
over the shares owned thereby.
|
|
39
|
Roman
Ryzkhov is the Managing Member of F&M Star Alliance, Inc. and has sole voting and
investment power over the shares owned thereby.
|
|
40
|
Robert
D. Burke, MD is the General Partner of Four JR Investments Ltd. and has sole voting and
investment power over the shares owned thereby.
|
|
41
|
Irwin
J. Frankel and Karen Frankel are joint tenants and have equal voting and investment power
over the shares owned thereby.
|
|
42
|
Shares
beneficially owned includes shares and warrants of Triage Capital Management L.P. for
which Leon Frenkel has sole voting and investment power over the shares owned thereby.
|
|
43
|
Ryan
Chen is the Chief Financial Officer of Gibralt Capital Corporation and has sole voting
and investment power over the shares owned thereby.
|
|
44
|
Julio
A. Marquez is the President of Gottbetter Capital Markets, LLC and has sole voting and
investment power over the shares owned thereby. Gottbetter Capital Markets, LLC is a
registered broker-dealer which acted as placement agent for the 2014 Offering. Gottbetter
Capital Markets LLC received the warrants as compensation for investment banking services.
|
|
45
|
Adam
S. Gottbetter is the President of Gottbetter Capital Group, Inc. and has sole voting
and investment power over the shares held thereby. Gottbetter Capital Group, Inc. is
an affiliate of Gottbetter Capital Markets, LLC which served as placement agent for the
2014 Offering. Mr. Gottbetter is the Managing Partner of Gottbetter & Partners, LLP,
which serves as legal counsel to the Company. Shares beneficially owned includes shares
held by Gottbetter Capital Group, Inc. which do not relate to shares purchased in the
2014 Offering.
|
|
46
|
David
Gubbay is the Manager of Gubbay Investments, LLC and has sole voting and investment power
over the shares held thereby.
|
|
47
|
Pamela
M. Baker is the Manager of H Investment Company LLC and has sole voting and investment
power over the shares held thereby.
|
|
48
|
Marilyn
Hamilton is a member of the Board of Directors of the Company. Shares beneficially owned
includes options to purchase 92,063 of Common Stock currently exercisable or exercisable
within 60 days of the Determination Date, warrants to purchase 200,000 shares of Common
Stock currently exercisable and 200,000 shares of common stock.
|
|
49
|
Kimberly
Hanley is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Ms. Hanley received the warrants in the ordinary course of business for her own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
50
|
Matthew
Rosenblum is the Managing Member of Hannah Rose Holdings LLC and has sole voting and
investment power over the shares held thereby.
|
|
51
|
Todd
Harrigan is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Harrigan received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
52
|
Jeffrey
W. Hayzlett and Tamara Hayzlett are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
|
53
|
Allan
Rothstein is the Managing Member of Hedge Capital Partners LLC and has sole voting and
investment power over the shares held thereby.
|
|
54
|
Anthony
Heller is the President of Helmsbridge Holdings Limited and has sole voting and investment
power over the shares held thereby.
|
|
55
|
Tim
Hermann is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Hermann received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
56
|
Shares
beneficially owned includes shares which do not relate to shares purchased in the 2014
Offering as well as warrants to purchase 8,163 shares of common stock held by The Hunstock
Living Trust dtd. July 18, 1995 for which Alan Hunstock is the trustee and has sole voting
and investment power over the shares held thereby.
|
|
57
|
John
P. Funkey is the trustee of John P. Funkey Revocable Trust dtd 2/26/96 and has sole voting
and investment power over the shares held thereby.
|
|
58
|
H.
Joshua Blatt is the trustee of Jonathan & Gina Blatt Children’s Trust and has
sole voting and investment power over the shares owned thereby. Shares beneficially owned
includes shares held by Jonathan & Gina Blatt Children’s Trust which do not
relate to shares purchased in the 2014 Offering.
|
|
59
|
Jong
T. Choi is the custodian of Jong T. Choi Roth IRA and has sole voting and investment
power over the shares owned thereby.
|
|
60
|
Howard
A. Kalka and Susan Kalka are tenants in common and have equal voting and investment power
over the shares held thereby.
|
|
61
|
Ryan
Konik is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Konik received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
62
|
David
Landskowsky is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Landskowsky received the warrants in the ordinary course of business for his own
account and, at the time of receipt, had no agreements or understandings with any person,
directly or indirectly, to further distribute the securities.
|
|
63
|
Shares beneficially
owned include shares held by Angela Layton which do not relate to shares purchased in
the 2014 Offering.
|
|
64
|
Lee
J. Seidler is the trustee of Lee J. Seidler Revocable Trust dtd April 12, 1990 and has
sole voting and investment power over the shares held thereby.
|
|
65
|
Shares beneficially
owned include shares held by David Eliot Levin and Juliet Scarpelli which do not relate
to shares purchased in the 2014 Offering as well as warrants to purchase 1,359 shares
of common stock.
|
|
66
|
Roman
Livson is an affiliate of a broker-dealer which acted as placement agent in the 2014
Offering. Mr. Livson received the warrants in the ordinary course of business for his
own account and, at the time of receipt, had no agreements or understandings with any
person, directly or indirectly, to further distribute the securities.
|
|
67
|
Shares beneficially
owned includes shares held by Rod Manning which do not relate to shares purchased in
the 2014 Offering as well as warrants to purchase 2,720 shares of common stock.
|
|
68
|
Mark
Pacchini is the trustee of Mark Pacchini Rev. Living Trust dtd 8/21/92 and has sole voting
and investment power over the shares owned thereby.
|
|
69
|
Paul
Conway is the Director of Martillo Finance Limited and has sole voting and investment
power over the shares owned thereby.
|
|
70
|
Ralph
Pastore is the Manager of Mat 9 LLC and has sole voting and investment power over the
shares owned thereby.
|
|
71
|
Lindsey
McGrandy is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Ms. McGrandy received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
72
|
Charles
Medici and Diane Medici are joint tenants and have equal voting and investment power
over the shares held thereby.
|
|
73
|
Robert
Merker is the Managing Member of the General Partner of Merker Family LP, and has sole
voting and investment power over the shares owned thereby.
|
|
74
|
Steven
Evans is the trustee of Meryle Evans Family Trust and has sole voting and investment
power over the shares held thereby.
|
|
75
|
Andrea
Nathanson is an employee of Gottbetter & Partners, LLP, which serves as legal counsel
to the Company and is an affiliate of Gottbetter Capital Markets, LLC, a registered broker-dealer.
|
|
76
|
Mario
Camia is the Chief Executive Officer of Nervi Immobiliare SRL and has sole voting and
investment power over the shares owned thereby.
|
|
77
|
John
Cotter is the custodian of Nexus Direct IRA, LLC FBO John Cotter IRA #09-111251 and has
sole voting and investment power over the shares owned thereby.
|
|
78
|
John
H. Abeles is the Manager of the General Partner of Northlea Partners LLLP and has sole
voting and investment power over the shares held thereby.
|
|
79
|
James
Silverman is the Managing Director of Opaleye, L.P. and has sole voting and investment
power over the shares owned thereby.
|
|
80
|
Michael
Weiss is the Manager of the General Partner of Opus Point Healthcare Innovations Fund
LP and has sole voting and investment power over the shares held thereby.
|
|
81
|
Lukas
Partridge and Joanna Partridge are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
|
82
|
Cathy
D'Azevedo Bathon is the trustee of Pauline M. Howard Trust and has sole voting and investment
power over the shares owned thereby.
|
|
83
|
Malcolm
Plett is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Plett received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
84
|
Karl
Stephen Post and Kelly Lynn Post are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
|
85
|
Martin
Prinz is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Prinz received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
86
|
Shares
beneficially owned includes shares of Stan Rabinovich c/f Benjamin Rabinovich UTMA, Stan
Rabinovich c/f Jordan Rabinovich UTMA and Stan Rabinovich c/f Mia Rabinovich UTMA for
which Stan Rabinovich is the custodian and has sole voting and investment power over
the shares held thereby.
|
|
87
|
Scott
Rapfogel is an employee of Gottbetter & Partners, LLP, which serves as legal counsel
to the Company and is an affiliate of Gottbetter Capital Markets, LLC, a registered broker-dealer.
|
|
88
|
Stan
Rabinovich is the custodian and has sole voting and investment power over the shares
held thereby.
|
|
89
|
Stan
Rabinovich is the custodian and has sole voting and investment power over the shares
held thereby.
|
|
90
|
Stan
Rabinovich is the custodian and has sole voting and investment power over the shares
held thereby.
|
|
91
|
Charles
S. Ramat is the trustee of Ramat Family Trust and has sole voting and investment power
over the shares held thereby.
|
|
92
|
William
L. Reinhardt and Susan I. Reinhardt are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
|
93
|
Stephen
A. Renaud is an affiliate of a broker-dealer which acted as placement agent in the 2014
Offering. Mr. Renaud received the warrants in the ordinary course of business for his
own account and, at the time of receipt, had no agreements or understandings with any
person, directly or indirectly, to further distribute the securities.
|
|
94
|
Philip
Rabinovich is the Managing Partner of RMR Wealth Management, LLC and has sole voting
and investment control over the shares held thereby. RMR Wealth Management, LLC is a
registered investment advisor. RMR Wealth Management, LLC received the warrants as compensation
for investment advisory services.
|
|
95
|
Shares beneficially
owned includes shares held by Kevin Roe which do not relate to shares purchased in the
2014 Offering as well as warrants to purchase 2,720 shares of common stock.
|
|
96
|
Shares beneficially
owned includes shares held by Steve Roe which do not relate to shares purchased in the
2014 Offering as well as warrants to purchase 2,720 shares of common stock.
|
|
97
|
Roland
F. Hartman is the trustee of Roland F. Hartman - Revocable Trust between Roland F. Hartman
and Roland T. Hartman Trust Dtd. 6/5/1998 and has sole voting and investment power over
the shares owned thereby.
|
|
98
|
Rodney
N. Schorlemmer is the Manager of RS & VS Ltd. and has sole voting and investment
power over the shares held thereby.
|
|
99
|
Eric
Rubenstein is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Rubenstein received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
100
|
Jonathan
Rubinstein and Amy Stevenson are joint tenants and have equal voting and investment power
over the shares owned thereby.
|
|
101
|
Burton
M. Sack is the Managing Member of Sack Family Investment Fund and has sole voting and
investment power over the shares held thereby.
|
|
102
|
Shares
beneficially owned includes shares held by Charles Saenger which do not relate to shares
purchased in the 2014 Offering.
|
|
103
|
Nick
Savvas and Kally Savvas are joint tenants and have equal voting and investment power
over the shares owned thereby. Kally Savvas is an employee of Gottbetter & Partners,
LLP, which serves as legal counsel to the Company and is an affiliate of Gottbetter Capital
Markets, LLC, a registered broker-dealer.
|
|
104
|
Aaron
Segal is an affiliate of a broker-dealer which acted as sub-agent in the 2014 Offering.
Mr. Segal received the warrants in the ordinary course of business for his own account
and, at the time of receipt, had no agreements or understandings with any person, directly
or indirectly, to further distribute the securities.
|
|
105
|
Samuel
Sherman is the brother of Steven Sherman, who serves as Chairman of the Board of Directors
of the Company.
|
|
106
|
Steven Sherman serves
as Chairman of the Board of Directors of the Company.
|
|
107
|
Michael
Silverman is an affiliate of a broker-dealer which acted as placement agent in the 2014
Offering. Mr. Silverman received the warrants in the ordinary course of business for
his own account and, at the time of receipt, had no agreements or understandings with
any person, directly or indirectly, to further distribute the securities.
|
|
108
|
James
Silverman is the trustee of Silverman Insurance Partnership and has sole voting and investment
power over the shares owned thereby.
|
|
109
|
Paul
V. Simpson is the trustee of Simpson Family Trust and has sole voting and investment
power over the shares owned thereby. Shares beneficially owned includes shares held by
Simpson Family Trust which do not relate to shares purchased in the 2014 Offering and
warrants to purchase 2,720 shares of common stock.
|
|
110
|
David
Stollwerk and Susan Stollwerk are joint tenants and have equal voting and investment
power over the shares held thereby.
|
|
111
|
Brian
Sundheim and Karen Sundheim are joint tenants and have equal voting and investment power
over the shares held thereby.
|
|
112
|
Adele
Glenn Helmers is the Sole Managing Member of Swiftwater FOF, LLC and has sole voting
and investment power over the shares owned thereby.
|
|
113
|
Jonathan
S. Bean is the trustee of The Jonathan S. Bean Family Trust and has sole voting and investment
power over the shares held thereby.
|
|
114
|
James
H. Wiesenberg is the trustee of Wiesenberg Family Revocable Trust and has sole voting
and investment power over the shares held thereby.
|
|
115
|
Shares
beneficially owned includes shares held by Lance White which do not relate to shares
purchased in the 2014 Offering.
|
|
116
|
Leon
Frenkel is the Senior Manager of Triage Capital Management L.P. and has sole voting and
investment power over the shares held thereby.
|
|
117
|
Shares
beneficially owned includes shares held which do not relate to shares purchased in the
2014 Offering as well as warrants to purchase 29,466 shares of common stock. Shares beneficially
owned also consists of warrants received by Venture Lending & Leasing VI, LLC in
connection with its consent to the sale of the Bridge Notes and waiver of certain events
of default under the senior note payable agreement.
|
|
118
|
Shares
beneficially owned include shares held by Lance A. White which do not relate to shares
purchased in the 2014 Offering as well as warrants to purchase 1,359 shares of common
stock.
|
|
119
|
Michael
Whitehead and Solange Whitehead are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
|
120
|
Jason
Michael Willis and Amanda Kathryn Willis are joint tenants and have equal voting and
investment power over the shares owned thereby.
|
|
121
|
Michael
L. Willis and Sharon D. Willis are joint tenants and have equal voting and investment
power over the shares owned thereby.
|
USE OF PROCEEDS
We will not receive proceeds from sales
of common stock made under this prospectus.
DETERMINATION OF
OFFERING PRICE
There currently is a limited public market
for our common stock. The selling stockholders will determine at what price they may sell the offered shares, and such sales may
be made at prevailing market prices or at privately negotiated prices. See “Plan of Distribution” below for more information.
MARKET FOR COMMON
EQUITY AND RELATED STOCKHOLDER MATTERS
Market Information and Holders
Our common stock is currently eligible
for quotation and trades on the OTC Market under the symbol “EKSO.” The quotation of our common stock began on or
about January 17, 2014. There has been very limited trading in our common stock to date.
As of June 20, 2014, we had
78,497,558 shares of our common stock issued and outstanding held by approximately 313 stockholders of record. To date, we
have not paid dividends on our common stock.
We also have outstanding warrants to purchase
36,676,363 shares of our common stock, subject to adjustment in certain circumstances as provided therein. See “Description
of Securities” below.
The following table sets forth the high
and low closing bid prices for our common stock for the fiscal quarter indicated as reported on OTC Markets. The quotations reflect
inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions. Our common stock
is very thinly traded and, thus, pricing of our common stock on OTC Markets does not necessarily represent its fair market value.
Period
|
|
High
|
|
|
Low
|
|
|
|
|
|
|
|
|
Quarter ended March 31, 2014 (beginning January 17, 2014)
|
|
$
|
7.60
|
|
|
$
|
2.30
|
|
Quarter ending June 30, 2014 (through June 18, 2014)
|
|
|
3.42
|
|
|
|
2.15
|
|
Dividends
We have never paid any cash dividends
on our capital stock and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend
to retain future earnings to fund ongoing operations and future capital requirements. Any future determination to pay cash dividends
will be at the discretion of our Board of Directors and will be dependent upon financial condition, results of operations, capital
requirements and such other factors as the Board of Directors deems relevant. Other than provisions of the Nevada Revised Statutes
requiring post-dividend solvency according to certain measures, there are no material restrictions limiting, or that are likely
to limit, our ability to pay dividends on our common stock.
Securities Authorized for Issuance
under Equity Compensation Plans
The Company had no equity compensation
plans as of the end of fiscal year 2013.
On January 15, 2014, our Board of Directors
adopted, and our stockholders approved, our 2014 Equity Incentive Plan, which reserves a total of 14,410,000 shares of our common
stock for issuance pursuant to awards granted under the 2014 Plan.
As of June 20, 2014, options to
purchase an aggregate of 10,764,411 shares of our Common Stock have been issued and, options to purchase an aggregate of
10,353,887 shares of our Common Stock remain outstanding under the 2014 Plan. There are 4,004,479 shares available for future
awards. See “Description of Securities—Options” below for more information
.
As described below, incentive awards authorized
under the 2014 Plan include, but are not limited to, incentive stock options within the meaning of Section 422 of the internal
Revenue Code of 1986, as amended (the “Code”). If an award granted under the 2014 Plan expires, terminates, is unexercised
or is forfeited, or if any shares are surrendered to us in connection with the exercise of an incentive award, the shares subject
to such award and the surrendered shares will become available for further awards under the 2014 Plan.
The number of shares of our Common Stock
subject to the 2014 Plan, and any number of shares subject to any numerical limit in the 2014 Plan, to the terms of any incentive
award or to any combination of the foregoing, is expected to be adjusted in the event of any change in our outstanding our Common
Stock by reason of any stock dividend, spin-off, split-up, stock split, reverse stock split, recapitalization, reclassification,
merger, consolidation, liquidation, business combination or exchange of shares or similar transaction.
Administration
The Compensation Committee of the Board,
or the Board in the absence of such a committee, will administer the 2014 Plan. Subject to the terms of the 2014 Plan, the Compensation
Committee or the Board has complete authority and discretion to determine the terms upon which awards may be granted under the
2014 Plan.
Grants
The 2014 Plan authorizes the grant to
participants of nonqualified stock options, incentive stock options, restricted stock awards, restricted stock units, performance
grants intended to comply with Section 162(m) of the Code and stock appreciation rights, as described below:
|
·
|
Options
granted under the 2014 Plan entitle the grantee, upon exercise, to purchase up to a specified
number of shares from us at a specified exercise price per share. The exercise price
for shares of our Common Stock covered by an option generally cannot be less than the
fair market value of our Common Stock on the date of grant unless agreed to otherwise
at the time of the grant. In addition, in the case of an incentive stock option granted
to an employee who, at the time the incentive stock option is granted, owns stock representing
more than 10% of the voting power of all classes of stock of the Company or any parent
or subsidiary, the per share exercise price will be no less than 110% of the fair market
value of our Common Stock on the date of grant.
|
|
·
|
Restricted
stock awards and restricted stock units may be awarded on terms and conditions established
by the Compensation Committee, which may include performance conditions for restricted
stock awards and the lapse of restrictions on the achievement of one or more performance
goals for restricted stock units.
|
|
·
|
The
Compensation Committee may make performance grants, each of which will contain performance
goals for the award, including the performance criteria, the target and maximum amounts
payable, and other terms and conditions.
|
|
·
|
The
2014 Plan authorizes the granting of stock awards. The Compensation Committee will establish
the number of shares of our Common Stock to be awarded (subject to the aggregate limit
established under the 2014 Plan upon the number of shares of our Common Stock that may
be awarded or sold under the 2014 Plan) and the terms applicable to each award, including
performance restrictions.
|
|
·
|
Stock
appreciation rights (“SARs”) entitle the participant to receive a distribution
in an amount not to exceed the number of shares of our Common Stock subject to the portion
of the SAR exercised multiplied by the difference between the market price of a share
of our Common Stock on the date of exercise of the SAR and the market price of a share
of our Common Stock on the date of grant of the SAR.
|
Duration, Amendment, and Termination
The Board has the power to amend, suspend
or terminate the 2014 Plan without stockholder approval or ratification at any time or from time to time. No change may be made
that increases the total number of shares of our Common Stock reserved for issuance pursuant to incentive awards or reduces the
minimum exercise price for options or exchange of options for other incentive awards, unless such change is authorized by our
stockholders within one year of such change. Unless sooner terminated, the 2014 Plan would terminate ten years after it is adopted.
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following management’s discussion
and analysis should be read in conjunction with the historical financial statements and the related notes thereto contained in
this prospectus. The management’s discussion and analysis contains forward-looking statements, such as statements of our
plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking
statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,”
“estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,”
“may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking
statements. These forward-looking statements are subject to risks and uncertainties, including those under “Risk Factors”
in this prospectus, that could cause actual results or events to differ materially from those expressed or implied by the forward-looking
statements. The Company’s actual results and the timing of events could differ materially from those anticipated in these
forward-looking statements as a result of several factors. The Company does not undertake any obligation to update forward-looking
statements to reflect events or circumstances occurring after the date of this prospectus.
Overview
We have pioneered the field of human robotic
exoskeletons to augment human strength, endurance and mobility. The Company designs, develops and sells wearable robots, or “human
exoskeletons,” that have applications in medical, military, industrial, and consumer markets. Our exoskeletons systems are
strapped over the user’s clothing, enabling individuals with neurological conditions affecting gait (e.g., spinal cord injury
or stroke) to walk again; permitting soldiers to carry heavy loads for long distances while mitigating lower back, knee, and ankle
injuries; and allowing industrial workers to perform heavy duty work for extended periods.
Since we sold our first medical devices
in 2012, the Ekso GT
TM
, or “Ekso device” has been placed in use at six of the top 10 rehabilitation centers
in the United States ranked by U.S. News and World Report as among the best for addressing challenging cases and procedures in
surveys conducted with medical rehabilitation specialists in 2011, 2012 and 2013. As of March 31, 2014, we have sold over 60 devices
to rehabilitation centers and individual users for rehabilitation.
Our products have been listed with the
U.S. Food and Drug Administration (“FDA”) and have received a CE Mark (indicating compliance with European Union legislation).
We have established an extensive intellectual property portfolio that includes seven patents that have been granted, 20 patent
applications that are currently pending (which means a complete patent application has been filed with the applicable patent authority
and additional action is pending), and three provisional patents (which means that we have filed a short form application to establish
an early filing date in anticipation of completion and submission of a complete application). All but three of the patents are
either solely owned by or exclusively licensed to us. Many of these have also been filed internationally as appropriate for their
respective subject matter and have begun to issue. Our patent portfolio includes product and method type claims, since the devices
that we produce and the processes performed by those devices are patentable. Our patents encompass technologies relevant to our
devices, including medical exsoskeletons, commercial exsoskeletons, actuators, and strength-enhancing exsoskeletons. The earliest
priority date reaches back to 2003, and new applications continue to be filed.
The Company also has a collaborative partnership
with Lockheed Martin Corporation to develop products for military applications.
Ekso Labs is our engineering services
division and is primarily focused on technology development and future applications. In essence it is an exoskeleton laboratory
that continually integrates emerging technologies into new product applications and expands on it for our partners. Ekso Labs
is responsible for developing intellectual property through research grants from government organizations including United States
Special Operations Command, the Defense Advanced Research Projects Agency and the National Science Foundation.
Strategy
Our Company is about augmenting and enabling
human strength and endurance with machines. The intellectual property to do this in different vertical markets is created in our
Ekso Labs group. The first technology developed by this group was the Human Universal Load Carrier or “HULC” military
technology. The commercialization of that technology has been started by entering into a licensing arrangement with Lockheed Martin.
The second technology developed by this group was the Ekso GT medical technology. This technology’s commercialization has
been started by building an internal medical device business. It is our belief that the next step in the creation of a human exoskeleton
industry is to drive adoption in the medical business. Once that path has been clearly developed, other vertical markets, such
as industrial and consumer applications, can be commercialized.
Our long-term goal in the medical market
is to have one million persons stand and walk in Ekso
TM
exoskeletons by February 2022. We plan to achieve
this goal by focusing on selling our medical exoskeletons to rehabilitation centers and hospitals in the United States, Europe
and Asia. There are approximately 5,700 registered hospitals in the U.S., providing services to the 12,000 to 14,000 spinal cord
injury (“SCI”) incidences and approximately 650,000 persons who survive a stroke per year with approximately 7,000,000
persons who have survived a stroke. In Europe there are approximately 12,000 public and private hospitals, of which an estimated
4,600 are classified as acute care facilities.
We began working toward our goal with
the February 2012 sale of the first Ekso device, a human exoskeleton for people with complete SCIs. We have expanded that work
with the launch of our Variable Assist software and the announcement of our newest hardware platform, Ekso GT. The Variable Assist
software enables users with any amount of lower extremity strength to contribute their own power for either leg to achieve self-initiated
walking. The Ekso GT builds on the experience of the Ekso device and incorporates the Variable Assist, allowing us to expand our
sales and marketing efforts beyond SCI-focused centers to centers supporting stroke and other neurological disorders.
In addition to furthering the field of
exoskeletons that can lead to the commercialization of exoskeletons outside our current medical applications, Ekso Bionics’
development work furthers technology that is also potentially applicable for use in future models of the Ekso, including potentially
a unit for home use.
Critical Accounting Policies, Estimates,
and Judgments
Our consolidated financial statements
are prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses
during the reporting period. We continually evaluate our estimates and judgments, our commitments to strategic alliance partners
and the timing of the achievement of collaboration milestones. We base our estimates and judgments on historical experience and
other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances
change and additional information becomes known. Besides the estimates identified above that are considered critical, we make
many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed
critical, affect reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent assets and
liabilities. These estimates and judgments are also based on historical experience and other factors that are believed to be reasonable
under the circumstances. Materially different results can occur as circumstances change and additional information becomes known,
even for estimates and judgments that are not deemed critical.
Revenue and Cost of Revenue
When collaboration, other
research arrangements and product sales include multiple-element revenue arrangements, we account for these transactions by determining
the elements, or deliverables, included in the arrangement and determining which deliverables are separable for accounting purposes.
We consider delivered items to be separable if the delivered item(s) have stand-alone value to the customer and delivery or performance
of the undelivered item is considered probable and substantially in control of the vendor.
We recognize revenue when the four basic criteria of revenue
recognition are met:
|
·
|
Persuasive
evidence of an arrangement exists. Customer contracts and purchase orders are generally
used to determine the existence of an arrangement.
|
|
·
|
The
transfer of technology or products has been completed or services have been rendered.
Customer acceptance, when applicable, is used to verify delivery.
|
|
·
|
The
sales price is fixed or determinable. We assess whether the cost is fixed or determinable
based on the payment terms associated with the transaction and whether the sales price
is subject to refund or adjustment.
|
|
·
|
Collectability
is reasonably assured. We assess collectability based primarily on the creditworthiness
of the customer as determined by credit checks and analysis as well as the customer’s
payment history.
|
Beginning in 2012, with the commercialization
of the Ekso, we began to recognize revenue from the sales of the Ekso and related services, in addition to our historical revenue
streams including collaborative research and development service arrangements, technology license agreements, and government grants.
Medical Device Revenue and Cost of Revenue
We build medical devices called the Ekso
for sale and capitalize into inventory materials, direct and indirect labor and overhead in connection with the manufacture and
assembly of these units.
In a typical Ekso sales arrangement, we
are obligated to deliver to the customer the Ekso unit and related software (the software is essential to the unit’s functionality),
post-sale training, technical support and maintenance. Because of the uniqueness of the Ekso unit and its use, none of these deliverables
has standalone value to the customer. Accordingly, once a sales arrangement with a fixed or determinable price and reasonably
assured payment is in place, the entire sales price is accounted for as a single unit of accounting. The combined total sales
price for the delivered and undelivered elements is deferred and amortized to revenue beginning at the completion of training,
on a straight line basis over the maintenance period, usually three years, which is the last delivered item.
Because of the limited guidance about
how to account for costs associated with a delivered item that cannot be separated from the undelivered items, the accounting
for such costs must be based on the conceptual framework and analogies to the limited guidance that does exist. Accordingly, we
account for the costs of the delivered items following, by analogy, the guidance in Accounting Standards Codification (“ASC”)
310-20,
Nonrefundable Fees and Other Costs
(“ASC 310-20”). Under this guidance, upon completion of training,
the costs capitalized into inventory including direct material, direct and indirect labor, as well as overhead costs are deferred
and then amortized to cost of revenue on the same basis as deferred revenue. Indirect labor and overhead costs are included in
inventory because, under the conceptual framework, they add value to the Ekso unit and are otherwise appropriate inventory costs.
Since we have an enforceable contract for the remaining deliverables and the entire arrangement is expected to generate positive
margins, realization of the capitalized costs is probable and, as such, deferring and amortizing them on the same basis as deferred
revenue is appropriate.
At the time of shipment to the customer, the related inventory
is reclassified to deferred cost of revenue where it is amortized to cost of revenue over the same period that revenue is recognized.
All costs incurred subsequent to the date of shipment are expensed as incurred. The cost of medical device revenue includes expenses
associated with the manufacture and delivery of devices including materials, payroll, benefits, subcontractor expenses, depreciation
of manufacturing equipment, excess and obsolete inventory costs, and shipping charges.
Engineering Services Revenue and Cost of Revenue
We enter into technology license agreements
that typically provide for annual minimum access fees. When these annual minimum payments have separate stand-alone values, we
recognize revenue when the technology is transferred or accessed, provided that the technology transferred or accessed is not
dependent on the outcome of continuing engineering and/or other development efforts.
Collaborative arrangements typically consist
of cost reimbursements for specific engineering and development spending, and future product royalty payments. Cost reimbursements
for engineering and development spending are recognized as the related project labor hours are incurred in relation to all labor
hours and when collectability is reasonably assured. Amounts received in advance are recorded as deferred revenue until the technology
is transferred, services are rendered, or milestones are reached. Product royalty payments are recorded when earned under the
arrangement.
Government grants, which support our research
efforts in specific projects, generally provide for reimbursement of approved costs as defined in the notices of grant awards.
Grant revenue is recognized as the associated project labor hours are incurred in relation to total labor hours. There are some
grants, like the National Science Foundation grants, which we draw upon and spend based on budgets preapproved by the grantor.
The cost of engineering services revenue
includes payroll and benefits, subcontractor expenses and materials. All costs related to engineering services are expensed as
incurred and reported as cost of revenue.
Research and Development
Research and development costs consist
of costs incurred for our own internal research and development activities. These costs primarily include salaries and other personnel-related
expenses, contractor fees, facility costs, supplies, and depreciation of equipment associated with the design and development
of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.
Inventories, net
Inventories are recorded at the lower
of cost or market value. Cost is principally determined using the average cost method. Parts from vendors are received and recorded
as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component
is recorded as work in progress (“WIP”). Direct and indirect labor and applicable overhead costs are also allocated
and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company
periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand.
Excess and obsolete inventories would be recorded as an inventory impairment charge to consolidated statement of operations.
Stock-based Compensation
We measure stock-based compensation expense for all stock-based
awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes
option pricing model and recognize the fair value less estimated forfeitures, on a straight-line basis over the requisite service
periods of the awards. Stock-based awards made to non-employees are measured and recognized based on the estimated fair value
on the vesting date and are remeasured at each reporting period.
Our determination of the fair value of
stock-based awards on the date of grant using the Black-Scholes option pricing model is affected by our stock price as well as
assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our
expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.
Because there is insufficient information available to estimate the expected term of the stock-based awards, we adopted the simplified
method of estimating the expected term pursuant to SEC Staff Accounting Bulletin No. 110. On this basis, we estimated the expected
term of options granted by taking the average of the vesting term and the contractual term of the option.
We have, from time to time, modified the
terms of stock options granted to our employees. We account for the incremental increase in the fair value over the original award
on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards.
The incremental compensation cost is the excess of the fair value based measure of the modified award on the date of modification
over the fair value of the original award immediately before the modification.
Convertible Instruments
We account for hybrid contracts that feature
conversion options in accordance with generally accepted accounting principles in the United States. ASC 815,
Derivatives and
Hedging Activities
, (“ASC 815”) requires companies to bifurcate conversion options from their host instruments
and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances
in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related
to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded
derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting
principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as
the embedded derivative instrument would be considered a derivative instrument.
Conversion options that contain variable
settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities
at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host
instrument.
We account for convertible instruments
when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance
with ASC 470-20,
Debt with Conversion and Other Options
(“ASC 470-20”). Under ASC 470-20, we record, when necessary,
discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences
between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion
price embedded in the note. We account for convertible instruments (when we have determined that the embedded conversion options
should be bifurcated from their host instruments) in accordance with ASC 815. Under ASC 815, a portion of the proceeds
received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently
marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.
We also follow ASC 480-10,
Distinguishing
Liabilities from Equity
(“ASC 480-10”) in its evaluation of the accounting for a hybrid instrument. A financial
instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified
as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (i) a fixed monetary amount known at inception (for example, a payable settleable with a variable
number of the issuer’s equity shares); (ii) variations in something other than the fair value of the issuer’s equity
shares (for example, a financial instrument indexed to the Standard and Poor's S&P 500 Index and settleable with a variable
number of the issuer’s equity shares); or (iii) variations inversely related to changes in the fair value of the issuer’s
equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are
not further evaluated for any embedded derivatives, and are carried as a liability at fair value at each balance sheet date with
remeasurements reported in interest expense in the accompanying consolidated statements of operations.
Warrants Issued in Connection with
Financings
We generally account for warrants issued
in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to
issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants
issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record
the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income (expense)
in the Consolidated Statements of Operations.
Results of Operations
Three months ended March 31,
2014 and 2013
The following table presents our results
of operation for the periods indicated and as a percentage of total revenue. The period-to-period comparison of results is not
necessarily indicative of results for future periods.
|
|
Three
months ended March 31,
|
|
|
|
2014($)
|
|
|
2014(%)
(1)
|
|
|
2013($)
|
|
|
2013(%)
(1)
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
devices
|
|
$
|
526,753
|
|
|
|
50
|
%
|
|
$
|
332,919
|
|
|
|
48
|
%
|
Engineering services
|
|
|
534,958
|
|
|
|
50
|
|
|
|
363,330
|
|
|
|
52
|
|
Total revenue
|
|
|
1,061,711
|
|
|
|
100
|
|
|
|
696,249
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of medical
devices
|
|
|
330,125
|
|
|
|
31
|
|
|
|
232,563
|
|
|
|
33
|
|
Cost of engineering
services
|
|
|
252,103
|
|
|
|
24
|
|
|
|
347,214
|
|
|
|
50
|
|
Total cost of
revenue
|
|
|
582,228
|
|
|
|
55
|
|
|
|
579,777
|
|
|
|
83
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
479,483
|
|
|
|
45
|
|
|
|
116,472
|
|
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing
|
|
|
1,531,382
|
|
|
|
144
|
|
|
|
1,216,043
|
|
|
|
175
|
|
Research and
development
|
|
|
768,542
|
|
|
|
72
|
|
|
|
921,706
|
|
|
|
132
|
|
General and administrative
|
|
|
2,071,443
|
|
|
|
195
|
|
|
|
1,133,454
|
|
|
|
163
|
|
Total operating
expenses
|
|
|
4,371,367
|
|
|
|
412
|
|
|
|
3,271,203
|
|
|
|
470
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
$
|
(3,891,884
|
)
|
|
|
(367
|
)%
|
|
$
|
(3,154,731
|
)
|
|
|
(453
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(426,603
|
)
|
|
|
(40
|
)
|
|
|
(639,113
|
)
|
|
|
(92
|
)
|
Loss on warrant
liability
|
|
|
(77,436,700
|
)
|
|
|
(7,294
|
)
|
|
|
—
|
|
|
|
—
|
|
Interest income
|
|
|
1,400
|
|
|
|
—
|
|
|
|
1,264
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expense,
net
|
|
|
(11,572
|
)
|
|
|
(1
|
)
|
|
|
(4,174
|
)
|
|
|
(1
|
)
|
Total other expense,
net
|
|
|
(77,873,475
|
)
|
|
|
(7,335
|
)
|
|
|
(642,023
|
)
|
|
|
(93
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(81,765,359
|
)
|
|
|
(7,701
|
)%
|
|
$
|
(3,796,754
|
)
|
|
|
(545
|
)%
|
|
(1)
|
Amounts
may not sum due to rounding.
|
The following tables present our revenue and operating expenses
for the periods indicated.
Revenue
|
|
Three Months Ended
March 31,
|
|
|
|
|
|
|
2014
|
|
|
2013
|
|
|
$ Change
|
|
Medical devices
|
|
$
|
526,753
|
|
|
$
|
332,919
|
|
|
$
|
193,834
|
|
Engineering services
|
|
|
534,958
|
|
|
|
363,330
|
|
|
|
171,628
|
|
Total revenue
|
|
$
|
1,061,711
|
|
|
$
|
696,249
|
|
|
$
|
365,462
|
|
Medical device revenue increased $0.2 million or approximately
58%, due to an increase in recognized revenue as the number of medical device sales being amortized to revenue nearly doubled
compared to the same period in the prior year. Engineering services revenue increased $0.2 million or approximately 47% primarily
due to an increase of $0.5 million in revenue related to a federal agency contract partially offset by $0.3 million in decreased
revenue resulting from the completion of projects with other government agencies.
Costs and Expenses
Cost of Revenue
|
|
Three
Months Ended
March 31,
|
|
|
|
|
|
|
2014
|
|
|
2013
|
|
|
$ Change
|
|
Medical
devices
|
|
$
|
330,125
|
|
|
$
|
232,563
|
|
|
$
|
97,562
|
|
Engineering services
|
|
|
252,103
|
|
|
|
347,214
|
|
|
|
(95,111
|
)
|
Total cost
of revenue
|
|
$
|
582,228
|
|
|
$
|
579,777
|
|
|
$
|
2,451
|
|
Medical device cost of revenue increased $0.1 million, or approximately
42%, due to an increase in recognized cost of revenue related the increase in medical device costs being amortized to revenue
as noted above. Engineering services cost of revenue decreased $0.1 million or approximately 27% primarily due to lower costs
related to the completion of projects with other government agencies noted above, partially offset by an increase in costs related
to the current federal agency contract.
Sales and Marketing
|
|
Three
Months Ended
March 31,
|
|
|
|
|
|
|
2014
|
|
|
2013
|
|
|
$ Change
|
|
Sales
and marketing
|
|
$
|
1,531,382
|
|
|
$
|
1,216,043
|
|
|
$
|
315,339
|
|
Sales and marketing expenses increased $0.3 million or approximately
26% primarily due to higher employee-related costs due to increased headcount and higher costs for compensation, travel and recruiting.
Research and Development
|
|
Three
Months Ended
March 31,
|
|
|
|
|
|
|
2014
|
|
|
2013
|
|
|
$ Change
|
|
Research and development
|
|
$
|
768,542
|
|
|
$
|
921,706
|
|
|
$
|
(153,164
|
)
|
Research and development expenses decreased $0.2 million or
approximately 17% primarily due to lower employee-related costs driven by the reduction in force in the third quarter of 2013
and a reallocation of some employee effort from research and development to engineering services.
General and Administrative
|
|
Three
Months Ended
March 31,
|
|
|
|
|
|
|
2014
|
|
|
2013
|
|
|
$ Change
|
|
General
and administrative
|
|
$
|
2,071,443
|
|
|
$
|
1,133,454
|
|
|
$
|
937,989
|
|
General and administrative
expenses increased $0.9 million or approximately 83% primarily due to an increase of approximately $0.4 million in employee-related
expenses driven primarily by higher headcount and higher compensation costs related to employee bonus compensation paid in January
2014 subsequent to the Merger. General and administrative expenses were also higher in the three months ended March 31, 2014 due
to approximately $0.5 million in professional services fees primarily related to the merger.
Other Income (Expense)
|
|
Three
Months Ended
March 31,
|
|
|
|
|
|
|
2014
|
|
|
2013
|
|
|
$ Change
|
|
Interest
income
|
|
$
|
1,400
|
|
|
$
|
1,264
|
|
|
$
|
136
|
|
Interest expense
|
|
|
(426,603
|
)
|
|
|
(639,113
|
)
|
|
|
212,510
|
|
Loss on warrant
liability
|
|
|
(77,436,700
|
)
|
|
|
—
|
|
|
|
(77,436,700
|
)
|
Other expense, net
|
|
|
(11,572
|
)
|
|
|
(4,174
|
)
|
|
|
(7,398
|
)
|
Total other
expense, net
|
|
$
|
(77,873,475
|
)
|
|
$
|
(642,023
|
)
|
|
$
|
(77,231,452
|
)
|
Total other expense, net increased by $
77.2
million or approximately 12,029% in the first quarter of 2014 as compared to the same period of 2013, primarily due to a
$77.4
million
non-cash loss related to the change in fair value of the warrant liability related
to warrants issued in the private placement financing. The warrant liability recorded at fair value will fluctuate with changes
in the price of our common stock resulting in a non-cash gain or loss during each financial reporting period. This increase in
total other expense, net was
partially offset by lower interest expense related to the payment of our debt obligations
as part of the private placement offering in January 2014.
Years ended December 31, 2013 and
2012
The following table presents our results
of operations for the periods indicated and as a percentage of total revenue. The year-to-year comparison of results is not necessarily
indicative of results for future periods.
|
|
Years
ended December 31,
|
|
|
|
2013
|
|
|
2013
(1)
|
|
|
2012
|
|
|
2012(1)
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical devices
|
|
$
|
1,611,709
|
|
|
|
49
|
%
|
|
$
|
566,222
|
|
|
|
21
|
%
|
Engineering services
|
|
|
1,690,235
|
|
|
|
51
|
|
|
|
2,140,355
|
|
|
|
79
|
|
Total revenue
|
|
|
3,301,944
|
|
|
|
100
|
|
|
|
2,706,577
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of medical
devices
|
|
|
1,460,692
|
|
|
|
44
|
|
|
|
553,429
|
|
|
|
20
|
|
Cost of engineering
services
|
|
|
1,253,942
|
|
|
|
38
|
|
|
|
1,782,848
|
|
|
|
66
|
|
Total cost of
revenue
|
|
|
2,714,634
|
|
|
|
82
|
|
|
|
2,336,277
|
|
|
|
86
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
587,310
|
|
|
|
18
|
|
|
|
370,300
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
3,913,047
|
|
|
|
119
|
|
|
|
4,381,067
|
|
|
|
162
|
|
Research and
development
|
|
|
2,677,310
|
|
|
|
81
|
|
|
|
4,304,317
|
|
|
|
159
|
|
Sales and marketing
|
|
|
4,291,282
|
|
|
|
130
|
|
|
|
5,925,905
|
|
|
|
219
|
|
Total operating
expenses
|
|
|
10,881,639
|
|
|
|
330
|
|
|
|
14,611,289
|
|
|
|
540
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
$
|
(10,294,329
|
)
|
|
|
(312
|
)%
|
|
$
|
(14,240,989
|
)
|
|
|
(526
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(1,726,455
|
)
|
|
|
(52
|
)
|
|
|
(736,346
|
)
|
|
|
(27
|
)
|
Interest income
|
|
|
5,225
|
|
|
|
—
|
|
|
|
10,692
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash gain
on changes in the fair value of warrants
|
|
|
186,075
|
|
|
|
6
|
|
|
|
17,126
|
|
|
|
—
|
|
Other expense,
net
|
|
|
(57,890
|
)
|
|
|
(2
|
)
|
|
|
(92,441
|
)
|
|
|
(3
|
)
|
Total other expense,
net
|
|
|
(1,593,045
|
)
|
|
|
(48
|
)
|
|
|
(800,969
|
)
|
|
|
(30
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(11,887,374
|
)
|
|
|
(360
|
)%
|
|
$
|
(15,041,958
|
)
|
|
|
(556
|
)%
|
|
(1)
|
Amounts may not sum due to rounding.
|
The following tables present our revenue and operating expenses
for the periods indicated.
Revenue
|
|
Years Ended
December 31,
|
|
|
|
|
|
|
2013
|
|
|
2012
|
|
|
$ Change
|
|
Medical devices
|
|
$
|
1,611,709
|
|
|
$
|
566,222
|
|
|
$
|
1,045,487
|
|
Engineering services
|
|
|
1,690,235
|
|
|
|
2,140,355
|
|
|
|
(450,120
|
)
|
Total revenue
|
|
$
|
3,301,944
|
|
|
$
|
2,706,577
|
|
|
$
|
595,367
|
|
Medical device revenue increased $1,045,487 or approximately
185%, due to an increase in recognized revenue related to 2012 sales and to a lesser extent to the revenue related to 2013 as
medical device revenue is generally recognized over the period of the device maintenance service agreement or three years from
the delivery date of the device. Engineering services revenue decreased $450,120 or approximately 21% primarily due to lower development
revenue related to the expiration of a four-year agreement with a single customer and a shift in resources to research and development,
partially offset by an increase of approximately $186,000 related to federal agency contracts.
Costs and Expenses
Cost of Revenue
|
|
Years Ended
December 31,
|
|
|
|
|
|
|
2013
|
|
|
2012
|
|
|
$ Change
|
|
|
|
|
|
Medical devices
|
|
$
|
1,460,692
|
|
|
$
|
553,429
|
|
|
$
|
907,263
|
|
Engineering services
|
|
|
1,253,942
|
|
|
|
1,782,848
|
|
|
|
(528,906
|
)
|
Total cost of revenue
|
|
$
|
2,714,634
|
|
|
$
|
2,336,277
|
|
|
$
|
378,357
|
|
Medical device cost of revenue increased $907,263 or approximately
164%, due to an increase in recognized cost of revenue related to 2012 sales and to a lesser extent to the cost of revenue related
to 2013 sales as cost of medical device revenue is generally recognized over the period of the device maintenance service agreement.
In addition, there was an increase of $250,000 in medical device cost of revenue related to a scheduled retrofit of previously
sold devices and an increase of $234,367 related to service agreements. Engineering services cost of revenue decreased $528,906
or approximately 30% primarily due to lower development costs related to the expiration of an agreement with a single customer
and the shift in resources to research and development.
General and Administrative
|
|
Years Ended
December
31,
|
|
|
|
|
|
|
2013
|
|
|
2012
|
|
|
$ Change
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
$
|
3,913,047
|
|
|
$
|
4,381,067
|
|
|
$
|
(468,020
|
)
|
General and administrative expenses decreased $468,020 or approximately
11% primarily due to a decrease in employee-related expenses driven by a reduction in force in the third quarter of 2013 in order
to reduce the Company’s cash burn prior to the completion of the PPO in January 2014.
Research and Development
|
|
Years Ended
December
31,
|
|
|
|
|
|
|
2013
|
|
|
2012
|
|
|
$ Change
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
$
|
2,677,310
|
|
|
$
|
4,304,317
|
|
|
$
|
(1,627,007
|
)
|
Research and development expenses decreased $1,627,007 or 38%
primarily due to lower employee-related costs driven by the reduction in force in the third quarter of 2013.
Sales and Marketing
|
|
Years Ended
December
31,
|
|
|
|
|
|
|
2013
|
|
|
2012
|
|
|
$ Change
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing
|
|
$
|
4,291,282
|
|
|
$
|
5,925,905
|
|
|
$
|
(1,634,623
|
)
|
Sales and marketing expenses decreased $1,634,623 or 28% primarily
due to lower employee-related costs largely in marketing, and other marketing-related expenses driven by the reduction in force
in the third quarter of 2013.
Other Income (Expense)
|
|
Years Ended
December 31,
|
|
|
|
|
|
|
2013
|
|
|
2012
|
|
|
$ Change
|
|
Interest expense
|
|
$
|
(1,726,455
|
)
|
|
$
|
(736,346
|
)
|
|
$
|
(990,109
|
)
|
Interest income
|
|
$
|
5,225
|
|
|
$
|
10,692
|
|
|
$
|
(5,467
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash gain on changes in the fair value of warrants
|
|
|
186,075
|
|
|
|
17,126
|
|
|
|
168,949
|
|
Other expense, net
|
|
|
(57,890
|
)
|
|
|
(92,441
|
)
|
|
|
34,551
|
|
Total other expense, net
|
|
$
|
(1,593,045
|
)
|
|
$
|
(800,969
|
)
|
|
$
|
(792,076
|
)
|
Total other expense, net increased $792,076 or 99% primarily
as a result of a full year of interest and accretion of the discount in 2013 on the $3.5 million loan we entered into in 2012,
along with the interest on a bridge loan we entered into in 2013, partially offset by the non-cash gain on the change in fair
value of the warrant liability.
Financial Condition, Liquidity and Capital Resources
We have financed our operations primarily
through the issuance and sale of equity securities for cash consideration and convertible and promissory notes, as well as from
government research grant awards and strategic collaboration payments. As of March 31, 2014, we had discharged all but $0.2 million
of our debt obligations.
Cash and Working Capital
Since the Company’s inception, we
have incurred recurring net losses and negative cash flows from operations. As of March 31, 2014, we had working capital
of $13.2 million, an accumulated deficit of $119.8 million and stockholders’ deficit of $74.5 million. We have incurred
net losses of $81.8 million and $3.8 million for the three months ended March 31, 2014 and 2013, respectively.
Liquidity and Capital Resources
Since the Company’s inception, we
have satisfied our operating cash requirements from proceeds associated with non-recurring engineering and development projects
and from grants. More recently, beginning in December 2010, we financed our operations primarily through private placements of
preferred stock and convertible debt sold principally to outside investors.
We sold approximately $8.0 million of
preferred stock to outside investors between December 2010 and June 2011, and approximately $9.0 million of preferred stock to
outside investors between December 2011 and March 2012. Between May 2013 and August 2013, we sold approximately $10.8 million
of preferred stock with warrants to purchase common stock. In November 2013, we secured $5.0 million through the issuance of convertible
bridge notes, which were subsequently converted into common stock and common stock warrants in our January 2014 PPO when we raised
an additional $25.3 million (excluding the conversion of the November 2013 convertible bridge notes) from January 15 through February
6, 2014. We believe that the Merger will provide additional opportunities to issue securities and raise capital in the future.
Immediately after the closing of the Merger
and private placement discussed above on January 15, 2014, we had approximately $11.0 million in cash, after payment of transaction-related
expenses of approximately $2.3 million and the repayment in full of our $2.5 million senior note payable from the proceeds of
the offering. We subsequently closed two additional private placement financings resulting in total gross proceeds of $9.8 million,
not including deductions for placement agent fees of approximately $1.0 million. During the next four quarters, we expect to spend
approximately $8.0 million on sales and marketing expenses (including regulatory, clinical and related expenses) in support of
our efforts to increase our product sales to rehabilitation hospital customers. We also expect to use approximately $9.5 million
to pay general and administrative expenses to support our ongoing research and development efforts.
We believe our cash resources as of March
31, 2014 are sufficient to implement our current business plan, support operations, fund research and development and meet current
obligations through the middle of 2015. We plan to raise additional capital to finance our operations beyond the middle of 2015.
There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all.
In the event that the necessary additional financing is not obtained, we may be required to reduce our discretionary overhead
costs substantially, including general and administrative, sales and marketing and research and development, or otherwise curtail
operations.
Cash and Cash Equivalents
The following table summarizes the sources
and uses of cash for the periods stated. The Company held no cash equivalents for any of the periods presented.
|
|
Three Months Ended
|
|
|
|
March
31,
|
|
|
|
2014
|
|
|
2013
|
|
Cash,
beginning of period
|
|
$
|
805,306
|
|
|
$
|
1,738,662
|
|
Net cash used
in operating activities
|
|
|
(5,562,822
|
)
|
|
|
(2,362,506
|
)
|
Net cash used
in investing activities
|
|
|
(144,655
|
)
|
|
|
(37,412
|
)
|
Net cash provided
by financing activities
|
|
|
19,478,549
|
|
|
|
1,116,592
|
|
Cash, end of period
|
|
$
|
14,576,378
|
|
|
$
|
455,336
|
|
Net Cash Used in Operating Activities
For the three months ended March 31, 2014,
net cash used in operating activities was $5.6 million. This consisted primarily of our net loss of $81.8 million and was partially
offset by non-cash charges totaling $78.1 million which primarily related to the loss on warrant liability of $77.4 million, $0.4
million in stock-based compensation expense, $0.2 million in amortization of debt discounts and accrued interest and $0.2 million
in depreciation and amortization expense. Net cash used in operating activities was also increased by the net changes in operating
assets and liabilities of $1.9 million. The increase can be attributed primarily to a $1.2 million increase in accounts receivable,
a $0.5 million increase in deferred cost of revenue and a $0.5 million increase in inventories, partially offset by a $0.8 million
increase in customer advances and deferred revenue related to an increase in the number of medical devices shipped in 2014 compared
to 2013.
For the three months ended March 31, 2013,
net cash used in operating activities was $2.4 million. This consisted primarily of our net loss of $3.8 million offset by non-cash
charges totaling $0.7 million which primarily related to a $0.4 million adjustment to record our convertible note at fair value
and $0.1 million in amortization of debt discounts and accrued interest. Our net loss was also offset by an increase in the changes
to our operating assets and liabilities of $0.8 million. This increase was due primarily to a $0.9 million increase in customer
advances and deferred revenue related to an increase in the number of medical devices shipped in 2013 compared to 2012, and partially
offset by an increase in deferred cost of revenue of $0.3 million.
Net Cash Used in Investing
Activities
Net cash used in investing activities
was $0.1 million and $37,412 during the three months ended March 31, 2014 and 2013, respectively. In 2014, net cash used in investing
related primarily to equipment purchases and was partially offset by the proceeds from a note receivable.
Net Cash Provided by Financing Activities
Net cash provided by financing activities
was $19.5 million and $1.1 million for the three months ended March 31, 2014 and 2013, respectively. The increase in cash for
2014 was primarily due to the proceeds from the issuance of common stock of approximately $22.0 million, partially offset by payments
of $2.5 million for notes payable. The increase in cash for 2013 was primarily related to proceeds from the issuance of convertible
debt.
Off-Balance Sheet Arrangements
As of March 31, 2014 and 2013, we did not have any off-balance
sheet arrangements.
Business Trends
Our operating results fluctuate from quarter
to quarter as a result of a variety of factors including the amounts and timing of the delivery of our engineering services and
the timing of production and delivery of our medical devices and clinical training on those devices. We expect our operating results
to continue to fluctuate in future quarters.
DESCRIPTION OF BUSINESS
Immediately following the Merger, the
business of Ekso Bionics
TM
became our business. Ekso Bionics was formed to design,
develop and commercialize wearable robots, or “exoskeletons,” that have a variety of applications in the medical,
military, industrial, and consumer markets.
History
As described above, we were incorporated
in Nevada as PN Med Group Inc. on January 30, 2012. Our original business was to distribute medical supplies and equipment to
municipalities, hospitals, pharmacies, care centers, and clinics throughout the country of Chile. Prior to the Merger, our Board
determined to discontinue operations in this area and to seek a new business opportunity. As a result of the Merger, we have acquired
the business of Ekso Bionics and its subsidiary.
Our authorized capital
stock currently consists of 500,000,000 shares of Common Stock, par value $0.001, and 10,000,000 shares of “blank check”
preferred stock, par value $0.001. Our Common Stock is quoted on the OTC Markets (OTCQB) under the symbol “EKSO.”
Our principal executive offices are located
at 1414 Harbour Way South, Suite 1201, Richmond, California 94804, USA. Our telephone number is 1-510-984-1761. Our website address
is
www.eksobionics.com
.
Ekso Bionics was incorporated on January
19, 2005, under the laws of the State of Delaware, to design, develop, and commercialize human robotic exoskeletons to augment
human strength, endurance and mobility. Since its inception, Ekso Bionics has achieved several significant milestones:
|
·
|
In
2006, Ekso Bionics designed and sold the first practical human exoskeleton.
|
|
·
|
In
2009, Ekso Bionics signed its first agreement with Lockheed establishing the companies’
collaborative partnership to ruggedize and commercialize a human exoskeleton for military
and other able-bodied applications. In July 2013, we entered into a new agreement with
Lockheed to further strengthen the collaborative efforts in non-medical applications.
|
|
·
|
In
February 2012, we sold our first human exoskeleton suit for medical applications, called
Ekso™ to a rehabilitation center for use by patients with complete spinal cord
injuries (“SCI”).
|
|
·
|
In
July 2013, Ekso Bionics delivered a key technology upgrade for Ekso called Variable Assist,
expanding the potential user population by adding utility for incomplete SCI patients,
stroke patients and patients with related neurological disorders who can benefit from
gait training and rehabilitation.
|
|
·
|
In
December 2013, we delivered our first Ekso GT
TM
(gait training), a new generation
Ekso with added hardware and software functionality, including Variable Assist.
|
Overview
Ekso Bionics designs, develops and sells
wearable robots, or “human exoskeletons,” that have applications in medical, military, industrial, and consumer markets.
Our exoskeletons systems are strapped over the user’s clothing, enabling individuals with neurological conditions affecting
gait (e.g., spinal cord injury or stroke) to walk again; permitting soldiers to carry heavy loads for long distances while mitigating
lower back, knee, and ankle injuries; and allowing industrial workers to perform heavy duty work for extended periods.
Our Ekso GT is used by hospitals on patients
with lower extremity weakness or paralysis. Our products have been listed with the U.S. Food and Drug Administration (“FDA”)
and have received a CE Mark (indicating compliance with European Union legislation). We have sold over 50 devices to rehabilitation
centers and individual users for rehabilitation since February 2012. We also have a collaborative partnership with Lockheed to
develop products for able-bodied exoskeleton applications.
We believe the Company is at a key point
in the growth of its business. From inception to December 2013, Ekso Bionics has accumulated over $38 million of losses and in
July 2013 furloughed 30 of its 71 employees in order to extend operations to the end of 2013. In November 2013, we completed a
bridge financing, then in January and February 2014, the Company completed the Merger and PPO, resulting in $30.3 million in gross
proceeds. With the additional capital resulting from the Merger and PPO, the Company believes that it now has the resources to
further penetrate the medical market and to begin to expand operations in the military and industrial markets over the next several
years.
Based on technology initially developed
by an engineering team from the University of California, Berkeley, Ekso Bionics’ devices employ a number of proprietary,
advanced robotics technologies.
Ekso Bionics’ Medical Technology
The Company’s most current product,
the Ekso GT, is a wearable bionic suit that provides individuals with spinal cord injuries, stroke and other lower-extremity paralysis
or weakness the ability to stand and walk over ground with a full weight-bearing, reciprocal gait using a cane, crutches or a
walker under the supervision of a physical therapist. Walking is achieved by the shifting of the user’s body to activate
sensors in the device that initiate steps. Battery-powered motors drive the legs, replacing deficient neuromuscular function.
First-time users can expect to walk with aid from the device the first time they put on the Ekso exoskeleton (after passing an
assessment), while an experienced user can transfer to or from their wheelchair and don or remove Ekso in less than five minutes.
By allowing individuals with spinal cord
injuries to stand and walk in a full weight-bearing setting, we believe the Ekso exoskeleton offers potential healthcare benefits
that may reduce post-injury medical costs through reduction in secondary complications such as pressure sores, urinary tract infections,
bowel problems, pneumonia and other respiratory issues, bone loss/osteoporosis, cardiovascular disease and psychological disorders.
For people with some motor ability intact (for example, after a stroke or an incomplete spinal cord injury), we believe Ekso offers
the potential to help them re-learn to walk again by teaching them proper step patterns and weight shifts using a task-based platform.
Ekso Bionics’ Engineering Services
(also known as Ekso Labs)
In addition to the design, development
and commercialization of exoskeletons for medical applications, Ekso Bionics performs research and development work on human exoskeletons
and related technologies paid for by grant funding, by collaboration partners such as Lockheed, or by engineering services customers
such as the U.S. military.
In addition to furthering exoskeleton
technology into markets outside Ekso Bionics’ current medical applications, this work has potential applications in future
models of the Ekso human exoskeleton. Many of the research projects funded by grants are focused on researching future medical
applications and capabilities not yet ready for commercial development. Other projects, often funded by commercial partners or
the U.S. military, focus on able-bodied human exoskeleton applications. One such development project is the HULC
®
(Human Universal Load Carrier), a robotic exoskeleton designed for Lockheed and potential military applications to augment
strength and endurance, allowing users to carry up to 200 pounds over long distances and rough terrain. Similarly, industrial
models that Ekso Bionics is developing are intended to increase an individual’s workload, endurance and efficiency, allowing
workers to carry heavy objects for much longer. The goal of these technologies is to increase worker productivity while at the
same time helping to prevent employee injuries. Both the HULC and our other industrial exoskeleton products are in the developmental
stage.
To date, the majority of our engineering
services revenue has been in the form of grants. The Company currently has four grants underway, representing approximately $3.75
million in total funding. Grantors include the U.S. National Science Foundation, the U.S. Defense Advanced Research Projects Agency
(DARPA), and the U.S. Department of Defense.
The Technology
Ekso Bionics has established an extensive
intellectual property (“IP”) portfolio that includes various U.S. patents and patent applications, including seven
patents that have been granted, 20 patent applications that are currently pending, which means a complete application has been
filed with the applicable patent authority and additional action is pending, and 3 provisional patent filings, which means that
we have filed a short form application to establish an early filing date in anticipation of completion and submission of a complete
application. Some of these patents and patent applications are owned either solely by or jointly with the University of California,
as further described below. Many of these have also been filed internationally as appropriate for their respective subject
matter and have begun to issue. Ekso Bionics’ patent portfolio includes product and method type claims, since the
devices that Ekso Bionics produces and the processes performed by those devices are patentable. Our patents encompass technologies
relevant to our devices, including medical exoskeletons, commercial exoskeletons, actuators, and strength-enhancing exoskeletons.
The earliest priority date of the portfolio reaches back to 2003, and new applications continue to be filed.
Two license agreements and one amendment constitute the licenses
from the University of California for various patents and applications relevant to the business of Ekso Bionics. The table
below indicates the cross section of patents by issuing status and license status.
|
|
Issuing Status
|
|
License Status
|
|
Issued
Patents
|
|
|
Pending
Applications
|
|
|
Provisional
Applications
|
|
Owned by University of California, exclusively licensed to Ekso Bionics
|
|
|
6
|
|
|
|
-
|
|
|
|
-
|
|
Co-owned with University of California, exclusively licensed to Ekso Bionics
|
|
|
1
|
|
|
|
3
|
|
|
|
-
|
|
Co-owned with University of California
|
|
|
-
|
|
|
|
3
|
|
|
|
-
|
|
Sole ownership by Ekso Bionics
|
|
|
-
|
|
|
|
14
|
|
|
|
3
|
|
Total: 30
|
|
|
7
|
|
|
|
20
|
|
|
|
3
|
|
The exclusive license with the Regents
of the University of California (“RUC”) consists of two agreements and one amendment covering ten patent cases, seven
of which have issued and three of which remain in prosecution (the “RUC License Agreements”). Inventions covered
by a further three patent applications are co-owned by Ekso Bionics and RUC, with no license agreement between Ekso Bionics and
RUC. As a result, RUC may license its rights in these patents to a third party. With respect to two of these co-owned
patent applications, RUC has licensed their rights in the U.S. to an unrelated third party. The third patent application
will need to be fully prosecuted before it can be determined which claims are exclusive to us (through a previous license) and
which claims RUC may license to other entities. The RUC License Agreements provide Ekso Bionics the right to grant sub-licenses.
We believe that the breadth of the coverage across various bionic systems and technologies, together with our freedom to grant
sub-licenses under the RUC License Agreements gives us the potential to generate licensing revenue in fields outside our present
areas of commercialization, To date we have generated approximately $1 million in such licensing revenue. Pursuant to the RUC
License Agreements, Ekso Bionics initially paid RUC consideration consisting of $5,000 in cash and 310,400 common shares of Ekso
Bionics, and is also committed to pay a 1% royalty on sales, including sales generated by sublicenses. We do not pay royalties
to RUC on products sold or to be resold to the U.S. government.
A remaining 17 cases are solely owned
by Ekso Bionics. In some cases, as a result of government funding received by Ekso Bionics, the patents have a government use
license, granting the U.S. government a non-exclusive, non-transferable, irrevocable, paid-up license for use of the inventions
for or on behalf of the U.S. government, as is typical in the case of government sponsored research.
Ekso in the Medical Market
Ekso is a robotic exoskeleton, or wearable
robot, used in the medical market to enable individuals living with lower extremity paralysis or weakness, due to such neurological
conditions as stroke or spinal cord injury, to stand and walk over ground with a full weight-bearing, reciprocal gait under the
supervision of a physical therapist. The suit is strapped over the users´ clothing, accommodates a wide range of patient
sizes and clinical presentations, and is currently used primarily in a clinic or rehabilitation setting. With medical clearance,
the suit typically facilitates walking for individuals who are non- or pre-ambulatory post-stroke, or with up to C7 (cervical
spinal nerve 7) complete or any level of incomplete SCI, along with other neurological conditions.
For those with medical clearance and who
pass a physical examination, first-time users can expect to walk in Ekso in their first session, and we expect that an experienced
user can transfer to/from their wheelchair and don or doff the Ekso in less than five minutes. Walking is achieved by the user
shifting his or her weight to activate sensors in the device that initiate the steps, or with the push of a button on a handheld
user interface. Battery-powered motors drive the legs, replacing deficient neuromuscular function.
For people with complete paralysis from
a spinal cord injury, for example, walking in Ekso provides the powerful benefit of seeing the world eye-to-eye again and we believe
may facilitate the reduction of complications commonly associated with life in a wheelchair, such as bowel and bladder dysfunction,
loss of bone density, muscle spasticity, neuropathic pain and pressure sores. For patients with some motor ability intact (for
example after a stroke or an incomplete spinal cord injury), Ekso may help them re-learn proper step patterns and weight shifts
using a task-based platform, which we believe could be important for people who have the potential to re-learn to walk.
In 2012 Ekso Bionics delivered its first
robotic exoskeleton for medical and rehabilitation purposes to Craig Hospital, a world-renowned institution in Englewood, Colorado,
that specializes in the neuro-rehabilitation and research of patients with SCI and traumatic brain injury (“TBI”).
By the end of 2013, Ekso Bionics had achieved two major Ekso software upgrades as well as two hardware upgrades. Among these advancements,
our new Variable Assist software provides the ability for patients with any amount of lower extremity strength to contribute their
own power from either leg to achieve self-initiated walking. The amount of assistance Ekso provides can be set to provide a specific
amount of power, or to allow the Ekso to dynamically adjust to the patient’s needs in real-time in order to follow the patient’s
progression with his or her rehabilitation.
Medical Market Strategy
Our initial go-to-market strategy in the
medical market, which began in the first quarter of 2012, was to establish proof of concept and credibility among thought leaders
and renowned rehabilitation centers specializing in SCI across the U.S. and Europe, and to initiate preliminary studies on safety
and efficacy. In this early phase of technology diffusion, the first two generations of the Ekso robotic exoskeleton provided
full power assistance to facilitate walking for individuals with as much as complete lower extremity paralysis, and the clinical
focus was primarily spinal cord injury.
We initiated our second, and current,
go-to-market strategy in the medical market in July 2013. The goal of our current go-to-market strategy is to broaden the addressable
market and drive deeper adoption among the neuro-rehabilitation community by adding more utility to the Ekso robotic exoskeleton
as a technology platform. Advancements in both software and hardware are represented in the introduction of Ekso GT
™
with Variable Assist. In their pursuit of the best possible outcomes for patients with a wider spectrum of clinical
presentations, such as hemiparesis (weakness on one side of the body) after stroke or TBI, therapists now have more opportunities
to explore therapeutic interventions and various impacts of patient/technology interaction, and to adjust therapy as the patient
regains function. This means the Ekso robotic exoskeleton has the potential to go beyond helping people with paralysis to stand
and walk, but also to provide a game-changing tool that may help those with some motor ability intact to learn to walk again.
Once we increase the adoption of Ekso
among the medical community in rehabilitation settings, we may seek to develop a device optimized for an individual’s personal
use, allowing users to perform rehabilitation in their home and to have a mobility option for activities of daily living; however,
our exploration of this potential market is in the very early stages.
Potential Market for our Medical Products
Today, primary current and potential customers
are SCI and stroke in-patient and outpatient rehabilitation centers in North America and Europe. According to the National
Spinal Cord Injury Statistical Center, there are approximately 12,000 to 14,000 incidences of spinal cord injuries every year
in the U.S., and the total U.S. SCI population is approximately 264,000
1
.
The Christopher and Dana Reeve Foundation estimates the total U.S. SCI population to be significantly higher, up to 1,200,000
2
.
Considering the range of paraplegics and quadriplegics receiving therapy using the Ekso robotic exoskeleton, either by Ekso Bionics
or its customers, the Company estimates that approximately 73% of the U.S. SCI population can potentially use an Ekso robotic
exoskeleton in such rehabilitation settings.
Additionally, there are approximately
5,700 registered hospitals in the U.S.
3
, many of which
provide stroke care, and over 1,000 of which are listed as primary stroke centers
4
.
There are approximately 800,000 strokes every year in the U.S., of which 650,000 patients survive, and approximately 7,000,000
stroke survivors in the U.S.
5
|
1
|
National Spinal Cord Injury Statistical Center (NSCISC).
Spinal cord injury facts and figures at a glance. Birmingham (AL): University of Alabama
at Birmingham; 2012 Feb. 2 p. Also available:
https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/Facts%202013.pdf
|
|
2
|
The Christopher and Dana Reeve Foundation, Paralysis
Facts and Figures. Available
http://www.christopherreeve.org/site/ c.mtKZKgMWKwG/b.5184255/k.6D74/Prevalence_of_Paralysis.htm
|
|
3
|
The American Hospital Association., Fast Facts on
US Hospitals;
http://www.aha.org/research/rc/stat-studies/ fast-facts.shtml
|
|
4
|
The Joint Commission, Facts about Primary Stroke
Center Certification:
http://www.jointcommission.org/certification/primary_stroke_centers.aspx
|
|
5
|
National Stroke Association,
http://www.stroke.org/site/PageServer?pagename=rehabt
|
In terms of the market in Europe, there
are approximately 12,000 private and public hospitals, of which an estimated 4,600 are classified as acute care facilities
6
.
Our goal is to penetrate the rehabilitation
centers, hospitals and similar facilities to become an integral part of their neuro-rehabilitation programs. The Company believes
that each facility has the potential to purchase 1-5 units, with the expectation that the useful life – or replacement cycle
– of the units will range from 3-5 years in such clinical settings.
During 2014, we expect to deepen our understanding
of the proper protocols, and potential benefits, of using Ekso for gait training and rehabilitation, and the corresponding value
propositions for our customers. The Company will further investigate the potential for use beyond SCI and stroke, including multiple
sclerosis, TBI, amyotrophic lateral sclerosis, Parkinson’s and other neurological conditions that inhibit gait. We will
also expand sales and marketing efforts beyond North America and Europe through partnering with country/region specific robotic/medical
device distributors. See “Current Sales and Marketing Efforts” below for more details.
Clinical Research
Ekso Bionics believes an important factor
in further technology adoption is demonstrating clinical evidence to support the Ekso for use in rehabilitation, gait training
and wellness. There is a compendium of existing studies examining the extra health care costs of SCI patients. These studies calculate
the costs of re-hospitalization, secondary complications and quality of life challenges facing such patients.
We are eager for further initiation of
clinical research that will demonstrate evidence of the health benefits of walking in the Ekso robotic exoskeleton. To that end,
some of our early clinical customers are undertaking research to evaluate the use of exoskeletons in general and the Ekso robotic
exoskeleton in particular. Centers that have announced publicly that they are undertaking such studies that include the
Ekso robotic exoskeleton are: the Kessler Foundation, Santa Clara Valley Medical Center, The Miami Project to Cure Paralysis of
the University of Miami, Rehabilitation Institute of Chicago (“RIC”), and Glostrup Hospital in Europe; with Kessler,
Santa Clara and RIC having already presented initial favorable findings indicating that the device is safe to use
7
and that there are positive results in function with training, increase in oxygen consumption and ventilation. Increased
muscle firing in lower leg muscles was also noted, which requires further study
8
.
In the much larger area of stroke treatment,
Ekso Bionics also plans to build a portfolio of clinical data intended to demonstrate that the Ekso human exoskeleton can allow
gait training to occur earlier in the treatment schedule, that it can mobilize much more difficult patients than traditional training,
and that it will be an effective gait training device. Though the Company has only recently entered the stroke field (with the
release of the Variable Assist upgrade package in July 2013), the two top rehabilitation centers in the United States (according
to
US News and World Report
rankings), the Rehabilitation Institute of Chicago and Kessler Foundation, are initiating Ekso
human exoskeleton studies in this area. As in the field of spinal cord injury, the field of stroke has a large body of existing
research, and there is broad evidence that early mobilization of stroke patients (by traditional manual means) results in lower
secondary complications and lower length of stay. Ekso Bionics currently benefits from this existing data by demonstrating to
customers that the Ekso human exoskeleton can mobilize more patients earlier, and we are evaluating the feasibility of direct
research to link the Ekso directly to such outcomes.
Current Sales and Marketing Efforts
Ekso Bionics historically focused its
sales efforts on key SCI centers in the U.S. and Europe. In 2013, the Company began to expand its sales efforts, and today the
sales and marketing team consists of:
|
·
|
Eight
direct sales persons (six in the U.S., two in Europe)
|
|
·
|
Five
distributors (Mexico, Italy, Poland, Finland and Turkey)
|
|
·
|
Six
clinical professionals/physical therapists (four in the U.S., two in Europe)
|
|
6
|
Based on a 2010 presentation by Paul Garassus, M.D.,
the Vice President of the French Health Economic Society and member of the European Private
Hospitals Union, http;//www.worldofhealthit.org/sessionhandouts/documents/PS21-4-Garassus.pdf
|
|
7
|
Kolakowsky-Hayner et al., J Spine 2013, S4.
|
|
8
|
Gail Forrest, PhD., presented at the Academy of Spinal
Cord Injury Professionals (ASCIP), Sept., 2012
|
|
·
|
Four
marketing professionals (three in the U.S. and one in Europe)
|
|
·
|
Three
customer relations personnel.
|
The Company plans on continuing to build
the sales and marketing team, with a particular emphasis on adding distributors in target markets/countries and on increasing
marketing and clinical efforts.
To succeed in the medical market, we believe
we need to better address the concerns of a series of stakeholders at each potential customer. These include: the customer’s
CEO/CFO (vision and economics), Medical/Research Director (moving their field/reputation forward), clinical staff (achieving improved
patient outcomes), user groups (improving the well-being of patients) and foundation director (seeking ways to ensure successful
and more frequent donor/capital campaigns).
The sales cycle to build consensus among
these stakeholders and achieve a sale of a device(s) is generally three to 12 months. We believe our ability to accelerate the
sales cycle and accelerate adoption will also be based, in part, on our ability to build on our (and our partners’) early
efforts to expand clinical evidence.
Exoskeleton Technology for Able-Bodied
Applications
Ekso Bionics’ original exoskeleton
technology was an evolution of the RUC technology related to able-bodied augmentation, enabling healthy individuals to carry heavy
loads.
The Ekso Bionics’ team’s original
exoskeleton design, called ExoHiker
TM
, was completed in February 2005 and was
intended to help hikers carry heavy loads over extended periods of time. The ExoHiker demonstrated load carriage at power consumption
levels that were approximately 1,000 times lower than the state-of-the-art human exoskeletons of the time. There was no user interface
required to operate the device. Instead, ExoHiker responded to the movements of the person wearing the device. It could be easily
strapped on or off, and it had a small handheld LCD display used to configure the device. The ExoHiker weighed approximately 30
pounds and operated at an average speed of 2.5 miles per hour for 42 miles with one 80 watt-hour lithium polymer battery.
ExoHiker evolved into the ExoClimber
TM
,
which injected power when ascending stairs and climbing steep slopes. It weighed 50 pounds and could assist the wearer to ascend
600 feet vertically with a 150-pound load. Neither ExoHiker nor ExoClimber was commercialized. The third generation device is
called the Human Universal Load Carrier (HULC) and includes hip actuation used to assist the user in swinging his or her legs
during walking, even on level ground.
This development of able-bodied, powered
and non-powered exoskeletons continues with funding from government grants and engineering contracts for Lockheed and U.S. government
customers. Investing in the ongoing development of exoskeleton technology through these non-dilutive forms of funding is intended
to help Ekso Bionics remain at the forefront of this nascent bionic robotics technology, working with leaders in complementary
fields such as materials, battery and sensor technology.
One of Ekso Bionics’ development
partners for able-bodied applications is Lockheed, for whom the Company continues to provide research and development services.
The Company’s collaboration with Lockheed focuses on anthropomorphic exoskeleton technology used to augment the strength
and endurance of people. For the commercial (able-bodied) field of use, the Company and Lockheed have co-exclusive rights,
with the Company having the right to sub-license technology and Lockheed having the right to sub-license only with our consent.
For the government (able-bodied) field of use, Lockheed and the Company have co-exclusive rights to military markets through 2017.
So long as certain annual minimum obligations are met, Lockheed will obtain exclusive rights to the government market after 2017.
Since 2008, Lockheed has purchased approximately
$6 million in non-recurring engineering services from Ekso Bionics and paid $1 million in licensing fees for the further development
of the HULC and other exoskeletons. More recently, Lockheed and Ekso Bionics initiated development of a non-powered exoskeleton
called MANTIS
TM
. MANTIS is designed to allow industrial workers in a dynamic
and unstructured work environment to achieve their tasks with reduced musculoskeletal injuries related to lifting and working
with heavy tools. Although the Company believes the MANTIS and similar industrial exoskeletons have the potential to help prevent
workforce injuries, improve productivity and over time reduce workmen’s compensation and related costs, the Company has
invested little of its own resources to date on these efforts. The focus of our work so far has been in building an IP portfolio
that will help us enter that market at a future date.
It is important to note that both the
HULC and industrial exoskeleton products are in the developmental stage. Nevertheless, Ekso Bionics plans to continue to pursue
able-bodied exoskeleton technology and will seek to commercialize products on its own or with partners when and if appropriate.
In December 2013, the Company was awarded
a twelve-month, $1 million fixed-price contract by United States Special Operations Command (USSOCOM) to develop design, build,
test and deliver a next generation military exoskeleton prototype. The statement of work describes four milestones divided
into tasks and sub-tasks, with required accomplishments and progress payments associated with each milestone. Each milestone must
be successfully accomplished and verified in order to receive payment and proceed to the next sub-task.
The first four milestones relate to the development and delivery of a functional prototype exoskeleton device that significantly
reduces the load on users while introducing a negligible metabolic impact and meets other specifications set forth in the agreement.
Payments for these milestones are $150,000, $200,000, $250,000 and $250,000 for each of the first four milestones. The final task
of the project relates to the submission of a report summarizing testing results and a recommended path forward for which the
payment is $146,000. This is the first award granted under USSOCOM's TALOS (Tactical Assault Light Operator Suit) project.
Governmental Regulation and Product
Approval
U.S. Regulation
Ekso Bionics’
medical technology products and operations are subject to regulation by the U.S. Food and Drug Administration (“FDA”)
and various other federal and state agencies, as well as by foreign governmental agencies. These agencies enforce laws and regulations
that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and market surveillance
of the Company’s medical device products.
Under the U.S.
Federal Food, Drug, and Cosmetic Act, medical devices are classified into one of three classes — Class I, Class II or Class
III — depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety
and effectiveness. Our current medical products are categorized as Class I. Class I devices are those for which safety and effectiveness
can be assured by adherence to a set of guidelines, which include compliance with the applicable portions of the FDA's Quality
System Regulation (“QSR”), facility registration and product listing, reporting of adverse medical events, and appropriate,
truthful and non-misleading labeling, advertising, and promotional materials (the “General Controls”).
Ekso Bionics actively maintains FDA 21
CFR Part 820 Quality System Regulation and ISO 13485:2003 Quality Management Systems that establish standards for its product
design, manufacturing, and distribution processes. Following the introduction of a product, the FDA and foreign agencies engage
in periodic reviews of our quality systems, as well as product performance and advertising and promotional materials. These regulatory
controls, as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction and
continued availability of new products. Where possible, Ekso Bionics anticipates these factors in our product development processes.
These agencies possess the authority to take various administrative and legal actions against the Company, such as product recalls,
product seizures and other civil and criminal sanctions.
Foreign Regulation
In addition to regulations in the United
States, Ekso Bionics will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution
of our products in foreign countries. Whether or not the Company obtains FDA approval for a product, Ekso Bionics must obtain
approval of a product by the comparable regulatory authorities of foreign countries before the Company can commence clinical trials
or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer
or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing,
pricing and reimbursement vary greatly from country to country.
The policies
of the FDA and foreign regulatory authorities may change and additional government regulations may be enacted which could prevent
or delay regulatory approval of our products and could also increase the cost of regulatory compliance. We cannot predict the
likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action,
either in the United States or abroad.
Research and Development
The Company engages in research and development
in an effort to enhance the effectiveness, ease of use, safety and reliability of its medical, commercial, and strength-enhancing
exoskeletons and to expand the applications for its products. The Company’s research and development expenditures were $2.7
million and $4.3 million in 2013 and 2012, respectively. In addition, as part of its engineering services, which are paid for
by grant funding, by collaboration partners, or by engineering services customers, the Company incurred research and development
costs associated with its engineering services revenue of $1.3 million and $1.8 million in 2013 and 2012, respectively.
Competition
The medical technology, industrial robotics
and military equipment industries are characterized by intense competition and rapid technological change. We believe a number
of other companies are developing competitive technology and devices for both the medical and able-bodied fields of use, and many
of these competitors have significantly more financial and other resources than we possess.
In the medical field, we face competition
from companies that are focused on technology for rehabilitation of patients suffering from stroke and related neurological disabilities
as well as from companies that focus on SCI. In stroke, Cyberdyne is developing over-ground exoskeletons, and Hocoma, AlterG,
Aretech and Reha Technology are selling treadmill-based gait therapies. In SCI, Argo Medical Technologies and Rex Bionics sell
over-ground exoskeletons. Parker Hannifin has announced plans to sell over-ground exoskeletons beginning in 2015.
Technologies developed by competitors
in the areas of stroke rehabilitation and SCI represent therapeutic interventions with utility at varying points of the continuum
of care. Clinically, the Ekso is unique in its broad ability to mobilize pre- or even non-ambulatory patients using a full weight
bearing, over ground, task-based platform. From a practice management perspective, the Ekso is less expensive than many other
systems, has a smaller footprint, the ability to move around the hospital, and uses standard power requirements that make it easy
to integrate into existing infrastructure. Other over-ground exoskeletons were initially designed as an individual user’s
alternative to a wheelchair with the primary goal of providing a means for patients to achieve mobility reliant on the device.
By contrast, the Ekso’s design accommodates patients with complete paraplegia and additionally includes features that are
optimized to assist therapists in helping patients with some motor ability learn to walk again in a clinical setting, treating
several patients and indications in a single day.
Notwithstanding the foregoing, the most pressing challenges
Ekso Bionics faces are not necessarily competitive technologies, but rather achieving rapid market awareness and adoption of this
emerging technology while acclimating prospects to a fundamentally new paradigm in neuro-rehabilitation and mobility. In addition,
there is the matter of securing the funds for acquisition in environments where capital expenses of this magnitude are not common
in the rehabilitation department of a clinic.
In the able-bodied field, Raytheon, Panasonic,
Honda and Cyberdyne are each developing some form of exoskeleton for military and industrial applications.
The field of robotic exoskeleton technology
remains in infancy. As this field develops, we believe we will face increased competition on the basis of product features, clinical
outcomes, price, services and other factors. Our competitive position will depend on multiple, complex factors, including our
ability to achieve market acceptance for our products, develop new products, implement production and marketing plans, secure
regulatory approvals for products under development and protect our intellectual property. In some instances, competitors may
also offer, or may attempt to develop, alternative therapies for disease states that may be delivered without a medical device.
Employees
We employ 60 persons on a full time basis,
including six in Europe. The Company currently plans to hire an additional 10 to 15 full time employees within the next three
months, whose principal responsibilities will be the support of our sales, marketing, research and development, and clinical development
activities. Should the Company secure further contracts for engineering services for our government work/clients, we would seek
to hire further engineering personnel.
Description of Properties
Our principal executive offices are currently
located at 1414 Harbour Way South, Suite 1201, Richmond, CA 94804, where the Company leases approximately 45,000 square feet.
The Company believes this facility is adequate for its current needs, including providing the space and infrastructure to assemble
Ekso exoskeletons and to accommodate its development work for able-bodied applications per its current operating plan.
Ekso Bionics does not own any real property.
LEGAL PROCEEDINGS
From time to time, we may become involved
in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.
We are currently not aware of any pending
legal proceedings to which we are a party or of which any of our property is the subject, nor are we aware of any such proceedings
that are contemplated by any governmental authority.
DIRECTORS, EXECUTIVE
OFFICERS, PROMOTERS AND CONTROL PERSONS
Directors and Executive Officers
Below are the names of and certain information regarding the
Company’s current executive officers and directors who were appointed effective as of the closing of the Merger:
Name
|
|
Age
|
|
Position
|
|
Date Named to Board of
Directors/as Executive Officer
|
Steven Sherman
|
|
68
|
|
Director and Chairman of the Board
|
|
January 15, 2014
|
Nathan Harding
|
|
46
|
|
Director and Chief Executive Officer
|
|
January 15, 2014
|
Dan Boren
|
|
40
|
|
Director
|
|
January 15, 2014
|
Marilyn Hamilton
|
|
65
|
|
Director
|
|
January 15, 2014
|
Jack Peurach
|
|
48
|
|
Director
|
|
January 15, 2014
|
Max Scheder-Bieschin
|
|
52
|
|
Chief Financial Officer
|
|
January 15, 2014
|
Russ Angold
|
|
37
|
|
Chief Technology Officer
|
|
January 15, 2014
|
Frank Moreman
|
|
55
|
|
Chief Operating Officer
|
|
January 15, 2014
|
Directors are elected to serve until the
next annual meeting of stockholders and until their successors are elected and qualified. Directors are elected by a plurality
of the votes cast at the annual meeting of stockholders and hold office until the expiration of the term for which he or she was
elected and until a successor has been elected and qualified.
A majority of the authorized number of
directors constitutes a quorum of the Board of Directors for the transaction of business. The directors must be present at the
meeting to constitute a quorum. However, any action required or permitted to be taken by the Board of Directors may be taken without
a meeting if all members of the Board of Directors individually or collectively consent in writing to the action.
Executive officers are appointed by the
Board of Directors and serve at its pleasure.
Each of our directors was elected pursuant
to an agreement between Pedro Perez Niklitschek, our sole director before the Merger, and Ekso Bionics. The principal occupation
and business experience during the past five years for our executive officers and directors is set forth below. In addition,
for
each director, set forth below is a summary of the specific experience, qualifications, attributes or skills that led to the conclusion
by Ekso Bionics that the person should serve as a director of the Company.
Directors
Steven Sherman – Director and
Chairman of the Board of Directors
Mr. Sherman has served on the Board of
Directors of Ekso Bionics since December 2013. Since 1988, Mr. Sherman has been a member of Sherman Capital Group, a Merchant
Banking organization with a portfolio of private and public investments. In addition to Ekso Bionics, Mr. Sherman is currently
Chairman of Purple Wave Inc. Mr. Sherman is a founder of Novatel Wireless, Inc., Vodavi Communications Systems Inc. and Main Street
and Main Inc. Previously, Mr. Sherman has served as a director of Telit; Chairman of Airlink Communications, Inc. until its sale
to Sierra Wireless, Inc.; Chairman of Executone Information Systems; and as a director of Inter-Tel (Delaware) Incorporated. Mr.
Sherman was appointed to the Board at the request of Ekso Bionics in connection with the reverse merger due to, among other factors,
his extensive business experience and his financial and investment expertise.
Nathan Harding – Director and
Chief Executive Officer
Mr. Harding is the co-founder of Ekso
Bionics and has served as the Chief Executive Officer since November 2012. From 2005 to 2012, Mr. Harding served in various positions
including Chief Executive Officer, Chief Operating Officer, and Chief Project Officer. He is also a co-inventor of the Company's
core exoskeleton technology. Prior to his work at Ekso Bionics, Mr. Harding worked as a Mechanical Engineer at Carnegie Mellon's
Field Robotics Center from 1989 to 1990, and Redzone Robotics in 1991. He served in various roles including Mechanical Engineering
Manager at Berkeley Process Control from 1994 to 2003, and served as a consultant to the Berkeley Robotics and Human Engineering
Laboratory from October 2003 until co-founding Ekso Bionics in 2005. Mr. Harding holds ten U.S. patents and has another eight
pending. Mr. Harding received his bachelor's degree in Mechanical Engineering and Economics from Carnegie Mellon University in
Pittsburgh and his master's in Mechanical Engineering from the University of California, Berkeley.
Mr.
Harding
was appointed to the Board at the request of Ekso Bionics in connection with the reverse merger due to, among other
factors, his
background in the
medical technology, industrial robotics and military
equipment industries, his role in developing the Company’s core exoskeleton technology
and his position as President and Chief Executive Officer of the Company.
Dan Boren – Director
Mr. Boren has served on the Board of Directors
of Ekso Bionics since April 2013. Since January 2013, Mr. Boren has served as the President of Corporate Development for the Chickasaw
Nation. Prior to that role, Mr. Boren served as the elected representative of Oklahoma's 2nd Congressional District in the U.S.
House of Representatives from 2005 through 2013. Before his election to the U.S. House of Representatives, Mr. Boren was elected
to the Oklahoma House of Representatives from 2002 to 2004. Mr. Boren earned his B.S. in Economics at Texas Christian University
and went on to obtain an M.B.A. at University of Oklahoma. Mr. Boren was appointed to the Board at the request of Ekso Bionics
in connection with the reverse merger due to, among other factors, his experience in governance matters and his nomination by
CNI Commercial LLC pursuant to their contractual right to nominate a director for election to the Board of Directors
.
Marilyn Hamilton – Director
Ms. Hamilton has served on the Board of
Directors of Ekso Bionics since January 2012. In 2009, Ms. Hamilton founded StimDesigns LLC, a neurotechnology company that
develops and distributes neuromuscular training devices for rehabilitation and has served as CEO from 2009 to present. In
2007, Ms. Hamilton launched Envision, a professional speaking and medical business consulting company, and has served as its CEO
from 2007 to present. Prior to this role, Ms. Hamilton co-founded Motion Designs Inc. in 1979, a manufacturing and marketing company
that pioneered innovative custom, ultra-lightweight Quickie wheelchairs that revolutionized the industry. She served in
various executive roles in sales, marketing and product development until it was sold ultimately to Sunrise Medical Inc., where
Ms. Hamilton served as Global VP. In 1990 Ms. Hamilton founded Winners on Wheels, a coed-scouting program for children in wheelchairs;
in 2003 she co-founded Discovery through Design and served as Chairwomen, raising awareness and funds for spinal cord injury research
and women's health; and for nine years she served as a founding board member and current emeritus board member of The California
Endowment, charged with expanding access to affordable, quality healthcare for underserved populations and to promote improvements
in the health status of all Californians. Ms. Hamilton is currently an advisory board member of the National Center for
Medical Rehabilitation Research at the National Institute of Health and has been a member of The Committee of 200 business women
since 1993 whose mission is to foster, celebrate and advance women's leadership in private and public companies. Ms. Hamilton
was appointed to the Board at the request of Ekso Bionics in connection with the reverse merger due to, among other factors, her
35 years of leadership expertise in business, the medical rehab industry, and her dedication to, and organizational and governance
experience gained from non-for-profit service. Ms. Hamilton holds a bachelor of sciences degree in Education and Secondary Teaching
Credential from California Polytechnic State University, San Luis Obispo.
Jack Peurach – Director
Mr. Peurach has served on the Board of
Directors of Ekso Bionics since January 2012. Since 2011, Mr. Peurach has been the Executive Vice President, Products for SunPower
Corp (NASDAQ: SPWR), where he is responsible for all aspects of SunPower's PV modules and residential, commercial and utility
PV systems. Prior to this role, from 2009 to 2011, Mr. Peurach served as Executive Vice President, Research and Development for
SunPower, where he led the research and development efforts of the PV Cells, Modules and Systems. From 2008 to 2009, Mr. Peurach
was the Vice President of the Advanced Product Development Group, and from 2007 to 2008, Mr. Peurach was the Senior Director of
Product Development at SunPower. Prior to SunPower's acquisition of PowerLight in 2007, Mr. Peurach served as PowerLight's Vice
President of Product Development. Earlier in his career, Mr. Peurach was a strategy consultant for Mercer Management Consulting
and director of engineering at Berkeley Process Control, Inc. He holds a Bachelor of Science degree in mechanical engineering
from Michigan State University, a Master of Science degree in mechanical engineering from the University of California, Berkeley,
and a Master of Business administration, finance and entrepreneurship from the Wharton School, University of Pennsylvania. Mr.
Peurach was appointed to the Board at the request of Ekso Bionics in connection with the reverse merger due to, among other factors,
his product development experience and strategic insight
.
Executive Officers
Russ Angold – Chief Technology
Officer
Mr. Angold is the Co-Founder and has served
as the Chief Technology Officer of Ekso Bionics since December 2011. From the founding of Ekso Bionics until December 2011, Mr.
Angold served as Vice President of Engineering. Prior to joining Ekso Bionics, Mr. Angold held various engineering positions at
Rain Bird Corporation, Berkeley Process Control and the Irrigation Training and Research Center in San Luis Obispo, California.
Mr. Angold is also the Founding President and Chairman of the Bridging Bionics Foundation. Mr. Angold is a registered Professional
Mechanical Engineer and holds a bachelor’s degree in BioResource and Agricultural Engineering from California Polytechnic
State University, San Luis Obispo.
Frank Moreman – Chief Operating
Officer
Mr. Moreman has served as the Chief Operating
Officer since November 2012. Previously, Mr. Moreman served as our Vice President of Manufacturing from July 2011 until November
2012. From January 2010 until joining Ekso Bionics, Mr. Moreman was an independent consultant, helping Silicon Valley companies
in the areas of management development and manufacturing capabilities. From August 2008 until January 2010, Mr. Moreman was the
Division Vice President for Sanmina-SCI's Semiconductor and Industrial Division, with manufacturing plants throughout the United
States and China. From October 2002 until being acquired by Ultra Clean Technology in July 2006, Mr. Moreman was Chief Operating
Officer and Owner of Sieger Engineering, a contract manufacturer serving the semiconductor and medical equipment markets. Following
the acquisition, Mr. Moreman remained with Ultra Clean as Vice President of Materials, Quality, and IT until leaving to join Sanmina
in 2008. Mr. Moreman received his BS in Mechanical Engineering from the United States Naval Academy.
Max Scheder-Bieschin – Chief
Financial Officer
Mr. Scheder-Bieschin joined Ekso Bionics
in January 2011 as its Chief Financial Officer. From November 2009 until he joined Ekso Bionics, Mr. Scheder-Bieschin was an independent
consultant for a number of emerging technology companies, including Ekso Bionics. From March 2007 to October 2009, he was co-founder
and CEO of Barefoot Motors, a designer and manufacturer of electric all-terrain vehicles. From October 2005 to February 2007,
Mr. Scheder-Bieschin served as President of ZAP, a publicly-traded distributor of electric vehicles. From August 1997 to March
2004, Mr. Scheder-Bieschin lived in Frankfurt, serving in senior investment banking roles for BHF-Bank, ING Barings and Deutsche
Bank. Mr. Scheder-Bieschin received his BA in economics from Stanford University. He attended New York University and Stanford
University’s Executive Program.
Director Independence
We are not currently subject to listing
requirements of any national securities exchange or inter-dealer quotation system which has requirements that a majority of the
board of directors be “independent” and, as a result, we are not at this time required to have our Board of Directors
comprised of a majority of “independent directors.” Nevertheless, our Board has determined that Messrs. Sherman, Boren
and Peurach and Ms. Hamilton are independent directors under the applicable standards of the SEC and the Nasdaq stock market.
Family Relationships
There are no family relationships among
our Directors or executive officers.
Involvement in Certain Legal Proceedings
None of our directors or executive officers
has been involved in any of the following events during the past ten years:
|
·
|
any
bankruptcy petition filed by or against any business of which such person was a general
partner or executive officer either at the time of the bankruptcy or within two years
prior to that time;
|
|
·
|
any
conviction in a criminal proceeding or being subject to a pending criminal proceeding
(excluding traffic violations and other minor offences);
|
|
·
|
being
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction, permanently or temporarily enjoining, barring,
suspending or otherwise limiting his or her involvement in any type of business, securities
or banking activities; or
|
|
·
|
being
found by a court of competent jurisdiction (in a civil action), the Commission or the
Commodity Futures Trading Commission to have violated a federal or state securities or
commodities law, and the judgment has not been reversed, suspended, or vacated.
|
Audit Committee
The Audit Committee currently consists
of Messrs. Sherman (Chairman) and Boren.
Each member of the Audit Committee is financially
sophisticated, as defined by the Marketplace Rules of NASDAQ, and able to read and understand fundamental financial statements,
including the Company’s consolidated balance sheet, consolidated statement of income and consolidated statement of cash
flows.
The Board of Directors has determined that Steven Sherman is an “audit committee financial expert” within
the meaning of Item 407(d)(5) for SEC regulation S-K.
Compensation Committee; Compensation
Committee Interlocks and Insider Participation
The Compensation Committee was formed
by the Board in February 2014, and currently consists of Messrs. Peurach (Chairman) and Sherman. Prior to February 2014, the Company
did not have a Compensation Committee.
No executive officer of the Company has
served as a director or member of the Compensation Committee (or other committee serving an equivalent function) of any other
entity, one of whose executive officers served as director of the Company during 2013.
Other Committees
We do not currently have a separately-designated
standing nominating committee. Further, we do not have a policy with regard to the consideration of any director candidates recommended
by security holders. To date, other than as described below, no security holders have made any such recommendations. The entire
Board of Directors performs all functions that would otherwise be performed by committees. Given the present size of our Board,
it is not practical for us to have committees other than those described above, or to have more than two directors on such committees.
If we are able to grow our business and increase our operations, we intend to expand the size of our board and our committees
and allocate responsibilities accordingly.
Director Nomination Agreement
Prior to the consummation of the Merger,
the Company entered into a director nomination agreement with Ekso Bionics’ largest shareholder, CNI Commercial LLC (“CNI”).
See “Certain Relationships and Related Party Transactions.”
EXECUTIVE COMPENSATION
Summary Compensation Table
The following table sets forth information
concerning the total compensation paid or accrued by us and by Ekso Bionics during the last two fiscal years indicated to (i)
all individuals that served as our or Ekso Bionics’ principal executive officer or acted in a similar capacity for us or
Ekso Bionics at any time during the most recent fiscal year indicated; (ii) the two most highly compensated executive officers
who were serving as executive officers of us or Ekso Bionics at the end of the most recent fiscal year indicated; and (iii) up
to two additional individuals for whom disclosure would have been provided pursuant to clause (ii) above but for the fact that
the individual was not serving as an executive officer of us or Ekso Bionics at the end of the most recent fiscal year indicated.
Name &
Principal
Position
|
|
Fiscal
Year
ended
March 31,
|
|
|
Salary
($)
|
|
|
Option
Awards($)
|
|
|
Total ($)
|
|
Pedro Perez Niklitschek,
|
|
|
2013
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
CEO of the Company (1)
|
|
|
2012
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Miguel Molina Urra,
|
|
|
2013
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Secretary of the Company (1)
|
|
|
2012
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Name &
Principal
Position
|
|
Fiscal
Year
ended
December 31,
|
|
|
Salary
($)
|
|
|
Option
Awards($)(2)
|
|
|
Total ($)
|
|
Nathan Harding,
|
|
|
2013
|
|
|
|
137,752
|
|
|
|
6,966
|
|
|
|
144,718
|
|
CEO of Ekso Bionics
|
|
|
2012
|
|
|
|
209,549
|
|
|
|
87,097
|
|
|
|
296,646
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Max Scheder-Bieschin,
|
|
|
2013
|
|
|
|
144,768
|
|
|
|
6,966
|
|
|
|
151,734
|
|
CFO of Ekso Bionics
|
|
|
2012
|
|
|
|
200,445
|
|
|
|
87,097
|
|
|
|
287,542
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Russ Angold,
|
|
|
2013
|
|
|
|
151,933
|
|
|
|
6,966
|
|
|
|
158,899
|
|
CTO of Ekso Bionics
|
|
|
2012
|
|
|
|
213,945
|
|
|
|
87,097
|
|
|
|
301,042
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frank Moreman,
|
|
|
2013
|
|
|
|
165,938
|
|
|
|
95,066
|
|
|
|
261,004
|
|
COO of Ekso Bionics
|
|
|
2012
|
|
|
|
218,757
|
|
|
|
17,419
|
|
|
|
236,176
|
|
|
(1)
|
On January
15, 2014, Messrs. Perez Niklitschek and Molina Urra resigned from these positions.
|
|
(2)
|
The amounts
in the "Option Awards" column reflect the aggregate grant date fair value of
stock options granted during the year computed in accordance with the provisions of ASC
718. The assumptions that we used to calculate these amounts are discussed in Note 14
to our financial statements included in this prospectus. In connection with the Merger,
the exercise prices for all outstanding options were adjusted to reflect the conversion
ratio used in the Merger.
|
We have no plans in place and have never
maintained any plans that provide for the payment of retirement benefits or benefits that will be paid primarily following retirement
including, but not limited to, tax qualified deferred benefit plans, supplemental executive retirement plans, tax-qualified deferred
contribution plans and nonqualified deferred contribution plans, except that the Company maintains a 401(k) plan in which all
eligible employees may participate by making elective deferral contributions to the plan. The Company does not make any matching
contributions to the plan.
Except as indicated below, we have no
contracts, agreements, plans or arrangements, whether written or unwritten, that provide for payments to the named executive officers
listed above.
Outstanding Equity Awards at Fiscal Year-End
We have one compensation plan approved
by our stockholders, the 2014 Plan. As of the end of our last completed fiscal year, we had not granted any awards under the 2014
Plan. In connection with the Merger, options to purchase 4,978,645 shares of Ekso Bionics common stock were converted into options
to purchase 7,586,459 shares of our Common Stock. Options to purchase an aggregate of 2,300,000 shares of our Common Stock were
awarded upon the closing of the Merger to our executive officers and directors and options to purchase 877,952 shares of our Common
Stock were granted to our employees subsequent to the Merger. See “Description of Securities—Options” below
for more information.
The following table sets forth certain
information concerning stock options held by the Named Executive Officers as of December 31, 2013.
Name
|
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
(#)
|
|
|
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)
|
|
|
Option
Exercise
Price
($)(1)
|
|
|
Option
Expiration
Date
|
|
Pedro Perez Niklitschek
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Miguel Molina Urra
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Nathan Harding
|
|
|
111,110
|
(2)
|
|
|
155,555
|
|
|
$
|
0.5381
|
|
|
|
4/24/2022
|
|
Nathan Harding
|
|
|
0
|
(3)
|
|
|
20,513
|
|
|
$
|
0.5381
|
|
|
|
7/15/2023
|
|
Max Scheder-Bieschin
|
|
|
177,777
|
(2)
|
|
|
66,031
|
|
|
$
|
0.3898
|
|
|
|
1/10/2021
|
|
Max Scheder-Bieschin
|
|
|
128,888
|
(2)
|
|
|
84,444
|
|
|
$
|
0.3898
|
|
|
|
7/20/2021
|
|
Max Scheder-Bieschin
|
|
|
111,110
|
(2)
|
|
|
155,555
|
|
|
$
|
0.5381
|
|
|
|
4/24/2022
|
|
Max Scheder-Bieschin
|
|
|
0
|
(3)
|
|
|
20,513
|
|
|
$
|
0.5381
|
|
|
|
7/15/2023
|
|
Russ Angold
|
|
|
111,110
|
(2)
|
|
|
155,555
|
|
|
$
|
0.5381
|
|
|
|
4/24/2022
|
|
Russ Angold
|
|
|
0
|
(3)
|
|
|
20,513
|
|
|
$
|
0.5381
|
|
|
|
7/15/2023
|
|
Frank Moreman
|
|
|
92,063
|
(2)
|
|
|
60,317
|
|
|
$
|
0.3898
|
|
|
|
7/11/2021
|
|
Frank Moreman
|
|
|
22,222
|
(2)
|
|
|
31,111
|
|
|
$
|
0.5381
|
|
|
|
4/24/2022
|
|
Frank Moreman
|
|
|
0
|
(3)
|
|
|
279,940
|
|
|
$
|
0.5381
|
|
|
|
7/15/2023
|
|
|
(1)
|
Reflects the exercise price
of the options after taking into account the adjustment of the exercise price in connection
with the Merger to reflect the conversion ratio used in the Merger.
|
|
(2)
|
Option becomes exercisable
as to 25% of the total number of shares on the first anniversary of the date of grant,
and thereafter vests in equal monthly installments for 36 months.
|
|
(3)
|
Option becomes exercisable
as to 12.5% of the total number of shares on the six-month anniversary of the date of
grant, and thereafter vests in equal monthly installments for 42 months.
|
Employment Agreements
On January 15, 2014, in connection with
the Merger, we entered into a two-year employment agreement with each of Messrs. Harding, Scheder-Bieschin, Angold and Moreman
(each, a “named executive officer”). After the initial two-year term, the agreements shall be automatically
renewed for successive one year periods unless terminated by a party on at least 30 days written notice prior to the end of the
then-current term. The base salary for each of Messrs. Harding, Scheder-Bieschin, Angold and Moreman is $275,000, $225,000, $225,000
and $225,000, respectively, in each case subject to increase as determined by our Board of Directors.
Each of our named executive officers other
than Mr. Harding is eligible, at the discretion of Chief Executive Officer or Board of Directors, to receive an annual bonus
of up to 30% of his annual base salary based on us achieving certain operational, financial or other milestones (the “Milestones”)
established by our Chief Executive Officer or Board of Directors in consultation with the named executive officer. Mr. Harding
is eligible, at the discretion of our Board of Directors, to receive an annual bonus of up to 50% of his annual base salary
based on us achieving the Milestones established by our Board of Directors in consultation with Mr. Harding. All or any portion
of the annual bonus may be paid in cash, securities or other property.
Each of our named executive officers is
entitled to receive perquisites and other fringe benefits that may be provided to, and is eligible to participate in any other
bonus or incentive program established by us, for our executives. Each named executive officer and his dependents are also
entitled to participate in any of our employee benefit plans subject to the same terms and conditions applicable to other employees.
Each named executive officer will be entitled to be reimbursed for all reasonable travel, entertainment and other expenses incurred
or paid by him in connection with, or related to, the performance of his duties, responsibilities or services under his employment
agreement, in accordance with policies and procedures, and subject to limitations, adopted by us from time to time.
In connection with the Merger, we granted
options to purchase 900,000 shares of our common stock to Mr. Harding, options to purchase 350,000 shares of our common stock
to Mr. Moreman and options to purchase 300,000 shares of our common stock to each of Messrs. Angold and Scheder-Bieschin, in each
case exercisable at a price of $1.00 per share, under our 2014 Plan. The options will become exercisable over a 4-year period,
with 1/4 of the shares becoming exercisable on the first anniversary of the date of grant and with 1/48 of the shares becoming
exercisable at the end of each month thereafter, and subject to Change of Control (as defined in his employment agreement), provided
that the named executive officer is employed by us or any of our subsidiaries on each vesting date.
In the event that a named executive officer
is terminated by us without Cause (as defined in his employment agreement) or he resigns for Good Reason (as defined in his employment
agreement) during the term of his employment, the named executive officer would be entitled to (x) an amount equal to his annual
base salary then in effect (payable in accordance with the Company’s normal payroll practices) for a period of 12 months
commencing on the effective date of his termination (the “Severance Period”), plus any accrued but unused vacation,
and (y) if and to the extent the Milestones are achieved for the annual bonus for the year in which the Severance Period commences
(or, in the absence of Milestones, our Board of Directors has, in its sole discretion, otherwise determined an amount of the named
executive officer’s annual bonus for such year), an amount equal to such annual bonus pro-rated for the portion of the performance
year completed before the named executive officer’s employment terminated, (z) any of his stock options, restricted stock
or similar incentive equity instruments, including the option grant summarized above, that would first have become vested or exercisable
during the Severance Period if the named executive officer continued to be employed by the Company. For the duration of the Severance
Period, the named executive officer will also be eligible to participate in our group health plan on the same terms applicable
to similarly situated active employees during the Severance Period, provided he was participating in such plan immediately prior
to the date of employment termination, and each other benefit program to the extent permitted under the terms of such program
(collectively, the “Termination Benefits”). If a named executive officer’s employment is terminated during
the term by us for Cause, by the named executive officer for any reason other than Good Reason or due to his death, then he will
not be entitled to receive the Termination Benefits, and shall only be entitled to the compensation and benefits which shall have
accrued as of the date of such termination (other than with respect to certain benefits that may be available to the named executive
officer as a result of a “disability” (as defined in his employment agreement)).
Director Compensation
Non-employee directors’ compensation
generally is determined and awarded by the Board. The Board is responsible for, among other things, reviewing, evaluating and
designing a director compensation package of a reasonable total value, typically based on comparisons with similar firms, and
aligned with long-term interests of the stockholders of the Company, and reviewing director compensation levels and practices
and considering, from time to time, changes in such compensation levels and practices. These matters also include making equity
awards to non-employee directors from time to time under the Company’s equity-based plans. As part of these responsibilities,
the Board may request that management of the Company provide it with recommendations on non-employee director compensation and/or
common director compensation practices, although the Board retains its ultimate authority to take compensatory actions.
The Company currently pays its non-employee
directors an annual retainer of $10,000. In addition, the Company will pay each member of a standing Board committee, once they
are established, an annual retainer of $5,000 per committee, except that the chairperson of the Audit Committee shall be paid
an annual retainer of $30,000 and the chairperson of the Compensation Committee shall be paid an annual retainer of $10,000. In
addition, the Company pays the Chairman of the Board an additional cash retainer of $5,000 per month.
The Company also grants to each new director
(not including those directors who were previously serving on the board of directors of Ekso Bionics) an option to purchase 100,000
shares of the Company’s common stock.
In connection with the Merger, Steven
Sherman was elected Chairman of the Board and granted an option to purchase 300,000 shares of the Company’s common stock.
Also in connection with the Merger, Marilyn Hamilton, Dan Boren and Jack Peurach, were each granted an option to purchase 50,000
shares of the Company’s common stock. Each of the option awards were made under our 2014 Plan, have an exercise price of
$1.00 per share and will become exercisable over a 4-year period, with 1/4 of the shares becoming exercisable on the first anniversary
of the date of grant and with 1/48 of the shares becoming exercisable at the end of each month thereafter.
The following table sets forth compensation
actually paid to or earned or accrued by Ekso Bionics’ directors during 2013:
Name
|
|
Fees earned
or paid in
cash
($)
|
|
|
Stock awards
($)
|
|
|
Option
awards
($)(1)
|
|
|
All other
compensation
($)
|
|
|
Total
($)
|
|
Steven Sherman
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Daniel Boren (2)
|
|
|
—
|
|
|
|
—
|
|
|
$
|
48,698
|
|
|
|
—
|
|
|
$
|
48,698
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marilyn Hamilton (3)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jack Peurach (4)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
(1)
|
The amounts in the “Option
Awards” column reflect the aggregate grant date fair value of stock options granted
during the year computed in accordance with the provisions of ASC 718. The assumptions
that we used to calculate these amounts are discussed in Note 14 to our financial
statements included in this prospectus. In connection with the Merger, the exercise prices
for all outstanding options were adjusted to reflect the conversion ratio used in the
Merger.
|
|
(2)
|
Reflects the grant of an option
to purchase 100,000 shares of Ekso Bionics’ common stock on April 25, 2013 in connection
with Mr. Boren’s appointment as a director. As of December 31, 2013, Mr. Boren
held options to purchase 152,380 shares of Common Stock at an exercise price of $0.5381
per share.
|
|
(3)
|
As of December 31, 2013, Ms.
Hamilton held options to purchase 152,380 shares of Common Stock at an exercise price
of $0.4594 per share.
|
|
(4)
|
As of December 31, 2013, Mr.
Peurach held options to purchase 152,380 shares of Common Stock at an exercise price
of $0.4594 per share.
|
SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Beneficial ownership is determined
in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. In
accordance with SEC rules, shares of our Common Stock which may be acquired upon exercise of stock options or warrants which
are currently exercisable or which become exercisable within 60 days after June 20, 2014 (the “Determination
Date”) are deemed beneficially owned by the holders of such options and warrants and are deemed outstanding for the
purpose of computing the percentage of ownership of such person, but are not treated as outstanding for the purpose of
computing the percentage of ownership of any other person. Subject to community property laws, where applicable, the persons
or entities named in the tables below have sole voting and investment power with respect to all shares of our Common Stock
indicated as beneficially owned by them.
The following table sets forth information
with respect to the beneficial ownership of our Common Stock as of the Determination Date by (i) each stockholder known by us
to be the beneficial owner of more than 5% of our Common Stock (our only classes of voting securities), (ii) each of our directors
and executive officers, and (iii) all of our directors and executive officers as a group. To the best of our knowledge, except
as otherwise indicated, each of the persons named in the table has sole voting and investment power with respect to the shares
of our Common Stock beneficially owned by such person, except to the extent such power may be shared with a spouse. To our knowledge,
none of the shares listed below are held under a voting trust or similar agreement, except as noted. Other than the Merger, to
our knowledge, there is no arrangement, including any pledge by any person of securities of the Company or any of its parents,
the operation of which may at a subsequent date result in a change in control of the Company.
The address for each director and executive
officer named in the table is c/o Ekso Bionics Holdings, Inc., 1414 Harbour Way South, Suite 1201, Richmond, California 94804,
USA.
Name and address of beneficial owner
|
|
Amount and
nature of
beneficial ownership
|
|
|
Percent of
class (1)
|
|
|
|
|
|
|
|
|
|
|
Directors
|
|
|
|
|
|
|
|
|
Steven Sherman (2)
|
|
|
2,885,482
|
|
|
|
3.7
|
%
|
Nathan Harding (3)
|
|
|
5,610,271
|
|
|
|
7.1
|
%
|
Daniel Boren (4)
|
|
|
87,619
|
|
|
|
*
|
|
Marilyn Hamilton (5)
|
|
|
495,238
|
|
|
|
*
|
|
Jack Peurach (6)
|
|
|
182,095
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
Executive Officers
|
|
|
|
|
|
|
|
|
Nathan Harding (3)
|
|
|
5,610,271
|
|
|
|
7.2
|
%
|
Max Scheder-Bieschin (7)
|
|
|
571,799
|
|
|
|
*
|
|
Russ Angold (8)
|
|
|
3,479,502
|
|
|
|
4.4
|
%
|
Frank Moreman (9)
|
|
|
224,627
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
All directors,
nominees and executive officers as a group (8 persons) (10)
|
|
|
13,536,633
|
|
|
|
17.2
|
%
|
|
|
|
|
|
|
|
|
|
5% Shareholders
|
|
|
|
|
|
|
|
|
Opaleye L.P. (11)
29 Colonial Way
Weston, MA 02493
|
|
|
19,000,000
|
|
|
|
24.2
|
%
|
CNI Commercial LLC (12)
2020 Lonnie Abbott Blvd.
Ada, OK 74820
|
|
|
10,129,599
|
|
|
|
12.9
|
%
|
Bionic Partners, LLC (13)
546 Fifth Avenue
New York, NY 10036
|
|
|
6,771,737
|
|
|
|
8.6
|
%
|
Homayoon Kazerooni (14)
2806 Ashby Ave
Berkeley, CA 94705
|
|
|
4,945,091
|
|
|
|
6.3
|
%
|
Mark Tompkins (15)
Via Guidino 23
6900 Lugano-Paradiso
Switzerland
|
|
|
5,072,348
|
|
|
|
6.5
|
%
|
* Less than 1%
|
(1)
|
Applicable percentage ownership
is based on 78,497,558 shares of Common Stock outstanding as of the Determination Date.
|
|
(2)
|
Includes warrants to purchase
1,500,000 shares of Common Stock currently exercisable and 1,385,482 shares of common
stock. Excludes 20,289 Indemnity Shares over which Mr. Sherman does not currently exercise
voting or dispositive power.
|
|
(3)
|
Includes
options to purchase 149,999 of Common Stock currently exercisable or exercisable within
60 days after the Determination Date and 3,329,503 shares of Common Stock. Also includes
2,130,769 Indemnity Shares which Mr. Harding may be deemed to beneficially own as a result
of his right to vote such shares as Indemnification Representative under the Indemnification
Shares Escrow Agreement dated January 15, 2014, entered into in connection with the Merger
and the PPO. Mr. Harding disclaims beneficial ownership of all but 175,237 of such Indemnity
Shares.
|
|
(4)
|
Includes
options to purchase 47,619 of Common Stock currently exercisable or exercisable within
60 days after the Determination Date, warrants to purchase 20,000 shares of Common Stock
currently exercisable and 20,000 shares of common stock.
|
|
(5)
|
Includes
options to purchase 95,238 of Common Stock currently exercisable or exercisable within
60 days after the Determination Date, warrants to purchase 200,000 shares of Common Stock
currently exercisable and 200,000 shares of common stock.
|
|
(6)
|
Includes
options to purchase 95,238 shares of Common Stock currently exercisable or exercisable
within 60 days after the Determination Date and 86,857 shares of Common Stock. Excludes
4,571 Indemnity Shares over which Mr. Peurach does not currently exercise voting or dispositive
power.
|
|
(7)
|
Includes
options to purchase 513,171 shares of Common Stock currently exercisable or exercisable
within 60 days after the Determination Date and 58,628 shares of Common Stock. Excludes
3,086 Indemnity Shares over which Mr. Scheder-Bieschin does not currently exercise voting
or dispositive power.
|
|
(8)
|
Includes
options to purchase 149,999 shares of Common Stock currently exercisable or exercisable
within 60 days after the Determination Date and 3,329,503 shares of Common Stock. Excludes
175,237 Indemnity Shares over which Mr. Angold does not currently exercise voting or
dispositive power.
|
|
(9)
|
Includes
options to purchase 144,285 shares of Common Stock currently exercisable or exercisable
within 60 days after the Determination Date and 80,342 shares of Common Stock. Excludes
4,229 Indemnity Shares over which Mr. Moreman does not currently exercise voting or dispositive
power.
|
|
(10)
|
Includes warrants to purchase
1,720,000 shares of Common Stock currently exercisable, options to purchase 1,135,391
shares of Common Stock currently exercisable or exercisable within 60 days after the
Determination Date and 8,872,964 shares of Common Stock. Also includes 2,130,769 Indemnity
Shares which Mr. Harding may be deemed to beneficially own as a result of his right to
vote such shares as Indemnification Representative under the Indemnification Shares Escrow
Agreement dated January 15, 2014, entered into in connection with the Merger and the
PPO.
|
|
(11)
|
Includes warrants to purchase
8,500,000 shares of Common Stock currently exercisable and 8,500,000 shares of Common
Stock, each held by Opaleye L.P. Also includes warrants to purchase 1,000,000 shares
of Common Stock and 1,000,000 shares of Common Stock held by Silverman Insurance Partnership.
James Silverman may be deemed to have voting and/or disposition control with respect
to the shares held by Opaleye L.P. and Silverman Insurance Partnership. The business
address of Opaleye L.P. is 9B Russell Street, Cambridge MA 02140.
|
|
(12)
|
Includes warrants to purchase
279,645 shares of Common Stock currently exercisable and 9,849,954 shares of Common Stock.
Excludes 518,419 Indemnity Shares over which CNI Commercial LLC does not currently exercise
voting or dispositive power. CNI Commercial LLC is a wholly-owned subsidiary of Chickasaw
Nation Industries, Inc. (“CNI”). CNI and its President and Chief Executive
Officer, David Nimmo, may be deemed to have voting and/or dispositive power with respect
to the shares held by CNI Commercial LLC. The business address of CNI Commercial LLC
is 2020 Lonnie Abbott Blvd., Ada, OK 74820.
|
|
(13)
|
Includes warrants to purchase
2,554,089 shares of Common Stock currently exercisable and 4,217,648 shares of Common
Stock. Excludes 93,297 Indemnity Shares over which Bionic Partners, LLC does not currently
exercise voting or dispositive power. The managing partner of Bionic Partners, LLC is
Hugh Regan. The mailing address for Bionic Partners, LLC is 546 5
th
Avenue,
5
th
Floor, New York, NY 10036.
|
|
(14)
|
Includes
options to purchase 457,140 shares of Common Stock currently exercisable or exercisable
within 60 days after the Determination Date and 4,487,951 shares of Common Stock. Excludes
236,189 Indemnity Shares over which Mr. Kazerooni does not currently exercise voting
or dispositive power. The mailing address of Professor Kazerooni is c/o University of
California at Berkeley, 6147 Etcheverry Hall, Mailstop 1740, Berkeley, CA 94720.
|
|
(15)
|
Includes
warrants to purchase 1,500,000 shares of Common Stock currently exercisable and 3,572,348
shares of Common Stock. The mailing address of Mr. Tompkins is Via Guidino, App.1, 6900
Lugano – Paradiso, Switzerland.
|
CERTAIN RELATIONSHIPS
AND RELATED PARTY TRANSACTIONS
SEC rules require us to disclose any transaction
or currently proposed transaction in which the Company is a participant and in which any related person has or will have a direct
or indirect material interest involving the lesser of $120,000.00 or one percent (1%) of the average of the Company’s total
assets as of the end of last two completed fiscal years. A related person is any executive officer, director, nominee for director,
or holder of 5% or more of the Company’s common stock, or an immediate family member of any of those persons.
The descriptions set forth above under
the captions “Executive Compensation—Employment Agreements” and —Director Compensation” and below
under “Description of Securities—Options” are incorporated herein by reference.
Merger Agreement
On January 15, 2014 (the “Closing
Date”), the Company, Acquisition Sub and Ekso Bionics entered into an Agreement and Plan of Merger and Reorganization (the
“Merger Agreement”), which closed on the same date. Pursuant to the terms of the Merger Agreement, Acquisition
Sub merged with and into Ekso Bionics, which was the surviving corporation and thus became our wholly-owned subsidiary.
Pursuant to the Merger, we acquired the
business of Ekso Bionics to design, develop and commercialize human exoskeletons to augment human strength, endurance and mobility.
At the closing of the Merger:
|
·
|
each
of the 10,450,500 shares of Ekso Bionics’ common stock issued and outstanding immediately
prior to the closing of the Merger was converted into 1.5238 shares of our Common Stock;
|
|
·
|
each
of the 4,624,840 shares of Ekso Bionics’ Series A preferred stock issued and outstanding
immediately prior to the closing of the Merger was converted into 1.6290 shares of our
Common Stock; and
|
|
·
|
each
of the 9,800,087 shares of Ekso Bionics’ Series A-2 and Series B preferred stock
issued and outstanding immediately prior to the closing of the Merger was converted into
1.9548 shares of our Common Stock.
|
As a result, an aggregate of 42,615,556
shares of our Common Stock were issued to the holders of Ekso Bionics’ stock.
In addition, pursuant to the Merger
Agreement:
|
·
|
warrants
to purchase 407,772 shares of Ekso Bionics’ common stock issued and outstanding
immediately prior to the closing of the Merger were converted into warrants to purchase
shares of our Common Stock at a conversion ratio of 1.5238 for one; and
|
|
·
|
options
to purchase 4,978,645 shares of Ekso Bionics’ common stock issued and outstanding
immediately prior to the closing of the Merger were converted into options to purchase
shares of our Common Stock at a conversion ratio of 1.5238 for one.
|
As a result, warrants
to purchase an aggregate of 621,363 shares of our Common Stock and options to purchase an aggregate of 7,586,459 shares of our
Common Stock were issued in connection with the Merger. See “Description of Securities—Warrants” and “—Options”
below for more information.
The Merger Agreement contained customary
representations and warranties and pre- and post-closing covenants of each party and customary closing conditions. Breaches of
the representations and warranties will be subject to certain indemnification provisions. Each of the stockholders of Ekso Bionics
as of the date of the Merger initially received in the Merger 95% of the shares to which each such stockholder is entitled, with
the remaining 5% of such shares being held in escrow for one year to satisfy post-closing claims for indemnification by the Company
(“Indemnity Shares”). Any of the Indemnity Shares remaining in escrow at the end of such one-year period shall
be distributed to the pre-Merger stockholders of Ekso Bionics on a pro rata basis. The Merger Agreement also contains a
provision providing for a post-Merger share adjustment as a means for which claims for indemnity may be made by the pre-Merger
stockholders of Ekso Bionics. Pursuant to this provision up to 1,000,000 additional shares (“R&W Shares”)
of Common Stock may be issued to the pre-Merger stockholders of Ekso, pro rata, during the one-year period following the Merger
for breaches of representations and warranties by the Company. The value of the Indemnity Shares and the R&W Shares
issued pursuant to the foregoing adjustment mechanisms is fixed at $1.00 per share. The foregoing mechanisms are the exclusive
remedies of the Company on one hand and the pre-Merger stockholders of Ekso Bionics for satisfying indemnification claims under
the Merger Agreement.
The Merger will be treated as a recapitalization
of the Company for financial accounting purposes. Ekso Bionics will be considered the acquirer for accounting purposes, and our
historical financial statements before the Merger will be replaced with the historical financial statements of Ekso Bionics before
the Merger in all future filings with the SEC.
The Merger is intended to be treated as
a tax-free reorganization under Section 368(a) of the Internal Revenue Code of 1986, as amended.
The issuance of shares of our Common Stock
to holders of Ekso Bionics’ capital stock in connection with the Merger was not registered under the Securities Act, in
reliance upon the exemption from registration provided by Section 4(2) of the Securities Act, which exempts transactions by an
issuer not involving any public offering, and Regulation D promulgated by the SEC under that section. These securities may not
be offered or sold in the United States absent registration or an applicable exemption from the registration requirement, and
some of these securities are subject to further contractual restrictions on transfer as described below.
We also agreed not to register under the
Securities Act the resale of the shares of our Common Stock received in the Merger by our officers, directors and key employees
and holders of 10% or more of our Common Stock for a period of two years following the closing of the Merger, provided that the
foregoing will not prohibit us from registering for resale shares of Common Stock held by such persons with the written approval
of the lead underwriter of any future underwritten public offering of our securities for gross proceeds of at least $25 million.
The form of the Merger Agreement is filed
as an exhibit to the registration statement of which this prospectus is a part. All descriptions of the Merger Agreement herein
are qualified in their entirety by reference to the text thereof filed as an exhibit hereto, which is incorporated herein by reference
.
Split-Off
Upon the closing of the Merger, under
the terms of a split-off agreement and a general release agreement, the Company transferred all of its pre-Merger operating assets
and liabilities to its wholly-owned special-purpose subsidiary, PN Med Split Off Corp, a Delaware corporation (“Split-Off
Subsidiary”), formed on January 7, 2014. Thereafter, pursuant to the split-off agreement, the Company transferred all of
the outstanding shares of capital stock of Split-Off Subsidiary to Pedro Perez Niklitschek and Miguel Molina Urra, the pre-Merger
majority stockholders of the Company, and the former officers and sole director of the Company (the “Split-Off”),
in consideration of and in exchange for (i) the surrender and cancellation of an aggregate of 17,483,100 shares of our Common
Stock held by Messrs. Perez Niklitschek and Molina Urra (which were cancelled and will resume the status of authorized but unissued
shares of our Common Stock) and (ii) certain representations, covenants and indemnities. All descriptions of the split-off agreement
and the general release agreement herein are qualified in their entirety by reference to the text thereof filed as exhibits hereto,
which are incorporated herein by reference.
The Bridge Financing
In November 2013, Ekso Bionics offered
and sold in a private placement to accredited investors $5,000,000 principal amount of its senior subordinated secured convertible
notes (the “Bridge Notes”). The Bridge Notes bore interest at 10% per annum and were payable on July 15, 2014, subject
to earlier conversion as described below.
Interest on the Bridge Notes would have
been payable at maturity; however, upon conversion of the Bridge Notes as described below, accrued interest was forgiven. The
Bridge Notes were secured by a second priority security interest on all of the assets of Ekso Bionics and its subsidiary, subject
to certain limited exceptions. This security interest terminated upon conversion of the Bridge Notes.
Upon the closing of the Merger and the
PPO, the outstanding principal amount of the Bridge Notes was automatically converted into Units of our securities (as described
below under “The Private Placement Offering”) at a conversion price of $1.00 per Unit, and investors in the Bridge
Notes received a warrant to purchase a number of shares of Common Stock equal to 50% of the number of shares of Common Stock contained
in the Units into which the Bridge Notes were converted, at an exercise price of $1.00 per share for a term of three years (the
“Bridge Warrants”). The Bridge Warrants have weighted average anti-dilution protection, subject to customary exceptions.
See “Description of Securities – Warrants” below.
In connection with the sale of the Bridge
Notes, Ekso Bionics paid to Gottbetter Capital Markets, LLC (the “Placement Agent”), a registered broker-dealer, cash
commissions of 10% of funds raised and issued to it warrants to purchase a number of shares of our Common Stock equal to 10% of
the number of shares of Common Stock into which Bridge Notes would convert at the closing of the Merger and PPO, with an exercise
price per share of $1.00 and a term of five years (“Bridge Agent Warrants”). The Bridge Agent Warrants have weighted
average anti-dilution protection, subject to customary exceptions. See “Description of Securities—Warrants”
below.
The Placement Agent and its sub-agents
were paid an aggregate commission of $500,000 and were issued Bridge Agent Warrants to purchase an aggregate of 500,000 shares
of our Common Stock. We also reimbursed the Placement Agent $25,000 for its legal and other expenses incurred in connection with
the Bridge Financing.
We agreed to indemnify the Placement Agent
and its sub-agents to the fullest extent permitted by law, against certain liabilities that may be incurred in connection with
the Bridge Notes, including certain civil liabilities under the Securities Act, and, where such indemnification is not available,
to contribute to the payments the placement agents and its sub-agents may be required to make in respect of such liabilities.
All descriptions of the Bridge Warrants
and the Bridge Agent Warrants herein are qualified in their entirety by reference to the text thereof filed as exhibits hereto,
which are incorporated herein by reference.
The Private Placement Offering
Concurrently with the closing of the Merger
and in contemplation of the Merger, we held a closing of our PPO in which we sold 20,580,000 Units (including Units issued upon
conversion of the Bridge Notes as described above) of our securities, at a purchase price of $1.00 per Unit, each Unit consisting
of one share of our Common Stock and a PPO Warrant. In addition, as a result of the foregoing, we issued to the holders of the
Bridge Notes prior to the merger Bridge Warrants to purchase 2,500,000 shares of our Common Stock. Between January 29, 2014 and
February 6, 2014, we issued an additional 9,720,000 Units in subsequent closings of the PPO.
Investors in the Units have weighted average
anti-dilution protection with respect to the shares of Common Stock included in the Units if within 24 months after the final
closing of the PPO the Company shall issue additional shares of Common Stock or Common Stock equivalents (subject to customary
exceptions, including but not limited to issuances of awards under the Company’s 2014 Plan (as defined below)) for consideration
per share less than $1.00. The PPO Warrants have weighted average anti-dilution protection, subject to customary exceptions. The
aggregate gross proceeds of the PPO were $30,300,000 (including the aggregate principal amount of Bridge Notes converted and before
deducting placement agent fees and expenses of the offering estimated at approximately $4,200,000).
The PPO was exempt from registration under
Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon the exemption provided
by Regulation D promulgated by the SEC thereunder. The PPO was sold to “accredited investors,” as defined in Regulation
D, and was conducted on a “best efforts” basis.
The closing of the PPO and the closing
of the Merger were conditioned upon each other.
Mr. Boren and Ms. Hamilton, each a director
of the Company, purchased 20,000 and 200,000 Units, respectively, in the PPO.
In connection with the PPO, we agreed
to pay the Placement Agent a cash commission of 10% (or 2% in the case of certain named investors) of the gross proceeds raised
from investors in the PPO. In addition, the Placement Agent received warrants to purchase a number of shares of Common Stock equal
to 10% (or 2% in the case of certain named investors) of the number of shares of Common Stock included in the Units sold in the
PPO, with a term of five years and an exercise price of $1.00 per share (the “PPO Agent Warrants”). The PPO Agent
Warrants have weighted average anti-dilution protection, subject to customary exceptions. In addition, we agreed to pay the Placement
Agent an additional cash commission of 5% of funds received by the Company from the exercise of Bridge Warrants and PPO Warrants
resulting from any future solicitation of the exercise of such warrants by the Company. Any sub-agent of the Placement Agent that
introduced investors to the PPO was entitled to share in the cash fees and warrants attributable to those investors as described
above.
As a result of the foregoing, the Placement
Agent and its sub-agents were paid an aggregate commission of $2,530,000 (not including the commission paid in connection with
the sale of the Bridge Notes) and were issued PPO Agent Warrants to purchase an aggregate of 2,530,000 shares of our Common Stock.
We were also required to reimburse the Placement Agent $17,500 of legal expenses incurred in connection with the PPO.
We agreed to indemnify the Placement Agent
and its sub-agents to the fullest extent permitted by law, against certain liabilities that may be incurred in connection with
the PPO, including certain civil liabilities under the Securities Act, and, where such indemnification is not available, to contribute
to the payments the placement agents and its sub-agents may be required to make in respect of such liabilities.
All descriptions of the PPO Warrants and
the PPO Agent Warrants herein are qualified in their entirety by reference to the text thereof filed as exhibits hereto, which
are incorporated herein by reference
.
Registration Rights
In connection with the PPO, we entered
into a Registration Rights Agreement, pursuant to which we have agreed that promptly, but no later than 90 calendar days from
the final closing of the PPO, the Company will file a registration statement with the SEC (the “Registration Statement”)
covering (a) the shares of Common Stock issued in the PPO (including those issued upon conversion of the Bridge Notes), (b) the
shares of Common Stock issuable upon exercise of the Bridge Warrants, (c) the shares of Common Stock issuable upon exercise of
the PPO Warrants, (d) the shares of Common Stock underlying Bridge Agent Warrants and PPO Agent Warrants and (e) 225,000 shares
of Common Stock underlying warrants issued to a lender
(the “Registrable Shares”). The Company must
use its commercially reasonable efforts to ensure that such Registration Statement is declared effective within 180 calendar days
after filing with the SEC. If the Company is late in filing the Registration Statement or if the Registration Statement is not
declared effective within 180 days after filing with the SEC, liquidated damages payable by the Company to the holders of Registrable
Shares (but excluding shares of Common Stock underlying Bridge Agent Warrants and PPO Agent Warrants) that have not been so registered
will commence to accrue and cumulate at a rate equal to 1.00% of the Offering Price per share for each full month that (i) the
Company is late in filing the Registration Statement or (ii) the Registration Statement is late in being declared effective by
the SEC; provided, however, that in no event shall the aggregate of any such liquidated damages exceed 8% of the PPO offering
price per share. No liquidated damages will accrue with respect to any Registrable Shares removed from the Registration Statement
in response to a comment from the staff of the SEC limiting the number of shares of Common Stock which may be included in the
Registration Statement (a “Cutback Comment”) or after the shares may be resold under Rule 144 under the Securities
Act or another exemption from registration under the Securities Act.
The Company must keep the Registration
Statement “evergreen” for one year from the date it is declared effective by the SEC or until Rule 144 is available
to the holders of Registrable Shares who are not and have not been affiliates of the Company with respect to all of their registrable
shares, whichever is earlier.
The holders of Registrable Shares (including
any shares of Common Stock removed from the Registration Statement as a result of a Cutback Comment) (but not holders of the shares
issued to the stockholders of Ekso Bionics in consideration for the Merger) shall have “piggyback” registration rights
for such Registrable Shares with respect to any registration statement filed by the Company following the effectiveness of the
Registration Statement that would permit the inclusion of such shares.
We will pay all expenses in connection
with any registration obligation provided in the Registration Rights Agreement, including, without limitation, all registration,
filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable securities laws, and the fees
and disbursements of our counsel and of our independent accountants. Each investor will be responsible for its own
sales commissions, if any, transfer taxes and the expenses of any attorney or other advisor such investor decides to employ.
All descriptions of the Registration Rights
Agreement herein are qualified in their entirety by reference to the text thereof filed as an exhibit hereto, which is incorporated
herein by reference
.
2014 Equity Incentive Plan
Before the Merger, our Board of Directors
adopted, and our stockholders approved, our 2014 Equity Incentive Plan (the “2014 Plan”), which provides for the issuance
of incentive awards of up to 14,410,000 shares of our Common Stock to officers, key employees, consultants and directors. In connection
with the Merger, options to purchase an aggregate of 7,586,459 shares of our Common Stock were issued under the 2014 Plan as described
above. See “Market Price of and Dividends on Common Equity and Related Stockholder Matters - Securities Authorized for Issuance
under Equity Compensation Plans” below for more information about the 2014 Plan and the outstanding stock options.
On the closing of the Merger, our Board
granted to our officers and directors options to purchase an aggregate of 2,300,000 shares of our Common Stock under the 2014
Plan. See “Description of Securities—Options” below for additional information about these awards.
Departure and Appointment of Directors
and Officers
Our Board of Directors currently consists
of five members. On the Closing Date, Pedro Perez Niklitschek, our sole director before the Merger, resigned his position as a
director, and Steven Sherman (Chairman), Nathan Harding, Daniel Boren, Marilyn Hamilton and Jack Peurach were appointed to the
Board of Directors.
Prior to consummation of the Merger, the
Company entered into an agreement with CNI, whereby the Company agreed to nominate Daniel Boren, or another individual designated
by CNI and reasonably acceptable to the remaining directors of the Company, for election as a director of the Company until the
earlier of such time as CNI no longer holds at least 10% of the Company’s outstanding voting securities, or the shares of
Common Stock held by CNI are no longer subject to a contractual lock-up agreement with the Company restricting the resale of such
shares of Common Stock.
Also on the Closing Date, Mr. Perez Niklitschek,
our Chief Executive Officer, President and Treasurer before the Merger, and Miguel Molina Urra, our Secretary before the Merger,
resigned from these positions, and Nathan Harding was appointed as our Chief Executive Officer and President, Max Scheder-Bieschin
was appointed as our Chief Financial Officer and Treasurer, Russ Angold was appointed as our Chief Technology Officer, and Frank
Moreman was appointed as our Chief Operating Officer by the Board.
See “Management – Directors
and Executive Officers” below for information about our new directors and executive officers.
Lock-up Agreements and Other Restrictions
In connection with the Merger, each of
our executive officers and directors named above and each person holding 10% or more of our Common Stock after giving effect to
the Merger, the Split-Off and the PPO (the “Restricted Holders”), holding at that date in the aggregate 19,021,337
shares of our Common Stock, entered into agreements (the “Lock-Up and No Shorting Agreements”), whereby they are restricted
for a period of 24 months after the Merger from certain sales or dispositions of shares of our Common Stock held by them immediately
after the Merger, except in certain limited circumstances.
Further, for a period of 24 months after
the Merger, each Restricted Holder has agreed in the Lock-Up and No Shorting Agreements to be subject to restrictions on engaging
in certain transactions, including effecting or agreeing to effect short sales, whether or not against the box, establishing any
“put equivalent position” with respect to our Common Stock, borrowing or pre-borrowing any shares of our Common Stock,
or granting other rights (including put or call options) with respect to our Common Stock or with respect to any security that
includes, relates to or derives any significant part of its value from our Common Stock, or otherwise seeks to hedge his position
in our Common Stock.
We agreed with each Restricted Holder
that, except in certain limited circumstances, we would not register for resale any of the shares of our Common Stock received
by stockholders of Ekso Bionics in exchange for their shares of Ekso Bionics’ common stock pursuant to the Merger (the “Merger
Shares”) unless we offer the Restricted Holders the opportunity to include the shares they received in the Merger in such
registration statement on a
pari passu
basis with the other Merger Shares.
Pro Forma Ownership
After giving effect to (i) the Merger
and (ii) the cancellation of 17,483,100 shares in the Split-Off, and (iii) the final closing of the PPO, there were 78,445,924
issued and outstanding shares of our Common Stock, as follows:
|
·
|
the
stockholders of Ekso Bionics prior to the Merger hold 42,615,556 shares of our Common
Stock;
|
|
·
|
the
stockholders of the Company prior to the Merger hold 5,280,368 shares of our Common Stock;
|
|
·
|
the
investors in the Bridge Notes and the PPO hold 30,300,000 shares of our Common Stock;
and
|
|
·
|
a
consultant was issued 250,000 shares of our Common Stock.
|
In addition,
|
·
|
investors
in the Bridge Notes hold Bridge Warrants to purchase 2,500,000 shares of our Common Stock;
|
|
·
|
investors
in the PPO hold PPO Warrants to purchase 30,300,000 shares of our Common Stock;
|
|
·
|
the
Placement Agent and its sub-agents hold:
|
|
○
|
Bridge
Agent Warrants to purchase 500,000 shares of our Common Stock; and
|
|
○
|
PPO
Agent Warrants to purchase 2,530,000 shares of our Common Stock;
|
|
·
|
holders
of warrants to purchase Ekso Bionics common stock prior to the Merger hold warrants to
purchase 621,363 shares of Common Stock;
|
|
·
|
warrants
to purchase an additional 225,000 shares of our Common Stock are held by Ekso Bionics’
prior lender; and
|
|
·
|
the
2014 Plan authorizes issuance of up to 14,410,000 shares of our Common Stock as incentive
awards to executive officers, key employees, consultants and directors; options to purchase
10,353,887 shares of Common Stock
have been granted and are outstanding under the 2014 Plan, and 4,004,479 shares remain
available for awards under the 2014 Plan.
|
We agreed in the Merger Agreement that
in the event that the aggregate gross proceeds of the PPO (including the principal of the Bridge Notes) exceed $20,000,000, we
will issue to the pre-Merger Company stockholders, pro rata, a number of restricted shares of our Common Stock such that the aggregate
ownership of the pre-Merger Company stockholders (not including any shares of Common Stock purchased by them in the PPO) remains
approximately 6.8% of our outstanding Common Stock as of the time of the Merger. We have issued an aggregate of 779,768 shares
of our Common Stock to such persons, which are included in the numbers set forth above.
No other securities convertible into or
exercisable or exchangeable for our Common Stock are outstanding.
Other Related Party Transactions
In November 2012, Ekso Bionics entered
a convertible bridge note agreement with CNI pursuant to which Ekso Bionics issued CNI a convertible bridge note in the aggregate
original principal amount of $3,190,000 in anticipation of closing a Series B convertible preferred stock financing in early 2013
(the “2012 CNI Bridge Note”). In March 2013, Ekso Bionics issued an additional convertible bridge note to CNI in the
aggregate original principal amount of $1,000,000 (the “2013 CNI Bridge Note”, and collectively, the “CNI Bridge
Notes”). The 2012 CNI Bridge Note carried interest at a rate of 5% per annum with a maturity date of November 12, 2013.
The 2013 CNI Bridge Note had identical terms to the 2012 CNI Bridge Note except that the 2013 CNI Bridge Note accrued interest
at 10% per annum instead of 5% per annum. In April 2013, Ekso Bionics modified the 2012 CNI Bridge Note retroactively increasing
the interest rate to 10%. Upon consummation of the Series B financing in May 2013, the CNI Bridge Notes were converted into 2,446,916
shares of Series B preferred stock of Ekso Bionics (which were converted into 4,783,231 shares of Company Common Stock in connection
with the Merger) and warrants to purchase 183,518 shares of common stock of Ekso Bionics (which were converted into 279,645 shares
of Company Common Stock in connection with the Merger).
On October 21, 2013, The Chickasaw Nation
Department of Commerce, an affiliate of CNI, purchased two receivables from Ekso Bionics for $180,000. The receivables represented
payments due to Ekso Bionics from two customers totaling $199,410, for which The Chickasaw Nation Department of Commerce was paid
in full on December 26, 2013.
Except as described in this prospectus,
no arrangements or understandings exist among present or former controlling stockholders with respect to the election of members
of our Board of Directors and, to our knowledge, no other arrangements exist that might result in a change of control of the Company.
PLAN OF DISTRIBUTION
The selling stockholders may, from time
to time, sell any or all of their shares of our common stock on any stock exchange, market or trading facility on which the shares
are traded or in private transactions. If the shares of common stock are sold through underwriters, the selling stockholders will
be responsible for underwriting discounts or commissions or agent’s commissions. All selling stockholders who are broker-dealers
are deemed to be underwriters. These sales may be at fixed prices, at prevailing market prices at the time of the sale, at varying
prices determined at the time of sale or at negotiated prices. The selling stockholders may use any one or more of the following
methods when selling shares:
|
·
|
any
national securities exchange or quotation service on which the securities may be listed
or quoted at the time of sale;
|
|
·
|
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
·
|
block
trades in which the broker-dealer will attempt to sell the shares as agent but may position
and resell a portion of the block as principal to facilitate the transaction;
|
|
·
|
purchases
by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
·
|
transactions
other than on these exchanges or systems or in the over-the-counter market;
|
|
·
|
through
the writing of options, whether such options are listed on an options exchange or otherwise;
|
|
·
|
an
exchange distribution in accordance with the rules of the applicable exchange;
|
|
·
|
privately
negotiated transactions;
|
|
·
|
broker-dealers
may agree with the selling stockholders to sell a specified number of such shares at
a stipulated price per share;
|
|
·
|
a
combination of any such methods of sale; and
|
|
·
|
any
other method permitted pursuant to applicable law.
|
The selling stockholders may also sell
shares under Rule 144 under the Securities Act, if available, rather than under this prospectus. Rule 144 under the Securities
Act, which generally permits the resale, subject to various terms and conditions, of restricted securities after they have been
held for six months will not immediately apply to our common stock because we were at one time designated as a “shell company”
under SEC regulations. Pursuant to Rule 144(i), securities issued by a current or former shell company that otherwise meet the
holding period and other requirements of Rule 144 nevertheless cannot be sold in reliance on Rule 144 until one year after the
date on which the issuer filed current “Form 10 information” (as defined in Rule 144(i)) with the SEC reflecting that
it ceased being a shell company, and provided that at the time of a proposed sale pursuant to Rule 144, the issuer has satisfied
certain reporting requirements under the Exchange Act. The filing of our Current Report on Form 8-K on January 23, 2014, with
the SEC started the running of such one-year period.
The selling stockholders may also engage
in short sales against the box, puts and calls and other transactions in our securities or derivatives of our securities and may
sell or deliver shares in connection with these trades.
Broker-dealers engaged by the selling
stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts
to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary in the types
of transactions involved. Any profits on the resale of shares of common stock by a broker-dealer acting as principal might be
deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar selling
expenses, if any, attributable to the sale of shares will be borne by a selling stockholder. The selling stockholders may agree
to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities
are imposed on that person under the Securities Act.
In connection with the sale of the shares
of our common stock or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may
in turn engage in short sales of the shares of common stock in the course of hedging in positions they assume. The selling stockholders
may also sell shares of common stock short and deliver shares of common stock covered by this prospectus to close out short positions
and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares of
common stock to broker-dealers that in turn may sell such shares.
The selling stockholders may from time
to time pledge or grant a security interest in some or all of the shares of our common stock owned by them and, if they default
in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of our common stock
from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable
provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors
in interest as selling stockholders under this prospectus.
The selling stockholders also may transfer
the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will
be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under
this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the
Securities Act amending the list of selling stockholders to include the pledgees, transferees or other successors in interest
as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the shares of common stock
in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial
owners for purposes of this prospectus.
The selling stockholders and any broker-dealers
or agents that are involved in selling the shares may be deemed to be “underwriters” within the meaning of the Securities
Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, such broker-dealers
or agents and any profit realized on the resale of the shares purchased by them may be deemed to be underwriting commissions or
discounts under the Securities Act. At the time a particular offering of the shares of common stock is made, a prospectus supplement,
if required, will be distributed which will set forth the aggregate amount of shares of common stock being offered and the terms
of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting
compensation from the selling stockholders and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.
Under the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed
brokers or dealers. In addition, in some states the shares of common stock may not be sold unless such shares have been registered
or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. There
can be no assurance that any selling stockholder will sell any or all of the shares of our common stock registered pursuant to
the shelf registration statement, of which this prospectus forms a part.
Each selling stockholder has informed
us that it does not have any agreement or understanding, directly or indirectly, with any person to distribute our common stock.
None of the selling stockholders who are affiliates of broker-dealers, other than the initial purchasers in private transactions,
purchased the shares of common stock outside of the ordinary course of business or, at the time of the purchase of the common
stock, had any agreements, plans or understandings, directly or indirectly, with any person to distribute the securities.
We are required to pay all fees and expenses
incident to the registration of the shares of common stock. Except as provided for indemnification of the selling stockholders,
we are not obligated to pay any of the expenses of any attorney or other advisor engaged by a selling stockholder. We have agreed
to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the
Securities Act.
If we are notified by any selling stockholder
that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock, we will file
a post-effective amendment to the registration statement. If the selling stockholders use this prospectus for any sale of the
shares of our common stock, they will be subject to the prospectus delivery requirements of the Securities Act.
The anti-manipulation rules of Regulation
M under the Exchange Act may apply to sales of our common stock and activities of the selling stockholders, which may limit the
timing of purchases and sales of any of the shares of common stock by the selling stockholders and any other participating person.
Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in
passive market-making activities with respect to the shares of common stock. Passive market making involves transactions in which
a market maker acts as both our underwriter and as a purchaser of our common stock in the secondary market. All of the foregoing
may affect the marketability of the shares of common stock and the ability of any person or entity to engage in market-making
activities with respect to the shares of common stock.
Once sold under the registration statement,
of which this prospectus forms a part, the shares of common stock will be freely tradable in the hands of persons other than our
affiliates.
Our common stock is currently quoted on
the OTCBB and trades below $5.00 per share; therefore, our common stock is considered a “penny stock” and subject
to SEC rules and regulations which impose limitations upon the manner in which such shares may be publicly traded. These regulations
require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market
and the associated risks. Under these regulations, certain brokers who recommend such securities to persons other than established
customers or certain accredited investors must make a special written suitability determination regarding such a purchaser and
receive such purchaser’s written agreement to a transaction prior to sale. These regulations have the effect of limiting
the trading activity of the common stock and reducing the liquidity of an investment in the common stock.
DESCRIPTION OF
SECURITIES
Authorized Capital Stock
We have authorized capital stock consisting
of 500,000,000 shares of Common Stock and 10,000,000 shares of preferred stock. As of the date of this prospectus, we had 78,497,558
shares of Common Stock issued and outstanding, and no shares of preferred stock issued and outstanding.
Common Stock
The holders of outstanding shares of Common
Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and
in such amounts as the board from time to time may determine. Holders of Common Stock are entitled to one vote for each share
held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing
for election. The Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation,
dissolution or winding up of our company, the assets legally available for distribution to stockholders are distributable ratably
among the holders of the Common Stock after payment of liquidation preferences, if any, on any outstanding payment of other claims
of creditors. Each outstanding share of Common Stock is duly and validly issued, fully paid and non-assessable.
Preferred Stock
We may issue shares of preferred stock
from time to time in one or more series, each of which will have such distinctive designation or title as shall be determined
by our Board of Directors and will have such voting powers, full or limited, or no voting powers, and such preferences and relative,
participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated
in such resolution or resolutions providing for the issue of such class or series of preferred stock as may be adopted from time
to time by the Board of Directors.
While we do not currently have any plans
for the issuance of additional preferred stock, the issuance of such preferred stock could adversely affect the rights of the
holders of Common Stock and, therefore, reduce the value of the Common Stock. It is not possible to state the actual effect of
the issuance of any shares of preferred stock on the rights of holders of the Common Stock until the Board of Directors determines
the specific rights of the holders of the preferred stock; however, these effects may include:
|
·
|
Restricting
dividends on the Common Stock;
|
|
·
|
Diluting
the voting power of the Common Stock;
|
|
·
|
Impairing
the liquidation rights of the Common Stock; or
|
|
·
|
Delaying
or preventing a change in control of the Company without further action by the stockholders.
|
Other than in connection with shares of
preferred stock (as explained above), which preferred stock is not currently designated nor contemplated by us, we do not believe
that any provision of our charter or By-Laws would delay, defer or prevent a change in control
Options
Options to purchase an aggregate of 10,764,411
shares of our Common Stock have been issued under the 2014 Plan, as follows:
|
·
|
Options
to purchase 4,978,645 shares of Ekso Bionics’ common stock issued and outstanding
immediately prior to the closing of the Merger were converted into options to purchase
7,586,459 shares of our Common Stock, with a weighted average exercise price of $0.46
per share. Most of these option grants vest over a term of 48 months, beginning on the
first anniversary of an employee’s employment, and have a term of ten years.
|
|
·
|
Options
to purchase 450,000 shares of our Common Stock were granted to our directors. These option
grants have an exercise price of $1.00 per share, will become exercisable over a term
of 48 months, with 1/4 of the shares becoming exercisable on the first anniversary of
the date of grant and with 1/48 of the shares becoming exercisable at the end of each
month thereafter, and have a term of ten years.
|
|
·
|
Options
to purchase 1,850,000 shares of our Common Stock were granted to our officers and employees
in connection with the Merger. These option grants have an exercise price of $1.00 per
share, will become exercisable over a term of 48 months, with 1/4 of the shares becoming
exercisable on the first anniversary of the date of grant and with 1/48 of the shares
becoming exercisable at the end of each month thereafter, and have a term of ten years.
|
|
·
|
Options
to purchase 877,952 shares of our Common Stock were granted to our employees subsequent
to the Merger. These option grants have a weighted average exercise price of $5.99 per
share, will become exercisable over a term of 48 months, with 1/4 of the shares becoming
exercisable on the first anniversary of the date of grant and with 1/48 of the shares
becoming exercisable at the end of each month thereafter, and have a term of ten years.
|
Options to purchase 10,353,887 shares
of our Common Stock remain outstanding under the 2014 Plan.
Warrants
As of the date hereof:
|
·
|
The
Bridge Warrants entitle their holders to purchase 2,500,000 shares of Common Stock, with
a term of three years and an exercise price of $1.00 per share.
|
|
·
|
The
Bridge Agent Warrants entitle their holders to purchase 500,000 shares of Common Stock,
with a term of five years and an exercise price of $1.00 per share.
|
|
·
|
The
PPO Warrants entitle their holders to purchase 30,300,000 shares of Common Stock, with
a term of five years and an exercise price of $2.00 per share.
|
|
·
|
The
PPO Agent Warrants entitle their holders to purchase 2,530,000 shares of Common Stock,
with a term of five years and an exercise price of $1.00 per share.
|
|
·
|
Holders
of warrants to purchase Ekso Bionics common stock prior to the Merger hold warrants to
purchase 621,363 shares of Common Stock, which expire on May 20, 2020 and have an exercise
price of $1.3781 per share. These warrants may, at the option of the holders, be exercised
on a “cashless exercise” basis, which means that in lieu of paying the aggregate
exercise price for the shares being purchased upon exercise of the warrants for cash,
the holder will forfeit a number of shares underlying the warrants with a “fair
market value” equal to such aggregate exercise price. We will not receive additional
proceeds to the extent these warrants are exercised on a “cashless exercise”
basis.
|
|
·
|
Other
warrants entitle their holder to purchase 225,000 shares of Common Stock, with a term
of three years and an exercise price of $1.00 per share.
|
The outstanding warrants, other than those
converted from warrants to purchase Ekso Bionics common stock, contain “weighted average” anti-dilution protection
in the event that we issue Common Stock or securities convertible into or exercisable for shares of Common Stock at a price lower
than the subject warrant’s exercise price, subject to certain customary exceptions, as well as customary provisions for
adjustment in the event of stock splits, subdivision or combination, mergers, etc.
See “Certain Relationships and Related
Transactions—Registration Rights” for a description of the registration rights granted to the holders of the shares
of common stock and common stock purchase warrants issued in connection with the 2014 Offering, which description is incorporated
herein by reference.
This summary descriptions of the warrants
described above is qualified in their entirety by reference to the forms of such warrants filed as an exhibit to the registration
statement of which this prospectus is a part.
Other Convertible Securities
As of the date hereof, other than the
securities described above, the Company does not have any outstanding convertible securities.
Transfer Agent
The transfer agent for our Common Stock
is VStock Transfer, LLC. The transfer agent’s address is 77 Spruce Street, Suite 201, Cedarhurst, NY 11516, and its telephone
number is +1-212 828-8436.
Anti-Takeover Effects of Provisions
of Nevada State Law
We may in the future become subject to
Nevada’s control share laws. A corporation is subject to Nevada’s control share law if it has more than 200 stockholders
of record, at least 100 of whom are residents of Nevada, and if the corporation does business in Nevada, including through an
affiliated corporation. This control share law may have the effect of discouraging corporate takeovers. The Company currently
has fewer than 100 stockholders of record who are residents of Nevada and does not do business in Nevada.
The control share law focuses on the acquisition
of a “controlling interest,” which means the ownership of outstanding voting shares that would be sufficient, but
for the operation of the control share law, to enable the acquiring person to exercise the following proportions of the voting
power of the corporation in the election of directors: (1) one-fifth or more but less than one-third; (2) one-third or more but
less than a majority; or (3) a majority or more. The ability to exercise this voting power may be direct or indirect, as well
as individual or in association with others.
The effect of the control share law is
that an acquiring person, and those acting in association with that person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders of the corporation, approved at a special or annual meeting of stockholders.
The control share law contemplates that voting rights will be considered only once by the other stockholders. Thus, there is no
authority to take away voting rights from the control shares of an acquiring person once those rights have been approved. If the
stockholders do not grant voting rights to the control shares acquired by an acquiring person, those shares do not become permanent
non-voting shares. The acquiring person is free to sell the shares to others. If the buyer or buyers of those shares themselves
do not acquire a controlling interest, the shares are not governed by the control share law any longer.
If control shares are accorded full voting
rights and the acquiring person has acquired control shares with a majority or more of the voting power, a stockholder of record,
other than the acquiring person, who did not vote in favor of approval of voting rights for the control shares, is entitled to
demand fair value for such stockholder’s shares.
In addition to the control share law,
Nevada has a business combination law, which prohibits certain business combinations between Nevada corporations and “interested
stockholders” for two years after the interested stockholder first becomes an interested stockholder, unless (a) the corporation’s
board of directors approves the combination in advance or (b) the corporation’s board of directors and at least 60% of the
corporation’s disinterested stockholders approve the combination at an annual or special meeting. For purposes of Nevada
law, an interested stockholder is any person who is: (a) the beneficial owner, directly or indirectly, of 10% or more of the voting
power of the outstanding voting shares of the corporation, or (b) an affiliate or associate of the corporation and at any time
within the previous two years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then-outstanding
shares of the corporation. The definition of “business combination” contained in the statute is sufficiently broad
to cover virtually any kind of transaction that would allow a potential acquirer to use the corporation’s assets to finance
the acquisition or otherwise to benefit its own interests rather than the interests of the corporation and its other stockholders.
The effect of Nevada’s business
combination law is to potentially discourage a party interested in taking control of the Company from doing so if it cannot obtain
the approval of our board of directors.
CHANGES IN AND
DISAGREEMENTS WITH ACCOUNTANTS
On January 15, 2014, Silberstein Ungar,
PLLC CPAs, was dismissed as our independent registered public accounting firm. On the same date, OUM & Co., LLP was engaged
as our new independent registered public accounting firm. The Board of Directors of the Company approved the dismissal of Silberstein
Ungar, PLLC CPAs, and approved the engagement of OUM & Co., LLP as our independent registered public accounting firm.
None of the reports of Silberstein Ungar,
PLLC CPAs, on our financial statements for either of the two most recent fiscal years or subsequent interim period contained an
adverse opinion or disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope or accounting principles,
except that our audited financial statements contained in our Annual Reports on Form 10-K for the fiscal years ended March 31,
2013, and March 31, 2012, filed with the SEC, included a going concern qualification in the report of Silberstein Ungar, PLLC
CPAs.
During the Company’s two most recent
fiscal years ended March 31, 2013 and 2012, and the subsequent interim periods preceding their dismissal, there were no disagreements
with Silberstein Ungar, PLLC CPAs, whether or not resolved, on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of Silberstein Ungar, PLLC CPAs, would
have caused them to make reference to the subject matter of the disagreement in connection with their report on the Company’s
financial statements.
The Company provided Silberstein Ungar,
PLLC CPAs, with a copy of the disclosures it is making in this prospectus and has requested that Silberstein Ungar, PLLC CPAs,
furnish it with a letter addressed to the SEC stating whether they agree with the above statements. The letter has not yet been
received but will be filed as an exhibit to the registration of which this prospectus is a part by amendment if and when it is
received.
During the two most recent fiscal years
and the interim periods preceding the engagement, and through the date of this prospectus, neither the Company nor anyone on its
behalf has previously consulted with OUM & Co., LLP regarding either (a) the application of accounting principles to a specified
transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial
statements, and neither a written report was provided nor oral advice was provided to the Company that OUM & Co., LLP concluded
was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting
issue; or (b) any matter that was either the subject of a disagreement (as defined in paragraph 304(a)(1)(iv) of Regulation S-K
and the related instructions thereto) or a reportable event (as described in paragraph 304(a)(1)(v)) of Regulation S-K).
DISCLOSURE OF COMMISSION
POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Under the Nevada Revised Statutes, our
directors and officers are not individually liable to us or our stockholders for any damages as a result of any act or failure
to act in their capacity as an officer or director unless it is proven that:
|
·
|
His
or her act or failure to act constituted a breach of his or her fiduciary duty as a director
or officer; and
|
|
·
|
His
or her breach of these duties involved intentional misconduct, fraud or a knowing violation
of law.
|
Nevada law allows corporations to provide
broad indemnification to its officers and directors. At the present time, our Articles of Incorporation and Bylaws
also provide for broad indemnification of our current and former directors, trustees, officers, employees and other agents.
Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to our directors, officers and controlling persons, we have been advised that
in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable.
LEGAL MATTERS
The validity of the common stock offered
hereby will be passed upon for us by Gottbetter & Partners, LLP, 488 Madison Avenue, 12
th
Floor, New York, NY 10022.
Adam S. Gottbetter is the owner of Gottbetter & Partners, LLP (“G&P”), Gottbetter Capital Group, Inc., Bretton
James, Inc. and Gottbetter Capital Markets LLC, a registered broker-dealer (“GCM”). GCM acted as the placement agent
for the 2014 Offering and received placement agent fees and warrants in accordance with an executed placement agent agreement.
GCM and its designees received aggregate commissions of approximately $3,030,000 and warrants to purchase an aggregate of 3,030,000
shares of our common stock exercisable for a period of five years at a per share exercise price of $1.00. G&P is counsel to
us and receives legal fees in accordance with an executed retainer agreement. G&P does not act as legal counsel for GCM.
EXPERTS
The consolidated financial statements
of Ekso Bionics as of, and for the fiscal years ended, December 31, 2013 and 2012, appearing in the registration statement, of
which this prospectus forms a part, have been audited by OUM & Co., LLP, an independent registered public accounting firm,
as set forth in their report appearing elsewhere herein and are included in reliance on such report given on the authority of
said firm as experts in auditing and accounting.
WHERE YOU CAN FIND
MORE INFORMATION
We file annual reports, quarterly reports,
current reports and other information with the SEC. You may read or obtain a copy of these reports at the SEC’s
public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation
of the public reference room and their copy charges by calling the SEC at 1-800-SEC-0330. The SEC maintains a website
that contains registration statements, reports, proxy information statements and other information regarding registrants that
file electronically with the SEC. The address of the website is http://www.sec.gov.
We have filed with the SEC a Registration
Statement on Form S-1 under the Securities Act to register the shares offered by this prospectus. The term “registration
statement” means the original registration statement and any and all amendments thereto, including the schedules and exhibits
to the original registration statement or any amendment. This prospectus is part of that registration statement. This
prospectus does not contain all of the information set forth in the registration statement or the exhibits to the registration
statement. For further information with respect to us and the shares we are offering pursuant to this prospectus, you
should refer to the registration statement and its exhibits. Statements contained in this prospectus as to the contents
of any contract, agreement or other document referred to are not necessarily complete, and you should refer to the copy of that
contract or other documents filed as an exhibit to the registration statement. You may read or obtain a copy of the
registration statement at the SEC’s public reference facilities and Internet site referred to above.
EKSO BIONICS, INC.
INDEX TO CONSOLIDATED
FINANCIAL STATEMENTS
|
Page
Number
|
Unaudited Condensed Consolidated
Financial Statements as of March 31, 2014
|
|
|
|
Condensed
Consolidated Balance Sheets as of March 31, 2014 (unaudited) and December 31, 2013
|
F-2
|
|
|
Condensed
Consolidated Statements of Operations for the Three Months Ended March 31, 2014 and 2013 (unaudited)
|
F-3
|
|
|
Condensed
Consolidated Statements of Stockholder’s Deficit for the Three and Twelve Months Ended March 31, 2014 and December 31,
2013 (unaudited)
|
F-4
|
|
|
Condensed
Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2014 and 2013 (unaudited)
|
F-5
|
|
|
Notes
to Condensed Consolidated Financial Statements (unaudited)
|
F-6
|
|
|
Audited Consolidated Financial Statements
as of December 31, 2013
|
|
|
|
Report
of Independent Registered Public Accounting Firm
|
F-21
|
|
|
Consolidated
Balance Sheets as of December 31, 2013 and 2012
|
F-
22
|
|
|
Consolidated
Statements of Operations for the years ended December 31, 2013 and 2012
|
F-
23
|
|
|
Consolidated
Statements of Convertible Preferred Stock and Stockholders’ Deficit for the years ended December 31, 2013 and 2012
|
F-
24
|
|
|
Consolidated
Statements of Cash Flows for the years ended December 31, 2013 and 2012
|
F-25
|
|
|
Notes
to Consolidated Financial Statements
|
F-
26
|
INDEX TO UNAUDITED
PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS
Ekso Bionics Holdings, Inc.
Condensed
Consolidated Balance Sheets
(Unaudited)
|
|
March
31,
2014
|
|
|
December
31,
2013
|
|
Assets
|
|
|
|
|
|
|
(See
Note 1)
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
14,576,378
|
|
|
$
|
805,306
|
|
Accounts
receivable
|
|
|
1,775,048
|
|
|
|
549,469
|
|
Inventories,
net
|
|
|
1,123,021
|
|
|
|
725,096
|
|
Note receivable
from stockholder
|
|
|
—
|
|
|
|
103,735
|
|
Prepaid
expenses and other current assets
|
|
|
406,993
|
|
|
|
250,998
|
|
Deferred
cost of revenue, current
|
|
|
974,405
|
|
|
|
768,599
|
|
Total current
assets
|
|
|
18,855,845
|
|
|
|
3,203,203
|
|
Property
and equipment, net
|
|
|
1,763,550
|
|
|
|
1,575,286
|
|
Deferred
cost of revenue, non-current
|
|
|
1,127,269
|
|
|
|
803,298
|
|
Other
assets
|
|
|
54,390
|
|
|
|
1,002,150
|
|
Total
assets
|
|
$
|
21,801,054
|
|
|
$
|
6,583,937
|
|
|
|
|
|
|
|
|
|
|
Liabilities,
Convertible Preferred Stock and Stockholders' Deficit
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Notes payable,
current
|
|
$
|
39,345
|
|
|
$
|
1,638,505
|
|
Convertible
debt
|
|
|
—
|
|
|
|
5,062,417
|
|
Accounts
payable
|
|
|
1,044,296
|
|
|
|
1,498,680
|
|
Accrued
liabilities
|
|
|
1,565,798
|
|
|
|
1,430,799
|
|
Customer
deposits, advances and deferred revenues, current
|
|
|
2,960,026
|
|
|
|
2,419,226
|
|
Liability
due to early stock option exercise
|
|
|
3,970
|
|
|
|
5,293
|
|
Total current
liabilities
|
|
|
5,613,435
|
|
|
|
12,054,920
|
|
Customer
deposits, advances and deferred revenues, non-current
|
|
|
2,447,380
|
|
|
|
2,209,111
|
|
Notes payable,
non-current
|
|
|
111,318
|
|
|
|
866,950
|
|
Warrant liability
|
|
|
88,050,250
|
|
|
|
377,747
|
|
Deferred
rent
|
|
|
114,657
|
|
|
|
123,709
|
|
Total
liabilities
|
|
|
96,337,040
|
|
|
|
15,632,437
|
|
Commitments
and contingencies (Note 12)
|
|
|
|
|
|
|
|
|
Convertible
preferred stock issuable in series, $0.001 par value; 10,000,000 and 22,000,000 shares authorized at March 31, 2014 (unaudited)
and December 31, 2013 respectively; none and 25,923,873 and shares issued and outstanding at March 31, 2014 (unaudited)
and December 31, 2013 respectively; liquidation preference of $2.85 - $4.11 per share at December 31, 2013
|
|
|
—
|
|
|
|
27,324,208
|
|
Stockholders'
deficit:
|
|
|
|
|
|
|
|
|
Common stock,
$0.001 par value; 500,000,000 and 40,000,000 shares authorized at March 31, 2014 (unaudited) and December 31, 2013, respectively;
78,480,019 and 21,114,783, shares issued and outstanding at March 31, 2014 (unaudited) and December 31, 2013, respectively
|
|
|
78,480
|
|
|
|
21,114
|
|
Additional
paid-in capital
|
|
|
45,182,512
|
|
|
|
1,637,797
|
|
Accumulated
deficit
|
|
|
(119,796,978
|
)
|
|
|
(38,031,619
|
)
|
Total
stockholders' deficit
|
|
|
(74,535,986
|
)
|
|
|
(36,372,708
|
)
|
Total
liabilities, convertible preferred stock and stockholders' deficit
|
|
$
|
21,801,054
|
|
|
$
|
6,583,937
|
|
See Accompanying Notes to Unaudited Condensed
Consolidated Financial Statements.
Ekso Bionics Holdings, Inc.
Condensed
Consolidated Statement of Operations
(Unaudited)
|
|
Three
months ended March 31,
|
|
|
|
2014
|
|
|
2013
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
Medical
devices
|
|
$
|
526,753
|
|
|
$
|
332,919
|
|
Engineering
services
|
|
|
534,958
|
|
|
|
363,330
|
|
Total
revenue
|
|
|
1,061,711
|
|
|
|
696,249
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
Cost of
medical devices
|
|
|
330,125
|
|
|
|
232,563
|
|
Cost
of engineering services
|
|
|
252,103
|
|
|
|
347,214
|
|
Total
cost of revenue
|
|
|
582,228
|
|
|
|
579,777
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
479,483
|
|
|
|
116,472
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
Sales and
marketing
|
|
|
1,531,382
|
|
|
|
1,216,043
|
|
Research
and development
|
|
|
768,542
|
|
|
|
921,706
|
|
General
and administrative
|
|
|
2,071,443
|
|
|
|
1,133,454
|
|
Total
operating expenses
|
|
|
4,371,367
|
|
|
|
3,271,203
|
|
|
|
|
|
|
|
|
|
|
Loss
from operations
|
|
|
(3,891,884
|
)
|
|
|
(3,154,731
|
)
|
|
|
|
|
|
|
|
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
|
(426,603
|
)
|
|
|
(639,113
|
)
|
Loss on
warrant liability
|
|
|
(77,436,700
|
)
|
|
|
—
|
|
Interest
income
|
|
|
1,400
|
|
|
|
1,264
|
|
Other
expense, net
|
|
|
(11,572
|
)
|
|
|
(4,174
|
)
|
Total
other expense, net
|
|
|
(77,873,475
|
)
|
|
|
(642,023
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(81,765,359
|
)
|
|
$
|
(3,796,754
|
)
|
|
|
|
|
|
|
|
|
|
Basic
and diluted net loss per share
|
|
$
|
(1.22
|
)
|
|
$
|
(0.18
|
)
|
Weighted-average number of shares
used in computing basic and diluted net loss per share amounts
|
|
|
67,072,057
|
|
|
|
20,636,529
|
|
|
|
|
|
|
|
|
|
|
See Accompanying Notes to the Unaudited
Condensed Consolidated Financial Statements
Ekso Bionics
Holdings, Inc.
Condensed
Consolidated Statements of Stockholders’ Deficit
(Unaudited)
|
|
Convertible Preferred
Stock
|
|
|
Common Stock
|
|
|
Additional
Paid-In
|
|
|
Accumulated
|
|
|
Total
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Deficit
|
|
Balance
at December 31, 2012
|
|
|
15,799,291
|
|
|
$
|
16,675,983
|
|
|
|
15,065,931
|
|
|
$
|
9,920
|
|
|
$
|
1,047,936
|
|
|
($
|
26,144,245
|
)
|
|
($
|
25,086,389
|
)
|
Issuance of Series
B convertible preferred stock at $2.10 per share issued in exchange for cash
|
|
|
4,083,225
|
|
|
|
4,294,259
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Issuance of Series
B convertible preferred stock upon conversion of convertible debt and accrued interest
|
|
|
6,041,356
|
|
|
|
6,490,071
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Common stock warrants
issued in connection with issuance of Series B convertible preferred stock
|
|
|
-
|
|
|
|
275
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Common stock warrants
issued in connection with issuance of Series B convertible preferred stock
|
|
|
-
|
|
|
|
(136,380
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
136,380
|
|
|
|
-
|
|
|
|
136,380
|
|
Issuance of common
stock upon exercise of options
|
|
|
-
|
|
|
|
-
|
|
|
|
771,341
|
|
|
|
94
|
|
|
|
65,499
|
|
|
|
-
|
|
|
|
65,593
|
|
Common stock repurchased
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,857
|
)
|
|
|
(2
|
)
|
|
|
(187
|
)
|
|
|
-
|
|
|
|
(189
|
)
|
Vesting of early
exercised options
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13
|
|
|
|
3,961
|
|
|
|
-
|
|
|
|
3,974
|
|
Compensation expense
for options issued a non-employee
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,679
|
|
|
|
-
|
|
|
|
4,679
|
|
Stock-based compensation
expense
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
390,618
|
|
|
|
-
|
|
|
|
390,618
|
|
Effect of merger
and recapitalization of share amounts
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5,809
|
|
|
|
(5,809
|
)
|
|
|
-
|
|
|
|
-
|
|
Issuance of shares
to shareholders of Ekso Bionics Holdings Inc.
|
|
|
-
|
|
|
|
-
|
|
|
|
5,280,368
|
|
|
|
5,280
|
|
|
|
(5,280
|
)
|
|
|
-
|
|
|
|
-
|
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(11,887,374
|
)
|
|
|
(11,887,374
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
December 31, 2013 (See Note 1)
|
|
|
25,923,872
|
|
|
$
|
27,324,208
|
|
|
|
21,114,783
|
|
|
|
21,114
|
|
|
|
1,637,797
|
|
|
|
(38,031,619
|
)
|
|
|
(36,372,708
|
)
|
Issuance of common
stock upon exercise of options
|
|
|
-
|
|
|
|
-
|
|
|
|
90,057
|
|
|
|
90
|
|
|
|
1,820
|
|
|
|
-
|
|
|
|
1,910
|
|
Fair value of
warrant liability transferred to equity upon net exercise
|
|
|
767,212
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
281,987
|
|
|
|
-
|
|
|
|
281,987
|
|
Conversion
of preferred stock
|
|
|
(26,691,084
|
)
|
|
|
(27,324,208
|
)
|
|
|
26,691,084
|
|
|
|
26,691
|
|
|
|
27,297,517
|
|
|
|
-
|
|
|
|
27,324,208
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
January 15, 2014 before Merger and PPO
|
|
|
-
|
|
|
$
|
-
|
|
|
|
47,895,924
|
|
|
|
47,895
|
|
|
|
29,219,121
|
|
|
|
(38,031,619
|
)
|
|
|
(8,764,603
|
)
|
PPO shares issued for cash
|
|
|
-
|
|
|
|
-
|
|
|
|
25,300,000
|
|
|
|
25,300
|
|
|
|
25,274,700
|
|
|
|
-
|
|
|
|
25,300,000
|
|
PPO shares issued
upon conversion of 2013 Bridge Notes
|
|
|
-
|
|
|
|
-
|
|
|
|
5,000,000
|
|
|
|
5,000
|
|
|
|
5,077,578
|
|
|
|
-
|
|
|
|
5,082,578
|
|
Shares issued
to consultant in PPO
|
|
|
-
|
|
|
|
-
|
|
|
|
250,000
|
|
|
|
250
|
|
|
|
(250
|
)
|
|
|
-
|
|
|
|
-
|
|
Fair value of warrant obligation
transferred to equity
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
95,760
|
)
|
|
|
-
|
|
|
|
95,760
|
|
Offering costs
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(4,250,744
|
)
|
|
|
-
|
|
|
|
(4,250,744
|
)
|
Issuance
of common stock warrants at fair value
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(10,613,550
|
)
|
|
|
-
|
|
|
|
(10,613,550
|
)
|
Balance at
January 15, 2014 after Merger and PPO
|
|
|
-
|
|
|
$
|
-
|
|
|
|
78,445,924
|
|
|
|
78,445
|
|
|
|
44,802,615
|
|
|
|
(38,031,619
|
)
|
|
|
6,849,441
|
|
Stock option exercises
|
|
|
-
|
|
|
|
-
|
|
|
|
34,095
|
|
|
|
35
|
|
|
|
13,257
|
|
|
|
-
|
|
|
|
13,292
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation
expense
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
366,640
|
|
|
|
-
|
|
|
|
366,640
|
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(81,765,359
|
)
|
|
|
(81,765,359
|
)
|
Balance
at March 31 , 2014 (unaudited)
|
|
|
-
|
|
|
$
|
-
|
|
|
|
78,480,019
|
|
|
$
|
78,480
|
|
|
$
|
45,182,512
|
|
|
$
|
(119,796,978
|
)
|
|
$
|
(74,535,986
|
)
|
See Accompanying Notes to the Unaudited
Condensed Consolidated Financial Statements
Ekso Bionics Holdings, Inc.
Condensed
Consolidated Statements of Cash Flows
(Unaudited)
|
|
Three months ended March 31,
|
|
|
|
2014
|
|
|
2013
|
|
|
|
|
|
|
|
|
Operating
activities:
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(81,765,359
|
)
|
|
$
|
(3,796,754
|
)
|
Adjustments
to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
156,
890
|
|
|
|
111,719
|
|
Amortization
of deferred rent
|
|
|
(9,052
|
)
|
|
|
(9,052
|
)
|
Amortization
of debt discounts
|
|
|
197,613
|
|
|
|
137,449
|
|
Adjustment
to record convertible notes at fair value
|
|
|
—
|
|
|
|
360,324
|
|
Stock-based
compensation expense
|
|
|
366,640
|
|
|
|
86,155
|
|
Loss on
increase in fair value of warrant liability
|
|
|
77,436,700
|
|
|
|
—
|
|
Other
|
|
|
—
|
|
|
|
(8,298
|
)
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(1,225,579
|
)
|
|
|
(111,842
|
)
|
Inventories
|
|
|
(494,689
|
)
|
|
|
4,950
|
|
Prepaid expense
and other assets
|
|
|
(155,893
|
)
|
|
|
(39,471
|
)
|
Deferred
costs of revenue
|
|
|
(529,777
|
)
|
|
|
(304,826
|
)
|
Accounts
payable
|
|
|
(454,384
|
)
|
|
|
234,510
|
|
Accrued liabilities
|
|
|
134,999
|
|
|
|
30,517
|
|
Customer
advances and deferred revenues
|
|
|
779,069
|
|
|
|
942,113
|
|
Net
cash used in operating activities
|
|
|
(5,562,822
|
)
|
|
|
(2,362,506
|
)
|
|
|
|
|
|
|
|
|
|
Investing
activities:
|
|
|
|
|
|
|
|
|
Note receivable
from stockholder
|
|
|
103,735
|
|
|
|
—
|
|
Acquisition
of property and equipment
|
|
|
(248,390
|
)
|
|
|
(37,412
|
)
|
Net
cash used in investing activities
|
|
|
(144,655
|
)
|
|
|
(37,412
|
)
|
|
|
|
|
|
|
|
|
|
Financing activities:
|
|
|
|
|
|
|
|
|
Principal payments
on notes payable
|
|
|
(2,532,244
|
)
|
|
|
(436,148
|
)
|
Proceeds from
Convertible Bridge Notes
|
|
|
—
|
|
|
|
1,500,000
|
|
Proceeds
from issuance of common stock, net of repurchases and issuance costs
|
|
|
22,010,793
|
|
|
|
52,740
|
|
Net
cash provided by financing activities
|
|
|
19,478,549
|
|
|
|
1,116,592
|
|
|
|
|
|
|
|
|
|
|
Net increase
(decrease) in cash
|
|
|
13,771,072
|
|
|
|
(1,283,326
|
)
|
Cash
at beginning of the period
|
|
|
805,306
|
|
|
|
1,738,662
|
|
|
|
|
|
|
|
|
|
|
Cash
at end of the period
|
|
$
|
14,576,378
|
|
|
$
|
455,336
|
|
Supplemental disclosure of cash flow activities:
|
|
|
|
|
|
|
|
|
Cash
paid for interest
|
|
$
|
130,271
|
|
|
$
|
135,558
|
|
Cash
paid for taxes
|
|
$
|
1,810
|
|
|
$
|
800
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash activities:
|
|
|
|
|
|
|
|
|
Conversion
of convertible preferred stock to common stock
|
|
$
|
27,324,208
|
|
|
$
|
—
|
|
See Accompanying Notes to Unaudited Condensed
Consolidated Financial Statements
Ekso Bionics Holdings, Inc.
Notes
to Unaudited Condensed Consolidated Financial Statements
Throughout
this Quarterly Report on Form 10-Q (this “Report”), the words “we,” “us,” “our,”
or “the Company” refer to Ekso Bionics Holdings, Inc. and its wholly owned subsidiaries, Ekso Bionics, Inc. and Ekso
Bionics Ltd. unless stated otherwise.
1. Organization
Description of Business and Liquidity
On January 15, 2014, a wholly-owned subsidiary
of Ekso Bionics Holdings, Inc. (formerly known as PN Med Group Inc.), Ekso Acquisition Corp, merged with and into Ekso Bionics,
Inc. Ekso Bionics, Inc. was the surviving corporation and became a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. As a
result of this transaction, Ekso Bionics Holdings, Inc. discontinued its pre-merger operations, acquired the business of Ekso
Bionics, inc. and will continue the operations of Ekso Bionics, Inc. as a publicly traded company. See
Note 3, The Merger,
Offering and Other Related Matters.
Ekso Bionics, Inc. was incorporated in January 2005 in the State of Delaware.
We are currently headquartered
in Richmond, California. We are a leading developer and manufacturer of human bionic exoskeletons and were founded after the University
of California at Berkeley’s Robotics and Human Engineering Laboratory had a breakthrough in demonstrating human exoskeletons
that are more energy efficient than previously thought possible.
We pioneered the field of human exoskeletons
to augment human strength, endurance and mobility. We design, develop and sell wearable robots, or “human exoskeletons,”
that have applications in medical, military, industrial, and consumer markets. Our exoskeleton systems are strapped over the user’s
clothing, enabling individuals with neurological conditions affecting gait (e.g., spinal cord injury or stroke) to walk again;
permitting soldiers to carry heavy loads for long distances while mitigating lower back, knee, and ankle injuries; and allowing
industrial workers to perform heavy duty work for extended periods.
We also have a collaborative partnership
with Lockheed Martin Corporation to develop products for military applications.
Ekso Labs is the engineering services
division of the Company and is primarily focused on technology development and future applications. In essence it is an exoskeleton
laboratory that continually integrates emerging technologies into new product applications and expands on it for our partners.
Ekso Labs develops intellectual property through research grants from government organizations, including the Department of Defense.
Liquidity
Largely, as a result of significant research
and development activities to create our advanced technology, we have incurred significant operating losses and negative cash
flows from operations. As of March 31, 2014, we had an accumulated deficit of $119.8 million and a stockholders’ deficit
of $74.5 million.
We believe that our cash resources as
of March 31, 2014 are sufficient to implement our business plan, support operations, fund research and development and meet our
obligations through at least the middle of 2015. We plan to raise additional capital to finance our operations beyond the middle
of 2015. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or
at all. In the event that the necessary additional financing is not obtained, we may have to reduce our discretionary overhead
costs substantially, including general and administrative, sales and marketing, and research and development or otherwise curtail
operations.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
Basis of Presentation
These unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.
GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”)
for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included
in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations.
The condensed consolidated balance sheet at December 31, 2013 and the condensed consolidated statement of stockholders’
deficit for the year ended December 31, 2013 have been derived from the audited consolidated financial statements at that date
but do not include all disclosures required for the annual financial statements and should be read in conjunction with our audited
consolidated financial statements and notes thereto included as part of our Current Report on Form 8-K/A filed with the SEC on
March 31, 2014 .
In management’s opinion, the condensed
consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary
to present fairly the financial position at March 31, 2014, and results of operations and cash flows for all periods presented.
The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated
financial statements included the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions
have been eliminated in consolidation.
2. Summary of Significant Accounting
Policies and Estimates
There have been no material changes to
our significant accounting policies as compared to those described in our Current Report on Form 8-K/A filed with the SEC on March
31, 2014 other than as noted below in
Common Stock Warrants.
Use of Estimates
The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
in the financial statements and accompanying footnotes. These estimates include, but are not limited to: revenue recognition,
useful lives assigned to long-lived assets, realizability of deferred tax assets, valuation of common and preferred stock options,
and the valuation of common stock for purposes of determining stock-based compensation and contingencies. Actual results could
differ from those estimates.
Concentration of Credit Risk and Other
Risks and Uncertainties
Financial instruments that potentially
subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts
in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial
position of the depository institutions in which these deposits are held.
We extend credit to customers in the normal
course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts
receivable exist to the full extent of amounts presented in the consolidated financial statements. We perform ongoing credit evaluations
of our customers and do not require collateral from our customers to secure accounts receivable.
Accounts receivable are derived from the
sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged
based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit
losses, as needed. We have not experienced any losses related to accounts receivable as of March 31, 2014 and December 31, 2013.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
Many of the sales contracts with customers
outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging
agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant
gains or losses upon settling foreign contracts.
As of March 31, 2014, we had three customers
with accounts receivable balances totaling 10% or more of our total accounts receivable (27%, 12% and 10%), compared with five
customers as of March 31, 2013 (18%, 18%, 16% 13% and 12%).
In the three months ended March 31, 2014,
we had two customers with net revenue balances of 10% or more of our total customer revenue (25% and 11%), compared with four
customers in the three months ended March 31, 2013 (14%, 13%, 11% and 10%).
Common Stock Warrants
We account for the common stock warrants
issued in connection with our merger, See
Note 3, The Merger, Offering and Other Related Matters,
in accordance with the
guidance in Accounting Standards Codification (“ASC”) 815-40 whereby under that provision the warrants do not meet
the criteria for equity treatment and are recorded as a liability. The warrants have an anti-dilution clause that allows for a
decrease in the exercise price of the warrants if the Company issues additional shares of common stock without consideration or
for consideration per share less than the common stock warrant’s exercise price. Accordingly, we classified the warrant
instruments as liabilities at their fair market value at the date of the merger and will re-measure the warrants at each balance
sheet date until they are exercised or they expire. Any change in the fair value is recognized in our consolidated statement of
operations.
The fair value of the warrant liability was
determined using the Binomial Lattice pricing model. This model is dependent upon several variables such as the instrument’s
term, expected strike price, current stock price, risk-free interest rate estimated over the expected term, and the estimated
volatility of our stock over the term of warrant. The expected strike price is estimated based on a weighted average probability
analysis of the strike price changes expected during the term as a result of the anti-dilution clause in the agreement. The risk-free
rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated
based on blending the volatility rates for a number of similar publicly-traded companies.
Recently Adopted Accounting Standards
No new accounting pronouncements issued
or effective during the three months ended March 31, 2014 had or is expected to have a material impact on our results of operations
or financial condition.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
3. The Merger, Offering and Other Related
Transactions
In January and February 2014, we entered
into and executed several contemporaneous and related transactions (together, the “Merger” or the “Transaction”),
as described below.
As used in this Note 3, the term “the
Company” refers to the combination of Ekso Bionics, Inc. and Ekso Bionics Holdings, Inc. formally known as PN Med Group,
Inc., after giving effect to the Merger; the term “Holdings” refers to the business of Ekso Bionics Holdings, Inc.
prior to the Merger, and the term “Ekso Bionics” refers to Ekso Bionics, Inc. prior to the Merger.
Holdings was incorporated in the State
of Nevada on January 30, 2012, as a distributor of medical supplies and equipment to municipalities, hospitals, pharmacies, care
centers, and clinics in Chile. At the time of the Merger, Holdings was a “shell company” as defined in Rule 12b-2
of the Exchange Act. Holdings’ fiscal year end was March 31 but has been changed to December 31 in connection with the Merger.
On January 15, 2014, Holdings and a newly
formed wholly-owned subsidiary of Holdings, Ekso Acquisition Corp. (“Acquisition Sub”) entered into an Agreement and
Plan of Merger and Reorganization (the “Merger Agreement”)with Ekso Bionics. Under the Merger Agreement, Acquisition
Sub merged with and into Ekso Bionics, with Ekso Bionics remaining as the surviving corporation and with the shareholders of Ekso
Bionics exchanging all of their common stock, preferred stock and warrants to purchase preferred stock issued and outstanding
immediately prior to the closing of the Merger into an aggregate of 42,615,556 shares of Holdings’ common stock and warrants
to purchase 621,363 shares of common stock. In addition, options to purchase 4,978,645 shares of common stock of Ekso Bionics
were converted into options to purchase 7,586,459 shares of common stock of Holdings. These shares are in addition to 5,280,368
outstanding shares of Holdings common stock held by pre-merger PN Med Group, Inc. shareholders, consisting of 4,500,600 shares
held by such shareholders prior to the merger and an additional 779,768 shares issued to such shareholders pursuant to a provision
in the Merger Agreement requiring us to issue a number of shares such that the aggregate ownership of the pre-Merger shareholders
(not including any shares of common stock purchased by them in the PPO) remained approximately 6.8% of our outstanding common
stock of the Company.
Upon the closing of the Merger, under
the terms of a split-off agreement and a general release agreement, Holdings transferred all of its pre-Merger operating assets
and liabilities to a newly formed wholly-owned special-purpose subsidiary (“Split-Off Subsidiary”), and transferred
all of the outstanding shares of capital stock of Split-Off Subsidiary to the pre-Merger stockholders of Holdings and the former
officers and sole director of Holdings (the “Split-Off”), in consideration of and in exchange for (i) the surrender
and cancellation of an aggregate of all shares of Holdings’ common stock held by such stockholders (which will be cancelled
and will resume the status of authorized but unissued shares of our common stock) and (ii) certain representations, covenants
and indemnities.
Accounting for Reverse Merger
Ekso Bionics, as the accounting acquirer,
recorded the merger as the issuance of stock for the net monetary assets of Holdings accompanied by a recapitalization. This accounting
was identical to that resulting from a reverse merger, except that no goodwill or intangible assets was recorded. The historical
financial statements of Holdings before the Merger will be replaced with the historical financial statements of Ekso Bionics before
the Merger in all future filings with the SEC. The Merger is intended to be treated as a tax-free exchange under Section 368(a)
of the Internal Revenue Code of 1986, as amended.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
Retroactive Conversion of all Share
and Per Share amounts
In accordance with reverse merger accounting
guidance, amounts for Ekso Bionics’ historical (pre-merger) common stock, preferred stock, warrants on stock and options
on common stock including share and per share amounts have been retroactively adjusted using their respective exchange ratios
in these financial statements, unless otherwise disclosed. The conversion ratios were 1.5238, 1.6290, 1.9548 and 1.9548 for shares
of common stock, Series A preferred stock Series A-2 preferred stock and Series B preferred stock, respectively.
Private Placement Offering and Repayment
of 2013 Bridge Note
As more fully discussed in
Note 8,
Capitalization and Equity Structure
, during January and February, 2014, in contemplation of the Merger, the Company completed
multiple closings of a private placement offering (the “PPO”) of 30,300,000 Units (as described below) at a purchase
price of $1.00 per Unit, consisting of the sale of 25,300,000 Units for a total of $25,300,000 in net cash proceeds, and the conversion
of the 2013 Bridge Notes (as defined below) into 5,000,000 Units and additional warrants to purchase 2,500,000 shares of common
stock. The Units consist of one share of common stock and a warrant to purchase one share of stock in the Company.
Other warrants, shares and stock options
were issued in connection with the Merger as more fully discussed in
Note 8, Capitalization and Equity Structure.
4. Fair Value Measurements
We record our consolidated financial assets
and liabilities at fair value. The accounting standard for fair value provides a framework for measuring fair value, and defines
fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly
transaction between market participants at the reporting date. The accounting standard establishes a three-tier hierarchy, which
prioritizes the inputs used in the valuation methodologies in measuring fair value:
|
•
|
Level 1
—Quoted prices
in active markets for identical assets or liabilities. We consider a market to be active when transactions for the asset occur
with sufficient frequency and volume to provide pricing information on an ongoing basis.
|
|
•
|
Level 2
—Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted
prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data
for substantially the full term of the assets or liabilities.
|
|
•
|
Level 3
—Unobservable inputs
that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The valuation of Level 3 assets or liabilities requires the use of significant management judgments or estimation.
|
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
Our fair value hierarchies for our financial
assets and liabilities which require fair value measurement on a recurring basis are as follows:
|
|
Total
|
|
|
Quoted Prices in
Active Markets for
Identical Items
Level 1
|
|
|
Significant Other
Observable Inputs
Level 2
|
|
|
Significant
Unobservable
Inputs
Level 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant
liability
|
|
$
|
88,050,250
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
88,050,250
|
|
Convertible
debt
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
Total
liabilities measured at estimated fair value
|
|
$
|
88,050,250
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
88,050,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant
liability
|
|
$
|
377,747
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
377,747
|
|
Convertible
debt
|
|
|
5,062,417
|
|
|
|
–
|
|
|
|
–
|
|
|
|
5,062,417
|
|
Total
liabilities measured at estimated fair value
|
|
$
|
5,440,164
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
5,440,164
|
|
The following table
sets forth a summary of the changes in the fair value of our Level 3 financial liabilities, which were measured at fair value
on a recurring basis.
|
|
Warrant liability
|
|
|
Convertible debt
|
|
Beginning balance December 31, 2013
|
|
$
|
377,747
|
|
|
$
|
5,062,417
|
|
Transfer to equity upon settlement
|
|
|
(377,747
|
)
|
|
|
(5,062,417
|
)
|
Fair value of warrants on date of issuance
|
|
|
10,613,550
|
|
|
|
–
|
|
Change in fair value of warrants during the period
|
|
|
77,436,700
|
|
|
|
–
|
|
Ending balance March 31, 2014
|
|
$
|
88,050,250
|
|
|
$
|
–
|
|
The fair value of each warrant was determined
using a lattice pricing model using the following assumptions:
|
|
Three months
ended
March 31,
|
|
|
2014
|
|
|
|
Dividend yield
|
|
—
|
Risk-free interest rate
|
|
0.81-0.90%
|
Current share price
|
|
$0.60 - $3.19
|
Expected term (in years)
|
|
2.80-3.00
|
Volatility
|
|
79.0%
|
Periodic rate
|
|
0.24-0.25%
|
Periods in the model
|
|
10
|
During the three months ended March 31,
2014 the Level 3 warrant liability and convertible debt outstanding as of December 31, 2013 were settled in transactions related
to the Merger.
See Note 3, The Merger, Offering and Other Related Transactions.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
5. Customer Deposits, Advances and Deferred
Revenues
In connection with our device sales and
research services, we often receive cash payments before our earnings process is complete. In these instances, we record the payments
as customer deposits or customer advances until the device is shipped to the customer or in the case of research services until
the earnings process or milestone is achieved.
As
described in our revenue recognition policy for Ekso
Ô
unit sales, revenues are deferred and recognized over the maintenance period. Accordingly, at the time of shipment the amount
billed is recorded as deferred revenue. Also, at the time of shipment to the customer, the related inventory is reclassified to
deferred cost of revenue where it is amortized to cost of revenue over the same period as the related revenue.
Customer deposits, advances, deferred revenues,
and deferred unit costs consist of the following:
|
|
March
31, 2014
|
|
|
December,
31, 2013
|
|
|
|
|
|
|
|
|
Customer deposits and advances
|
|
$
|
501,893
|
|
|
$
|
443,436
|
|
Deferred Ekso unit revenues
|
|
|
3,928,224
|
|
|
|
3,462,980
|
|
Deferred service, leasing and
software revenues
|
|
|
977,289
|
|
|
|
721,921
|
|
Customer advances and deferred revenues
|
|
|
5,407,406
|
|
|
|
4,628,337
|
|
Less current portion
|
|
|
(2,960,026
|
)
|
|
|
(2,419,226
|
)
|
Customer advances and deferred
revenues, non-current
|
|
$
|
2,447,380
|
|
|
$
|
2,209,111
|
|
|
|
|
|
|
|
|
|
|
Deferred Ekso unit costs
|
|
$
|
2,101,674
|
|
|
$
|
1,571,897
|
|
Less current portion
|
|
|
(974,405
|
)
|
|
|
(768,599
|
)
|
|
|
|
|
|
|
|
|
|
Deferred cost of revenue, non-current
|
|
$
|
1,127,269
|
|
|
$
|
803,298
|
|
6. Accrued Liabilities
Accrued liabilities consist of the following:
|
|
March
31, 2014
|
|
|
December
31, 2013
|
|
|
|
|
|
|
|
|
Salaries, benefits and related expenses
|
|
$
|
792,095
|
|
|
$
|
657,628
|
|
Professional fees
|
|
|
502,044
|
|
|
|
421,966
|
|
Warranty expense
|
|
|
232,211
|
|
|
|
288,110
|
|
Taxes
|
|
|
39,448
|
|
|
|
62,283
|
|
Other
|
|
|
–
|
|
|
|
812
|
|
Total
|
|
$
|
1,565,798
|
|
|
$
|
1,430,799
|
|
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
7. Debt Instruments
Senior Notes Payable and Warrants
On April 27, 2011, we entered into a senior
note payable agreement with Venture Lending & Leasing VI, Inc. (the “Lender”). The initial loan commitment of
$1,500,000 was funded in two tranches: $1,000,000 in April 2011 and $500,000 in October 2011. In May 2012, the Lender funded an
additional $3,500,000 under an amendment to the 2011 agreement. The aggregate of $5,000,000 in funded loans is referred to as
the “Senior Note Payable”.
The Senior Note Payable was
interest-only for the first six months, after which it converted into a fully-amortizing 30-month term note. The Senior Note Payable
was secured by substantially all of our assets, including accounts receivable, inventories, property and equipment, and intangible
assets, including intellectual property.
Under the terms of the 2011 agreement
and 2012 amendment thereto, the Lender received warrants to purchase shares of our preferred stock. Under the 2011 agreement,
the Lender received warrants to purchase 128,570 shares of our Series A convertible preferred stock.
In connection with the 2012 amendment,
the Lender received additional warrants to purchase shares of Series B convertible preferred stock.
On January 15, 2014, upon the closing
of the Merger and the private placement financing discussed in
Note 3, The
Merger, Offering and Related Transactions
,
the Senior Notes Payable were settled with proceeds from the Transaction, and the warrants to purchase preferred stock issued
to the Lender were exchanged for warrants to purchase common stock, which warrants remain outstanding.
As of March 31, 2014 and December 31,
2013, the outstanding principal of the loan amounted to $0 and $2,344,302 respectively, and the Company recorded interest expense
of $421,793 and $631,098, respectively, for the periods then ended.
2013 Convertible Bridge Notes
In November 2013, in anticipation of the
Merger and related financing completed in January and February 2014, we completed a private placement to accredited investors
of $5,000,000 of its senior subordinated secured convertible notes (the “2013 Bridge Notes”). The 2013 Bridge Notes
bore interest at 10% per annum and were payable on July 15, 2014, subject to earlier conversion as described below. Interest on
the 2013 Bridge Notes was to be payable at maturity, provided that upon conversion of the 2013 Bridge Notes accrued interest was
forgiven.
Similar to the accounting for the 2012
Bridge Notes, we determined that the 2013 Bridge Notes should be recorded at fair market value at inception and remeasured at
each subsequent reporting period. The 2013 Bridge Notes were secured by a second priority security interest on all of our assets,
subject to certain limited exceptions. This security interest terminated upon conversion of the 2013 Bridge Notes in connection
with the Merger and related private placement financing.
On January 15, 2014, upon the closing of
the Merger and the private placement financing discussed in
Note 3, The Merger, Offering and Related Transactions
, the
outstanding principal amount and accrued interest of the 2013 Bridge Notes was converted into Units at a conversion price of $1.00
per Unit. Also, the investors received an additional warrant to purchase a number of shares of Company common stock equal to 50%
of the number of shares of Company common stock contained in the Units into which the Bridge Notes were converted (i.e. 2,500,000
shares in the aggregate), at an exercise price of $1.00 per share, for a term of three years (the “Bridge Warrants”).
As of March 31, 2014 and December 31,
2013, the outstanding principal of the notes amounted to $0 and $5,062,417 including accrued interest of $62,417, respectively.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
Other Notes Payable
We also financed certain leasehold improvements
to our Richmond, California facility. As of March 31, 2014 and December 31, 2013, the outstanding principal on the loan was $134,626
and $144,041, respectively. Interest expense for each three month period then ending was approximately $2,466 and $2,629, respectively.
8. Capitalization and Equity Structure
Merger Agreement, Recapitalization
and PPO
As discussed in
Note 3. The Merger,
Offering and Other Related Transactions
, on January 15, 2014 (the “Closing Date”), Ekso Bionics, Inc., Ekso Acquisition
Corp. and Ekso Bionics Holdings, Inc. entered into an Agreement and Plan of Merger and Reorganization, which closed on the same
date. Pursuant to the terms of the Merger Agreement, Ekso Acquisition Corp. merged with and into Ekso Bionics, Inc. which was
the surviving corporation and thus became a wholly-owned subsidiary of Ekso Bionics Holdings, Inc.. The Merger, Offering and other
Related Transactions are described more fully in our Form 8-K/A filed with the SEC on March 31, 2014.
Share Exchanges
At the closing of the Merger, all of the
outstanding capital stock of Ekso Bionics, Inc. was exchanged for an aggregate of 42,615,556 shares of our common stock.
In addition, pursuant to the Merger Agreement
warrants to purchase 407,772 shares of Ekso Bionics’ common stock issued and outstanding immediately prior to the closing
of the Merger were converted into warrants to purchase 621,363 shares of the Company’s common stock and options to purchase
4,978,645 shares of Ekso Bionics’ common stock issued and outstanding immediately prior to the closing of the Merger were
converted into options to purchase 7,586,459 shares of the Company’s common stock.
Upon the closing of the Merger and the
PPO, $5,000,000 of outstanding of convertible bridge notes issued by Ekso Bionics in November 2013 (the “2013 Bridge Notes”)
automatically converted into Units, each consisting of one share of the Company’s common stock and a warrant to purchase
one share of common stock (the “Units”) at a conversion price of $1.00 per Unit, and investors in the 2013 Bridge
Notes received a warrant to purchase 2,500,000 shares of common stock at an exercise price of $1.00 per share for a term of three
years (the “Bridge Warrants”). The Bridge Warrants have weighted average anti-dilution protection, subject to customary
exceptions.
Concurrently with the closing of the Merger
and in contemplation of the Merger, the Company held a closing of the PPO in which it sold 20,580,000 Units (including Units issued
upon conversion of the Bridge Notes as described above) of securities, at a purchase price of $1.00 per Unit, each Unit consisting
of one share of our common stock and a warrant to purchase one share of common stock with an exercise price per share of $2.00
and a term of 5 years (the “PPO Warrants”). Between January 29, 2014 and February 6, 2014, the Company issued an additional
9,720,000 Units in subsequent closings of the PPO.
Investors in the Units have weighted average
anti-dilution protection with respect to the shares of common stock included in the Units if within 24 months after the final
closing of the PPO the Company shall issue additional shares of common stock or common stock equivalents (subject to customary
exceptions, including but not limited to issuances of awards under the Company’s 2014 Plan (as defined below)) for consideration
per share less than $1.00.
In connection with the conversion of the
2013 Bridge Notes and the PPO, the Placement Agent and its sub-agents were paid an aggregate commission of $3,030,000 and were
issued warrants to purchase an aggregate of 500,000 shares of our common stock, with an exercise price per share of $1.00 and
a term of five years (“Bridge Agent Warrants”) and warrants to purchase an aggregate of 2,500,000 shares of common
stock with a term of five years and an exercise price of $1.00 per share (the “PPO Agent Warrants”). The Bridge Agent
Warrants and PPO Agent Warrants have weighted average anti-dilution protection, subject to customary exceptions.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
2014 Equity Incentive
Plan
Before the Merger, the Board of Directors
adopted, and the stockholders approved, the 2014 Equity Incentive Plan (the “2014 Plan”), which provides for the issuance
of incentive awards of up to 14,410,000 shares of common stock to officers, key employees, consultants and directors. In connection
with the Merger, options to purchase an aggregate of 7,586,459 shares of our common stock were issued under the 2014 Plan.
On the closing of the Merger, the Board
granted to officers and directors options to purchase an aggregate of 2,300,000 shares of common stock under the 2014 Plan.
Summary Capitalization Subsequent to
Reverse Merger and PPO
The Company’s authorized capital
stock consists of 500,000,000 shares of common stock and 10,000,000 shares of preferred stock. At March 31, 2014, 78,480,019 shares
of common stock were issued and outstanding, and no shares of preferred stock were issued and outstanding.
Common Stock
The holders of outstanding shares of common
stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and
in such amounts as the board from time to time may determine. Holders of common stock are entitled to one vote for each share
held on all matters submitted to a vote of stockholders. There is no cumulative voting for the election of directors. The common
stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding
up of our company, the assets legally available for distribution to stockholders are distributable ratably among the holders of
the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. Each
outstanding share of common stock is duly and validly issued, fully paid and non-assessable.
Preferred Stock
We may issue shares of preferred stock
from time to time in one or more series, each of which will have such distinctive designation or title as shall be determined
by our Board of Directors and will have such voting powers, full or limited, or no voting powers, and such preferences and relative,
participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated
in such resolution or resolutions providing for the issue of such class or series of preferred stock as may be adopted from time
to time by the Board of Directors.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed
Consolidated Financial Statements
Options on Common Stock
Options to purchase an aggregate of 10,748,459
shares of our common stock have been issued under the 2014 Plan, as follows:
|
·
|
Options
to purchase 4,978,645 shares of Ekso Bionics, Inc.’s common stock issued and outstanding
immediately prior to the closing of the Merger were converted into options to purchase
7,586,459 shares of our common stock, with a weighted average exercise price of $0.46
per share. Most of these option grants vest over a term of 48 months, beginning on the
first anniversary of an employee’s employment, and have a term of ten years.
|
|
·
|
Options
to purchase 450,000 shares of our common stock were granted to our directors. These option
grants have an exercise price of $1.00 per share, will become exercisable over a term
of 48 months, with 1/4 of the shares becoming exercisable on the first anniversary of
the date of grant and with 1/48 of the shares becoming exercisable at the end of each
month thereafter, and have a term of ten years.
|
|
·
|
Options
to purchase 1,850,000 shares of our common stock were granted to our officers in connection
with the Merger. These option grants have an exercise price of $1.00 per share, will
become exercisable over a term of 48 months, with 1/4 of the shares becoming exercisable
on the first anniversary of the date of grant and with 1/48 of the shares becoming exercisable
at the end of each month thereafter, and have a term of ten years.
|
|
|
|
|
·
|
Options
to purchase 862,000 shares of our common stock were granted to officers and employees
subsequent to the Merger through March 31, 2014. These options have a weighted average
exercise price of $5.99, will become exercisable over a term of 48 months, with 1/4 of
the shares becoming exercisable on the first anniversary of the date of grant and with
1/48 of the shares becoming exercisable at the end of each month thereafter, and have
a term of ten years.
|
Warrants
As of the date hereof:
|
·
|
The
Bridge Warrants entitle their holders to purchase 2,725,000 shares of common stock, with
a term of three years and an exercise price of $1.00 per share.
|
|
·
|
The
Bridge Agent Warrants entitle their holders to purchase 500,000 shares of common stock,
with a term of five years and an exercise price of $1.00 per share.
|
|
·
|
The
PPO Warrants entitle their holders to purchase 30,300,000 shares of common stock, with
a term of five years and an exercise price of $2.00 per share.
|
|
·
|
The
PPO Agent Warrants entitle their holders to purchase 2,500,000 shares of common stock,
with a term of five years and an exercise price of $1.00 per share.
|
|
·
|
Holders
of warrants to purchase Ekso Bionics, Inc. common stock prior to the Merger hold warrants
to purchase 621,363 shares of common stock, which expire on various dates from June 1,
2022 to August 30, 2023 and have an exercise price of $1.38 per share. These warrants
may, at the option of the holders, be exercised on a “cashless exercise”
basis, which means that in lieu of paying the aggregate exercise price for the shares
being purchased upon exercise of the warrants for cash, the holder will forfeit a number
of shares underlying the warrants with a “fair market value” equal to such
aggregate exercise price. We will not receive additional proceeds to the extent these
warrants are exercised on a “cashless exercise” basis.
|
|
·
|
Other
warrants entitle their holders to purchase 225,000 shares of common stock, with a term
of three years and an exercise price of $1.00 per share.
|
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
The outstanding warrants, other than those
converted from warrants to purchase Ekso Bionics common stock, contain “weighted average” anti-dilution protection
in the event that we issue common stock or securities convertible into or exercisable for shares of common stock at a price lower
than the subject warrant’s exercise price, subject to certain customary exceptions, as well as customary provisions for
adjustment in the event of stock splits, subdivision or combination, mergers, etc.
The fair value of the warrant liability was
determined using the Binomial Lattice pricing model. This model is dependent upon several variables such as the instrument’s
term, expected strike price, risk-free interest rate estimated over the expected term, and the estimated volatility of our stock
over the term of warrant. The expected strike price is estimated based on a weighted average probability analysis of the strike
price changes expected during the term as a result of the anti-dilution clause in the agreement. The risk-free rate is based on
U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending
the volatility rates for a number of similar publicly-traded companies.
9. Stock-based Compensation Plans and
Awards
In January 2014, the Board of Directors
adopted the 2014 Equity Incentive Plan. Options previously issued under the 2007 Equity Incentive Plan were converted into options
to purchase shares of the Company’s common stock under the 2014 Equity Incentive Plan. Under the terms of the 2014 Equity
Incentive Plan, the Board of Directors may award stock, options or similar rights having either a fixed or variable price related
to the fair market value of the shares and with an exercise or conversion privilege related to the passage of time, the occurrence
of one or more events, or the satisfaction of performance criteria or other conditions, or any other security with the value derived
from the value of the shares. Such awards include stock options, restricted stock, restricted stock units, stock appreciation
rights and dividend equivalent rights.
The Board of Directors may grant stock
options under the 2014 Equity Incentive Plan at a price of not less than 100% of the fair market value of our common stock on
the date the option is granted. Incentive stock options granted to employees who, on the date of grant, own stock representing
more than 10% of the voting power of all of our classes of stock are granted at an exercise price of not less than 110% of the
fair market value of our common stock. The maximum term of these incentive stock options, granted to employees who own stock possessing
more than 10% of the voting power of all classes of the our stock, may not exceed five years. The maximum term of an incentive
stock option granted to any other participant may not exceed ten years. Subject to the limitations discussed above, the Board
of Directors determines the term and exercise or purchase price of other awards granted under the 2014 Equity Incentive Plan.
The Board of Directors also determines the terms and conditions of awards, including the vesting schedule and any forfeiture provisions.
Awards under the 2014 Equity Incentive Plan may vest upon the passage of time or upon the attainment of certain performance criteria
established by the Board of Directors.
We may from time to time grant options
to purchase common stock to non-employees for advisory and consulting services. Pursuant to ASC 505-50,
Equity-Based Payments
to Non-Employees
, we periodically remeasure the fair value of these stock options using the Black-Scholes option pricing model
and recognize expense ratably over the vesting period of each stock option award. Non-employee stock compensation is included
in the Condensed Consolidated Statements of Operation in general and administrative, research and development or sales and marketing
expenses, depending upon the nature of the non-employee services provided.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
The per-share fair value of each stock
option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions:
|
|
Three
months ended March 31,
|
|
|
2014
|
|
2013
|
|
|
|
|
|
Dividend yield
|
|
—
|
|
—
|
Risk-free interest rate
|
|
1.74% - 2.68%
|
|
0.83%-1.13%
|
Expected term (in years)
|
|
5-10
|
|
5-10
|
Volatility
|
|
66%
|
|
65%
|
Total stock-based compensation expense
related to options granted to employees and non-employees was included in the unaudited Condensed Consolidated Statements of Operations
as follows:
|
|
Three
months ended
March 31,
|
|
|
|
2014
|
|
|
2013
|
|
|
|
|
|
|
|
|
Sales and marketing
|
|
$
|
100,522
|
|
|
$
|
24,686
|
|
Research and development
|
|
|
87,947
|
|
|
|
19,655
|
|
General and administrative
|
|
|
178,171
|
|
|
|
41,814
|
|
|
|
$
|
366,640
|
|
|
$
|
86,155
|
|
10. Income Taxes
The effective tax rate for the three months
ended March 31, 2013 was less than one percent based on the estimated tax loss for the fiscal year. There were no material changes
to the unrecognized tax benefits in the three months ended March 31, 2014 and the Company does not expect significant changes
to unrecognized tax benefits through the end of the fiscal year. Because of the Company’s history of tax losses, all years
remain open to tax audit.
11. Commitments and
Contingencies
Contingencies
In the normal course of business, we may
be subject to various legal matters. As of March 31, 2014 we were not a party to any legal matters that could have a material
affect on our consolidated financial position, results of operations or cash flows.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
Material Contracts
We enter into various license, research
collaboration and development agreements which provide for payments to us for government grants, fees, cost reimbursements typically
with a markup, technology transfer and license fees, and royalty payments on sales. As of March 31, 2014 we were not a party to
any agreements that were not in the normal course of our business.
In connection
with the PPO, we entered into a Registration Rights Agreement, pursuant to which we have agreed that promptly, but no later than
90 calendar days from the final closing of the PPO, the Company will file a registration statement with the SEC (the “Registration
Statement”) covering (a) the shares of common stock issued in the PPO (including those issued upon conversion of the Bridge
Notes), (b) the shares of common stock issuable upon exercise of the Bridge Warrants, (c) the shares of common stock issuable
upon exercise of the PPO Warrants, and (d) the shares of common stock underlying Bridge Agent Warrants and PPO Agent Warrants
(the “Registrable Shares”). The Company is required to use its commercially reasonable efforts to ensure that such
Registration Statement is declared effective within 180 calendar days of filing with the SEC. In the unanticipated event that
the Company fails to file the registration statement or the registration statement is not declared effective by the applicable
deadline, the Company will pay to each holder of Registrable Securities an amount equal to 1.0% of the PPO offering price per
share for each full month after the deadline until the registration statement is filed or declared effective, as applicable, up
to a maximum of 8% of the PPO offering price per share (the “Liquidated Damages”). The Company must keep the Registration
Statement “evergreen” for one year from the date it is declared effective by the SEC or until Rule 144 is available
to the holders of Registrable Shares who are not and have not been affiliates of the Company with respect to all of their registrable
shares, whichever is earlier. During such time, the Company will be required to pay Liquidated Damages if the Registration Statement,
after being filed and declared effective, ceases to be continuously effective for more than 30 calendar days.
12. Net Loss Per Share
Basic net loss per share excludes the
effect of dilution and is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding
less the weighted-average number of shares subject to repurchase during the period.
Diluted net loss per share is computed
by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net
loss per share was the same as diluted net loss per share for the three months ended March 31, 2014 and 2013 as the inclusion
of all potential common shares outstanding would have had an anti-dilutive effect.
The following table sets forth the computation
of historical basic and diluted net loss per share:
|
|
Three Months Ended
March 31,
|
|
|
|
2014
|
|
|
2013
|
|
Numerator
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(81,765,359
|
)
|
|
$
|
(3,796,754
|
)
|
Denominator
|
|
|
|
|
|
|
|
|
Weighted-average
common shares outstanding used in computing basic and
diluted net loss per share
|
|
|
67,072,057
|
|
|
|
20,636,529
|
|
Net
loss per share, basic and diluted
|
|
$
|
(1.22
|
)
|
|
$
|
(0.18
|
)
|
A total of 5,280,368 shares of common stock
held by pre-merger shareholders of Ekso Bionics Holdings, Inc. as described in Note 3,
The Merger, Offering and Related Transactions
have been retroactively reflected as outstanding for the three months ended March 31, 2014 and 2013 for purposes of determining
the basic and diluted net loss pershare in the accompanying Condensed Consolidated Statements of Operations.
Ekso Bionics Holdings, Inc.
Notes to Unaudited Condensed Consolidated
Financial Statements
13.
Segment Disclosures
We have two reportable segments, Engineering
Services and Medical Devices. Engineering Services generates revenue principally from collaborative research and development service
arrangements, technology license agreements, and government grants where we use our robotics domain knowledge in bionic exoskeletons
to bid on and procure contracts and grants from entities such as the United States Special Operations Command, the Defense Advanced
Research Projects Agency and the National Science Foundation. The Medical Devices segment designs, engineers, and manufactures
exoskeletons for applications in the medical markets.
We evaluate performance and allocate resources
based on segment gross profit margin. The reportable segments are each managed separately because they serve distinct markets,
and one segment provides a service and the other manufactures and distributes a unique product. We do not consider net assets
as a segment measure and, accordingly, assets are not allocated.
Segment reporting information is as follows:
|
|
Engineering
|
|
|
Medical
|
|
|
|
|
|
|
Services
|
|
|
Devices
|
|
|
Total
|
|
Three months ended March 31, 2014
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
534,958
|
|
|
$
|
526,753
|
|
|
$
|
1,061,711
|
|
Cost of revenue
|
|
|
252,103
|
|
|
|
330,125
|
|
|
|
582,228
|
|
Gross profit
|
|
$
|
282,855
|
|
|
$
|
196,628
|
|
|
$
|
479,483
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
363,330
|
|
|
$
|
332,919
|
|
|
$
|
696,249
|
|
Cost of revenue
|
|
|
347,214
|
|
|
|
232,563
|
|
|
|
579,777
|
|
Gross profit
|
|
$
|
16,116
|
|
|
$
|
100,356
|
|
|
$
|
116,472
|
|
Geographic information for revenue based
on location of customer is as follows:
|
|
For
the three months ended
March 31,
|
|
|
|
2014
|
|
|
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
$
|
889,785
|
|
|
$
|
623,485
|
|
Europe, Middle East, Asia
|
|
|
171,926
|
|
|
|
72,764
|
|
|
|
$
|
1,061,711
|
|
|
$
|
696,249
|
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Stockholders
Ekso Bionics, Inc.
We have audited the accompanying consolidated
balance sheets of Ekso Bionics, Inc. and Subsidiary as of December 31, 2013 and 2012 and the related consolidated statements of
operations, convertible preferred stock and stockholders’ deficit, and cash flows for each of the two years in the period
ended December 31, 2013. These financial statements are the responsibility of the Company’s management. Our responsibility
is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance
with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our
audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that
our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial
statements audited by us present fairly, in all material respects, the consolidated financial position of Ekso Bionics, Inc. and
Subsidiary at December 31, 2013 and 2012, and the consolidated results of its operations and its cash flows for each of the two
years in the period ended December 31, 2013, in conformity with accounting principles generally accepted in the United States
of America.
/s/ OUM & CO. LLP
San Francisco, California
March 31, 2014
Ekso Bionics, Inc.
and Subsidiary
Consolidated Balance Sheets
|
|
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
Assets
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
805,306
|
|
|
$
|
1,738,662
|
|
Accounts receivable
|
|
|
549,469
|
|
|
|
788,241
|
|
Inventories, net
|
|
|
725,096
|
|
|
|
615,365
|
|
Note receivable from stockholder
|
|
|
103,735
|
|
|
|
99,035
|
|
Prepaid expenses and other current assets
|
|
|
250,998
|
|
|
|
109,236
|
|
Deferred cost of revenue, current
|
|
|
768,599
|
|
|
|
436,483
|
|
Total current assets
|
|
|
3,203,203
|
|
|
|
3,787,022
|
|
Property and equipment, net
|
|
|
1,575,286
|
|
|
|
1,665,191
|
|
Deferred cost of revenue, non-current
|
|
|
803,298
|
|
|
|
693,763
|
|
Security deposits
|
|
|
54,390
|
|
|
|
54,390
|
|
Security issuance costs
|
|
|
947,760
|
|
|
|
9,460
|
|
Total assets
|
|
$
|
6,583,937
|
|
|
$
|
6,209,826
|
|
Liabilities, Convertible Preferred
Stock and Stockholders' Deficit
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Notes payable, current
|
|
$
|
1,638,505
|
|
|
$
|
1,656,040
|
|
Convertible debt
|
|
|
5,062,417
|
|
|
|
3,528,313
|
|
Accounts payable
|
|
|
1,498,680
|
|
|
|
1,729,731
|
|
Accrued liabilities
|
|
|
1,430,799
|
|
|
|
997,476
|
|
Customer advances and deferred revenues, current
|
|
|
2,419,226
|
|
|
|
1,566,153
|
|
Liability due to early stock
option exercise
|
|
|
5,293
|
|
|
|
10,587
|
|
Total current liabilities
|
|
|
12,054,920
|
|
|
|
9,488,300
|
|
Customer advances and deferred revenues, non-current
|
|
|
2,209,111
|
|
|
|
1,898,560
|
|
Notes payable, non-current
|
|
|
866,950
|
|
|
|
2,509,634
|
|
Warrant liability
|
|
|
377,747
|
|
|
|
563,822
|
|
Deferred rent
|
|
|
123,709
|
|
|
|
159,916
|
|
Total liabilities
|
|
|
15,632,437
|
|
|
|
14,620,232
|
|
Commitments and contingencies (Note 16)
|
|
|
|
|
|
|
|
|
Convertible preferred stock issuable
in series, $0.001 par value; 22,000,000, and 10,365,000 shares authorized at December 31, 2013 and 2012 respectively; 14,011,028
and 8,831,684 shares issued and outstanding at December 31, 2013 and 2012 respectively; liquidation preference
of $1.75 - $2.10 per share at December 31, 2013 and 2012
|
|
|
27,324,208
|
|
|
|
16,675,983
|
|
Stockholders' deficit:
|
|
|
|
|
|
|
|
|
Common stock, $0.001 par value; 40,000,000 and 30,000,000
shares authorized at December 31, 2013 and 2012, respectively; 10,391,400 and 9,887,079, shares issued and outstanding
at December 31, 2013 and 2012, respectively
|
|
|
10,025
|
|
|
|
9,920
|
|
Additional paid-in capital
|
|
|
1,648,886
|
|
|
|
1,047,936
|
|
Accumulated deficit
|
|
|
(38,031,619
|
)
|
|
|
(26,144,245
|
)
|
Total stockholders' deficit
|
|
|
(36,372,708
|
)
|
|
|
(25,086,389
|
)
|
Total liabilities, convertible
preferred stock and stockholders' deficit
|
|
$
|
6,583,937
|
|
|
$
|
6,209,826
|
|
See Accompanying Notes to Consolidated
Financial Statements
Ekso Bionics, Inc.
and Subsidiary
Consolidated Statement of Operations
|
|
For the years ended December
31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
Medical devices
|
|
$
|
1,611,709
|
|
|
$
|
566,222
|
|
Engineering services
|
|
|
1,690,235
|
|
|
|
2,140,355
|
|
Total revenue
|
|
|
3,301,944
|
|
|
|
2,706,577
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
Cost of medical devices
|
|
|
1,460,692
|
|
|
|
553,429
|
|
Cost of engineering services
|
|
|
1,253,942
|
|
|
|
1,782,848
|
|
Total cost of revenue
|
|
|
2,714,634
|
|
|
|
2,336,277
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
587,310
|
|
|
|
370,300
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
3,913,047
|
|
|
|
4,381,067
|
|
Research and development
|
|
|
2,677,310
|
|
|
|
4,304,317
|
|
Sales and marketing
|
|
|
4,291,282
|
|
|
|
5,925,905
|
|
Total operating expenses
|
|
|
10,881,639
|
|
|
|
14,611,289
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(10,294,329
|
)
|
|
|
(14,240,989
|
)
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(1,726,455
|
)
|
|
|
(736,346
|
)
|
Interest income
|
|
|
5,225
|
|
|
|
10,692
|
|
Non-cash gain on changes in fair value of warrants
|
|
|
186,075
|
|
|
|
17,126
|
|
Other expense, net
|
|
|
(57,890
|
)
|
|
|
(92,441
|
)
|
Total other income (expense),
net
|
|
|
(1,593,045
|
)
|
|
|
(800,969
|
)
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(11,887,374
|
)
|
|
$
|
(15,041,958
|
)
|
See Accompanying Notes to Consolidated
Financial Statements
Ekso Bionics, Inc.
and Subsidiary
Consolidated Statements of Convertible
Preferred Stock and Stockholders' Deficit
|
|
Convertible Preferred
Stock
|
|
|
Common Stock
|
|
|
Additional
Paid-In
|
|
|
Accumulated
|
|
|
Total
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Deficit
|
|
Balance
at December 31, 2011
|
|
|
4,820,549
|
|
|
$
|
8,199,909
|
|
|
|
9,738,580
|
|
|
$
|
9,739
|
|
|
|
670,514
|
|
|
$
|
(11,102,287
|
)
|
|
$
|
(10,422,034
|
)
|
Issuance of Series
A-2 convertible preferred stock at $2.10 per share issued in exchange for cash
|
|
|
4,011,135
|
|
|
|
8,476,074
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Issuance of common
stock upon exercise of options
|
|
|
-
|
|
|
|
-
|
|
|
|
156,624
|
|
|
|
156
|
|
|
|
31,560
|
|
|
|
-
|
|
|
|
31,716
|
|
Common stock repurchased
|
|
|
-
|
|
|
|
-
|
|
|
|
(8,125
|
)
|
|
|
(8
|
)
|
|
|
(804
|
)
|
|
|
-
|
|
|
|
(812
|
)
|
Vesting of early exercised
options
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
33
|
|
|
|
13,200
|
|
|
|
-
|
|
|
|
13,233
|
|
Stock-based compensation
expense
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
333,466
|
|
|
|
-
|
|
|
|
333,466
|
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(15,041,958
|
)
|
|
|
(15,041,958
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December
31, 2012
|
|
|
8,831,684
|
|
|
|
16,675,983
|
|
|
|
9,887,079
|
|
|
|
9,920
|
|
|
|
1,047,936
|
|
|
|
(26,144,245
|
)
|
|
|
(25,086,389
|
)
|
Issuance of Series
B convertible preferred stock at $2.10 per share issued in exchange for cash
|
|
|
2,088,820
|
|
|
|
4,294,259
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Issuance of Series
B convertible preferred stock upon conversion of convertible debt and accrued interest
|
|
|
3,090,524
|
|
|
|
6,490,071
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Common stock warrants
issued in connection with issuance of Series B convertible preferred stock
|
|
|
-
|
|
|
|
275
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Common stock warrants
issued in connection with issuance of Series B convertible preferred stock
|
|
|
-
|
|
|
|
(136,380
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
136,380
|
|
|
|
-
|
|
|
|
136,380
|
|
Issuance of common
stock upon exercise of options
|
|
|
-
|
|
|
|
-
|
|
|
|
506,196
|
|
|
|
94
|
|
|
|
65,499
|
|
|
|
-
|
|
|
|
65,593
|
|
Common stock repurchased
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,875
|
)
|
|
|
(2
|
)
|
|
|
(187
|
)
|
|
|
-
|
|
|
|
(189
|
)
|
Vesting of early exercised
options
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13
|
|
|
|
3,961
|
|
|
|
-
|
|
|
|
3,974
|
|
Compensation expense
for options issued a non-employee
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,679
|
|
|
|
-
|
|
|
|
4,679
|
|
Stock-based compensation
expense
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
390,618
|
|
|
|
-
|
|
|
|
390,618
|
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(11,887,374
|
)
|
|
|
(11,887,374
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at December 31, 2013
|
|
|
14,011,028
|
|
|
$
|
27,324,208
|
|
|
|
10,391,400
|
|
|
$
|
10,025
|
|
|
$
|
1,648,886
|
|
|
$
|
(38,031,619
|
)
|
|
$
|
(36,372,708
|
)
|
See Accompanying Notes to Consolidated
Financial Statements
Ekso Bionics, Inc.
and Subsidiary
Consolidated Statements of Cash Flows
|
|
For the Years ended December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
Operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(11,887,374
|
)
|
|
$
|
(15,041,958
|
)
|
Adjustments to reconcile net loss to net cash used in
operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
468,906
|
|
|
|
342,078
|
|
Loss on sale of property and equipment
|
|
|
223
|
|
|
|
20,212
|
|
Inventory allowance expense
|
|
|
(7,574
|
)
|
|
|
19,432
|
|
Amortization of deferred rent
|
|
|
(36,207
|
)
|
|
|
157,066
|
|
Amortization of debt discounts
|
|
|
169,248
|
|
|
|
120,931
|
|
Amortization of notes payable offering costs
|
|
|
21,137
|
|
|
|
7,871
|
|
Interest expense accrued to convertible notes
|
|
|
230,805
|
|
|
|
42,475
|
|
Interest income added to note receivable from stockholder
|
|
|
—
|
|
|
|
(3,810
|
)
|
Fair value of warrant accounted for as a reduction
of revenue
|
|
|
—
|
|
|
|
57,494
|
|
Adjustment to record convertible note at fair value
|
|
|
799,194
|
|
|
|
174,292
|
|
Stock-based compensation expense
|
|
|
390,617
|
|
|
|
333,466
|
|
Gain due to changes in fair value of warrant liability
|
|
|
(186,075
|
)
|
|
|
(17,126
|
)
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
238,771
|
|
|
|
(396,603
|
)
|
Inventories
|
|
|
(102,157
|
)
|
|
|
(828,776
|
)
|
Prepaid expense and other assets
|
|
|
(87,335
|
)
|
|
|
(5,326
|
)
|
Deferred costs of revenue
|
|
|
(441,650
|
)
|
|
|
(1,130,246
|
)
|
Accounts payable
|
|
|
(231,050
|
)
|
|
|
808,813
|
|
Accrued liabilities
|
|
|
433,323
|
|
|
|
74,259
|
|
Customer advances and deferred
revenues
|
|
|
1,163,626
|
|
|
|
2,602,311
|
|
Net cash used in operating activities
|
|
|
(9,063,577
|
)
|
|
|
(12,663,145
|
)
|
|
|
|
|
|
|
|
|
|
Investing activities:
|
|
|
|
|
|
|
|
|
Security deposits
|
|
|
—
|
|
|
|
10,000
|
|
Note receivable from stockholder
|
|
|
—
|
|
|
|
(45,000
|
)
|
Acquisition of property and equipment
|
|
|
(393,734
|
)
|
|
|
(832,303
|
)
|
Proceeds from sales of property
and equipment
|
|
|
14,511
|
|
|
|
2,465
|
|
Net cash used in investing activities
|
|
|
(379,223
|
)
|
|
|
(864,838
|
)
|
Financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from issuance of 2013 Series B Convertible Bridge
Notes, net of issuance costs
|
|
|
4,929,196
|
|
|
|
—
|
|
Proceeds from issuance of notes payable and warrants,
net of issuance costs
|
|
|
—
|
|
|
|
3,500,000
|
|
Principal payments on notes payable
|
|
|
(1,829,466
|
)
|
|
|
(609,753
|
)
|
Proceeds from issuance of 2012 Series B Convertible Bridge
Notes
|
|
|
2,000,000
|
|
|
|
3,311,546
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible preferred stock
and warrants, net of issuance costs
|
|
|
4,152,329
|
|
|
|
8,476,074
|
|
Payments for private placement offerings
|
|
|
(947,758
|
)
|
|
|
—
|
|
Proceeds from issuance of common stock, net of repurchases
|
|
|
205,143
|
|
|
|
30,904
|
|
Net cash provided by financing
activities
|
|
|
8,509,444
|
|
|
|
14,708,771
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash
|
|
|
(933,356
|
)
|
|
|
1,180,788
|
|
Cash at beginning of year
|
|
|
1,738,662
|
|
|
|
557,874
|
|
|
|
|
|
|
|
|
|
|
Cash at end of year
|
|
$
|
805,306
|
|
|
$
|
1,738,662
|
|
Supplemental disclosure of cash flow activities:
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
632,540
|
|
|
$
|
387,391
|
|
Cash paid for taxes
|
|
$
|
25,035
|
|
|
$
|
172
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash
activities:
|
|
|
|
|
|
|
|
|
Acquisition of property and equipment with note payable
|
|
$
|
-
|
|
|
$
|
200,000
|
|
Acquisition of property and equipment with capital
lease
|
|
$
|
-
|
|
|
$
|
23,079
|
|
Transfer to property and equipment from inventory
|
|
$
|
-
|
|
|
$
|
467,547
|
|
Preferred stock and common warrants issued to lender
|
|
$
|
5,293
|
|
|
$
|
355,116
|
|
Conversion of principal on convertible notes into
Series B convertible preferred stock
|
|
$
|
6,490,071
|
|
|
$
|
-
|
|
Common stock warrants issued in connection with Series
B convertible preferred stock offering
|
|
$
|
168,872
|
|
|
$
|
-
|
|
Vesting of early exercised stock options
|
|
$
|
5,283
|
|
|
$
|
13,233
|
|
See Accompanying Notes to Consolidated
Financial Statements
Ekso Bionics, Inc.
and Subsidiary
Notes to Consolidated Financial Statements
1. Organization
Description of Business
Ekso Bionics, Inc. (the “Company”)
was incorporated in January 2005 in the State of Delaware and is currently headquartered in Richmond, California. The Company,
a leading developer and manufacturer of human bionic exoskeletons, was founded after the University of California at Berkeley’s
Robotics and Human Engineering Laboratory had a breakthrough in demonstrating human exoskeletons that are more energy efficient
than previously thought possible.
Ekso Bionics pioneered the field of human
exoskeletons to augment human strength, endurance and mobility. Ekso Bionics designs, develops and sells wearable robots, or “human
exoskeletons,” that have applications in medical, military, industrial, and consumer markets. The Company’s exoskeleton
systems are strapped over the user’s clothing, enabling individuals with neurological conditions affecting gait (e.g., spinal
cord injury or stroke) to walk again; permitting soldiers to carry heavy loads for long distances while mitigating lower back,
knee, and ankle injuries; and allowing industrial workers to perform heavy duty work for extended periods.
Ekso Bionics’ current medical device,
or exoskeleton - the Ekso GT
TM
, or “Ekso,” is used by hospitals on patients with lower extremity weakness
or paralysis. Our products have been listed with the U.S. Food and Drug Administration (“FDA”) and have received a
CE Mark (indicating compliance with European Union legislation). We have sold over 50 devices to rehabilitation centers and individual
users for rehabilitation since February 2012. Ekso Bionics also has a collaborative partnership with Lockheed Martin Corporation
(“Lockheed”) to develop products for military applications.
A wholly-owned UK subsidiary serves as
the Company’s sales and marketing agent for Ekso products in Europe.
Subsequent to December 31, 2013, the Company entered into a
merger agreement with PN Medical Group Inc. See
Note 18, Subsequent Events, Merger with Ekso Bionics Holdings, Inc.
Liquidity
The Company has incurred significant operating
losses and negative cash flows from operations. At December 31, 2013, the Company had an accumulated deficit of $38,031,619, a
working capital deficit of $8,851,717 and a stockholders’ deficit of $36,372,708.
Management believes that the Company’s
cash resources as of December 31, 2013, along with the proceeds received in connection with the PPO discussed in
Note 18, Subsequent
Events, Merger with Ekso Bionics Holdings, Inc.
, received in January and February 2014, are sufficient to implement its business
plan, support operations, fund research and development and meet its obligations through at least the middle of 2015. The Company
plans to raise additional capital to finance its operations beyond the middle of 2015. There can be no assurance that financing
will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional
financing is not obtained, the Company may have to reduce its discretionary overhead costs substantially, including research and
development, general and administrative and sales and marketing expenses or otherwise curtail operations.
2. Summary of Significant Accounting
Policies and Estimates
Principles of Consolidation
The accompanying consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States and include the
accounts of Ekso Bionics, Inc. and its wholly-owned subsidiary, Ekso Bionics, Ltd. All significant intercompany transactions and
balances have been eliminated.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Use of Estimates
The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting
period. For the Company, these estimates include, but are not limited to: revenue recognition, useful lives assigned to long-lived
assets, realizability of deferred tax assets, valuation of common and preferred stock warrants and options, and the valuation
of common stock for purposes of determining stock-based compensation and contingencies. Actual results could differ from those
estimates.
Foreign Currency Translation
The Company uses the U.S. dollar as its
functional currency. Since some of the Company's transactions are executed in various non-U.S. dollar currencies, the Company
converts these transactions into U.S. dollars for reporting purposes. Income, expenses and cash flows are translated at average
exchange rates prevailing during the reporting period, and assets and liabilities are translated at year-end exchange rates. Foreign
exchange transaction gains and losses are included in other income (expense), in the accompanying consolidated statements of operations.
Amounts of such gains and losses were not significant through December 31, 2013.
Cash and Cash Equivalents
The Company considers all highly liquid
investments purchased with a maturity of three months or less to be cash equivalents. The Company’s cash is deposited in
bank accounts with the Company’s primary cash management bank. The Company places its cash and cash equivalents in highly
liquid instruments with, and in the custody of, financial institutions with high credit ratings and limits the amounts invested
with any one institution, type of security and issuer. The Company did not have any cash equivalents or investments in money market
funds as of December 31, 2013 and 2012.
Concentration of Credit Risk and Other
Risks and Uncertainties
Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains
its cash accounts in excess of federally insured limits. However, management believes the Company is not exposed to significant
credit risk due to the financial position of the depository institutions in which these deposits are held.
The Company extends credit to customers
in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with
respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company
performs ongoing credit evaluations of its customers and does not require collateral from its customers to secure accounts receivable.
Accounts receivable are derived from the
sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged
based on contractual terms with the customer. The Company reviews its accounts receivable for collectability and provides an allowance
for credit losses, as needed. The Company has not experienced any losses related to accounts receivable as of December 31, 2013
and 2012.
Many of the sales contracts with customers
outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign
currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has
not experienced significant gains or losses upon settling foreign contracts.
In 2013, the Company had two customers
with accounts receivable balances totaling 10% or more of the Company’s total accounts receivable (28% and 19%), compared
with four customers in 2012 (26%, 24%, 21% and 17%).
In 2013, the Company had three customers
with net revenue balances of 10% or more of the Company’s total customer revenue (24%, 12% and 10%), compared with four
customers in 2012 (32%, 15%, 12% and 10%).
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Inventories, net
Inventories are recorded at the lower
of cost or market value. Cost is principally determined using the average cost method. Parts from vendors are received and recorded
as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component
is recorded as work in progress (“WIP”). Direct and indirect labor and applicable overhead costs are also allocated
and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company
periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand.
Excess and obsolete inventories identified would be recorded as an inventory impairment charge to the consolidated statement of
operations.
Property and Equipment
Property and equipment are stated at cost
less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally
ranging from three to five years. Leasehold improvements are amortized over the shorter of their estimated useful lives or the
related terms of the leases, generally ranging from five to ten years.
The costs of repairs and maintenance are
expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity
or extend the useful life of an asset are capitalized. When assets are retired or sold, the asset cost and related accumulated
depreciation or amortization are removed from the accompanying consolidated balance sheets, with any gain or loss reflected in
the accompanying consolidated statements of operations.
Impairment of Long-Lived Assets
The Company assesses the impairment of
long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the
estimated future cash flows expected to result from their use or eventual disposition. The Company’s long-lived assets subject
to this evaluation include only property and equipment. If estimates of future undiscounted net cash flows are insufficient to
recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value
of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally
estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful
lives. For each of the years ended December 31, 2013 and 2012, none of the Company’s property and equipment was determined
to be impaired. Accordingly, no impairment loss has been recognized.
Convertible Debt Instruments
The Company accounts for hybrid contracts
that feature conversion options in accordance with applicable GAAP. Accounting Standards Codification (“ASC”) 815,
Derivatives and Hedging Activities
, (“ASC 815”) requires companies to bifurcate conversion options from their
host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria
includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly
and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies
both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally
accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with
the same terms as the embedded derivative instrument would be considered a derivative instrument.
Conversion options that contain variable
settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities
at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host
instrument.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
The Company accounts for convertible instruments,
when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, in
accordance with ASC 470-20,
Debt with Conversion and Other Options
(“ASC 470-20”). Under ASC 470-20 the Company
records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments
based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction
and the effective conversion price embedded in the note. The Company accounts for convertible instruments (when the Company has
determined that the embedded conversion options should be bifurcated from their host instruments) in accordance with ASC 815. Under
ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract are allocated to the fair value of the derivative.
The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value
reported in results of operations.
The Company also follows ASC 480-10,
Distinguishing
Liabilities from Equity
(“ASC 480-10”) in its evaluation of the accounting for a hybrid instrument. A financial
instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified
as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settleable with a variable
number of the issuer’s equity shares); (b) variations in something other than the fair value of the issuer’s equity
shares (for example, a financial instrument indexed to the Standard and Poor's S&P 500 Index and settleable with a variable
number of the issuer’s equity shares); or (c) variations inversely related to changes in the fair value of the issuer’s
equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are
not further evaluated for any embedded derivatives, and are carried as a liability at fair value at each balance sheet date with
remeasurements reported in interest expense in the accompanying consolidated statements of operations.
Warrants Issued in Connection with
Financings
The Company generally accounts for warrants
issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation
to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash.
For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement,
the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value
in other income (expense) in the accompanying consolidated statements of operations.
Fair Value of Financial Instruments
ASC
820,
Fair Value Measurements
(“ASC 820”) clarifies that fair value is an exit price, representing the amount
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would
use in pricing an asset or liability.
ASC 820 requires
that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable
inputs. ASC 820 establishes a three tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows:
|
•
|
Level 1—Observable inputs that reflect quoted
prices for identical assets or liabilities in active markets.
|
|
•
|
Level 2—Observable inputs other than Level
1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets
that are not active; or other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or liabilities.
|
|
•
|
Level 3—Unobservable inputs that are supported
by little or no market activity and that are significant to the fair value of the assets
or liabilities.
|
The carrying amounts of current assets,
current liabilities and the non-current portion of customer advances and deferred revenues approximate their fair values because
of the relatively short periods until they mature or are required to be settled. The fair values of the notes payable also approximate
their fair values because of the relatively short periods until they mature. A majority of the notes are payable in 2014 and 2015.
The fair value of convertible debt is based on its settlement value “as if” conversion occurred on the reporting date,
and stock options and preferred stock warrant liabilities are estimated using the Black-Scholes option pricing model, all as more
fully discussed in their respective footnotes.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Deferred Rent
Deferred rent consists of the difference
between cash payments and the recognition of rent expense on a straight-line basis over the life of the lease.
Revenue and Cost of Revenue Recognition
When collaboration, other research arrangements
and product sales include multiple-element revenue arrangements, the Company accounts for these transactions by identifying the
elements, or deliverables, included in the arrangement and determining which deliverables are separable for accounting purposes.
The Company considers delivered items to be a separate unit of accounting if the delivered item(s) have stand-alone value to the
customer and delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor.
The Company recognizes revenue when the four basic criteria
of revenue recognition are met:
|
•
|
Persuasive evidence
of an arrangement exists. Customer contracts and purchase orders are generally used to
determine the existence of an arrangement.
|
|
•
|
The transfer of technology
or products has been completed or services have been rendered. Customer acceptance, when
applicable, is used to verify delivery.
|
|
•
|
The sales price is fixed
or determinable. The Company assesses whether the cost is fixed or determinable based
on the payment terms associated with the transaction and whether the sales price is subject
to refund or adjustment.
|
|
•
|
Collectability is reasonably
assured. The Company assesses collectability based primarily on the creditworthiness
of the customer as determined by credit checks and analysis as well as the customer’s
payment history.
|
Beginning in 2012, with the commercialization
of the Ekso, the Company began to recognize revenue from the sales of the Ekso and related services.
Medical Device Revenue and Cost
of Revenue Recognition
The Company builds medical devices called
the Ekso for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with manufacture
and assembly of these units.
In a typical Ekso sales arrangement, the
Company is obligated to deliver to the customer the Ekso unit and related software (the software is essential to the unit’s
functionality), post-sale training, technical support and maintenance. Because of the uniqueness of the Ekso unit and its use,
none of these deliverables has standalone value to the customer. Accordingly, once a sales arrangement with a fixed or determinable
price and reasonably assured payment is in place, the entire arrangement is accounted for as a single unit of accounting. The
total sales price for the delivered and undelivered elements are deferred and amortized to revenue beginning at the completion
of training on a straight line basis over the maintenance period, usually three years, which is the last delivered item.
Because of the limited guidance about
how to account for costs associated with a delivered item that cannot be separated from the undelivered items, the accounting
for such costs must be based on the conceptual framework and analogies to the limited guidance that does exists. Accordingly,
the Company accounts for the costs of the delivered items following, by analogy, the guidance in Accounting Standards Codification
(“ASC”) 310-20,
Nonrefundable Fees and Other Costs
(“ASC 310-20”). Under this guidance, upon completion
of training, the costs capitalized into inventory including direct material, direct and indirect labor, as well as overhead costs
are deferred and then amortized to costs of sales on the same basis as deferred revenue. The Company’s inclusion of indirect
labor and overhead costs are included in inventory because, under the conceptual framework, they add value to the Ekso unit and
are otherwise appropriate inventory costs. Since the Company has an enforceable contract for the remaining deliverables and the
entire arrangement is expected to generate positive margins, realization of the capitalized costs is probable and, as such, deferring
and amortizing them on the same basis as deferred revenue is appropriate.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
At the time of shipment to the customer,
the related inventory is reclassified to deferred cost of revenue where it is amortized to cost of revenue over the same period
that revenue is recognized. All costs incurred subsequent to the date of shipment are expensed as incurred. The cost of medical
device revenue includes expenses associated with the manufacture and delivery of devices including materials, payroll, benefits,
subcontractor expenses, depreciation of manufacturing equipment, excess and obsolete inventory costs, and shipping charges.
Engineering Services Revenue and
Cost of Revenue
The Company enters into technology license
agreements that typically provide for annual minimum access fees. When these annual minimum payments have separate stand-alone
values, the Company recognizes revenue when the technology is transferred or accessed, provided that the technology transferred
or accessed is not dependent on the outcome of continuing research and/or other development efforts.
Collaborative arrangements typically consist
of cost reimbursements for specific engineering and development spending, and future product royalty payments. Cost reimbursements
for engineering and development spending are recognized as the related project labor hours are incurred in relation to all labor
hours and when collectability is reasonably assured. Amounts received in advance are recorded as deferred revenue until the technology
is transferred, services are rendered, or milestones are reached. Product royalty payments are recorded when earned under the
arrangement.
Government grants, which support the Company’s
research efforts in specific projects, generally provide for reimbursement of approved costs as defined in the notices of grant
awards. Grant revenue is recognized as the associated project labor hours are incurred in relation to total labor hours. There
are some grants, like the National Science Foundation grants, which the Company draws upon and spends based on budgets preapproved
by the grantor.
The cost of engineering services revenue
includes payroll and benefits, subcontractor expenses and materials. All costs related to engineering services are expensed as
incurred and reported as cost of revenue.
Research and Development
Research and development costs consist of costs incurred for
the Company’s own internal research and development activities. These costs primarily include salaries and other personnel-related
expenses, contractor fees, facility costs, supplies, and depreciation of equipment associated with the design and development
of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.
Advertising and Marketing Costs
Advertising and marketing costs are charged
to sales and marketing expense as incurred. Advertising and marketing expense was $113,223 and $518,747 for the years ended December
31, 2013 and 2012, respectively.
Shipping Costs
Amounts billed to customers for shipping
costs are recognized as revenue. Costs incurred to ship devices from the Company’s manufacturing facility are recorded in
cost of revenues. Shipping revenues and costs were immaterial for all periods presented.
Income Taxes
The Company accounts for income taxes
using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable
or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that
have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax
contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and
liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have
not been considered.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the preparation of the Company's consolidated
financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions
in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax
expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for
tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess
the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely,
the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers
all the evidence available to it, both positive and negative, including historical levels of income, legislative developments,
expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies.
Stock-based Compensation
The Company measures stock-based compensation
expense for all stock-based awards made to employees and directors based on the estimated fair value of the award on the date
of grant using the Black-Scholes option pricing model and recognizes the fair value less estimated forfeitures, on a straight-line
basis over the requisite service periods of the awards. Stock-based awards made to non-employees are measured and recognized based
on the estimated fair value on the vesting date and are remeasured at each reporting period.
The Company’s determination of the
fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model is affected by the Company’s
stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but
are not limited to the Company’s expected stock price volatility over the term of the awards, and actual and projected employee
stock option exercise behaviors. Because there is insufficient information available to estimate the expected term of the stock-based
awards, we adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin No. 110. On
this basis, we estimated the expected term of options granted by taking the average of the vesting term and the contractual term
of the option.
The Company has, from time to time, modified
the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original
award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested
awards. The incremental compensation cost is the excess of the fair value based measure of the modified award on the date of modification
over the fair value of the original award immediately before the modification.
Comprehensive Income/(Loss)
ASC 220,
Comprehensive Income
requires
that an entity’s change in equity (or net assets) be reported if it arises from transactions and other events having non-owner
sources. Comprehensive loss for the periods presented was comprised solely of the Company’s consolidated net loss. The comprehensive
loss for the years ended December 31, 2013 and 2012 was $11,887,374 and $15,041,958, respectively. There were no other changes
in equity that were excluded from the Company’s consolidated net loss for all periods presented.
Recently Adopted Accounting
Standards
In February 2013, the Financial Accounting
Standards Board (‘‘FASB’’) issued Accounting Standards Update (“ASU”) 2013-02,
Comprehensive
Income (ASC Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.
The new ASU requires
entities to disclose in a single location (either on the face of the financial statement that reports net income or in the notes)
the effects of reclassifications out of accumulated other comprehensive income (‘‘AOCI’’). For items reclassified
out of AOCI and into net income in their entirety, entities must disclose the effect of the reclassification on each affected
net income item. For AOCI reclassification items that are not reclassified in their entirety into net income, entities must provide
a cross-reference to other required U.S. GAAP disclosures. There is no change in the requirement to present the components of
net income and other comprehensive income in either a single continuous statement or two separate consecutive statements. The
ASU does not change the items currently reported in other comprehensive income.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For public entities, the new disclosure
requirements are effective for annual reporting periods beginning after December 15, 2012, and interim periods within those years
(i.e., the second quarter of 2013 for entities with calendar year-ends). For nonpublic entities, ASU 2013-02 is effective prospectively
for reporting periods beginning after December 15, 2013. The ASU applies prospectively, and early adoption is permitted. The adoption
of this ASU did not have a material impact on the Company’s consolidated financial statements as of and for the years ended
December 31, 2013 and 2012.
3. Fair Value Measurements
The Company records its consolidated financial
assets and liabilities at fair value. The accounting standard for fair value provides a framework for measuring fair value, and
defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an
orderly transaction between market participants at the reporting date. The accounting standard establishes a three-tier hierarchy,
which prioritizes the inputs used in the valuation methodologies in measuring fair value:
|
•
|
Level
1
—Quoted prices in active markets for identical assets or liabilities. The
Company considers a market to be active when transactions for the asset occur with sufficient
frequency and volume to provide pricing information on an ongoing basis.
|
|
•
|
Level
2
—Inputs other than Level 1 that are observable, either directly or indirectly,
such as quoted prices for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or liabilities.
|
|
•
|
Level
3
—Unobservable inputs that are supported by little or no market activity and
that are significant to the fair value of the assets or liabilities. The valuation of
Level 3 investments requires the use of significant management judgments or estimation.
|
The Company’s fair value hierarchies
for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows:
|
|
Total
|
|
|
Quoted Prices in
Active Markets for
Identical Items
Level 1
|
|
|
Significant Other
Observable Inputs
Level 2
|
|
|
Significant
Unobservable
Inputs
Level 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant liability
|
|
$
|
377,747
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
377,747
|
|
Convertible debt
|
|
|
5,062,417
|
|
|
|
–
|
|
|
|
–
|
|
|
|
5,062,417
|
|
Total liabilities measured
at estimated fair value
|
|
$
|
5,440,164
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
5,440,164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant liability
|
|
$
|
563,822
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
563,822
|
|
Convertible debt
|
|
|
3,528,313
|
|
|
|
–
|
|
|
|
–
|
|
|
|
3,528,313
|
|
Total liabilities measured
at estimated fair value
|
|
$
|
4,092,135
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
4,092,135
|
|
The valuation of the convertible debt
and the warrant liability are more fully discussed in
Note 9, Convertible Debt, and Note 13, Capital Stock.
During the years ended December 31, 2013
and 2012, there were no transfers to or from Level 3. The Company had no assets measured on a recurring basis at fair value at
December 31, 2013 and 2012.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
The changes in the value of the Level
3 liabilities are summarized below:
|
|
Convertible Notes
Payable
|
|
|
Warrant
Liability
|
|
|
|
|
|
|
|
|
Balance at January 1, 2012
|
|
$
|
—
|
|
|
$
|
168,338
|
|
Issuance of warrants at fair value
|
|
|
—
|
|
|
|
412,610
|
|
Issuance of 2012 Series B convertible bridge notes at fair value
|
|
|
3,354,021
|
|
|
|
—
|
|
Mark to market, included in other expense, net
|
|
|
—
|
|
|
|
(17,126
|
)
|
Mark to market, included in interest expense
|
|
|
174,292
|
|
|
|
—
|
|
Balance at December 31, 2012
|
|
|
3,528,313
|
|
|
|
563,822
|
|
Issuance of 2012 Series B convertible bridge notes at fair value
|
|
|
2,162,564
|
|
|
|
—
|
|
Issuance of 2013 Series B convertible bridge notes at fair value
|
|
|
5,062,417
|
|
|
|
—
|
|
Issuance of right to receive common stock warrants at fair value included
in other expense, net
|
|
|
—
|
|
|
|
95,760
|
|
Mark to market, included in other expense, net
|
|
|
—
|
|
|
|
(281,835
|
)
|
Mark to market, included in interest expense
|
|
|
799,194
|
|
|
|
—
|
|
Converted to Series B convertible preferred stock
|
|
|
(6,490,071
|
)
|
|
|
—
|
|
Balance at December 31, 2013
|
|
$
|
5,062,417
|
|
|
$
|
377,747
|
|
4. Inventories
Inventories, net consist of the following:
|
|
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
Raw materials
|
|
$
|
501,187
|
|
|
$
|
346,634
|
|
Work in process
|
|
|
235,767
|
|
|
|
288,163
|
|
|
|
|
736,954
|
|
|
|
634,797
|
|
Less inventory reserve
|
|
|
(11,858
|
)
|
|
|
(19,432
|
)
|
|
|
|
|
|
|
|
|
|
Inventory, net
|
|
$
|
725,096
|
|
|
$
|
615,365
|
|
5. Property and Equipment, net
Property and equipment, net, consists of the following:
|
|
Estimated
|
|
December 31,
|
|
|
|
Life
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
Machinery and equipment
|
|
3-5 years
|
|
$
|
1,137,240
|
|
|
$
|
790,165
|
|
Computers and peripherals
|
|
5 years
|
|
|
327,152
|
|
|
|
326,443
|
|
Computer software
|
|
3-5 years
|
|
|
78,351
|
|
|
|
78,351
|
|
Leasehold improvement
|
|
5-10 years
|
|
|
606,483
|
|
|
|
598,740
|
|
Tools, molds, dies and jigs
|
|
5 years
|
|
|
36,932
|
|
|
|
36,932
|
|
Furniture and office equipment
|
|
3-7 years
|
|
|
251,019
|
|
|
|
251,019
|
|
Other
|
|
5 years
|
|
|
23,079
|
|
|
|
23,079
|
|
|
|
|
|
|
2,460,256
|
|
|
|
2,104,729
|
|
Accumulated depreciation and amortization
|
|
|
|
|
(884,970
|
)
|
|
|
(439,538
|
)
|
Property and equipment, net
|
|
|
|
$
|
1,575,286
|
|
|
$
|
1,665,191
|
|
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Depreciation and amortization expense
totaled $468,906 and $342,078 in 2013 and 2012, respectively.
6. Customer Advances and Deferred Revenues
In connection with its research services,
the Company often receives cash payments before its earnings process is complete. In these instances, the Company records the
payments as customer advances until the earnings process or milestone is achieved.
As described in its revenue recognition
policy for Ekso
Ô
unit sales, revenues are deferred and recognized over the expected
maintenance period. Accordingly, at the time of shipment the amount billed is recorded as deferred revenue. Also, at the time
of shipment to the customer, the related inventory is reclassified to deferred costs of revenue where it is amortized to cost
of revenue over the same period as the related revenue.
Customer advances, deferred revenues, and deferred unit costs
consist of the following:
|
|
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
Customer advances and deposits
|
|
$
|
443,436
|
|
|
$
|
329,006
|
|
Deferred Ekso unit revenues
|
|
|
3,462,980
|
|
|
|
2,928,411
|
|
Deferred service and software revenues
|
|
|
721,921
|
|
|
|
207,296
|
|
Customer advances and deferred revenues
|
|
|
4,628,337
|
|
|
|
3,464,713
|
|
Less current portion
|
|
|
(2,419,226
|
)
|
|
|
(1,566,153
|
)
|
Customer advances and deferred revenues, non-current
|
|
$
|
2,209,111
|
|
|
$
|
1,898,560
|
|
|
|
|
|
|
|
|
|
|
Deferred Ekso unit costs
|
|
$
|
1,571,897
|
|
|
$
|
1,130,246
|
|
Less current portion
|
|
|
(768,599
|
)
|
|
|
(436,483
|
)
|
|
|
|
|
|
|
|
|
|
Deferred cost of revenue, non-current
|
|
$
|
803,298
|
|
|
$
|
693,763
|
|
7. Accrued Liabilities
Accrued liabilities consist of the following:
|
|
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
Salaries, benefits and related expenses
|
|
$
|
657,628
|
|
|
$
|
771,137
|
|
Professional fees
|
|
|
421,966
|
|
|
|
114,676
|
|
Warranty expense
|
|
|
288,110
|
|
|
|
—
|
|
Taxes
|
|
|
62,283
|
|
|
|
35,810
|
|
Other
|
|
|
812
|
|
|
|
75,853
|
|
Total
|
|
$
|
1,430,799
|
|
|
$
|
997,476
|
|
8. Senior Notes Payable
Principle and Interest
On April 27, 2011, the Company entered into a senior note payable
agreement with Venture Lending & Leasing VI, Inc. (the “Lender”). The initial loan commitment of $1,500,000 was
funded in two tranches: $1,000,000 in April 2011 and $500,000 in October 2011. In May 2012, the Lender funded an additional $3,500,000
under an amendment to the 2011 agreement. Collectively, the $5,000,000 funded is referred to as the “Senior Note Payable”.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
The Senior Note Payable was interest-only
for the first 6 months, after which it converted into a fully-amortizing 30-month term note. During the interest only period,
interest on the Senior Note Payable was fixed at 13% and during the repayment period interest was charged at the prime rate plus
6.25%, subject to a minimum rate of 9.5%. The Senior Note Payable was secured by substantially all of the Company's assets, including
accounts receivable, inventories, property and equipment, and intangible assets, including intellectual property.
As of December 31, 2013 and 2012, the
outstanding principal of the loan amounted to $2,552,632 and $4,341,862, respectively, and the Company recorded interest expense
of $447,570 and $379,312, respectively, for the years then ended.
Debt Covenants
The Senior Note Payable had various covenants
that, among other things, limited the Company’s ability to incur debts and liens and to make asset sales and dividend payments.
In July 2013, the Company defaulted on the Senior Note Payable by failing to make a required payment when due. In November 2013,
the Lender waived the default. In return for the waiver, the Lender required the Company to cure the payment default using proceeds
from the November 2013 Bridge Note financing which is more fully described in
Note 9, Convertible Debt
. Additionally, the
Company agreed to cause the surviving parent company in the Merger (
see Note 18,
Subsequent Events, Merger with Ekso
Bionics Holdings, Inc.
) to subsequently issue to the Lender warrants to purchase 225,000 shares of the surviving parent company’s
common stock at an exercise price of $1.00 per share. The fair value of the Lender’s right to receive warrants was $95,760
based on the Black-Scholes option pricing model and was recorded as a warrant liability and reflected in other expense, net in
the consolidated statement of operations.
As of December 31, 2013, the Company was
in compliance with all of the Senior Note Payable's covenants.
Warrants
Under the terms of the 2011 and 2012 agreements,
the Lender received warrants to purchase shares of the Company's preferred stock. Under the 2011 agreement, the Lender received
warrants to purchase 128,570 shares of the Company’s Series A convertible preferred stock. The 2011 warrants had an exercise
price of $1.75 per share and were to expire on October 31, 2021. The fair value of the 2011 warrants at the issuance date was
estimated to be $167,256 using the Black-Scholes option-pricing model.
In connection with the 2012 amendment,
the Lender received additional warrants to purchase shares of Series B convertible preferred stock. The terms of the 2012 warrants
varied depending on which of three conversion options the Lender chose. Since the funding date, the Lender chose to receive 257,829
shares of the Company's Series B convertible preferred stock at an exercise price of $2.10 per share and warrants to purchase
19,337 of the Company’s common stock at an exercise price of $2.10 per share. The warrants expire on June 1, 2022. The fair
value of the 2012 warrants on the issuance date was determined to be $355,116 using probability weighted models.
The fair value of the 2013 and 2012 warrants
was recorded as a debt discount and is being amortized to expense over the term of the loan using the interest method. The accounting
for the warrants is more fully discussed in
Note 13, Capital Stock
.
Repayment of Senior Notes Payable Subsequent
to December 31, 2013
Subsequent to December 31, 2013, upon
the closing of the Merger and the private placement financing discussed in
Note 18,
Subsequent Events, Merger
with Ekso Bionics Holdings, Inc.
, the Senior Notes Payable were settled with proceeds from the Merger, and the warrants to
purchase preferred stock issued to the Lender were exchanged for common stock; the common stock warrants remain outstanding.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
9. Convertible Debt
2012 Series B Convertible Bridge Notes
In November 2012, the Company entered
into two convertible bridge note agreements pursuant to which the Company issued convertible bridge notes in the aggregate original
principal amount of $3,311,546 (the “2012 Tranche 1 Bridge Notes”) in anticipation of closing a Series B convertible
preferred stock financing in early 2013. In January through April 2013, the Company issued additional convertible bridge notes
in the aggregate original principal amount of $2,000,000 (the “2012 Tranche 2 Bridge Notes”) (collectively, the “2012
Bridge Notes”). The 2012 Tranche 1 Bridge Notes carried interest at a rate of 5% per annum with a maturity date of November
12, 2013. The 2012 Tranche 2 Bridge Notes had identical terms to the 2012 Tranche 1 Bridge Notes except that the 2012 Tranche
2 Bridge Notes accrued interest at 10% per annum instead of 5% per annum. In April 2013, the Company modified the 2012 Tranche
1 Bridge Notes retroactively increasing the interest rate to 10%.
The terms of conversion of the 2012 Bridge
Notes provided for issuance of a variable number of shares and warrants which could increase the amount of the obligation depending
upon the timing of the Series B preferred stock offering.
The Company determined that the 2012 Bridge
Notes should be recorded at fair value at inception and remeasured at each subsequent reporting period through conversion since
the terms of the agreements provided that the principal and interest would be converted into a variable number of Series B preferred
stock. Fair value was determined by calculating the settlement value of the debt “as if” converted at the end of each
reporting period. At December 31, 2012, the fair value of the 2012 Bridge Notes was determined to be $3,528,313 based on a conversion
discount of 5% comprised of $3,311,546 of principle, $42,475 of accrued interest and $174,292 of unrealized appreciation.
On May 20, 2013, the fair value of the
2012 Bridge Notes was determined to be $6,490,071. In accordance with the terms of the 2012 Bridge Note agreements, the fair value
of the 2012 Bridge Notes was converted into 3,090,524 shares of Series B convertible preferred stock with detachable warrants
for the purchase of 388,435 shares of common stock.
The Company determined that the common
stock warrants issued upon conversion of the Series B Bridge Notes were more closely related to equity than debt due to their
conversion into common stock and lack of debt-like features and, accordingly, their fair value of $136,380 as of May 20, 2013
based on the Black-Scholes option pricing model was reallocated to additional paid-in capital.
2013 Series B Convertible Bridge Notes
In November 2013, in anticipation of the
Merger and related financing completed in January and February 2014, the Company completed a private placement to accredited investors
of $5,000,000 of its senior subordinated secured convertible notes (the “2013 Bridge Notes”). The 2013 Bridge Notes
bore interest at 10% per annum and were payable on July 15, 2014, subject to earlier conversion as described below. Interest on
the 2013 Bridge Notes was to be payable at maturity; provided that upon conversion of the 2013 Bridge Notes as described below,
accrued interest was forgiven.
The 2013 Bridge Notes were secured by
a second priority security interest on all of the assets of the Company and its subsidiary, subject to certain limited exceptions.
This security interest terminated upon conversion of the 2013 Bridge Notes in connection with the Merger and related private placement
financing.
Similar to the accounting for the 2012
Bridge Notes, the Company determined that the 2013 Bridge Notes should be recorded at fair value at inception and remeasured each
subsequent reporting period through conversion since the terms of the agreements provided that the principal and interest would
be converted into a variable number of Series B preferred stock. Fair value was determined by calculating the settlement value
of the debt “as if” converted at the end of each reporting period. At December 31, 2013, the fair value of the 2013
Bridge Notes was determined to be $5,062,417.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Subsequent to December 31, 2013, upon the closing of the Merger
and the private placement financing discussed in
Note 18,
Subsequent Events, Merger with Ekso Bionics Holdings,
Inc.
, the outstanding principal amount of the Bridge Notes was converted into Units of Holdings at a conversion price of $1.00
per Unit. Also, the investors received an additional warrant to purchase a number of shares of common stock of Holdings equal
to 50% of the number of shares of common stock of Holdings contained in the Units into which the Bridge Notes were converted (i.e.
2,500,000 shares in the aggregate), at an exercise price of $1.00 per share, for a term of three years (the “Bridge Warrants”).
10. Employee Benefit Plan
The Company administers a 401(k) retirement
plan (the “Plan”) in which all employees are eligible to participate. Each eligible employee may elect to contribute
to the Plan. During the years ended December 31, 2013 and 2012, the Company has made no matching contributions.
11. Operating Lease
On November 29, 2011, the Company entered
into an operating lease agreement for its new headquarters and manufacturing facility in Richmond, California. The lease term
commenced in March 2012 and expires in May 2017. The lease provides the Company with one option to renew for 5 additional years.
Prior to moving to the Richmond location, the Company’s operations were run from a leased facility in Berkeley, California
that expired in June 2012.
Rent expense under the Company’s
operating leases was $339,197 and $388,945 for the years ended December 31, 2013 and 2012, respectively.
Future minimum annual lease payments under
these leases are as follows as of December 31, 2013:
2014
|
|
$
|
375,404
|
|
2015
|
|
|
375,404
|
|
2016
|
|
|
375,405
|
|
2017
|
|
|
156,419
|
|
Total
|
|
$
|
1,282,632
|
|
Under the lease agreement, the landlord
agreed to provide the Company a loan with interest at 7% in the amount of $80,055 to finance a portion of planned leasehold improvements.
On March 28, 2012, the lease agreement was modified to increase the landlord financing by $119,945 for a total of $200,000. The
terms of the amended loan agreement with the landlord require the Company to make monthly loan payments of $3,960 from June 1,
2012 to May 31, 2017. These loan payments are incremental to the minimum monthly rent payments. The balances included in notes
payable current and long-term at December 31, 2013 and 2012 were $162,370 and $209,893, respectively. Payments of $47,523 are
due in years 2014, 2015 and 2016 with a remainder of $19,801 due in 2017.
12. Related Party Transactions
The Regents of the University of California,
Berkeley (“UCB” or “University”) own 310,400 shares of common stock. The Company has license agreements
and various collaboration agreements (see Note 16,
Commitments and Contingencies
) with UCB. Total payments made to UCB
for the years ended December 31, 2013 and 2012 were $15,904 and $255,523, respectively. As of December 31, 2013 and 2012, amounts
payable to UCB amounted to $458,755 and $295,462, respectively.
On June 24, 2011, the Company and Eythor
Bender, the then Chief Executive Officer, entered into an agreement in which the Company loaned to Mr. Bender $49,000. On May
8, 2012, the Company and Mr. Bender, the then Chief Executive Officer, entered into an agreement in which the Company loaned to
Mr. Bender $20,000. On June 6, 2012, the Company and Mr. Bender, the then Chief Executive Officer, entered into an agreement in
which the Company loaned to Mr. Bender $25,000. All of these loans were due within 12 months and had an interest rate of 5% per
annum. Under the terms of an employment separation agreement dated November 28, 2012, the Company and Mr. Bender agreed to consolidate
and extend the term of the outstanding notes receivable totaling $94,000. Interest will continue to accrue at 5% per annum. The
note was due June 30, 2015. On January 15, 2014 Mr. Bender repaid his loan in full, including interest.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
On November 29, 2011, the Company entered
into a development agreement with a government entity which also owns 571,420 shares of the Company’s Series A preferred
stock as of December 31, 2013 and 2012, and 119,047 shares of the Company’s Series A-2 preferred stock as of December 31,
2013 and 2012. As part of the agreement, the Company developed, fabricated and tested Alpha, Beta, and Pilot versions of a custom
exoskeleton system. In exchange, the government entity agreed to make certain milestone payments to the Company over the 1.5 year
term of the agreement. For the years ended December 31, 2013 and 2012, the Company recognized as revenue approximately $0 and
$424,000, respectively, related to this project. Additionally, accounts receivable, including unbilled receivables representing
earned milestone payments, amounted to $114,500 as of December 31, 2012. There were no amounts receivable related to this project
in 2013.
Astrolink International LLC (“Astrolink”),
an affiliate of Lockheed (a significant customer), owned 857,140 shares of the Company’s Series A convertible preferred
stock as of December 31, 2013 and 2012. As of December 31, 2013, Astrolink also owned 758,604 shares of the Company’s Series
B convertible preferred stock. For the years ended December 31, 2013 and 2012, the Company recognized as revenue approximately
$337,796 and $568,002, respectively, related to this project.
13. Capital Stock
Common stock
Certain shares of outstanding common stock
are subject to the terms of the common stock purchase agreements. According to the terms of the agreements, in the event that
a holder of common stock ceases their relationship with the Company, the Company has the right to repurchase all or any shares
at fair value. The repurchase option terminates in the event that the Company consummates a change of control transaction and
involuntary termination, or involuntary termination, as defined.
Convertible Preferred stock
Issued and outstanding convertible preferred
stock (without regard to the conversion ratio used in the Merger discussed in
Note 18,
Subsequent Events, Merger with
Ekso Bionics Holdings, Inc.
) consisted of the following at December 31, 2013:
|
|
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Shares
|
|
|
Liquidation
|
|
|
Aggregate
|
|
|
|
Shares
|
|
|
Issued and
|
|
|
Preference
|
|
|
Liquidation
|
|
Series
|
|
Authorized
|
|
|
Outstanding
|
|
|
Per Share
|
|
|
Preference
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A
|
|
|
4,624,840
|
|
|
|
4,496,270
(1)
|
|
|
$
|
1.75
|
|
|
$
|
7,868,473
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A-2
|
|
|
4,527,010
|
|
|
|
4,335,414
|
|
|
$
|
2.10
|
|
|
$
|
9,104,369
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
B
|
|
|
12,000,000
|
|
|
|
5,179,344
|
|
|
$
|
2.10
|
|
|
$
|
10,876,622
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
27,849,464
|
|
|
(1)
|
Series A financing efforts
commenced in December 2010 were completed in July 2011. The Company issued 4,496,270
of the 4,650,000 authorized shares of Series A convertible preferred stock in connection
with this transaction. The total amount of equity raised amounted to $7.87 million. Of
this amount $2.43 million was received in cash and $393,000 was completed through a conversion
of debt during the year ended December 31, 2010 and the rest of the funds were raised
during 2011. Lockheed, a key customer, participated in this round of financing by making
an equity investment totaling $1.5 million.
|
The rights, privileges and restrictions
of Series A, A-2 and B convertible preferred stock (“the Preferred Stock”) were set forth in the Company’s Amended
and Restated Certificate of Incorporation. Voting and conversion rights are summarized below:
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
|
•
|
Voting rights - Holders
are entitled to one vote for each share of common stock into which such share of Preferred
Stock is convertible.
|
|
•
|
Conversion - Each share
of the Preferred Stock is convertible, at the option of the holder, according to the
conversion ratio obtained by dividing the Original Issue Price (described above) by the
Conversion Price, which initially is the Original Issue Price, subject to adjustment
for dilution. Each share of Series A, A-2, and B Preferred Stock is currently convertible
into one share of common stock. The number of fully paid and nonassessable shares of
common stock is determined by dividing the Original Issue Price by the Conversion Price.
Each share of the Preferred Stock automatically converts into the number of shares of
common stock into which such shares are convertible at the then effective conversion
ratio upon: (1) the closing of a public offering of common stock with proceeds to the
Company of at least $25,000,000 and in which the pre-money valuation of the Company is
not less than $75,000,000 or (2) the date or time specified by vote, written consent
or agreement of the holders of the majority of the then outstanding shares of convertible
preferred stock, voting together as a class.
|
For financial accounting purposes, the
Company determined that the convertible preferred stock does not meet the requirements under ASC 480-10-25 to be accounted for
as a liability because the shares are not mandatorily redeemable, except in the case of a liquidation event in which case the
holders are entitled to be paid out a liquidation preference, and the conversion ratio is based on a pre-determined number of
shares rather than a variable number of shares. However, it was determined that a “deemed liquidation event” could
occur that would be outside the control of the Company. In accordance with ASC 480-10-S99, the convertible preferred stock will
be in the “mezzanine” section between liabilities and stockholders’ deficit.
During the years ended December 31, 2013
and 2012, because the timing of any such liquidation event was uncertain, the Company elected not to adjust the carrying values
of its preferred stock to their respective liquidation values.
Warrants
The Company issued warrants to lenders
in connection with convertible debt and to a customer in connection with a service contract. The outstanding warrants (without
regard to the conversion ratio used in the Merger discussed in
Note 18,
Subsequent Events, Merger with Ekso Bionics
Holdings, Inc
.) were as follows:
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value
as of
|
|
Warrants to
|
|
of
|
|
|
Date of
|
|
Exercise
|
|
|
Expiration
|
|
|
|
|
December 31
|
|
purchase shares of:
|
|
shares
|
|
|
issue
|
|
Price
|
|
|
Date
|
|
At Inception
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A,
to lender
|
|
|
128,570
|
|
|
4/29/2011
|
|
$
|
1.75
|
|
|
10/31/2021
|
|
$
|
167,256
|
|
|
$
|
69,312
|
|
|
$
|
151,738
|
|
Series B, to lender
|
|
|
257,829
|
|
|
5/31/2012
|
|
$
|
2.10
|
|
|
6/1/2022
|
|
$
|
348,327
|
|
|
|
181,567
|
|
|
|
354,593
|
|
Common stock, to lender
|
|
|
19,337
|
|
|
5/31/2012
|
|
$
|
2.10
|
|
|
6/1/2022
|
|
$
|
6,789
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Series B to customer
|
|
|
27,500
|
|
|
11/16/2012
|
|
$
|
0.01
|
|
|
11/16/2019
|
|
$
|
57,494
|
|
|
|
31,108
|
|
|
|
57,491
|
|
Common
stock, to investors in Series B
|
|
|
388,435
|
|
|
Various from 5/20/2013 to 8/29/2013
|
|
$
|
2.10
|
|
|
10 years from issue
|
|
$
|
136,380
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
281,987
|
|
|
|
563,822
|
|
Obligation
to issue warrant (see last paragraph)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95,760
|
|
|
|
—
|
|
Total
warrant liability
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
377,747
|
|
|
$
|
563,822
|
|
(Note: The fair value as of period end
is not applicable (N/A) for the warrants on common stock because such instruments are carried in equity without revaluation to
periodic fair value.)
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
The fair value of the warrants to purchase
preferred stock issued to lenders was recorded as a liability at inception with a corresponding charge to discount on debt which
is being amortized to interest expense as an adjustment to yield. The fair value of the warrants to purchase common stock issued
to lenders was recorded in additional paid in capital at inception with a corresponding charge to discount on debt which is being
amortized to interest expense as an adjustment to yield. The fair value of the warrant issued to the customer was recorded as
a liability at inception with a corresponding reduction to the amount of revenue recognized under the service contract. The warrants
classified as liabilities are marked to market at the end of each reporting period as an item of other income or loss in the accompanying
consolidated statement of operations. The warrants to purchase common stock have no further accounting consequence after inception.
The warrants are exercisable during their
term at the option of the holder, upon a liquidation event, or the consummation of an initial public offering by the Company,
whichever is earlier.
The Company estimates the fair value of
warrants using the Black-Scholes option pricing model with inputs for dividend yield, risk-free rate of return, expected life
in years and volatility, as applicable, for each instrument at inception and then for each measurement date. Because the terms
in the agreement for the warrants on the Series B preferred stock provided the Lender with three conversion options, the Company
used a valuation technique with probability weighted inputs.
In addition to the warrant obligation
discussed above and as discussed in
Note 8, Senior Notes Payable, Debt Covenants
, the Company agreed to cause the surviving
parent company in the Merger (
see Note 18,
Subsequent Events, Merger with Ekso Bionics Holdings, Inc.
) to subsequently
issue to the Lender warrants to purchase 225,000 shares of the surviving parent company’s Common Stock at an exercise price
of $1.00 per share. The fair value of the warrant obligation of $95,760 based on the Black-Scholes option pricing model was recorded
as a warrant liability. This warrant is marked to market at the end of each reporting period as an item of other income or loss
in the accompanying consolidated statements of operations until conversion into common shares in January 2014.
Reverse Merger
Share amounts for common stock, convertible
preferred stock, stock options and warrants of the Company included in the consolidated financial statements and notes thereto
have not been adjusted to give effect to the conversion of the Company’s stock, warrants and options in connection with
the reverse merger transaction in January 2014 described in Note 18,
Subsequent Events
, except as set forth in Note 18.
At the closing of the reverse merger transaction, each share of Ekso Bionics’ common stock issued and outstanding immediately
prior to the closing of the Merger was converted into 1.5238 shares of Common Stock of Holdings (as defined in Note 18), each
share of Ekso Bionics’ Series A preferred stock issued and outstanding immediately prior to the closing of the Merger was
converted into 1.6290 shares of Holdings’ Common Stock, and each share of Ekso Bionics’ Series A-2 and Series B preferred
stock issued and outstanding immediately prior to the closing of the Merger was converted into 1.9548 shares of Holdings’
Common Stock.
14. Employee Stock Options
Under the terms of the 2007 Equity Incentive
Plan, which was adopted by the Board of Directors in November 2007, the Board of Directors may award stock, options or similar
rights having either a fixed or variable price related to the fair market value of the shares and with an exercise or conversion
privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or
other conditions, or any other security with the value derived from the value of the shares. Such awards include stock options,
restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
The Board of Directors may grant nonstatutory
stock options under the 2007 Equity Incentive Plan at a price of not less than 100% of the fair market value of the Company’s
common stock on the date the option is granted. Incentive stock options under the 2007 Equity Incentive Plan may be granted at
a price of not less than 100% of the fair market value of the Company’s common stock on the date the option is granted.
Incentive stock options granted to employees who, on the date of grant, own stock representing more than 10% of the voting power
of all of the Company’s classes of stock are granted at an exercise price of not less than 110% of the fair market value
of the Company’s common stock. The maximum term of these incentive stock options, granted to employees who own stock possessing
more than 10% of the voting power of all classes of the Company’s stock, may not exceed five years. The maximum term of
an incentive stock option granted to any other participant may not exceed ten years. The Board of Directors determines the term
and exercise or purchase price of all other awards granted under the 2007 Equity Incentive Plan. The Board of Directors also determines
the terms and conditions of awards, including the vesting schedule and any forfeiture provisions. Awards under the 2007 Equity
Incentive Plan may vest upon the passage of time or upon the attainment of certain performance criteria established by the Board
of Directors.
Unless terminated sooner, the 2007 Equity
Incentive Plan will automatically terminate in 2017. The Board of Directors may at any time amend, suspend or terminate the Company’s
2007 Equity Incentive Plan.
The following table summarizes stock option
activity under the Company’s stock option plan (without regard to the conversion ratio used in the Merger discussed in Note
18,
Subsequent Events
):
|
|
Shares
|
|
|
Number of
|
|
|
Weighted-Average
|
|
|
|
Available
For Grant
|
|
|
Options
Outstanding
|
|
|
Exercise
Price
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2011
|
|
|
2,473,010
|
|
|
|
3,539,600
|
|
|
$
|
0.357
|
|
Options granted
|
|
|
(1,879,375
|
)
|
|
|
1,879,375
|
|
|
|
0.792
|
|
Options exercised
|
|
|
-
|
|
|
|
(156,624
|
)
|
|
|
0.203
|
|
Options repurchased
|
|
|
8,122
|
|
|
|
-
|
|
|
|
-
|
|
Options cancelled
|
|
|
958,679
|
|
|
|
(958,679
|
)
|
|
|
0.463
|
|
Balance at December 31, 2012
|
|
|
1,560,436
|
|
|
|
4,303,672
|
|
|
|
0.524
|
|
Options granted
|
|
|
(1,794,782
|
)
|
|
|
1,794,782
|
|
|
|
0.930
|
|
Options exercised
|
|
|
—
|
|
|
|
(504,321
|
)
|
|
|
0.127
|
|
Options cancelled
|
|
|
624,388
|
|
|
|
(624,388
|
)
|
|
|
0.718
|
|
Balance at December 31, 2013
|
|
|
390,042
|
|
|
|
4,969,745
|
|
|
$
|
0.686
|
|
Options exercisable at December 31, 2013 totaled $2,540,220
with a weighted-average exercise price of $0.517 and a weighted average remaining contractual term of 8.03 years.
The fair value of options granted to employees
during 2013 and 2012 was $835,896 and $898,963, respectively.
At December 31, 2013 and 2012, the total
unamortized employee stock-based compensation expense amounted to $1,125,308 and $817,637 respectively, and is to be recognized
over the stock options’ remaining vesting term of approximately three years.
In 2012, the Board of Directors approved
an extension to the post termination exercise period for 64,568 vested stock options held by former employees from three months
to two years. Since this modification was made post termination, this modification was treated as a new award to nonemployees
using the new term. The Company recognized $30,792 during the year ended December 31, 2012 as compensation expense.
In October 2013, the Board of Directors
approved an extension to the post-termination exercise period for 233,735 vested stock options held by former employees from three
months to two years. The Board of Directors also approved an extension to the post termination exercise period for 86,318 vested
stock options held by former employees from three months to December 31, 2013.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
The Company from time to time grants options
to purchase common stock to non-employees for advisory and consulting services. Pursuant to ASC 505-50,
Equity-Based Payments
to Non-Employees
, the Company periodically remeasures the fair value of these stock options using the Black-Scholes option
pricing model and recognizes expense ratably over the vesting period of each stock option award. Non-employee stock compensation
expense was $32,590 and $46,470 for the years ended December 31, 2013 and 2012, respectively, and is included in the consolidated
statements of operation in the cost center of the employee.
The following assumptions were used to determine the fair value
of options granted to employees:
|
-
|
The expected dividend yield
is zero, as the Company has not paid any dividends and does not anticipate paying dividends
in the near future.
|
|
-
|
The risk-free interest rate
for periods related to the expected life of the options is based on the U.S. Treasury
yield curve in effect at the time of grant.
|
|
-
|
The expected volatility is
based on historical volatilities of peer group public companies’ stock over the
expected term of the option.
|
|
-
|
The expected term of options
represents the period that the Company’s stock-based compensation awards are expected
to be outstanding. The Company has used the “simplified” method provided
in Securities and Exchange Commission’s Staff Accounting Bulletin No. 110 to estimate
the expected term which takes into consideration the grant’s contractual life and
vesting period, because the Company lacks relevant historical data due to its limited
historical experience.
|
|
-
|
The Company also estimates
the number of options that are expected to be forfeited. Because of the lack of sufficient
history, commencing in 2011, the Company used the average forfeiture rate of comparable
peer companies which management determined to be 10%. Management estimates that such
average rate represents a reasonable approximation of the currently anticipated rate
of forfeiture for granted and outstanding stock options that have not vested.
|
The assumptions used in the Black-Scholes option pricing model
in calculating the fair value of stock options granted to employees are as follows:
|
|
Years ended December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
Dividend yield
|
|
|
—
|
|
|
|
—
|
|
Risk-free interest rate
|
|
|
0.83% - 1.93%
|
|
|
|
1.20%-2.49%
|
|
Expected term (in years)
|
|
|
5-6
|
|
|
|
6
|
|
Volatility
|
|
|
65%-70%
|
|
|
|
65%
|
|
The assumptions used in the Black-Scholes
option pricing model in calculating the fair value of stock options granted to non-employees are as follows:
|
|
Years ended December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
Dividend yield
|
|
|
—
|
|
|
|
—
|
|
Risk-free interest rate
|
|
|
0.83%-1.73%
|
|
|
|
1.63%
|
|
Expected term (in years)
|
|
|
5
|
|
|
|
5
|
|
Volatility
|
|
|
66%-71%
|
|
|
|
67%
|
|
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Total stock-based compensation expense
related to options granted to employees and non-employees was included in the consolidated statements of operations as follows:
|
|
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
General and administrative
|
|
$
|
197,072
|
|
|
$
|
171,968
|
|
Research and development
|
|
|
82,608
|
|
|
|
69,609
|
|
Sales and marketing
|
|
|
110,937
|
|
|
|
91,889
|
|
|
|
$
|
390,617
|
|
|
$
|
333,466
|
|
15. Income Taxes
The Company had no current or deferred
federal and state income tax expense or benefit for the years ended December 31, 2013 and 2012 because the Company generated net
operating losses, and currently management does not believe it is more likely than not that the net operating losses will be realized.
The Company’s non-U.S. tax obligation is primarily for business activities conducted through the United Kingdom for which
taxes included in other expense (net) for the years ended December 31, 2013 and 2012 were immaterial and accordingly, such amounts
were excluded from the following tables.
At December 31, 2013 and 2012, the Company
has provided a full valuation allowance against its net deferred tax assets as realization is dependent on future earnings, if
any, the timing and amount which is uncertain. The valuation allowance for 2013 increased $4,805,742 from 2012. Significant components
of the Company’s deferred tax assets consist of the following:
|
|
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Depreciation and other
|
|
$
|
1,032,972
|
|
|
$
|
172,727
|
|
Net operating loss carryforwards
|
|
|
13,631,820
|
|
|
|
9,966,468
|
|
Unused R& D tax credits
|
|
|
280,145
|
|
|
|
—
|
|
Less: Valuation allowance
|
|
|
(14,944,937
|
)
|
|
|
(10,139,195
|
)
|
Net deferred tax asset (liability)
|
|
$
|
—
|
|
|
$
|
—
|
|
At December 31, 2013, the Company had
federal and state net operating loss tax carryforwards of approximately $34,300,000 and $29,200,000, respectively. These net operating
loss carryforwards expire in various amounts starting in 2027 and 2017, respectively. In addition, the Company has unused research
and development tax credit carryforwards which expire in various amounts beginning in the year 2031. The utilization of the federal
net operating loss carryforwards and unused research and development tax credits will depend on the Company’s ability to
generate sufficient taxable income prior to the expiration of the carryforwards.
Utilization of the net operating loss
and tax credit carry forwards may be subject to substantial annual limitations due to past and future ownership change provisions
of Section 382 of the Internal Revenue Code and similar state provisions. The Company has not performed a change in ownership
analysis since its formation and, accordingly, some or all of its net operating loss and tax carryforwards may not be available
to offset future taxable income, if any.
The Company has evaluated its tax positions
to consider whether it has any unrecognized tax benefits. As of December 31, 2013 and 2012, the Company has not recorded any amounts
associated with unrecognized tax benefits. The Company recognizes interest and penalties related to uncertain tax positions in
the provision for income taxes. As of December 31, 2013, the Company had no accrued interest related to uncertain tax positions.
The Company is subject to U.S. federal and state income tax examinations by authorities for tax years 2007 through 2012 due to
net operating losses that are being carried forward for tax purposes. No income tax returns are currently under examination by
taxing authorities.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Taxes computed at the statutory federal
income tax rate of 34% are reconciled to the provision for income taxes as follows for the years ended December 31:
|
|
2013
|
|
|
2012
|
|
|
|
Amount
|
|
|
Percent of
Pretax
Earnings
|
|
|
Amount
|
|
|
Percent of
Pretax
Earnings
|
|
United
States federal tax statutory rate
|
|
$
|
(4,077,982
|
)
|
|
|
34.0
|
%
|
|
$
|
(4,947,324
|
)
|
|
|
34.0
|
%
|
State
taxes (net of deferred benefit)
|
|
|
(698,354
|
)
|
|
|
5.8
|
%
|
|
|
(834,558
|
)
|
|
|
5.7
|
%
|
Non-U.S. taxes
|
|
|
16,863
|
|
|
|
(0.1
|
)%
|
|
|
—
|
|
|
|
—
|
%
|
Non-deductible expenses
|
|
|
430,631
|
|
|
|
(3.6
|
)%
|
|
|
44,883
|
|
|
|
(0.3
|
)%
|
Tax credits
|
|
|
(280,145
|
)
|
|
|
2.3
|
%
|
|
|
—
|
|
|
|
—
|
%
|
Other, net
|
|
|
(196,756
|
)
|
|
|
1.6
|
%
|
|
|
3,153
|
|
|
|
—
|
%
|
Change in valuation allowance
|
|
|
4,805,742
|
|
|
|
(40.1
|
)%
|
|
|
5,733,844
|
|
|
|
(39.4
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
$
|
—
|
|
|
|
—
|
%
|
|
$
|
—
|
|
|
|
—
|
%
|
16. Commitments and Contingencies
Contingencies
In the normal course of business, the
Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material
adverse effect on the Company’s consolidated financial position, results of operations, or cash flows as of and for the
years ended December 31, 2013 and 2012.
Material Contracts
The Company enters into various license,
research collaboration and development agreements which provide for payments to the Company for government grants, fees, cost
reimbursements typically with a markup, technology transfer and license fees, and royalty payments on sales.
The Company has two license agreements
to maintain exclusive rights to patents. The Company is also required to pay 1% of net sales of products sold to entities other
than the U.S. government. In the event of a sublicense, the Company will owe 21% of license fees and must pass through 1% of the
sub-licensee’s net sales of products sold to entities other than the U.S. government.
The agreements also stipulate minimum
annual royalties of $10,000 for 2012, $20,000 for 2013, $40,000 for 2014 and $50,000 for subsequent years.
17.
Segment Disclosures
The Company has two reportable segments,
Engineering Services and Medical. Engineering Services generates revenue principally from collaborative research and development
service arrangements, technology license agreements, and government grants where it used its robotics domain knowledge in bionic
exoskeletons to bid on and procure contracts and grants from entities such as such as the National Science Foundation and the
Defense Advanced Research Projects Agency. The Medical segment designs, engineers, and manufactures exoskeletons for applications
in the medical and military markets.
The Company evaluates performance and
allocates resources based on segment gross profit margin. The reportable segments are each managed separately because they serve
distinct markets, and one segment provides a service and the other manufactures and distributes a unique product. The Company
does not consider net assets as a segment measure and, accordingly, assets are not allocated.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Segment reporting information is as follows:
|
|
Engineering
|
|
|
Medical
|
|
|
|
|
|
|
Services
|
|
|
Devices
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
1,690,235
|
|
|
$
|
1,611,709
|
|
|
$
|
3,301,944
|
|
Cost of revenue
|
|
|
1,253,942
|
|
|
|
1,460,692
|
|
|
|
2,714,634
|
|
Gross profit
|
|
$
|
436,293
|
|
|
$
|
151,017
|
|
|
$
|
587,310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
2,140,355
|
|
|
$
|
566,222
|
|
|
$
|
2,706,577
|
|
Cost of revenue
|
|
|
1,782,848
|
|
|
|
553,429
|
|
|
|
2,336,277
|
|
Gross profit
|
|
$
|
357,507
|
|
|
$
|
12,793
|
|
|
$
|
370,300
|
|
Geographic information based on location of customer is as
follows:
|
|
For the years ended
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
|
|
|
|
|
|
|
United States
|
|
$
|
2,810,973
|
|
|
$
|
2,652,265
|
|
Europe
|
|
|
418,876
|
|
|
|
54,312
|
|
Other
|
|
|
72,095
|
|
|
|
-
|
|
|
|
$
|
3,301,944
|
|
|
$
|
2,706,577
|
|
Major customers based on revenue are as
follows:
|
|
For the years ended
December 31,
|
|
|
|
2013
|
|
|
2012
|
|
Lockheed Martin (Astrolink)
|
|
$
|
337,796
|
|
|
$
|
568,002
|
|
National Science Foundation
|
|
|
780,579
|
|
|
|
874,492
|
|
U.S. Federal Government
|
|
|
150,000
|
|
|
|
416,422
|
|
Defense Advanced Research Projects Agency
|
|
|
411,360
|
|
|
$
|
281,440
|
|
18. Subsequent Events
Management’s Evaluation
The Company’s management has evaluated
subsequent events occurring after December 31, 2013 and through the issuance date of March 31, 2014, and has determined that t
he
following material events and transactions occurred during this period.
Ekso Bionics, Inc. and Subsidiary
Notes to Consolidated Financial Statements
Merger with Ekso Bionics Holdings, Inc.
The Merger
On January 15, 2014, the Company entered
into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Ekso Bionics Holdings, Inc.,
formerly known as PN Med Group, Inc. (“Holdings”), a public reporting company, and Ekso Acquisition Sub, Inc. (“Acquisition
Sub”), a newly formed wholly-owned subsidiary of Ekso Bionics Holdings, Inc. Under the Merger Agreement, Acquisition Sub
merged with and into the Company, with the Company remaining as the surviving corporation in the Merger, and became a wholly-owned
subsidiary of Holdings (the “Merger”).
Holdings was incorporated in the State
of Nevada on January 30, 2012, as a distributor of medical supplies and equipment to municipalities, hospitals, pharmacies, care
centers, and clinics in Chile. Holdings was until the consummation of the Merger a “shell company” as defined in Rule
12b-2 of the Exchange Act. As a result of the Merger, Holdings discontinued its pre-Merger business and acquired the business
of the Company and will continue the existing business operations of the Company.
At the closing of the Merger on January
15, 2014, (a) all shares of the Company’s common stock and preferred stock issued and outstanding immediately prior to the
closing of the Merger were converted into an aggregate of 42,615,556 restricted shares of Holdings’ common stock, (b) all
warrants to purchase Company stock outstanding immediately prior to the closing of the Merger were converted into warrants to
purchase an aggregate of 621,363 restricted shares of Holdings’ common stock, and (c) all options to purchase Company stock
outstanding immediately prior to the closing of the Merger were converted into options to purchase an aggregate of 7,586,459 restricted
shares of Holdings’ common stock. Additionally, in connection with the Merger, Holdings issued 250,000 shares of Holdings’
common stock to three consultants under a consulting agreement in consideration of business and consulting services provided by
the consultants.
In January and February 2014, Holdings
completed closings of a private placement to accredited investors of 30,300,000 Units at a price of $1.00 per Unit, resulting
in $30.3 million in gross proceeds to Holdings (including the conversion of $5,000,000 of 2013 Bridge Notes issued in November
2013 (the 2013 Bridge Notes are more fully discussed in
Note 9,
Convertible Debt
) and before deducting commissions
and expenses of the offering). Each Unit consists of one share of common stock of Holdings and a warrant to purchase one share
of common stock of Holdings with a term of five years and an exercise price of $2.00 per share. These warrants have weighted average
anti-dilution protection, subject to customary exceptions.
Also, upon the closing of the Merger and
the private placement financing, investors in the Bridge Notes received additional warrants (also discussed in
Note 9, Convertible
Debt
) to purchase a number of shares of common stock of Holdings equal to 50% of the number of shares of common stock of Holdings
contained in the Units into which the Bridge Notes were converted (i.e. 2,500,000 shares in the aggregate), at an exercise price
of $1.00 per share, for a term of three years (the “Bridge Warrants”). The Bridge Warrants have weighted average anti-dilution
protection, subject to customary exceptions.
Other Warrants
In connection with the Merger and the
private placement financing, in addition to the Bridge Warrants, Holdings issued 500,000 warrants on common stock to the placement
agent for the Bridge Notes financing, warrants to purchase 2,530,000 shares of common stock to the private placement offering
agent and warrants to purchase 225,000 shares of common stock to the senior lender (also discussed in
Note 8, Senior Notes
Payable
).
Accounting for
the Merger
Ekso Bionics, Inc., as the accounting
acquirer, will record the merger as the issuance of stock for the net monetary assets of Ekso Bionics Holdings, Inc. (formerly
known as PN Med Group, Inc.), accompanied by a recapitalization. This accounting will be identical to that resulting from a reverse
merger, except that no goodwill or intangible assets will be recorded. The historical financial statements of Holdings before
the Merger will be replaced with the historical financial statements of the Company before the Merger in all future filings with
the SEC. The Merger is intended to be treated as a tax-free exchange under Section 368(a) of the Internal Revenue Code of 1986,
as amended.
Unaudited Pro Forma
Consolidated Financial Statements
(Introductory Note)
The unaudited pro forma consolidated balance
sheet as of December 31, 2013, and the unaudited pro forma consolidated statement of operations for the year ended December 31,
2013, give effect to transactions by Ekso Bionics, Inc. (“Ekso Bionics”) and Ekso Bionics Holdings, Inc. (formerly
known as PN Med Group, Inc.) (“Holdings”) occurring in connection with the Merger and include (a) the recapitalization
of Holdings and spin-off of pre-Merger assets and liabilities, and conversion of Ekso Bionics common and preferred stock and warrants
into Holdings common stock and warrants to purchase Holdings common stock, (c) the private placement of securities including conversion
of the 2013 Bridge Notes, and (d) the repayment of the senior secured note, all of which occurred on January 15, 2014, and are
based on the historical financial statements of Ekso Bionics, as if those transactions occurred on December 31, 2013 for purposes
of the pro forma consolidated balance sheet, and on the first day of the respective period for purposes of the pro forma consolidated
statement of operations. These pro forma financial statements are also prepared adopting the Ekso Bionics’ year end of December
31.
The unaudited pro forma consolidated financial
information is presented for illustrative purposes only and does not purport to represent what Ekso Bionics’ actual results
of operations or financial position would have been had the transactions actually been completed on or at the beginning of the
indicated periods, and is not indicative of future results of operations or financial condition.
The historical financial information of
Holdings for the year ended December 31, 2013 has been derived from the unaudited financial statements for various periods from
January 30, 2012 (inception) to December 31, 2013. The unaudited pro forma consolidated financial information should be read in
conjunction with the Company's audited and unaudited consolidated financial statements and notes thereto. The pro forma adjustments
are based upon available information and assumptions that management believes are reasonable.
Ekso Bionics, Inc. and Subsidiary
Pro Forma Consolidated Balance Sheet
Year ended December 31, 2013
(unaudited)
|
|
|
Ekso
Bionics
|
|
|
|
Holdings
|
|
|
|
|
Total Pro
Forma
Adjustments
|
|
|
|
As Adjusted
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
805,306
|
|
|
$
|
78
|
|
(b)
|
|
$
|
(78
|
)
|
|
$
|
19,907,895
|
|
|
|
|
|
|
|
|
|
|
(c)
|
|
|
21,781,335
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(d)
|
|
|
(2,678,746
|
)
|
|
|
|
|
Accounts receivable
|
|
|
549,469
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
549,469
|
|
Inventories, net
|
|
|
725,096
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
725,096
|
|
Prepaid expenses and other current assets
|
|
|
1,123,332
|
|
|
|
—
|
|
(c)
|
|
|
(70,801
|
)
|
|
|
1,052,531
|
|
Total Current Assets
|
|
|
3,203,203
|
|
|
|
78
|
|
|
|
|
19,031,710
|
|
|
|
22,234,991
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
1,575,286
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
1,575,286
|
|
Deferred costs of revenue, non-current
|
|
|
803,298
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
803,298
|
|
Security deposits
|
|
|
54,390
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
54,390
|
|
Capitalized security issuance costs
|
|
|
947,760
|
|
|
|
—
|
|
(c)
|
|
|
(947,760
|
)
|
|
|
—
|
|
Total assets
|
|
$
|
6,583,937
|
|
|
$
|
78
|
|
|
|
$
|
18,083,950
|
|
|
$
|
24,667,965
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities, Convertible Preferred Stock and Stockholders' Deficit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable, current portion
|
|
$
|
1,638,505
|
|
|
$
|
—
|
|
(d)
|
|
$
|
(1,599,841
|
)
|
|
$
|
38,664
|
|
Convertible debt
|
|
|
5,062,417
|
|
|
|
—
|
|
(c)
|
|
|
(5,062,417
|
)
|
|
|
—
|
|
Accounts payable
|
|
|
1,498,680
|
|
|
|
4,170
|
|
(b)
|
|
|
(4,170
|
)
|
|
|
1,178,077
|
|
|
|
|
|
|
|
|
|
|
(c)
|
|
|
(320,603
|
)
|
|
|
|
|
Accrued liabilities
|
|
|
1,430,799
|
|
|
|
11,619
|
|
(b)
|
|
|
(11,619
|
)
|
|
|
1,430,799
|
|
|
|
|
|
|
|
|
|
|
(d)
|
|
|
—
|
|
|
|
|
|
Customer advances and deferred revenue
|
|
|
2,419,226
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
2,419,226
|
|
Convertible debt
|
|
|
—
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
—
|
|
Liability due to early stock option exercise
|
|
|
5,293
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
5,293
|
|
Total current liabilities
|
|
|
12,054,920
|
|
|
|
15,789
|
|
|
|
|
(6,998,650
|
)
|
|
|
5,072,059
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer advances and deferred revenues
|
|
|
2,209,111
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
2,209,111
|
|
Notes payable, less current portion
|
|
|
866,950
|
|
|
|
—
|
|
(d)
|
|
|
(744,462
|
)
|
|
|
122,488
|
|
Warrant liability
|
|
|
377,747
|
|
|
|
—
|
|
(a)
|
|
|
(281,987
|
)
|
|
|
—
|
|
|
|
|
|
|
|
|
—
|
|
(d)
|
|
|
(95,760
|
)
|
|
|
—
|
|
Deferred rent
|
|
|
123,709
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
123,709
|
|
Debt issuance costs
|
|
|
—
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
—
|
|
Total liabilities
|
|
$
|
15,632,437
|
|
|
$
|
15,789
|
|
|
|
$
|
(8,120,859
|
)
|
|
$
|
7,527,367
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock
|
|
|
27,324,208
|
|
|
|
—
|
|
(c)
|
|
|
(27,324,208
|
)
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' deficit:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock
|
|
|
10,025
|
|
|
|
6,350
|
|
(b)
|
|
|
31,521
|
|
|
|
78,446
|
|
|
|
|
|
|
|
|
|
|
(c)
|
|
|
30,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(e)
|
|
|
250
|
|
|
|
|
|
Additional paid-in capital
|
|
|
1,648,886
|
|
|
|
25,650
|
|
(a)
|
|
|
27,606,195
|
|
|
|
55,428,214
|
|
|
|
|
|
|
|
|
|
|
(b)
|
|
|
(63,521
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c)
|
|
|
26,115,494
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(d)
|
|
|
95,760
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(e)
|
|
|
(250
|
)
|
|
|
|
|
Accumulated deficit
|
|
|
(38,031,619
|
)
|
|
|
(47,711
|
)
|
(b)
|
|
|
47,711
|
|
|
|
(38,366,063
|
)
|
|
|
|
|
|
|
|
|
|
(d)
|
|
|
(334,444
|
)
|
|
|
|
|
Total stockholders' equity (deficit)
|
|
|
(36,372,708
|
)
|
|
|
(15,711
|
)
|
|
|
|
53,529,017
|
|
|
|
17,140,598
|
|
Total liabilities, convertible preferred stock and stockholders'
deficit
|
|
$
|
6,583,937
|
|
|
$
|
78
|
|
|
|
$
|
18,083,950
|
|
|
$
|
24,667,965
|
|
Ekso Bionics, Inc. and Subsidiary
Pro Forma Consolidated Statements of
Operations
Year ended December 31, 2013
(unaudited)
|
|
Ekso Bionics
|
|
|
Holdings
|
|
|
|
Total Pro
Forma
Adjustments
|
|
|
As Adjusted
|
|
Revenue
|
|
$
|
3,301,944
|
|
|
|
—
|
|
|
|
|
—
|
|
|
$
|
3,301,944
|
|
Cost of revenue
|
|
|
(2,714,634
|
)
|
|
|
—
|
|
|
|
|
—
|
|
|
|
(2,714,634
|
)
|
Gross profit
|
|
|
587,310
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
587,310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
3,913,047
|
|
|
|
35,130
|
|
(f)
|
|
|
(35,130
|
)
|
|
|
3,967,215
|
|
|
|
|
|
|
|
|
|
|
(g)
|
|
|
54,168
|
|
|
|
—
|
|
Research and development
|
|
|
2,677,310
|
|
|
|
—
|
|
(g)
|
|
|
22,547
|
|
|
|
2,699,857
|
|
Sales and marketing
|
|
|
4,291,282
|
|
|
|
—
|
|
(g)
|
|
|
107,235
|
|
|
|
4,398,517
|
|
Total operating expenses
|
|
|
10,881,639
|
|
|
|
35,130
|
|
|
|
|
148,820
|
|
|
|
11,065,589
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(10,294,329
|
)
|
|
|
(35,130
|
)
|
|
|
|
(148,820
|
)
|
|
|
(10,478,279
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
5,225
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
5,225
|
|
Interest expense
|
|
|
(1,726,455
|
)
|
|
|
—
|
|
(h)
|
|
|
62,417
|
|
|
|
(1,664,038
|
)
|
Non-cash gain on changes in fair value of warrants
|
|
|
186,075
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
186,075
|
|
Other expense, net
|
|
|
(57,890
|
)
|
|
|
—
|
|
|
|
|
—
|
|
|
|
(57,890
|
)
|
|
|
|
(1,593,045
|
)
|
|
|
—
|
|
|
|
|
62,417
|
|
|
|
(1,530,628
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss before provision for income taxes
|
|
|
(11,887,374
|
)
|
|
|
(35,130
|
)
|
|
|
|
(86,403
|
)
|
|
|
(12,008,907
|
)
|
Provision for income taxes
|
|
|
—
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
—
|
|
Net loss
|
|
$
|
(11,887,374
|
)
|
|
$
|
(35,130
|
)
|
|
|
|
(86,403
|
)
|
|
$
|
(12,008,907
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic shares assumed outstanding
|
|
|
|
|
|
|
|
|
(i)
|
|
|
|
|
|
|
78,445,924
|
|
Pro forma net loss per share
|
|
|
|
|
|
|
|
|
(i)
|
|
|
|
|
|
$
|
(0.153
|
)
|
Ekso Bionics Holdings, Inc. (f.k.a.
PN Med Group Inc.)
,
and
Ekso Bionics, Inc.
Notes to Proforma
Condensed Combined Financial Statements
(Unaudited)
Note 1 - INTRODUCTION
The Merger, Offering and Other Related Transactions
In January and February 2014, Ekso Bionics
entered into and executed several contemporaneous and related transactions (together, the “Transaction”), as described
below.
Merger
Ekso Bionics Holdings, Inc. (formerly
known as PN Med Group, Inc.) (“Holdings”) was incorporated in the State of Nevada on January 30, 2012, as a distributor
of medical supplies and equipment to municipalities, hospitals, pharmacies, care centers, and clinics in Chile. Holdings was a
“shell company” as defined in Rule 12b-2 of the Exchange Act. Holdings’ fiscal year end was previously March
31 but has been changed to December 31 in connection with the Merger as discussed below.
Ekso Bionics, Inc. (“Ekso Bionics”)
was incorporated in the State of Delaware on January 19, 2005 and is a leading developer and manufacturer of bionic exoskeletons
where it has pioneered the field of robotic exoskeletons to augment human strength, endurance and mobility.
On January 15, 2014, Holdings and a newly
formed wholly-owned subsidiary of Holdings, Ekso Acquisition Corp. (“Acquisition Sub”) entered into an Agreement and
Plan of Merger and Reorganization (the “Merger”) with Ekso Bionics. Under the Merger agreement, Acquisition Sub merged
with and into Ekso Bionics, with Ekso Bionics remaining as the surviving corporation and with the shareholders of Ekso Bionics
exchanging all of their common stock, preferred stock and warrants issued and outstanding immediately prior to the closing of
the Merger into an aggregate of 42,615,556 shares of Holdings’ common stock and 621,363 warrants to purchase common stock.
These shares are in addition to 5,280,368 outstanding shares of Holdings common stock held by pre-merger PN Med Group, Inc. shareholders.
Upon the closing of the Merger, under
the terms of a split-off agreement and a general release agreement, Holdings transferred all of its pre-Merger operating assets
and liabilities to a newly formed wholly-owned special-purpose subsidiary (“Split-Off Subsidiary”), and transferred
all of the outstanding shares of capital stock of Split-Off Subsidiary to the pre-Merger majority stockholders of Holdings and
the former officers and director of Holdings (the “Split-Off”), in consideration of and in exchange for (i) the surrender
and cancellation of an aggregate of all shares of Holdings’ common stock held by such stockholders (which will be cancelled
and will resume the status of authorized but unissued shares of our common stock) and (ii) certain representations, covenants
and indemnities.
Holdings’ Articles of Incorporation
were amended prior to the Merger to authorize the issuance of 500,000,000 shares of common stock and 10,000,000 shares of “blank
check” preferred stock.
Ekso Bionics, as the accounting acquirer,
will record the Merger as the acquisition of Holdings, accompanied by a recapitalization, as the sellers of Ekso Bionics effectively
control the combined companies immediately following the transaction. As such, Ekso Bionics is deemed to be the accounting acquirer
in the transaction and, consequently, the transaction is being treated as a reverse acquisition. Accordingly, the assets
and liabilities and the historical operations that will be reflected in Holdings’ ongoing financial statements will be those
of Ekso Bionics and will be recorded at the historical cost basis of Ekso Bionics. Holdings’ historical capital
accounts and retained earnings will be retroactively adjusted to reflect the split-off of assets and liabilities, and the equivalent
number of shares issued by it in the Transaction while Ekso Bionics’ historical accumulated deficit will be carried forward.
In accordance with “reverse merger”
accounting treatment, Holdings’ historical financial statements as of period end, and for periods ended, prior to the Merger
will be replaced with the historical financial statements of Ekso Bionics prior to the Merger in all future filings with the SEC.
This accounting is identical to that resulting from a reverse merger, except that no goodwill or other intangible assets are recorded.
Merger costs (consisting of legal, accounting and other professional fees) have been reflected as a reduction of PPO proceeds
in the pro forma financial statements. The Merger is intended to be treated as a tax-free exchange under Section 368(a) of the
Internal Revenue Code of 1986, as amended.
Private Placement Offering
During January and February, 2014, in
contemplation of the Merger, Holdings completed a private placement (the “PPO”) for 30,300,000 Units at a purchase
price of $1.00 per Unit, each Unit consisting of one share of the common stock and a warrant to purchase one share of common stock
at an exercise price of $2.00 per share and a term of five years (the “PPO Warrants”) for a total of $25,300,000 in
cash proceeds and the conversion of the 2013 Bridge Note payable into 5,000,000 Units of securities (each Unit consisting of one
share of the common stock and a PPO Warrant) and also a warrant to purchase 2,500,000 shares of common stock (“Bridge Warrants”);
the 2013 Bridge Note financing is discussed below.
In January 2014, 250,000 shares of Holdings’
common stock were issued to an adviser to Ekso Bionics in connection with the Merger.
2013 Bridge Note Financing
In November 2013, Ekso completed a private
placement to accredited investors of $5,000,000 of its senior subordinated secured convertible notes (the “2013 Bridge Notes”).
Stated interest on the 2013 Bridge Notes was 10% per annum payable on July 15, 2014, subject to earlier conversion as described
below. Interest on the 2013 Bridge Notes was payable at maturity; provided that if the 2013 Bridge Notes are converted as described
below, accrued interest would be forgiven.
Upon the closing of the Merger and the
PPO, the outstanding principal amount of the 2013 Bridge Notes was automatically converted into Units of the securities (as described
above) at a conversion price of $1.00 per Unit, and investors in the 2013 Bridge Notes received a warrant to purchase a number
of shares of common stock equal to 50% of the number of shares of common stock contained in the Units into which the 2013 Bridge
Notes were converted (equal to an aggregate of warrants to purchase 2,500,000 shares of common stock), at an exercise price of
$1.00 per share for a term of three years (the “Bridge Warrants”).
Other Warrants
In addition to the PPO Warrants and Bridge
Warrants discussed above, warrants to purchase 3,030,000 shares of common stock were issued to certain placement agents for services
in connection with the PPO. Warrants to purchase 225,000 shares of common stock were also issued to a prior lender in connection
with the Merger who provided an accommodation.
Stock Options to Directors, Officers and Employees
Director, officer and employee options
to purchase shares of Ekso Bionics’ common stock issued and outstanding immediately prior to the closing of the Merger converted
into like options to purchase equivalent shares of Holdings common stock. It is assumed that the conversion of options does not
give rise to any gain or loss for financial reporting purposes, and therefore, there is no accounting consequence reflected in
these pro forma financial statements.
Director options to purchase 450,000 shares
of common stock and officer and employee options to purchase 1,850,000 shares of common stock were issued in connection with the
Merger. The options have an exercise price of $1.00 per share exercisable over a term of 48 months, with 25% of the shares becoming
exercisable on the first anniversary of the date of grant and with 1/48 of the shares becoming exercisable monthly thereafter.
Note 2 – PRO FORMA PRESENTATION
General
The unaudited pro forma consolidated balance
sheet as of December 31, 2013, and the unaudited pro forma consolidated statements of operations for the nine months ended December
31, 2013 and for the year ended December 31, 2012 give effect to:
|
1)
|
The Merger with PN Med Group, Inc. in exchange for
stock, warrants and options including conversion of Ekso Bionics’ preferred stock
to common stock,
|
|
2)
|
The offering and sale of (a) 25,300,000 Units of securities,
at a purchase price of $1.00 per Unit, each Unit consisting of one share of common stock
and a warrant to purchase one share of common stock (at an exercise price of $2.00 per
share and a term of five years), for $25,300,000 in cash proceeds, and (b) 5,000,000
Units of securities, at a purchase price of $1.00 per Unit, each Unit consisting of one
share of common stock and a warrant to purchase one share of common stock (at an exercise
price of $2.00 per share and a term of five years) and additional warrants to purchase
2,500,000 shares of common stock issued upon conversion of the Bridge Loan,
|
|
3)
|
The repayment of the Senior Secured Note,
|
|
4)
|
Issuance of 250,000 shares to a consultant to Ekso
Bionics, and
|
|
5)
|
The issuance of warrants for the purchase of 3,030,000
shares of common stock to the placement agents for services in connection with the transaction,
and a warrant for the purchase of 225,000 shares of common stock to a prior lender as
an accommodation,
|
as if those transactions occurred on December
31, 2013 for purposes of the pro forma consolidated balance sheet, and on the first day of the respective period for purposes
of the pro forma consolidated statement of operations.
Pro forma Adjustments
Adjustments to the accompanying unaudited pro forma consolidated
financial statements are as follows:
Balance Sheet:
|
(a)
|
Reflects all outstanding
pre-merger Ekso Bionics convertible preferred stock and warrants on preferred stock converted
into equivalent Holdings common stock or warrants to purchase common stock, as if such
conversions and exchanges occurred as of December 31, 2013. The conversion of pre-merger
convertible preferred stock into Holdings common stock will be accounted for at the carryover
basis because the conversion/exchange was pursuant to the original terms of the respective
agreements.
|
|
(b)
|
Reflects the recapitalization
of Holdings to adjust the par value to $0.001 per share for 42,615,556 shares of common
stock issued to Ekso Bionics shareholders and to the 5,280,368 shares held by Holdings
pre-merger shareholders as if such recapitalization occurred at December 31, 2013. Also
reflects the split-off of Holdings’ assets and liabilities, and the elimination
of Holdings’ accumulated deficit for periods prior to the Merger into Ekso Bionics
for accounting purposes.
|
|
(c)
|
Reflects the proceeds
from the sale of 25,300,000 Units of securities for $25,300,000 in cash and the conversion
of the 2013 Bridge Notes into 5,000,000 Units of securities and also warrants to purchase
2,500,000 shares of common stock, net of estimated costs (consisting of placement agent
commissions, legal and accounting fees) of approximately $4,217,000 in cash (including
amounts prepaid and accrual), assumed to be paid in cash at time of closing as if the
transactions occurred at December 31, 2013. The fair value of (i) the 250,000 shares
issued to an adviser, and (ii) 3,030,000 warrants issued to the Bridge Placement Agent
and Placement Agent, will be accounted for at fair value as an increase in accumulated
paid in capital (APIC) and a decrease to the proceeds raised in the offering; accordingly,
there is no net effect on equity and therefore, not reflected in the pro forma financial
statements. The conversion of the 2013 Bridge Notes into Holdings’ common stock
is assumed to be accounted for at the carryover basis because the conversion/exchange
was pursuant to the original terms of the agreement.
|
|
(d)
|
Reflects the repayment
of the Senior Note Payable, and write-off of unamortized debt issue costs plus a prepayment
penalty recorded as interest expenses/accumulated deficit as if such repayment and write-off
occurred at December 31, 2013. Also, reflects the issuance of warrants to purchase 225,000
shares of common stock to settle the “obligation to issue warrants” accrued
as of December 31, 2013 of $95,760 owed to the prior lender in connection with an accommodation
related to the issuance of the 2013 Bridge Notes as if such settlement occurred at December
31, 2013.
|
|
(e)
|
Reflects
adjustment to par value for 250,000 shares of common stock issued to a consultant in
connection with the offering.
|
Pro forma consolidated statement of
operations for the year ended December 31, 2013:
|
(f)
|
Eliminates Holdings expenses
as if the split-off occurred at the beginning of the periods presented.
|
|
(g)
|
Reflects the issuance
of options to directors to purchase 450,000 shares of common stock and to officers and
employees to purchase 1,850,000 shares of common stock issued in connection with the
Merger as if such issuance occurred on January 1, 2013. The amount of expense for the
year of $183,950 was calculated using the Black-Scholes option pricing model with inputs
based on data as of January 15, 2014.
|
|
(h)
|
Eliminates interest expense
on the 2013 Bridge Notes since issuance and conversion were directly related to the Merger
and PPO.
|
|
(i)
|
The pro forma weighted
average shares outstanding gives effect to the exchange of pre-merger shares and the
newly issued shares in the Merger as if the exchange and issuance occurred at the beginning
of the periods presented. The effect of any potentially dilutive warrants and options
were anti-dilutive; therefore, dilutive earnings per share is equivalent to basic earnings
per share.
|
The pro forma consolidated
statements of operations
do not eliminate interest expense (including the mark-to-market adjustments) related to the 2012
Series B Bridge Notes which were converted into Series B convertible preferred stock in May 2013 and then converted into common
stock in the Merger, nor the interest expense (including the mark-to-market adjustments) related to the warrants on preferred
stock accounted for as liabilities prior to being converted into common stock in the Merger because the assumption that such financings
would not have occurred because of the Merger is not sufficiently supportable. Interest expense and the gain/loss on mark-to market
which has not been eliminated in the pro forma consolidated statement of operations for these liabilities is as follows:
|
|
Year
ended December 31, 2013
|
|
|
|
|
|
|
Senior Notes Payable
|
|
$
|
649,000
|
|
2012 Series B Bridge Notes
|
|
$
|
962,000
|
|
Ekso
Bionics Holdings, Inc.
67,134,768 Shares of Common Stock
________________________
PROSPECTUS
________________________
June
20, 2014
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024